<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0910246024
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1996
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARBATOL 200MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARBAMAZEPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AF01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Carbamazepine<strong>, </strong>the<strong> </strong>active ingredient<strong> </strong>in<strong> Carbatol</strong><strong><sup>&reg;</sup></strong> tablets, can affect the body in several different ways. It is an anti-convulsant medicine (prevents fits); it can also modify some types of pain and can control mood disorders.</p><p><strong>Carbatol</strong><strong><sup>&reg;</sup></strong> is used:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat some forms of epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat a painful condition of the face called trigeminal neuralgia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to help control serious mood disorders when some other medicines don&rsquo;t work.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take Carbatol<sup>&reg;</sup></strong>&nbsp;</p><p><strong>Some people MUST NOT take </strong><strong>Carbatol</strong><strong><sup>&reg;</sup></strong><strong> Tablets. Talk to your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you think you may be hypersensitive (allergic) to carbamazepine or similar drugs such as oxcarbazepine, or to any of a related group of drugs known as tricyclic antidepressants (such as amitriptyline or imipramine). If you are allergic to carbamazepine there is a one in four (25%) chance that you could also have an allergic reaction to oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you think you may be allergic to any of the other ingredients of <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> Tablets (these are listed at the end of the leaflet). Signs of a hypersensitivity reaction include swelling of the face or mouth (angioedema), breathing problems, runny nose, skin rash, blistering or peeling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any heart problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had problems with your bone marrow,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a blood disorder called porphyria,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have taken drugs called monoamine oxidase inhibitors (MAOIs), used to treat depression, within the last 14 days.</p><p>A small number of people being treated with anti-epileptics such as carbamazepine have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p>Serious skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of carbamazepine. Frequently, the rash can involve ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These serious skin rashes are often preceded by influenza like symptoms fever, headache, body ache (flu-like symptoms). The rash may progress to widespread blistering and peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first months of treatment.</p><p>These serious skin reactions can be more common in people from some Asian countries. The risk of these reactions in patients of Han Chinese or Thai origin may be predicted by testing a blood sample of these patients. Your doctor should be able to advise if a blood test is necessary before taking carbamazepine.</p><p>If you develop a rash or these skin symptoms, stop taking <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> and contact your doctor immediately.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take special care with Carbatol<sup>&reg;</sup></strong></p><p>You should also ask yourself these questions before taking<strong> </strong><strong>Carbatol</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets. If the answer to any of these questions is yes, discuss your treatment with your doctor or pharmacist because<strong> </strong><strong>Carbatol</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets might not be the right medicine for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you pregnant or planning to become pregnant?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you breastfeeding?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you suffer from the sort of epilepsy where you get mixed seizures which include absences?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have any mental illness?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you allergic to an epilepsy medicine called phenytoin?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have liver problems?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have kidney problems associated with low sodium blood level or do you have kidney problems and you are taking certain medicines that lower sodium blood levels (diuretics such as hydrochlorothiazide, furosemide)?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you elderly?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have any eye problems such as glaucoma (increased pressure in the eye) or do you have difficulty retaining your urine?</p><p><strong>&nbsp;</strong></p><p><u>Other special warnings</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drinking alcohol may affect you more than usual. Discuss whether you should stop drinking with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating grapefruit, or drinking grapefruit juice, may increase your chance of experiencing side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may want you to have a number of blood tests before you start taking <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> and from time to time during your treatment. This is quite usual and nothing to worry about.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Because of the way that <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> works, it can affect, and be affected by, lots of other things that you might be eating or medicines that you are taking. It is very important to make sure that your doctor knows all about what else you are taking, including anything that you have bought from a chemist or health food shop. It may be necessary to change the dose of some medicines, or stop taking something altogether.</p><p><strong>Tell the doctor if you are taking:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone contraceptives, e.g. pills, patches, injections or implants. <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> affects the way the contraceptive works in your body, and you may get breakthrough bleeding or spotting. It may also make the contraceptive less effective and there will be a risk of getting pregnant. Your doctor will be able to advise you about this, and you should think about using other contraceptives.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone Replacement Therapy (HRT). <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> can make HRT less effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any medicines for depression or anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids (&lsquo;steroids&rsquo;). You might be taking these for inflammatory conditions such as asthma, inflammatory bowel disease, muscle and joint pains.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticoagulants to stop your blood clotting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antibiotics to treat infections including skin infections and TB (e.g. ciprofloxacillin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antifungals to treat fungal infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painkillers containing paracetamol, dextropropoxyphene, tramadol, methadone or buprenorphine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to treat epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for high blood pressure or heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamines (medicines to treat allergy such as hayfever, itch, etc).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics (water tablets).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine or omeprazole (medicines to treat gastric ulcers).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isotretinoin (a medicine for the treatment of acne).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metoclopramide or aprepitant (anti-sickness medications).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetazolamide (a medicine to treat glaucoma - increased pressure in the eye).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Danazol or gestrinone (treatment for endometriosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Theophylline or aminophylline (used in the treatment of asthma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin, tacrolimus or sirolimus (immunosuppressants used after transplant operations, but also sometimes in the treatment of arthritis or psoriasis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs to treat schizophrenia (e.g. paliperidone, aripiprazole).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer drugs (e.g. temsirolimus, cyclophasphamide, lapatinib).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The anti-malarial drug, mefloquine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs to treat HIV.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Levothyroxine (used to treat hypothyroidism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tadalafil (used to treat impotence).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Albendazole (used to treat worms).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bupropion (used to help stop smoking).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A herbal remedy called St John&rsquo;s Wort or Hypericum.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs or supplements containing Vitamin B (nicotinamide).</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>You must discuss your epilepsy treatment with your doctor well before you become pregnant. If you do get pregnant while you&rsquo;re taking <strong>Carbatol<sup>&reg;</sup></strong> Tablets you must tell the doctor straightaway. It is important that your epilepsy remains well controlled, but, as with other anti-epilepsy treatments, there is a risk of harm to the fetus. Make sure you are very clear about the risks and the benefits of taking <strong>Carbatol<sup>&reg;</sup></strong> Tablets.</p><p>Mothers taking <strong>Carbatol<sup>&reg;</sup></strong> Tablets can breastfeed their babies, but you must tell the doctor as soon as possible if you think that the baby is suffering side effects such as excessive sleepiness or skin reactions or yellow skin and eyes, dark urine or pale stools.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Driving and using machines</strong></p><p><strong>Carbatol<sup>&reg;</sup></strong> Tablets can make you feel dizzy or drowsy, or may cause blurred vision, double vision, or you may have a lack of muscular coordination, especially at the start of treatment or when the dose is changed. If you are affected in this way, or if your eyesight is affected, you should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will tell you how many <strong>Carbatol</strong><sup>&reg;</sup> Tablets to take and when to take them. Always follow his/her instructions carefully. The dose will be on the pharmacist&rsquo;s label. Check the label carefully.</p><p>It is important to take the tablets at the right times. If you are not sure, ask your doctor or pharmacist. Keep taking your tablets for as long as you have been told, unless you have any problems. In that case, check with your doctor.</p><p>Your doctor will usually start <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> at a fairly low dose which can then be increased to suit you individually. The dose needed varies between patients. You can take <strong>Carbatol</strong><strong><sup>&reg;</sup></strong> Tablets during, after or between meals. Swallow the tablets with a drink. You are usually told to take a dose two or three times a day. If necessary you may break the tablets in half along the scored line.</p><p>&nbsp;</p><p><strong>To treat epilepsy, the usual doses are:</strong></p><p><strong><em>Adult</em></strong><strong>s: </strong>800-1,200 mg a day, although higher doses may be necessary. If you are elderly you might require a lower dose.</p><p><strong><em>Children:</em></strong></p><p>Aged 5-10 years: 400-600 mg a day</p><p>Aged 10-15 years: 600-1,000 mg a day.</p><p><strong>Carbatol</strong><strong><sup>&reg;</sup></strong> Tablets are not recommended for children under 5.</p><p><strong>&nbsp;</strong></p><p><strong>To treat trigeminal neuralgia, the usual dose is:</strong></p><p>600 - 800 mg a day. The maximum dose is 1200mg a day. If you are elderly you might require a lower dose.</p><p>&nbsp;</p><p><strong>To treat mood swings the usual dose is</strong>:</p><p>400 - 600 mg a day.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take more Carbatol<sup>&reg;</sup> than you should</strong></p><p>If you accidentally take too many <strong>Carbatol<sup>&reg;</sup></strong> Tablets, tell your doctor or your nearest hospital casualty department. Take your medicine pack with you so that people can see what you have taken.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you forget to take Carbatol<sup>&reg;</sup> </strong></p><p>If you forget to take a dose, take one as soon as you remember. If it is nearly time for your next dose, though, just take the next dose and forget about the one you missed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Carbatol<sup>&reg;</sup></strong> tablets do not usually cause problems, but like all medicines, they can sometimes cause side effects.</p><p><strong>Some side effects can be serious.</strong></p><p><strong>Stop taking </strong><strong>Carbatol<sup>&reg;</sup></strong><strong> Tablets and tell your doctor straight away if you notice:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions such as rash, red skin, blistering of the lips, eyes or mouth, or skin peeling accompanied by fever. These reactions may be more frequent in patients of Chinese or Thai origin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth ulcers or unexplained bruising or bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat or high temperature, or both</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen ankles, feet or lower legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any signs of nervous illness or confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your joints and muscles, a rash across the bridge of the nose and cheeks and problems with breathing (these may be the signs of a rare reaction known as lupus erythematosus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, skin rash, joint pain, and abnormalities in blood and liver function tests (these may be the signs of a multi-organ sensitivity disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchospasm with wheezing and coughing, difficulty in breathing, feeling faint, rash, itching or facial swelling (these may be the signs of a severe allergic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the area near the stomach.</p><p>&nbsp;</p><p><strong>The side effects listed below have also been reported.</strong></p><p><strong>More than 1 in 10 people have experienced:</strong></p><p>Leucopenia (a reduced number of the cells which fight infection making it easier to catch infections); dizziness and tiredness; feeling unsteady or finding it difficult to control movements; feeling or being sick; changes in liver enzyme levels (usually without any symptoms); skin reactions which may be severe.</p><p><strong>Up to 1 in 10 people have experienced:</strong></p><p>Changes in the blood including an increased tendency to bruise or bleed; fluid retention and swelling; weight increase; low sodium in the blood which might result in confusion; headache; double or blurred vision; dry mouth.</p><p><strong>Up to 1 in 100 people have reported:</strong></p><p>Abnormal involuntary movements including tremor or tics; abnormal eye movements; diarrhoea; constipation.</p><p><strong>Up to 1 in 1,000 people have reported:</strong></p><p>Disease of the lymph glands; folic acid deficiency; a generalized allergic reaction including rash, joint pain, fever, problems with the kidneys and other organs; hallucinations; depression; loss of appetite; restlessness; aggression; agitation; confusion; speech disorders; numbness or tingling in the hands and feet; muscle weakness; high blood pressure (which may make you feel dizzy, with a flushed face, headache, fatigue and nervousness); low blood pressure (the symptoms of which are feeling faint, light headed, dizzy, confused, having blurred vision); changes to heart beat; stomach pain; liver problems including jaundice; symptoms of lupus.</p><p>&nbsp;</p><p><strong>Up to 1 in 10,000 people have reported:</strong></p><p>Changes to the composition of the blood including anemia; porphyria; meningitis; swelling of the breasts and discharge of milk which may occur in both male and females; abnormal thyroid function tests; osteomalacia (which may be noticed as pain on walking and bowing of the long bones in the legs); osteoporosis; increased blood fat levels; taste disturbances; conjunctivitis; glaucoma; cataracts; hearing disorders; heart and circulatory problems including deep vein thrombosis (DVT), the symptoms of which could include tenderness, pain, swelling, warmth, skin discoloration and prominent superficial veins; lung or breathing problems; severe skin reactions including Stevens- Johnson syndrome (These reactions may be more frequent in patients of Chinese or Thai origin); sore mouth or tongue; liver failure; increased sensitivity of the skin to sunlight; alterations in skin pigmentation; acne; excessive sweating; hair loss; increased hair growth on the body and face; muscle pain or spasm; sexual difficulties which may include reduced male fertility, loss of libido or impotence; kidney failure; blood spots in the urine; increased or decreased desire to pass urine or difficulty in passing urine.</p><p>&nbsp;</p><p><strong>The following have also been reported, but the frequency cannot be estimated from the available information:</strong></p><p>Severe skin reactions accompanied by feeling unwell and changes in blood results. Diarrhoea, abdominal pain, and fever (signs of inflammation of the colon), reactivation of herpes virus infection (can be serious when immune system is depressed), complete loss of nails, fracture, decrease in the measure of the bone density, drowsiness, memory loss, purple or reddish-purple bumps that may be itchy.</p><p><em>&nbsp;</em></p><p><em>Do not be alarmed by this list. Most people take </em><strong><em>Carbatol</em></strong><em><sup>&reg;</sup></em><em> Tablets without any problems.</em></p><p><em>If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor. He/she may want to give you a different medicine.</em></p><p>&nbsp;</p><p>There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis, or take steroids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a dry place. Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take <strong>Carbatol</strong><sup>&reg;</sup> after the expiry date which is printed on the outside of the pack. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.&nbsp; These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>What Carbatol<sup>&reg;</sup> contains</strong></p><p><strong>Carbatol</strong><sup>&reg;</sup> tablets contain Carbamazepine as active ingredient. Each tablet contains 200 mg of Carbamazepine.</p><p>The other ingredients are: Microcrystalline cellulose, silica colloidal anhydrous, sodium starch glycolate, magnesium stearate, sodium laurilsulfate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -	What Carbatol® looks like and contents of the pack
Carbatol ® Tablets are white to off-white round normal biconvex tablets with a groove and DAD engraving on one side, plain on the other side.

Carbatol® Tablets are packed in blisters of 10. Carbatol® tablets are available in packs of 30 ( 3 blisters ), 50 ( 5 blisters ) , 300 ( 30 blisters ) and 500 ( 50 blisters ). 
Not all pack sizes may be marketed

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment CO. LTD (Na&rsquo;ur &minus; Jordan).</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776&nbsp;</p><p><strong>To report any side effects:</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jordan</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>&nbsp;Contact marketing authorization holder</li></ul></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>&nbsp;National Pharmacovigilance and Drug Safety Centre (NPC)</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 966 112057662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Arab Emirates</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacovigilance and Medical Device Section</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Department</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UAE Ministry of Health &amp; Prevention</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hotline: 80011111</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: pv@moh.gov.ae</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box: 1853 Dubai UAE</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudan</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>National Medicines and Poisons Board (NMPB)</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 249 183522263</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: info@nmpb.gov.sd</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website : www.nmpb.gov.sd</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other countries</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>Please contact the relevant competent authority.</li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">قد يؤثر كاربامازيبين، المادة الفعالة في أقراص <strong>كارباتول</strong>، على الجسم بطرق متعددة. فهو دواء مضاد للاختلاجات (يمنع حدوث النوبات)، كما قد يعمل أيضا على تخفيف بعض أنواع الالم والتحكم باضطرابات المزاج.</p><p dir="RTL">يستخدم <strong>كارباتول</strong>:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج بعض أشكال الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج حالة مؤلمة في الوجه تسمى التهاب العصب الثالث</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد في التحكم باضطرابات المزاج الشديدة في حال لم تعمل بعض الادوية الاخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال</strong><strong> كارباتول </strong></p><p dir="RTL"><strong>على بعض الناس عدم تناول أقراص كارباتول</strong><strong>.</strong><strong> تحدث الى طبيبك في حال: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعتقد بأنك قد تعاني من فرط الحساسية تجاه كاربامازيبين أو أي أدوية مشابهة مثل اوكساكاربازين أو مجموعة من الادوية المعروفة بمضادات الاكتئاب ثلاثية الحلقة (مثل اميتريبتيلين او ايميبرامين). اذا كنت تعاني من حساسية تجاه كاربامازيبين، هناك احتمال 1 من4 (25%) بأنك ستعاني من تفاعلات حساسية ايضا لدى تناول اوكساكاربازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعتقد بأنك تعاني من فرط الحساسية تجاه أي من مكونات أقراص <strong>كارباتول</strong> (المذكورة في نهاية النشرة). تشمل علامات حدوث تفاعل حساسية انتفاخ الوجه أو الفم (وذمة وعائية)، مشاكل في التنفس، سيلان الانف ، طفح جلدي، تقشر او تقرح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من اي مشاكل في القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق وعانيت من مشاكل في نخاع العظم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من اضطراب في الدم يعرف بالبورفيريا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولت أدوية تعرف بمثبطات أكسدة المركبات أحادية الامين، تستخدم في علاج الاكتئاب، خلال14 يوم السابقة</p><p dir="RTL">ظهرت لدى عدد قليل من الناس الذين تم علاجهم بمضادات الصرع مثل كاربامازيبين أفكار تتعلق بإيذاء أنفسهم أو الانتحار. اذا تكونت لديك هذه الافكار في أي وقت، اتصل بطبيبك على الفور.</p><p dir="RTL">تم رصد حدوث طفح جلدي خطير (متلازمة ستيفنز &ndash; جونسون ، انحلال البشرة السمي) بالتزامن مع استخدام كاربامازيبين. في كثير من الاحيان، يشمل الطفح ظهور تقرحات في الفم، الحلق، الانف، الاعضاء التناسلية و التهاب الملتحمة ( احمرار وانتفاخ العيون). يسبق ظهور مثل هذا الطفح الجلدي الخطير اعراض شبيهة بالانفلونزا مثل حمى، صداع، الم في الجسم. قد يتطور الطفح الى تقرح واسع الانتشار و تقشر في الجلد. تكون خطورة حدوث هذه التفاعلات الجلدية الخطيرة أعلى خلال الاشهر الاولى من العلاج.</p><p dir="RTL">تكون هذه التفاعلات الجلدية الخطيرة أكثر شيوعا في الاشخاص من البلاد الاسيوية. يتم توقع احتمال حدوث هذه التفاعلات في المرضى من أصل صيني أو تايلاندي من خلال إجراء فحص للدم في هؤلاء المرضى. سيقوم الطبيب بنصحك اذا كان من الضروري إجراء فحص للدم قبل تناول كاربامازيبين.</p><p dir="RTL">اذا ظهر لديك طفح او أي من هذه الاعراض الجلدية، توقف عن تناول <strong>كارباتول</strong> واتصل بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>كارباتول</strong></p><p dir="RTL">يجب أن تسأل نفسك هذه الاسئلة قبل تناول أقراص<strong> كارباتول. </strong>اذا كان جواب أي من هذه الاسئلة هو (نعم) ، قم بمناقشة العلاج مع الطبيب أو الصيدلي، قد لا تكون أقراص<strong> كارباتول </strong>هي الدواء المناسب لك<strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل انت حامل أو تخططين للحمل؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل انت مرضع؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من نوع من الصرع بحيث يكون لديك نوبات مختلطة تشمل النوبات الصرعية المصحوبة بغيبة؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من أي مرض عقلي؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من حساسية تجاه دواء للصرع يسمى فيناتوين؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من مشاكل في الكبد؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من مشاكل في الكلى مرتبطة بانخفاض في مستوى الصوديوم في الدم او كنت تعاني من مشاكل في الكلى وكنت تتناول ادوية معينة تخفض من مستويات الصوديوم في الدم (مدرات البول مثل هيدروكلوروثيازيد، فيوروسامايد)؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل انت من كبار السن؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من اي مشاكل في العين مثل الزرقة ( ارتفاع ضغط العين) او تعاني من صعوبة في حبس البول؟</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>احتياطات اخرى </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤثر شرب الكحول عليك أكثر من المعتاد. ناقش مع طبيبك اذا كان عليك وقف شرب الكحول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد تناول الجريب فروت أو شرب عصير الجريب فروت من احتمالية ظهور الاعراض الجانبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب منك الطبيب إجراء عدد من فحوصات الدم قبل بدء تناول <strong>كارباتول</strong> ومن وقت لآخر خلال فترة العلاج. إن هذا إجراء طبيبعي ، ليس هناك شيء يدعو للقلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء </strong><strong>&nbsp;</strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong><strong> </strong><strong>&nbsp;</strong></p><p dir="RTL">نظرا للطريقة التي يعمل بها <strong>كارباتول</strong>، قد يؤثر او يتأثر بالكثير من الاطعمة التي قد تتناولها أو الادوية التي تأخذها. من المهم جدا أن تتأكد أن طبيبك على علم بأي شيء أخر قد تناولته ، تشمل التي قمت بشرائها من الصيدلي أو متجر الاغذية الصحية. قد يكون تغيير جرعة بعض الادوية او وقف تناولها بالكامل بالتزامن مع الدواء ضروريا.</p><p dir="RTL"><strong>أخبر طبيبك اذا كنت تتناول</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل الهرمونية مثل الاقراص، اللصقات، الحقن أو الغرسات. يؤثر <strong>كارباتول </strong>على الطريقة التي تعمل بها موانع الحمل في الجسم، قد يحدث نزيف اختراقي او تظهر بقع من الدم. وقد تصبح موانع الحمل أقل فعالية وبالتالي تزيد احتمالية حدوث حمل. سيقوم الطبيب بنصحك بخصوص هذا الامر، يجب عليك التفكير باستخدام وسائل اخرى لمنع الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج بالهرمونات البديلة. قل يقلل <strong>كارباتول</strong> من فعاليتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي ادوية لعلاج الاكتئاب او القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات القشرية ( الستيرويدات) والتي قد تتناولها لعلاج حالات من الالتهاب مثل الربو، مرض التهاب الامعاء، آلام العضلات والمفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر لوقف تجلط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية لعلاج العدوى و تشمل العدوى الجلدية و السل ( مثل سيبروفلوكساسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الفطريات لعلاج العدوى الفطرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسكنات التي تحتوي على الباراسيتامول، ديكستروبروبوكسيفين، ترامادول، ميثادون أو بابرينوفين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الادوية الاخرى لعلاج الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الادوية لعلاج ضغط الدم المرتفع أو مشاكل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين ( الادوية التي تعالج الحساسية مثل حمى القش ، الحكة وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين أو اوميبرازول ( ادوية لعلاج قرحة المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايزوتريتينوين ( دواء لعلاج حب الشباب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتوكلوبرامايد او ابريبيتانت ( أدوية لعلاج الغثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسيتازولامايد (دواء لعلاج الزرقة &ndash; ارتفاع ضغط العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازول او جيسترينون ( لعلاج التهاب بطانة الرحم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين او امينوفيلين ( تستخدم لعلاج الربو)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، تاكروليمس او سيروليمس ( مثبطات للمناعة تستخدم بعد عمليات الزرع، لكن قد يتم استخدامها أحيانا في علاج التهاب المفاصل أو الصدفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج انفصام الشخصية ( شيزوفرينيا) ( مثل باليبيريدون، اريبيبرازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السرطان (مثل تيمسيروليمس، سيكلوفوسفامايد، لاباتينيب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء مضاد للملاريا، ميفلوكوين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض الايدز ( نقض المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليفوثيروكسين ( يستخدم في علاج قصور الغدة الدرقية )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تادالافيل (يستخدم في علاج العجز الجنسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألبيندازول (يستخدم في علاج الديدان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوبروبيون (يساعد في الاقلاع عن التدخين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء عشبي يعرف (سانت جونز وورت)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أو مكملات تحتوي على فيتامين ب ( نيكوتينامايد)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل و</strong><strong>الرضاعة </strong></p><p dir="RTL">يجب مناقشة علاج الصرع الخاص بك مع الطبيب قبل حدوث حمل. في حال حدوث حمل بالتزامن مع تناول اقراص <strong>كارباتول</strong>، يجب إخبار الطبيب على الفور. من المهم أن يبقى الصرع تحت السيطرة لكن كما هو الحال مع الأدوية الأخرى المضادة للصرع، قد يحدث ضرر للجنين. تأكد من معرفة المخاطر والفوائد المرجوة من تناول اقراص <strong>كارباتول.</strong></p><p dir="RTL">تستطيع الامهات اللاتي يتناولن أقراص <strong>كارباتول</strong> إرضاع اطفالهن، لكن يجب إخبار الطبيب بأسرع وقت ممكن اذا كنت تعتقد بأن طفلك يعاني من أعراض جانبية مثل النعاس الشديد أو تفاعلات جلدية او اصفرار في الجلد والعينين، بول داكن او براز شاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تأثير كارباتول على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تسبب أقراص <strong>كارباتول </strong>الشعور بالدوار أو الدوخة، او قد يسبب تشويش، ازدواج في الرؤية او نقص في التناسق العضلي، خصوصا عند بدء العلاج أو تغيير الجرعة. اذا تأثرت بهذا الشكل أو اذا تأثر بصرك، لا تقم بالقيادة أو استخدام الالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيخبرك الطبيب كم عليك أن تتناول من أقراص <strong>كارباتول</strong> وموعد تناول الاقراص. اتبع دائما تعليمات الطبيب بدقة. إن الجرعة موجودة على ملصق الصيدلي. تحقق من الملصق بعناية.</p><p dir="RTL">من المهم ان تتناول الاقراص في أوقاتها الصحيحة. تحقق من الطبيب أو الصيدلي اذا لم تكن متأكدا. استمر في تناول الاقراص طيلة الفترة التي اوصى بها الطبيب، الا اذا عانيت من أي مشاكل. في هذه الحالة ، اسال الطبيب.</p><p dir="RTL">يبدأ الطبيب عادة بإعطائك <strong>كارباتول</strong> بجرعة منخفضة نسبيا و قد يزيد الجرعة بما يناسب حالتك. تختلف الجرعة اللازمة بين المرضى. تستطيع تناول أقراص <strong>كارباتول</strong> أثناء أو بعد أو بين الوجبات. إبلع الاقراص مع الماء. تؤخذ الجرعة مرتين الى ثلاث مرات يوميا عادة. قد تحتاج الى كسر القرص الى نصفين عن طريق الخط العرضي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعات الاعتيادية لعلاج الصرع هي: </strong></p><p dir="RTL"><strong><em>البالغين</em></strong>: 800 &ndash; 1200 ملغم يوميا، على الرغم من أنه قد تكون هناك حاجة الى جرعات اكبر. اذا كنت من كبار السن، قد تحتاج الى جرعة أقل.</p><p dir="RTL"><strong><em>الاطفال</em></strong>:</p><p dir="RTL">عمر 5 &ndash; 10 سنوات: 400 &ndash; 600 ملغم يوميا</p><p dir="RTL">عمر 10- 15 سنة : 600-1000 ملغم يوميا</p><p dir="RTL">لا يوصى باستخدام <strong>كارباتول </strong>في الاطفال دون 5 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الاعتيادية لعلاج التهاب العصب الثالث هي:</strong></p><p dir="RTL">600 &ndash; 800 ملغم يوميا. الجرعة القصوى هي 1200 ملغم يوميا. اذا كنت من كبار السن قد تحتاج الى جرعة أصغر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الاعتيادية لعلاج تقلبات المزاج هي</strong> :</p><p dir="RTL">400 &ndash; 600 ملغم يوميا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من &nbsp;كارباتول </strong></p><p dir="RTL">اذا تجاوزت الجرعة من أقراص <strong>كارباتول</strong> عن طريق الخطأ، أخبر طبيبك أو أقرب مركز طوارئ. خذ عبوة الدواء معك حتى يعلم الناس الدواء الذي تناولته.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة كارباتول</strong></p><p dir="RTL">اذا نسيت تناول جرعة، تناولها فور تذكرها. اذا اقترب موعد الجرعة التالية ، تناول الجرعة في موعدها ولا تتناول الجرعة المنسية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن أقراص <strong>كارباتول</strong><strong> </strong>لا تسبب عادة<strong> </strong>مشاكل. لكن شأنها شأن الادوية الاخرى، قد تسبب أحيانا أعراضا جانبية.</p><p dir="RTL">&nbsp;<strong>قد تكون بعض الاعراض الجانبية خطيرة. </strong></p><p dir="RTL"><strong>توقف عن تناول أقراص كارباتول وأخبر طبيبك على الفور اذا لاحظت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية خطيرة مثل طفح، احمرار الجلد، تقرح الشفاه، العينين أو الفم، أو تقشر الجلد المصحوب بالحمى. تكون هذه الاعراض أكثر شيوعا في المرضى من أصل صيني او تايلاندي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم أو كدمات أو نزيف بشكل غير مبرر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الحلق أو ارتفاع درجة الحرارة، أو كلاهما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار في الجلد أو بياض العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الكاحل، القدمين او أسفل الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي علامات على وجود مرض عصبي أو ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل والعضلات، طفح يظهر عبر المنطقة ما بين الانف و الوجنتين مع مشاكل في التنفس (قد تكون هذه علامات على حدوث تفاعل نادر يسمى الذئبة الحمامية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، طفح جلدي، ألم في المفاصل، نتائج غير طبيعية في فحوصات الدم ووظائف الكبد (قد تكون هذه علامات على حدوث اضطراب حساسية لأعضاء متعددة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج قصبي مع صفير وسعال، صعوبة في التنفس، الشعور بالاغماء، طفح ، حكة أو انتفاخ في الوجه ( قد تكون هذه علامات على حدوث رد فعل فعل تحسسي شديد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المنطقة بجانب المعدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم رصد الاعراض الجانبية التالية أيضا:</strong></p><p dir="RTL"><strong>تؤثر على أكثر من شخص من كل 10 أشخاص:</strong></p><p dir="RTL">انخفاض في تعداد كريات الدم البيضاء ( انخفاض في عدد الخلايا التي تكافح العدوى وبالتالي يصبح من السهل التقاط العدوى)، دوار وتعب، الشعور بعدم الاستقرار أو صعوبة في السيطرة على الحركات، الغثيان أو القيء، تغيرات في مستويات انزيمات الكبد (تكون عادة بلا اعراض) ، تفاعلات جلدية قد تكون شديدة.</p><p dir="RTL"><strong>تؤثر على 1 من كل10 أشخاص كحد اعلى :</strong></p><p dir="RTL">تغيرات في الدم تشمل زيادة احتمالية ظهور الكدمات او النزيف، احتباس السوائل و الانتفاخ، زيادة الوزن، انخفاض الصوديوم في الدم والذي قد يؤدي الى ارتباك، صداع، ازدواج أو عدم وضوح الرؤية، جفاف الفم.</p><p dir="RTL"><strong>تؤثر على 1 من كل 100 شخص كحد اعلى:</strong></p><p dir="RTL">حركات غير طبيعية لا ارادية تشمل الاختلاج او التشنجات ، حركات غير طبيعية في العين، إسهال، إمساك.</p><p dir="RTL"><strong>تؤثر على 1 من كل 1000 شخص كحد اعلى:</strong></p><p dir="RTL">مرض في الغدد اليمفاوية، نقص في حمض الفوليك، تفاعل تحسسي عام يشمل الطفح، الم المفاصل، حمى، مشاكل في الكلية و أعضاء أخرى، هلوسات، اكتئاب، فقدان الشهية، اضطراب، عصبية، تهيج، ارتباك، اضطرابات في الكلام، تنميل او وخز في اليدين والساقين، ضعف في العضلات، ارتفاع ضغط الدم (والذي قد يجعلك تشعر بالدوار، احمرار الوجه ، صداع، تعب و عصبية) ، انخفاض ضغط الدم ( تشمل الاعراض الشعور بالاغماء، الدوار، الدوخة، الارتباك ، عدم وضوح الرؤية)، تغيرات في ضربات القلب، ألم في البطن، مشاكل في الكبد تشمل اليرقان، أعراض الحمى الذئبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تؤثر على 1 من كل 10000 شخص كحد اعلى: </strong></p><p dir="RTL">تغيرات في تركيب الدم تشمل فقر الدم ، البورفيريا، التهاب السحايا، تضخم في الثديين و ترشح الحليب الذي قد يحدث في الذكور والاناث، فحوصات غير طبيعية في وظائف الغدة الدرقية، لين العظام ( قد تتم ملاحظته عن طريق حدوث ألم أثناء السير و انحناء العظام الطويلة في الساقين)، هشاشة العظام، زيادة مستويات الدهون في الدم، اضطرابات في التذوق، التهاب الملتحمة، زرقة، إعتام عدسة العين، اضطرابات سمعية، مشاكل في القلب والدورة الدموية تشمل تخثر الاوردة العميقة، و التي قد تشمل أعراضها طراوة، ألم، انتفاخ، دفئ، تغير في لون الجلد و أوردة سطحية بارزة ، مشاكل في الرئة أو التنفس، تفاعلات جلدية شديدة تشمل متلازمة ستيفنس-جونسون ( تكون هذه الاعراض أكثر شيوعا في المرضى من أصل صيني أو تايلاندي) ، تقرح الفم أو اللسان، فشل في الكبد، زيادة حساسية الجلد لأشعة الشمس، تغيرات في تصبغ الجلد، حب الشباب، تعرق شديد، فقدان الشعر، زيادة نمو الشعر على الجسم والوجه، وجع قي العضلات أو تشنج ، صعوبات جنسية تشمل انخفاض في خصوبة الرجال، فقدان الرغبة الجنسية او العجز الجنسي، فشل كلوي، بقع دم في البول، زيادة او نقصان الرغبة في التبول او صعوبة في التبول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم رصد الاعراض التالية ايضا، لكن لم يتم تقييم معدل التكرار من المعلومات المتاحة:</strong></p><p dir="RTL">تفاعلات جلدية شديدة مع الشعور بأنك لست على ما يرام مع تغيرات في نتائج الدم. اسهال، ألم في البطن وحمى (علامات التهاب القولون)، اعادة تنشيط العدوى بفيروس هيربس (قد تكون خطيرة في حال كان هناك تثبيط لجهاز المناعة)، فقدان كلي للأظافر، كسر، انخفاض في قياس كثافة العظم، دوار، فقدان الذاكرة، نتوءات حمراء ارجوانية قد تسبب الحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>لا تقلق من هذه القائمة. معظم الناس تتناول اقراص <strong>كارباتول</strong> بدون اي مشاكل.</em></p><p dir="RTL"><em>اذا أصبحت اي من الآثار الجانبية مزعجة، او اذا لاحظت حدوث أعراض جانبية أخرى غير المذكورة في هذه النشرة ، يرجى زيارة الطبيب ، قد يصرف لك الطبيب دواء آخر.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث مشاكل في العظم تشمل نقص في كثافة العظم وهشاشة العظام (ترقق العظم) و كسور. تحقق من الطبيب أو الصيدلي اذا كنت تخضع لعلاج مضاد للصرع طويل الامد أو لديك تاريخ في هشاشة العظام أو تتناول الستيرويدات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الاطفال ونظرهم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في مكان جاف على درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول <strong>&nbsp;كارباتول</strong> بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على آخر يوم في الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الادوية في المياه العادمة او النفايات المنزلية. اسأل الصيدلي حول الطريقة السليمة للتخلص من الادوية التي لم تعد بحاجة اليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ماهي محتويا</strong><strong>ت</strong><strong> &nbsp;</strong><strong>كارباتول</strong><strong>&nbsp; </strong></p><p dir="RTL">تحتوي أقرص <strong>كارباتول</strong> على كاربامازيبين كمادة فعالة. يحتوي كل قرص على 200 ملغم من كاربامازيبين.</p><p dir="RTL">المكونات الأخرى هي: سيليلوز دقيق البلورية، سيليكا غروية لا مائية، أملاح الصوديوم لجليكولات النشا، ستيارات المغنيسيوم، ملح الصوديوم للوريل السلفات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>الشكل</strong><strong> </strong><strong>الصيدلاني</strong><strong> </strong><strong>لكارباتول ووصفه</strong><strong> </strong><strong>وحجم</strong><strong> </strong><strong>عبوته</strong></p><p dir="RTL"><strong>أقراص</strong> <strong>كارباتول</strong> هي أقراص لونها أبيض الى سكري ، مستديرة الشكل، محدبة الوجهين مع قطع عرضي و نقش ( (DADعلى جهة واحدة.</p><p dir="RTL"><strong>أقراص</strong> <strong>كارباتول</strong><strong> &nbsp;</strong>معبأة في أشرطة من الالومنيوم &nbsp;يحتوي كل منها 10 اقراص.<strong> أقراص</strong> <strong>كارباتول</strong><strong> </strong>متوفرة في عبوات سعة 30 قرص (3 أشرطة)، 50 قرص (5 أشرطة)، 300 قرص ( 30 شريط) و500 قرص ( 50 شريط).</p><p dir="RTL">قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور- الأردن)</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية :</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأردن</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الإتصال بمالك رخصة التسويق</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-205-11-966 +</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم:</p><p dir="LTR">2038222-11-966+، فرعي: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني www.sfda.gov.sa/npc :</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قسم اليقظة الدوائية والوسائل الطبية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدارة الدواء</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزارة الصحة ووقاية المجتمع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن : ٨٠٠١١١١١</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايميل : pv@moh.gov.ae</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صندوق بريد : ١٨٥٣ دبي الامارات العربية المتحدة</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السودان</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:639px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المجلس القومي للأدوية والسموم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 522263 183 (249+)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: info@nmpb.gov.sd</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.nmpb.gov.sd</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدول الأخرى</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;-الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carbatol® 200 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carbatol® 200 mg Tablets: Each tablet contains 200 mg Carbamazepine.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.
Carbatol® Tablets are white to off-white round normal biconvex tablets with a groove and DAD engraving on one side, plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Epilepsy - generalized tonic-clonic and partial seizures.<br />Note: Carbatol&reg; is not usually effective in absences (petit mal) and myoclonic seizures. Moreover, anecdotal evidence suggests that seizure exacerbation may occur in patients with atypical absences.<br />&bull; The paroxysmal pain of trigeminal neuralgia.<br />&bull; For the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carbatol&reg; is given orally, usually in two or three divided doses. Carbatol&reg; may be taken during, after or between meals, with a little liquid e.g. a glass of water.<br />Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be screened for HLA-B*1502 as this allele strongly predicts the risk of severe carbamazepine-associated Stevens-Johnson syndrome (See information on genetic testings and cutaneous reactions in section 4.4).<br />Epilepsy:<br />The dose of carbamazepine should be adjusted to the needs of the individual patient to achieve adequate control of seizures. Determination of plasma levels may help in establishing the optimum dosage. In the treatment of epilepsy, the dose of carbamazepine usually requires total plasma-carbamazepine concentrations of about 4 to 12 micrograms/mL (17 to 50 micromoles/liter) (see warnings and precautions).<br />Adults: It is advised that with all formulations of Carbatol&reg;, a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.<br />Carbatol&reg; should be taken in a number of divided doses although initially 100-200mg once or twice daily is recommended. This may be followed by a slow increase until the best response is obtained, often 800-1200mg daily. In some instances, 1600mg or even 2000mg daily may be necessary.<br />Elderly: Due to the potential for drug interactions, the dosage of Carbatol&reg; should be selected with caution in elderly patients.<br />Children and adolescents: It is advised that with all formulations of Carbatol&reg; , a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.<br />Usual dosage 10-20mg/kg bodyweight daily taken in several divided doses.<br />Carbatol&reg; tablets are not recommended for very young children.<br />5-10 years:<br />400 to 600mg daily (2-3 x 200mg tablets per day, to be taken in divided doses).<br />10-15 years:<br />600 to 1000mg daily (3-5 x 200mg tablets per day, to be taken in several divided doses).<br />&gt;15 years of age:<br />800 to 1200mg daily (same as adult dose).<br />Maximum recommended dose<br />Up to 6 years of age: 35mg/kg/day<br />6-15 years of age: 1000mg/day<br />&gt;15 years of age: 1200mg/day.<br />Wherever possible, anti-epileptic agents should be prescribed as the sole anti-epileptic agent but if used in polytherapy the same incremental dosage pattern is advised.<br />When Carbatol&reg; is added to existing antiepileptic therapy, this should be done gradually while maintaining or, if necessary, adapting the dosage of the other antiepileptic(s) (see 4.5 Interaction with other Medicaments and other forms of Interaction).<br />Trigeminal neuralgia:<br />Slowly raise the initial dosage of 200-400mg daily until freedom from pain is achieved (normally at 200mg 3-4 times daily). In the majority of patients a dosage of 200mg 3 or 4 times a day is sufficient to maintain a pain free state. In some instances, doses of 1600mg Carbatol&reg; daily may be needed. However, once the pain is in remission, the dosage should be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.<br />Elderly:<br />Dosage in Trigeminal neuralgia<br />Due to drug interactions and different antiepileptic drug pharmacokinetics, the dosage of Carbatol&reg; should be selected with caution in elderly patients.<br />In elderly patients, an initial dose of 100mg twice daily is recommended. The initial dosage of 100mg twice daily should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.<br />For the prophylaxis of manic depressive psychosis in patients unresponsive to lithium therapy:<br />Initial starting dose of 400mg daily, in divided doses, increasing gradually until symptoms are controlled or a total of 1600mg given in divided doses is reached. The usual dosage range is 400-600mg daily, given in divided doses.<br />Special populations<br />Renal impairment / Hepatic impairment<br />No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to carbamazepine or structurally related drugs (e.g. tricyclic antidepressants) or any other component of the formulation.
Patients with atrioventricular block, a history of bone marrow depression or a history of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).
The use of Carbatol® is contraindicated in combination with monoamine oxidase inhibitors (MAOIs) (see section 4.5 Interaction with other medicinal products and other forms of interaction).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warnings<br />Agranulocytosis and aplastic anaemia have been associated with Carbamazepine; however, due to the very low incidence of these conditions, meaningful risk estimates for carbamazepine are difficult to obtain. The overall risk in the general untreated population has been estimated at 4.7 persons per million per year for agranulocytosis and 2.0 persons per million per year for aplastic anaemia.<br />Decreased platelet or white blood cell counts occur occasionally to frequently in association with the use of carbamazepine. Nonetheless, complete pre-treatment<br />blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained as a baseline, and periodically thereafter.<br />Patients and their relatives should be made aware of early toxic signs and symptoms indicative of a potential haematological problem, as well as symptoms of dermatological or hepatic reactions. If reactions such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric haemorrhage appear, the patient should be advised to consult his physician immediately.<br />If the white blood cell or platelet count is definitely low or decreased during treatment, the patient and the complete blood count should be closely monitored (see Section 4.8 Undesirable Effects). However, treatment with carbamazepine should be discontinued if the patient develops leucopenia which is severe, progressive or accompanied by clinical manifestations, e.g. fever or sore throat. Carbamazepine should also be discontinued if any evidence of significant bone marrow depression appears.<br />Liver function tests should also be performed before commencing treatment and periodically thereafter, particularly in patients with a history of liver disease and in elderly patients. The drug should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease.<br />Some liver function tests in patients receiving carbamazepine may be found to be abnormal, particularly gamma glutamyl transferase. This is probably due to hepatic enzyme induction. Enzyme induction may also produce modest elevations in alkaline phosphatase. These enhancements of hepatic metabolising capacity are not an indication for the withdrawal of carbamazepine.<br />Severe hepatic reactions to carbamazepine occur very rarely. The development of signs and symptoms of liver dysfunction or active liver disease should be urgently evaluated and treatment with carbamazepine suspended pending the outcome of the evaluation.<br />Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for carbamazepine.<br />Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.<br />Serious dermatological reactions, including toxic epidermal necrolysis (TEN: also known as Lyell&#39;s syndrome) and Stevens Johnson syndrome (SJS) have been reported very rarely with carbamazepine. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal. Most of the SJS/TEN cases appear in the first few months of treatment with carbamazepine. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations. If signs and symptoms suggestive of severe skin reactions (e.g. SJS, Lyell&#39;s syndrome/TEN) appear, carbamazepine should be withdrawn at once and alternative therapy should be considered.<br />Cutaneous reactions<br />Serious and sometimes fatal cutaneous reactions including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with carbamazepine. These reactions are estimated to occur in 1-6 per 10 000 new users in countries with mainly Caucasian populations, but the risk in some Asian countries is estimated to be about 10 times higher.<br />There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions (see section 4.2).<br />HLA-B*1502 allele - in Han Chinese, Thai and other Asian populations<br />HLA-B*1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing Stevens-Johnson syndrome (SJS) when treated with carbamazepine. The prevalence of HLA-B*1502 carrier is about 10% in Han Chinese and Thai populations. Whenever possible, these individuals should be screened for this allele before starting treatment with carbamazepine (see section 4.2). If these individuals test positive, carbamazepine should not be started unless there is no other therapeutic option. Tested patients who are found to be negative for HLA-B*1502 have a low risk of SJS, although the reactions may still very rarely occur.<br />There are some data that suggest an increased risk of serious carbamazepine-associated TEN/SJS in other Asian populations. Because of the prevalence of this allele in other Asian populations (e.g. above 15% in the Philippines and Malaysia), testing genetically at risk populations for the presence of HLA-B*1502 may be considered.<br />The prevalence of the HLA-B*1502 allele is negligible in e.g. European descent, African, Hispanic populations sampled, and in Japanese and Koreans (&lt; 1%).<br />HLA-A*3101 allele - European descent and Japanese populations<br />There are some data that suggest HLA-A*3101 is associated with an increased risk of carbamazepine induced cutaneous adverse drug reactions including SJS, TEN, Drug rash with eosinophilia (DRESS), or less severe acute generalized exanthematous pustulosis (AGEP) and maculopapular rash (see section 4.8) in people of European descent and the Japanese.<br />The frequency of the HLA-A*3101 allele varies widely between ethnic populations. HLA-A*3101 allele has a prevalence of 2 to 5% in European populations and about 10% in Japanese population.<br />The presence of HLA-A*3101 allele may increase the risk for carbamazepine induced cutaneous reactions (mostly less severe) from 5.0% in general population to 26.0% among subjects of Northern European ancestry, whereas its absence may reduce the risk from 5.0% to 3.8%.<br />There are insufficient data supporting a recommendation for HLA-A*3101 screening before starting carbamazepine treatment.<br />If patients of European descent or Japanese origin are known to be positive for HLA-A*3101 allele, the use of carbamazepine may be considered if the benefits are thought to exceed risks.<br />Other dermatologic reactions<br />Mild skin reactions e.g. isolated macular or maculopapular exanthema, can also occur and are mostly transient and not hazardous. They usually disappear within a few days or weeks, either during the continued course of treatment or following a decrease in dosage. However, since it may be difficult to differentiate the early signs of more serious skin reactions from mild transient reactions, the patient should be kept under close surveillance with consideration given to immediately withdrawing the drug should the reaction worsen with continued use.<br />The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption).<br />Hypersensitivity<br />carbamazepine may trigger hypersensitivity reactions, including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), reactivation of HHV6 associated with DRESS, a delayed multi-organ hypersensitivity disorder with fever, rash, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leukopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), that may occur in various combinations. Other organs may also be affected (e.g.<br />lungs, kidneys, pancreas, myocardium, and colon) see section 4.8 Undesirable Effects.<br />In general, if signs and symptoms suggestive of hypersensitivity reactions occur, carbamazepine should be withdrawn immediately.<br />Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that 25-30 % of these patients may experience hypersensitivity reactions with oxacarbazepine.<br />Cross-hypersensitivity can occur between carbamazepine and phenytoin.<br />Carbamazepine should be used with caution in patients with mixed seizures which include absences, either typical or atypical. In all these conditions, carbamazepine may exacerbate seizures. In case of exacerbation of seizures, carbamazepine should be discontinued.<br />An increase in seizure frequency may occur during switchover from an oral formulation to suppositories.<br />Dose reduction and withdrawal effects<br />Abrupt withdrawal of carbamazepine may precipitate seizures therefore carbamazepine withdrawal should be gradual. If treatment with carbamazepine has to be withdrawn abruptly in a patient with epilepsy, the changeover to another anti-epileptic drug should if necessary be effected under the cover of a suitable drug.<br />Endocrinological effects<br />Breakthrough bleeding has been reported in women taking carbamazepine while using hormonal contraceptives. The reliability of hormonal contraceptives may be adversely affected by carbamazepine and women of childbearing potential should be advised to consider using alternative forms of birth control while taking carbamazepine.<br />Patients taking carbamazepine and requiring hormonal contraception should receive a preparation containing not less than 50&igrave;g oestrogen or use of some alternative non-hormonal method of contraception should be considered.<br />Monitoring of plasma levels<br />Although correlations between dosages and plasma levels of carbamazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma levels may be useful in the following conditions: dramatic increase in seizure frequency/verification of patient compliance; during<br />pregnancy; when treating children or adolescents; in suspected absorption disorders; in suspected toxicity when more than one drug is being used (see 4.5 Interaction with other Medicaments and other forms of Interaction).<br />Precautions<br />Carbamazepine should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with carbamazepine.<br />Baseline and periodic complete urinalysis and BUN determinations are recommended.<br />Hyponatremia<br />Hyponatremia is known to occur with carbamazepine. In patients with pre-existing renal conditions associated with low sodium or in patients treated concomitantly with sodium-lowering medicinal products (e.g. diuretics, medicinal products associated with inappropriate ADH secretion), serum sodium levels should be measured prior to initiating carbamazepine therapy. Thereafter, serum sodium levels should be measured after approximately two weeks and then at monthly intervals for the first three months during therapy, or according to clinical need. These risk factors may apply especially to elderly patients. If hyponatraemia is observed, water restriction is an important counter-measurement if clinically indicated.<br />Hypothyroidism<br />Carbamazepine may reduce serum concentrations of thyroid hormones through enzyme induction requiring an increase in dose of thyroid replacement therapy in patients with hypothyroidism. Hence thyroid function monitoring is suggested to adjust the dosage of thyroid replacement therapy.<br />Anticholinergic effects<br />Carbamazepine has shown mild anticholinergic activity; patients with increased intraocular pressure and urinary retention should therefore be closely observed during therapy (see section 4.8).<br />Psychiatric effects<br />The possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind.<br />Interactions<br />Co-administration of inhibitors of CYP3A4 or inhibitors of epoxide hydrolase with carbamazepine can induce adverse reactions (increase of carbamazepine or carbamazepine-10, 11 epoxide plasma concentrations respectively). The dosage of carbamazepine should be adjusted accordingly and/or the plasma levels monitored.<br />Co-administration of CYP3A4 inducers with carbamazepine may decrease carbamazepine plasma concentrations and its therapeutic effect, while discontinuation of a CYP3A4 inducer may increase carbamazepine plasma concentrations. The dosage of carbamazepine may have to be adjusted.<br />Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism. See section 4.5 Interactions.<br />Female patients of childbearing potential should be warned that the concurrent use of carbamazepine with hormonal contraceptives may render this type of contraceptive ineffective (see sections 4.5 Interactions and 4.6 Pregnancy and lactation). Alternative non-hormonal forms of contraception are recommended when using carbamazepine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytochrome P450 3A4 (CYP 3A4) is the main enzyme catalysing formation of the active metabolite carbamazepine 10, 11-epoxide. Co-administration of inhibitors of CYP 3A4 may result in increased carbamazepine plasma concentrations which could induce adverse reactions. Co-administration of CYP 3A4 inducers might increase the rate of carbamazepine metabolism, thus leading to potential decreases in the carbamazepine serum level and therapeutic effect.<br />Similarly, discontinuation of a CYP3A4 inducer may decrease the rate of metabolism of carbamazepine, leading to an increase in carbamazepine plasma levels.<br />Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of comedications mainly metabolized by CYP3A4 by induction of their metabolism.<br />Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. Co-administration of inhibitors of human<br />microsomal epoxide hydrolase may result in increased carbamazepine-10,11 epoxide plasma concentrations.<br />Interactions resulting in a contraindication<br />The use of Carbamazepine is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs); before administering Carbamazepine MAOIs should be discontinued for a minimum of 2 weeks, or longer if the clinical situation permits (see contraindications).<br />Agents that may raise carbamazepine plasma levels:<br />Since raised plasma carbamazepine levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Carbamazepine should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:<br />Analgesics, anti-inflammatory drugs: dextropropoxyphene.<br />Androgens: danazol.<br />Antibiotics: macrolide antibiotics (e.g. erythromycin, clarithromycin), ciprofloxacine.<br />Antidepressants: fluoxetine, fluvoxamine, paroxetine, trazodone.<br />Antiepileptics: vigabatrin.<br />Antifungals: azoles (e.g. itraconazole, ketoconazole, fluconazole, voriconazole). Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole.<br />Antihistamines: loratadine.<br />Antipsychotics: olanzapine.<br />Antituberculosis: isoniazid.<br />Antivirals: protease inhibitors for HIV treatment (e.g. ritonavir).<br />Carbonic anhydrase inhibitors: acetazolamide.<br />Cardiovascular drugs: diltiazem, verapamil.<br />Gastrointestinal drugs: possibly cimetidine, omeprazole.<br />Other interactions: grapefruit juice, nicotinamide (only in high dosage).<br />Agents that may raise the active metabolite carbamazepine-10,11-epoxide plasma levels:<br />Since raised plasma carbamazepine-10,11-epoxide levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Carbamazepine should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:<br />Quetiapine, primidone, progabide, valproic acid, valnoctamide and valpromide.<br />Agents that may decrease carbamazepine plasma levels:<br />The dose of Carbamazepine may have to be adjusted when used concomitantly with the substances described below:<br />Antiepileptics: oxcarbazepine, phenobarbital, phenytoin (to avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms /mL before adding carbamazepine to the treatment) and fosphenytoin, primidone, and, although the data are partly contradictory, possibly also clonazepam.<br />Antineoplastics: cisplatin or doxorubicin.<br />Antituberculosis: rifampicin.<br />Bronchodilatators or anti-asthma drugs: theophylline, aminophylline.<br />Dermatological drugs: isotretinoin.<br />Other interactions: herbal preparations containing St John&#39;s wort (Hypericum perforatum).<br />Effect of Carbamazepine on plasma levels of concomitant agents:<br />Carbamazepine may lower the plasma level, diminish or even abolish the activity of certain drugs. The dosage of the following drugs may have to be adjusted to clinical requirement:<br />Analgesics, anti-inflammatory agents: buprenorphine, methadone, paracetamol (long term administration of carbamazepine and paracetamol (acetaminophen) may be associated with hepatotoxicity), tramadol.<br />Antibiotics: doxycycline, rifabutin.<br />Anticoagulants: oral anticoagulants (e.g. warfarin and acenocoumarol).<br />Antidepressants: bupropion, citalopram, mianserin, sertraline, trazodone, tricyclic antidepressants (e.g. imipramine, amitriptyline, nortriptyline, clomipramine).<br />Antiemetics: aprepitant<br />Antiepileptics: clobazam, clonazepam, ethosuximide, lamotrigine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid, zonisamide. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms /mL before adding carbamazepine to the treatment. There have been rare reports of an increase in plasma mephenytoin levels.<br />Antifungals: itraconazole, voriconazole. Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole.<br />Antihelmintics: albendazole.<br />Antineoplastics: imatinib, cyclophosphamide, lapatinib, temsirolimus.<br />Antipsychotics: clozapine, haloperidol and bromperidol, olanzapine, quetiapine, risperidone, aripiprazole, paliperidone.<br />Antivirals: protease inhibitors for HIV treatment (e.g. indinavir, ritonavir, saquinavir).<br />Anxiolytics: alprazolam.<br />Bronchodilatators or anti-asthma drugs: theophylline.<br />Contraceptives: hormonal contraceptives (alternative contraceptive methods should be considered).<br />Cardiovascular drugs: calcium channel blockers (dihydropyridine group) e.g. felodipine, digoxin, simvastatin, atorvastatin, lovastatin, cerivastatin, ivabradine.<br />Corticosteroids: corticosteroids (e.g. prednisolone, dexamethasone).<br />Drugs used in erectile dysfunction: tadalafil.<br />Immunosuppressants: ciclosporin, everolimus, tacrolimus, sirolimus.<br />Thyroid agents: levothyroxine.<br />Other drug interactions: products containing oestrogens and/or progesterones.<br />Combinations that require specific consideration:<br />Concomitant use of carbamazepine and levetiracetam has been reported to increase carbamazepine-induced toxicity.<br />Concomitant use of carbamazepine and isoniazid has been reported to increase isoniazid-induced hepatotoxicity.<br />The combination of lithium and carbamazepine may cause enhanced neurotoxicity in spite of lithium plasma concentrations being within the therapeutic range. Combined use of carbamazepine with metoclopramide or major tranquillisers, e.g. haloperidol, thioridazine, may also result in an increase in neurological side-effects.<br />Concomitant medication with Carbamazepine and some diuretics (hydrochlorothiazide, furosemide) may lead to symptomatic hyponatraemia.<br />Carbamazepine may antagonise the effects of non-depolarising muscle relaxants (e.g. pancuronium). Their dosage should be raised and patients monitored closely for a more rapid recovery from neuromuscular blockade than expected.<br />Carbamazepine, like other psychoactive drugs, may reduce alcohol tolerance. It is therefore advisable for the patient to abstain from alcohol.<br />Interference with serological testing<br />Carbamazepine may result in false positive perphenazine concentrations in HPLC analysis due to interference.<br />Carbamazepine and the 10,11-epoxide metabolite may result in false positive tricyclic antidepressant concentration in fluorescence polarized immunoassay method.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy category D<br />Offspring of epileptic mothers with untreated epilepsy are known to be more prone to developmental disorders, including malformations. Developmental disorders and malformations, including spina bifida, and also other congenital anomalies e.g. craniofacial defects such as clept lip/palate, cardiovascular malformations, hypospadias and anomalies involving various body systems, have been reported in<br />association with the use of Carbamazepine. Patients should be counselled regarding the possibility of an increased risk of malformations and given the opportunity of antenatal screening. Based on data in a North American pregnancy registry, the rate of major congenital malformations, defined as a structural abnormality with surgical, medical, or cosmetic importance, diagnosed within 12 weeks of birth was 3.0% (95% CI 2.1 to 4.2%) among mothers exposed to carbamazepine monotherapy in the first trimester and 1.1% (95% CI 0.35 to 2.5%) among pregnant women not taking any antiepileptic drug (relative risk 2.7, 95% CI 1.1 to 7.0).<br />Taking these data into consideration:<br />- Pregnant women with epilepsy should be treated with special care.<br />- If women receiving Carbamazepine become pregnant or plan to become pregnant, or if the problem of initiating treatment with Carbamazepine arises during pregnancy, the drug&#39;s expected benefits must be carefully weighed against its possible hazards, particularly in the first 3 months of pregnancy.<br />- In women of childbearing potential Carbamazepine should, wherever possible, be prescribed as monotherapy, because the incidence of congenital abnormalities in the offspring of women treated with a combination of antiepileptic drugs is greater than in those of mothers receiving the individual drugs as monotherapy. The risk of malformations following exposure to carbamazepine as polytherapy may vary depending on the specific drugs used and may be higher in polytherapy combinations that include valproate.<br />- Minimum effective doses should be given and monitoring of plasma levels is recommended. The plasma concentration could be maintained in the lower side of the therapeutic range 4 to 12 micrograms/mL provided seizure control is maintained. There is evidence to suggest that the risk of malformation with carbamazepine may be dose-dependent i.e. at a dose &lt; 400mg per day, the rates of malformation were lower than with higher doses of carbamazepine.<br />- Patients should be counseled regarding the possibility of an increased risk of malformations and given the opportunity of antenatal screening.<br />- During pregnancy, an effective antiepileptic treatment should not be interrupted, since the aggravation of the illness is detrimental to both the mother and the fetus.<br />Monitoring and prevention<br />Folic acid deficiency is known to occur in pregnancy. Antiepileptic drugs have been reported to aggravate deficiency. This deficiency may contribute to the increased incidence of birth defects in the offspring of treated epileptic women.<br />Folic acid supplementation has therefore been recommended before and during pregnancy.<br />In the neonate<br />In order to prevent bleeding disorders in the offspring, it has also been recommended that vitamin K1 be given to the mother during the last weeks of pregnancy as well as to the neonate.<br />There have been a few cases of neonatal seizures and/or respiratory depression associated with maternal Carbamazepine and other concomitant antiepileptic drug use. A few cases of neonatal vomiting, diarrhoea and/or decreased feeding have also been reported in association with maternal Carbamazepine use. These reactions may represent a neonatal withdrawal syndrome.<br />Women of child-bearing potential and contraceptive measures<br />Due to enzyme induction, Carbamazepine may result in a failure of the therapeutic effect of oral contraceptive drugs containing oestrogen and/or progesterone. Women of child bearing potential should be advised to use alternative contraceptive methods while on treatment with Carbamazepine.<br />Breast-feeding:<br />Carbamazepine passes into the breast milk (about 25-60% of the plasma concentrations). The benefits of breast-feeding should be weighed against the remote possibility of adverse effects occurring in the infant. Mothers taking Carbamazepine may breast-feed their infants, provided the infant is observed for possible adverse reactions (e.g. excessive somnolence, allergic skin reaction). There have been some reports of cholestatic hepatitis in neonates exposed to carbamazepine during antenatal and or during breast feeding. Therefore breast-fed infants of mothers treated with carbamazepine should be carefully observed for adverse hepatobiliary effects.<br />Fertility:<br />There have been very rare reports of impaired male fertility and/or abnormal spermatogenesis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&#39;s ability to react may be impaired by the medical condition resulting in seizures and adverse reactions including dizziness, drowsiness, ataxia, diplopia, impaired accommodation and blurred vision reported with Carbamazepine, especially at the start of treatment or in connection with dose adjustments. Patients<br />should therefore exercise due caution when driving a vehicle or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Particularly at the start of treatment with Carbamazepine, or if the initial dosage is too high, or when treating elderly patients, certain types of adverse reaction occur very commonly or commonly, e.g. CNS adverse reactions (dizziness, headache, ataxia, drowsiness, fatigue, diplopia); gastrointestinal disturbances (nausea, vomiting), as well as allergic skin reactions.<br />The dose-related adverse reactions usually abate within a few days, either spontaneously or after a transient dosage reduction. The occurrence of CNS adverse reactions may be a manifestation of relative overdosage or significant fluctuation in plasma levels. In such cases it is advisable to monitor the plasma levels and divide the daily dosage into smaller (i.e. 3-4) fractional doses.<br />Tabulated summary of adverse drug reactions compiled from clinical trials and from spontaneous reports<br />Adverse drug reactions from clinical trials are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:</p></td><td style="vertical-align:top"><p>leucopenia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>thrombocytopenia, eosinophilia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>leucocytosis, lymphadenopathy.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>agranulocytosis, aplastic anaemia, pancytopenia, aplasia pure red cell, anaemia, anaemia megaloblastic, reticulocytosis, haemolytic anaemia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known:</em></p></td><td style="vertical-align:top"><p>bone marrow depression.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare: </em></p></td><td style="vertical-align:top"><p>a delayed multi-organ hypersensitivity disorder with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leucopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts) occurring in various combinations. Other organs may also be affected (e.g. liver<strong>, </strong>lungs, kidneys, pancreas, myocardium, colon).</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>anaphylactic reaction, oedema angioedema, hypogammaglobulinaemia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>reactivation of Human herpesvirus 6 infection.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Endocrine disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em>:</p></td><td style="vertical-align:top"><p>Oedema, fluid retention, weight increase, hyponatraemia and blood osmolarity decreased due to an antidiuretic hormone (ADH)-like effect, leading in rare cases to water intoxication accompanied by lethargy, vomiting, headache, confusional state, neurological disorders.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>galactorrhoea, gynaecomastia,</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>folate deficiency, decreased appetite.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>porphyria acute (acute intermittent porphyria and variegate porphyria), porphyria non-acute (porphyria cutanea tarda).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>hallucinations (visual or auditory), depression, aggression, agitation, restlessness, confusional state.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>activation of psychosis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common: </em></p></td><td style="vertical-align:top"><p>ataxia, dizziness, somnolence.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common: </em></p></td><td style="vertical-align:top"><p>diplopia, headache.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon: </em></p></td><td style="vertical-align:top"><p>abnormal involuntary movements (e.g. tremor, asterixis, dystonia, tics), nystagmus.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare: </em></p></td><td style="vertical-align:top"><p>dyskinesia, eye movementdisorder, speech disorders (e.g. dysarthria or slurred speech), choreoathetosis, neuropathy peripheral, paraesthesia, and paresis.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, aseptic meningitis with myoclonus and peripheral eosinophilia, dysgeusia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>sedation, memory impairment</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common: </em></p></td><td style="vertical-align:top"><p>accommodation disorders (e.g. blurred vision)</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>lenticular opacities, conjunctivitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>hearing disorders, e.g. tinnitus, hyperacusis, hypoacusis, change in pitch perception.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare: </em></p></td><td style="vertical-align:top"><p>cardiac conduction disorders.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>arrhythmia, atrioventricular block with syncope, bradycardia, cardiac failure congestive, coronary artery disease aggravated.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>hypertension or hypotension.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very Rare:</em></p></td><td style="vertical-align:top"><p>circulatory collapse, embolism (e.g. pulmonary embolism), thrombophlebitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>pulmonary hypersensitivity characterised e.g. by fever, dyspnoea, pneumonitis or pneumonia.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastro-intestinal disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:</p></td><td style="vertical-align:top"><p>vomiting, nausea.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common: </em></p></td><td style="vertical-align:top"><p>dry mouth, with suppositories rectal irritation may occur.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon: </em></p></td><td style="vertical-align:top"><p>diarrhoea, constipation.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>abdominal pain.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>Pancreatitis, glossitis, stomatitis,.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>colitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare: </em></p></td><td style="vertical-align:top"><p>hepatitis of cholestatic, parenchymal (hepatocellular) or mixed type, vanishing bile duct syndrome, jaundice.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>hepatic failure, granulomatous liver disease.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders:</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:</p></td><td style="vertical-align:top"><p>urticaria, which may be severe dermatitus allergic,</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em>:</p></td><td style="vertical-align:top"><p>dermatitis exfoliative.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>systemic lupus erythematosus, pruritus.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em>:</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome*, toxic epidermal necrolysis, photosensitivity reaction, erythema multiforme, erythema nodosum, pigmentation disorder, purpura, acne, hyperhydrosis, alopecia, hirsutism.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>Acute Generalized Exanthematous Pustulosis (AGEP)**, lichenoid keratosis, onychomadesis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeletal, connective tissue and bone disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>muscular weakness.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em>:</p></td><td style="vertical-align:top"><p>bone metabolism disorders (decrease in plasma calcium and blood 25-hydroxy-cholecalciferol) leading to osteomalacia/osteoporosis, arthralgia, myalgia, muscle spasms.</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>fracture.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em>:</p></td><td style="vertical-align:top"><p>tubulointerstitial nephritis, renal failure, renal impairment (e.g. albuminuria, haematuria, oliguria and blood urea/ azotaemia), urinary retention, urinary frequency.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Reproductive System</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>sexual disturbances/erecticle dysfunction spermatogenesis abnormal (with decreased sperm count and/or motility).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common: </em></p></td><td style="vertical-align:top"><p>fatigue.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common:</em></p></td><td style="vertical-align:top"><p>gamma-glutamyltransferase increased (due to hepatic enzyme induction), usually not clinically relevant.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>blood alkaline phosphatase increased.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>transaminases increased.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>intraocular pressure increased, blood cholesterol increased, high density lipoprotein increased, blood triglycerides increased. Thyroid function test abnormal: decreased L-Thyroxin (free thyroxine, thyroxine, tri-iodothyronine) and increased blood thyroid stimulating hormone, usually without clinical manifestations, blood prolactin increased,</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>bone density decreased.</p></td></tr></tbody></table><p>* In some Asian countries also reported as rare. See also section 4.4 Special warnings and precautions for use.<br />**Additional adverse drug reactions from spontaneous reports (frequency not known)<br />The following adverse drug reactions have been derived from post-marketing experience with Carbamazepine via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.<br />There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with carbamazepine. The mechanism by which carbamazepine affects bone metabolism has not been identified.<br />There is increasing evidence regarding the association of genetic markers and the occurrence of cutaneous ADRs such as SJS, TEN, DRESS, AGEP and maculopapular rash. In Japanese and European patients, these reactions have been reported to be associated with the use of carbamazepine and the presence of the HLA-A*3101 allele. Another marker, HLA-B*1502 has been shown to be strongly associated with SJS and TEN among individuals of Han Chinese, Thai and some other Asian ancestry (see sections 4.2 and 4.4 for further information).<br /><strong>To report any side effects:</strong><br />National Pharmacovigilance and Drug Safety Centre (NPC)<br />oFax: + 966-11-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340<br />oToll free phone: 8002490000<br />oEmail: npc.drug@sfda.gov.sa<br />oWebsite: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms<br />The presenting signs and symptoms of overdosage involve the central nervous, cardiovascular, respiratory systems and the adverse drug reactions mentioned under section 4.8.<br />Central nervous system: CNS depression; disorientation, depressed level of consciousness, somnolence, agitation, hallucination, coma; blurred vision, slurred speech, dysarthria, nystagmus, ataxia, dyskinesia, initially hyperreflexia, later hyporeflexia; convulsions, psychomotor disturbances, myoclonus, hypothermia, mydriasis.<br />Respiratory system: Respiratory depression, pulmonary oedema.<br />Cardiovascular system: Tachycardia, hypotension and at times hypertension, conduction disturbance with widening of QRS complex; syncope in association with cardiac arrest.<br />Gastro-intestinal system: Vomiting, delayed gastric emptying, reduced bowel motility.<br />Musculoskeletal system: There have been some cases which reported rhabdomyolysis in association with carbamazepine toxicity.<br />Renal function: Retention of urine, oliguria or anuria; fluid retention, water intoxication due to ADH-like effect of carbamazepine.<br />Laboratory findings: Hyponatraemia, possibly metabolic acidosis, possibly hyperglycaemia, increased muscle creatine phosphokinase.<br />Treatment<br />There is no specific antidote.<br />Management should initially be guided by the patient&#39;s clinical condition; admission to hospital. Measurement of the plasma level to confirm carbamazepine poisoning and to ascertain the size of the overdose.<br />Evacuation of the stomach, gastric lavage, and administration of activated charcoal. Delay in evacuating the stomach may result in delayed absorption, leading to relapse during recovery from intoxication. Supportive medical care in an intensive care unit with cardiac monitoring and careful correction of electrolyte imbalance.<br />Special recommendations:<br />Charcoal haemoperfusion has been recommended. Hemodialysis is the effective treatment modality in the management of the carbamazepine overdose.<br />Relapse and aggravation of symptomatology on the 2nd and 3rd day after overdose, due to delayed absorption, should be anticipated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapeutic class: Anti-epileptic, neurotropic and psychotropic agent; (ATC Code: N03 AF01). Dibenzazepine derivative.<br />As an antiepileptic agent its spectrum of activity embraces: partial seizures (simple and complex) with and without secondary generalisation; generalised tonic-clonic seizures, as well as combinations of these types of seizures.<br />The mechanism of action of carbamazepine, the active substance of Carbatol&reg; , has only been partially elucidated. Carbamazepine stabilises hyperexcited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses. It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarised neurons via use- and voltage-dependent blockade of sodium channels may be its main mechanism of action.<br />Whereas reduction of glutamate release and stabilisation of neuronal membranes may account for the antiepileptic effects, the depressant effect on dopamine and noradrenaline turnover could be responsible for the antimanic properties of carbamazepine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Carbamazepine is absorbed almost completely but relatively slowly from the tablets. The conventional tablets yield mean peak plasma concentrations of the unchanged substance within 12 hours (chewable tablets 6 hours; syrup 2 hours) following single oral doses. With respect to the amount of active substance absorbed, there is no clinically relevant difference between the oral dosage forms. After a single oral dose of 400mg carbamazepine (tablets) the mean peak concentration of unchanged carbamazepine in the plasma is approx. 4.5&igrave;g/ml.<br />The bioavailability of carbamazepine in various oral formulations has been shown to lie between 85-100%.<br />Ingestion of food has no significant influence on the rate and extent of absorption, regardless of the dosage form of carbamazepine.<br />Steady-state plasma concentrations of carbamazepine are attained within about 1-2 weeks, depending individually upon auto-induction by carbamazepine and hetero-induction by other enzyme-inducing drugs, as well as on pre-treatment status, dosage, and duration of treatment.<br />Different preparations of carbamazepine may vary in bioavailability; to avoid reduced effect or risk of breakthrough seizures or excessive side effects, it may be prudent to avoid changing the formulation.<br />Distribution<br />Carbamazepine is bound to serum proteins to the extent of 70-80%. The concentration of unchanged substance in cerebrospinal fluid and saliva reflects the non-protein bound portion in plasma (20-30%). Concentrations in breast milk were found to be equivalent to 25-60% of the corresponding plasma levels.<br />Carbamazepine crosses the placental barrier. Assuming complete absorption of carbamazepine, the apparent volume of distribution ranges from 0.8 to 1.9 L/kg.<br />Biotransformation<br />Carbamazepine is metabolised in the liver, where the epoxide pathway of biotransformation is the most important one, yielding the 10, 11-transdiol derivative and its glucuronide as the main metabolites.<br />Cytochrome P450 3A4 has been identified as the major isoform responsible for the formation of carbamazepine 10, 11-epoxide from carbamazepine. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. 9-Hydroxy-methyl-10-carbamoyl acridan is a minor metabolite related to this pathway. After a single oral dose of carbamazepine about 30% appears in the urine as end-products of the epoxide pathway.<br />Other important biotransformation pathways for carbamazepine lead to various monohydroxylated compounds, as well as to the N-glucuronide of carbamazepine produced by UGT2B7.<br />Elimination<br />The elimination half-life of unchanged carbamazepine averages approx. 36 hours following a single oral dose, whereas after repeated administration it averages only 16-24 hours (auto-induction of the hepatic mono-oxygenase system), depending on the duration of the medication. In patients receiving concomitant treatment with other enzyme-inducing drugs (e.g. phenytoin, phenobarbitone), half-life values averaging 9-10 hours have been found.<br />The mean elimination half-life of the 10, 11-epoxide metabolite in the plasma is about 6 hours following single oral doses of the epoxide itself.<br />After administration of a single oral dose of 400mg carbamazepine, 72% is excreted in the urine and 28% in the faeces. In the urine, about 2% of the dose is recovered as unchanged drug and about 1% as the pharmacologically active 10, 11-epoxide metabolite.<br />Characteristics in patients<br />The steady-state plasma concentrations of carbamazepine considered as &ldquo;therapeutic range&rdquo; vary considerably inter-individually; for the majority of patients a range between 4-12&igrave;g/ml corresponding to 17-50&igrave;mol/l has been reported. Concentrations of carbamazepine 10, 11-epoxide (pharmacologically active metabolite): about 30% of carbamazepine levels.<br />Owing to enhanced carbamazepine elimination, children may require higher doses of carbamazepine (in mg/kg) than adults to maintain therapeutic concentrations.<br />There is no indication of altered pharmacokinetics of carbamazepine in elderly patients as compared with young adults.<br />No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, local tolerance, genotoxicity and carcinogenic potential. Reproductive toxicity studies in animals were insufficient to rule out a teratogenic effect of carbamazepine in humans.<br />Carcinogenicity<br />In rats treated with carbamazepine for two years, there was an increased incidence of hepatocellular tumours in females and benign testicular tumours in males. However, there is no evidence to date that these observations are of any relevance to the therapeutic use of carbamazepine in humans.<br />Reproductive toxicity<br />In animals studies in mice, rats and rabbits oral administration of carbamazepine during organogenesis led to increased embryo-fetal mortality and fetal growth retardation at daily doses which were associated with maternal toxicity (above 200mg/kg/day). Carbamazepine was teratogenic in a number of studies, particularly in mice, however showed no or only minor teratogenic potential at doses relevant to humans. In a reproduction study in rats, nursing offspring demonstrated a reduced weight gain at a maternal dosage level of 192 mg/kg/day.<br />Fertility<br />In chronic toxicity studies dose related testicular atrophy and aspermatogenesis occurred in rats receiving carbamazepine. The safety margin for this effect is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, silica colloidal anhydrous, sodium starch glycolate, magnesium stearate, sodium laurilsulfate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a dry place. Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate package: PVDC/ Alum. Foil.<br />Outer package: Outer carton and insert.<br />Carbatol&reg; Tablets are available in aluminum foil in packs of 30 ( 3 strips of 10 ), 50 ( 5 strips of 10 ) , 300 ( 30 strips of 10 ) and 500 ( 50 strips of 10 ).<br />Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Note: Carbatol&reg; must be kept out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O.Box 9364
Na’ur - Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/02/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAABAAAAAQACAYAAAB/HSuDAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAyZpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8&#x2B;IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDcuMC1jMDAwIDc5LmRhYmFjYmIsIDIwMjEvMDQvMTQtMDA6Mzk6NDQgICAgICAgICI&#x2B;IDxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI&#x2B;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&#x2B;IDwvcmRmOlJERj4gPC94OnhtcG1ldGE&#x2B;IDw/eHBhY2tldCBlbmQ9InIiPz71K8oCAAIEpklEQVR42uzdB3RU95n38WeKupBEE9WAKKYIUQ2YZjDgho2JjYPjOMROvLazqU42S&#x2B;JNsJ3d92RzknM2cYrfxM46zjqxN&#x2B;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&#x2B;gyWTiWQcAAAAAQKUoyoB9LUYAAAAAAAAwDBAAAAAAAAAwDFh5CgAMEn/7gRSeQgAAAIAAAMDQLOr7&#x2B;2sRGgAAAIAAAACCtNAfiO&#x2B;bYAAAAAAEAAAwhAt&#x2B;f34&#x2B;QgEAAAAQAACg6A&#x2B;Cf88bJcDfL4EAAAAACAAAUPjrfLzJx38n0MW3EqCfi1AAAAAABAAAhk3Rb/Ljuv78/kxuCnQlgMU8owQAAABAAAAgZAt/PcW9qZ&#x2B;&#x2B;tjeKzu9V0REKEAgAAACAAADAsCv8TQY/D9RjjRb&#x2B;ntoGFC/fg2Lg6/jzPBMKAAAAgAAAQFAV/X0fo7dwN&#x2B;l8fKBCAHdD&#x2B;k1u7qPoCA/0fh1GCQAAAIAAAMCQLfxNBkIAd7frvV8gAgBPRb23n6&#x2B;nqFd0BAJ6RgkQCAAAAIAAAMCQKvz1Fv0mP&#x2B;/jaxigeCnOPRXVSp/iv/f93Y0UUHx8Tn0p6GkbAAAAAAEAgIAX/UYKf28FvdHbff1&#x2B;vT3OXeGuuCj2PRXYfUMBXwIB2gYAAAAQPMWCogzs60iTycSzDgx&#x2B;4a&#x2B;nOHd1m8ngbd7CAH8DAUVH8e/qdsXL4xUD/4a3glzv9&#x2B;QPAgEAAIAhaiBrckYAAMO38Pf13X53Rb&#x2B;e642EAf4GAK4KdpN88l15T7crbu4j4rltQPHw8zGPAAAAAAYFAQBA4S9&#x2B;FvcmD4W&#x2B;kSDA23WKwYLZ07v5eot&#x2B;b4GBq&#x2B;&#x2B;VeQQAAABAAABgQIt&#x2B;EWMz9Lt7t99TYe/tOiNhgtGf1ZfCv&#x2B;dzb6GAq6Jf8RJMMI8AAAAACAAADGjhH6hh/iYv1&#x2B;m9j68hgC9Fq953/V3d5ul6k5d/y1MgYLRtgOUHAQAAQAAAUPgHvPD3VpT7EgQYCQFMPv6sRot/PUW&#x2B;3sKftgEAAAAQAAAI&#x2B;sI/UO/2&#x2B;/u5kQDApLMg1fvuv97i392/SdsAAAAACAAADErRL&#x2B;J9hn09hb&#x2B;rd&#x2B;rNOov6/ggATDqKfX8CAH&#x2B;u6xseeBoJIB6&#x2B;L1/aBvQEArQNAAAAgAAACKHC35f&#x2B;fj3D/I0U&#x2B;mYfAwF31xl9ThSdIYCRYt/IKAFf5hHQ0zZgZISACG0DAAAAIAAAhnXhr3c2f18KfbOXx&#x2B;gNFYz8bO6KTE8hgNFCXvEzJPAWOri6PlDzCPR9rNFAgLYBAAAAAgAAg1T0uyuIfVnGz9vQfyMFvdHNVYDgbYSCLwGALz3/ej8XH0ICb1/f5CUQcPV4kYFrGyAQAAAAIAAA0M&#x2B;Ff3/193v73OzlsllHse8tSPD0vfgakuhZ3s/IEH/tY5cfoYEv17n7vj3NIxCotgHFzb6nZx4BXwp6AgEAAAACAIDCX8dlEf&#x2B;W8fP0zryry&#x2B;4KfLOH6zxd1jM3gN7nzteh/3o&#x2B;N4vxUQJGRg14us7TzxBsyw8GYpQA8wgAAAAQAPQvReH15U3PxyWzmEZ&#x2B;XpS63w/wF1a3UU&#x2B;LadKroVHxq/wMCvzp79c7AkDv5q7Yd3U/TyMBPI4KGDFihPk73/nOzEcffXRLUlLSZvVvs6Opqamotra28MyZM0eysrIqX3nllfzy8vJ2D4WtqzDAl6Ld1ef&#x2B;/ltGQwIRlh809Tlec8AGgGH8mr3vy6ue67SPXV1dYrFYHB&#x2B;d99Ouc55&#x2B;zGaz4/qej9rZRLuL9tFqtUhHR6f6WOdtXV3Kx493nnW0z83d/57SfUJTr9NOUSZxfv0uxXGd9oDeX0u7rVP7et3fk3bZrP1bJkUsZqu0d7R/Irrv&#x2B;d46O53/huNnlJ7bFMfjbc3NEh0d1ev7vvE8xI2Ilbr6RgkPtzpuv/F4U/dl5xfQHnPj&#x2B;XA&#x2B;vrOzU/331Z&#x2B;s&#x2B;&#x2B;tq30zPt9fW3u54fns/x13OJ1giwsOlra3N&#x2B;cKj1&#x2B;&#x2B;k9&#x2B;&#x2B;o5&#x2B;dR/&#x2B;e43PN458/Y/fvQ/uv&#x2B;vrTvRbtPZGSENDfb1a9r6v5ete/G&#x2B;TvUNu370e6rPQ/t7R1i1r6/zg7HY6OiokR9LSlhYWGO50L7dzvU27THmLt/Xs20qVMIAAAMWOE/EMv4GQkB9Lyz37vYN3J/l0HAyJEjrW&#x2B;99dbdCxcuXDtu3LiV6sE5vOcHS0hISNG2pKSkB9QTSOc3vvGNPJvNVpmRkXFclXXs2LHKffv21bkpevVO4Beoot&#x2B;fAMDbfUQGtm3A0zwCru4/IMsP9v37IhAAAAAgAACGWuE/kMv46e3p91TQ6wkCvLUOmNSCP/all15auXHjxs&#x2B;NGDEiqddt7p5jS1xc3CxtmzBhwupNmzZJS0tLRW1tbV5lZWXBnj17juTl5dX97ne/K9NZbHvq&#x2B;e&#x2B;PgMDI5yK&#x2B;zy1gkqHRNuB3KODq745QAAAAgAAAGMqFf38s4&#x2B;ftnX93Rb7Jw/V6WgRkzZo1CT/72c&#x2B;23XrrrevVwn&#x2B;qP89/VFTUOG2bOHHiykWLFj3W0dHR8sMf/jCjoaGh4uTJk6cOHjyYv3///qqysrI2DwV1l47iXm9YoOc22gbcF/9&#x2B;tw0wSgAAAIAAABjMot9dsT9Yy/jpGbZv1lHoe/p40781bdq0yOnTp0e//vrrXxs3blxKZGTkmH45kFmtUePHj79N3eTWW2&#x2B;9f8eOHZ319fV51dXVBfn5&#x2B;VcPHTqUfuDAgbKzZ8826Sz2PYUAnoIDb5MHGgkIxMf7iOhrG1B0FO&#x2B;KjkCAtgEAAAACAGDYFv7BuIyfu6H&#x2B;7gIAvz4uWbJkxBe&#x2B;8IXZ27dv/8yYMWMWmM3msAH&#x2B;nVkSEhJmadvMmTPvUskLL7xQef369Zzi4uKcixcvXn3rrbcyU1NTG2w2W1efot7bZYsYaxvofb9ArC4wkMsP0jYAAABAAABQ&#x2B;Hsp/INpGT9vk/kZ/ejyNqvVahk1apR19&#x2B;7d2xYtWrQxPj5&#x2B;ejD9PqOiohInT56sbatWrlwp//AP/2CrqqrKLC0tvZqTk5P/yiuvnM/OzraVl5e3uSjmuwwU/npHDHi7zZfPxUBIIELbAKMEAAAAAQBA4T/ghb&#x2B;v/f3ehvx7muDPSIHv9vqYmBjLjh07bnn22WfvmTNnzsbIyMjRQ&#x2B;LgZ7XGTJgwYam23Xbbbcojjzxit9lsFXl5eWeqq6sr//znP6fu3bu3vKSkpFX8axuweCj0zRL4iQZFAts24G0kgHgo&#x2B;n1pG9ATCNA2AAAAQAAADErRLxK8y/jpmbyv70eLh1Dgptv&#x2B;8Ic/rFu&#x2B;fPntSUlJq7U&#x2B;/KG8C2jff3x8/LTFixdP067YsGGDXZtcsKio6GxJSUn&#x2B;2bNns1999dWsnJyc5u7HGG0b0DPpoEjgRwUEY9uAkRECIrQNAAAAEAAAg1z4D4Vl/Dz1&#x2B;Xsq9M1uPjfNnDkz5te//vXmlJSU1YmJifNDdd&#x2B;wWCyR2jZr1qy71E3Wr1/f8fWvf72xtra2IDc392J&#x2B;fn7xO&#x2B;&#x2B;8c2XPnj3VHR0dPUV731YBd5c9hQD9MSogUMsPivjeNhCIeQT6XjYSCNA2AAAACAB4CkDh32&#x2B;Ff7At4&#x2B;dtuL9ZPLzr//jjj0967rnn7r311ltXxcXFTRmG&#x2B;4w1IiJi5Pjx47Vt8erVq2X79u0Ndru9trCw8HxOTk720aNHc995550S9XO7BH61AT0rCAzk8oMixtsGBnMeAVf3IxAAAAAEAABFv8difygs49f3Pnr6&#x2B;j8xMkAteC1q0T/r2Wef/fSkSZMWhoeHJ7An3aA&#x2B;H3HalpKSMlXd5MEHH2z713/91&#x2B;uVlZXZubm56ampqXkHDhwo2r9/f02fot7XuQPchQB62wZ8nTegv9sGxMX34K1twOjyg67&#x2B;NplHAAAAEAAAw7zwD8Zl/FwV/kaX8fNa8PdsY8eODf/FL36xbuPGjfcnJCQkWa3WaPYk7ywWS3hMTMyEpKQkbbtj06ZN8rWvfa2qsbHxWlFRUeapU6cuXrp0qfz3v/99sd1uV1wU9X0vh0LbgKf2AHeBAMsPAgAAEAAAA1b4h&#x2B;Iyfu4K/o&#x2B;vmzRpUuTbb7/9yPz581ePHDlyJnuR/6KiosZqW2Ji4sLbbrvtUW1iwR/&#x2B;8IdFZWVlWYcOHTqemZlZ/eqrrxb1mkcgEJuI97YBPS0Fej43GhKIsPwgowQAAAABADCEC/9gXsbPIh56/uPi4sK2bt06/vvf//5nx48fP3s49vcP6EHXao0aNWrUbG1LTk5&#x2B;sKurq/0HP/hBTmNjY9W5c&#x2B;dOnj59uuBvf/tbaVpamq37IUaCgd7391To9x414G9A4M99RALbNuAtEDDaNsDygwAAgAAACLGiX6T/&#x2B;vvNMrjL&#x2B;LlqAXBcpxb64f/2b/&#x2B;2cNu2bQ&#x2B;rhX&#x2B;KNuM9e9LAM5vNYWPGjJmrbVrbwCOPPKK88MILJTU1NSXFxcVZx44dS9&#x2B;/f3/xgQMHrrsozvUuOeithcDV/bwFBAO9/KBJaBsAAAAgAACFv4&#x2B;F/1BZxs9TAOCur9/dbWa12I/47W9/e8&#x2B;yZcs2JCYmJrMXBd9uHRsbe4u2TZkyZaW22sBzzz1XX1tbm19eXp579erV7LfeeitN1ZCXl&#x2B;dqtQEjcwcYmUxQ70SDej8XoW3A52MdgQAAACAAAIV/YAv/UFjG7&#x2B;Nty5YtY//pn/7prgULFqwdOXLkDPaioSM8PDx&#x2B;3Lhxi7Rt4cKFsm3btjZtYsGSkpL0ioqKknfffffckSNHKi9fvtzs51wCFg&#x2B;FvtlLUW80IBAf7&#x2B;Ou&#x2B;Pe0/GB/tQ34svygu5CAQAAAABAAAH4U/e6K/cFaxs/du/x6AgCfZ/X//ve/P2f79u0bZ86cuSYqKmo0e9LQZzabw&#x2B;Pj46dpW3Jystx5550dra2t9WVlZenXrl0rOH/&#x2B;fOZPf/rT9OvXr7fV19d3iutWAXeX9Y4ekD738xYQDEbbgIj/bQNGRgiI0DYAAAAIAIABLfyH/TJ&#x2B;2vbmm2&#x2B;uW7169ZqpU6ferhWM7Ekh/TdijYyMHJ2UlLRO21atWqU8&#x2B;&#x2B;yzjWrxX5ydnX22vLy88rXXXjt36tSp&#x2B;pqamnZx3SrgqvDXEwK4e&#x2B;e/P5YfFAMhgYjvbQP&#x2B;ziPQ97FGAwHaBgAAAAEAKPwNFP7BtIyf0Vn8fV7GLyIiwvLBBx88PH/&#x2B;/OXacHH2ouH7txMWFhY3ZsyYZG3TrnvggQeaWltbG/Lz808XFxcXfvjhh1dffvnlbPU6f5cftPgYAvTX8oMigWkb8GcegUC3DRAIAAAAAgBQ&#x2B;Aew8A/mZfw&#x2B;MYN/3&#x2B;ueeeaZqV/60pfumTVr1qrY2NiJ7EXoKywsLFbbUlJSPqVucs8997Tu2rWruqKiIjMnJ&#x2B;dKampq/ttvv5176dKlpu6HGG0b0LPygIjxuQK6vBT3A902IG6K/UC0DSgejmXMIwAAAAgAMGyLfnfFfrAt4ydi/N1&#x2B;i5cA4OP7vfLKK8vvvffejbfccssyq9Uaw54EvSwWS0RsbOwkbZsxY8bGu&#x2B;&#x2B;&#x2B;u/O5556rraurK8zNzU1LT0/PPXjwYMH7779f2WtiQU9tA3rnDvA0V4Crgj4QyxGKjyGBiPdlCVl&#x2B;EAAAEAAAepgXaC9qX/O36Hf14nioLuPn9R3/jRs3jt6xY8f8&#x2B;&#x2B;&#x2B;//&#x2B;ExY8bMYy9CIKi1nyUqKmqMtk2YMGHpmjVr5Kmnnmqw2WyVpaWl2giB8xkZGeWvvfZafq95BAKxiXgeMeDttkC0DbD8oM5QgEAAAAACAMB44Z8iobqMn699/R4n9NO2733ve7PvuOOO&#x2B;WvXrn1YK9LEt3cEAd20eQQSEhK0bWZycvIWtfbr&#x2B;O53v1vU1NRUeebMmaPZ2dnlb7/9ds6FCxf6tg3oLfz1tA0YGQXgTwBgdG4Bd0FB3zCgP5YfdHV/lh8EAAAEABjSRb/Rwn8wlvFzV/Tr6ev3OKGf9nlcXFzYt7/97Tlbt25dv2DBgq3sRRhM2moDCQkJ07Vt8uTJt2vXffnLXy5taWmpvXr16tljx46lnzt3rmL37t1lLop6vUsO6l1&#x2B;sD9XG/CnbcBd4U/bAAAAIAAAhb&#x2B;Xol9k4JbxM9rf7214v6/L&#x2B;JkWLlwY94UvfGHutm3bHpw4ceJSs9nM3yqCUs88AmPHjp2/evVqaW9vb/j5z39eUFdXV3LkyJGTly5dKtu9e3dpeXl5mwxc24DRiQZpG7j5sT4HAq5CAQIBAAAIAEDh763wH4xl/Hzp7/d1uL/ZVQjw0EMPjXv66advVwupB&#x2B;Pi4qawF2Go0doGxo0bt0DbZs&#x2B;evVmt/TpffPHF3Pr6&#x2B;vIrV65cOHLkSNaHH35YduLEiYYAhADuCn2zl6LeaEAgPt5HRF/bgKKjeKdtAAAAEACAwl&#x2B;Cbxk/PQX/Tdd94xvfmL5jx46Nc&#x2B;fOXR8dHT2WvQihQptccNSoUbdqW1JS0h2bN28Wm81WXltbW3Dt2rX8PXv2HD927FjF8ePHa&#x2B;12uyLGlx800jbQcz9vAUF/jBrwdp2I/20DipdCnbYBAAAIAIBBKfrdFfuhsIyf2UsA4LjeqnrllVdWrF&#x2B;//o4ZM2bcYTabw9iTMBzExMSM1zZtHoHly5c/1tHR0VxRUXFJ3QovXbqU&#x2B;Z//&#x2B;Z&#x2B;X8vPzm0tKSlpdFPNGlhw08s5/INsG9IwaEAlM24C70QO0DQAAAAIADHrhH&#x2B;zL&#x2B;Lmb0M&#x2B;XZfxczuqfkpIS&#x2B;/TTT8/bvn37o4mJifO0idXYkzCsT0RWa/SkSZNWaNuSJUuUz33uc&#x2B;2NjY3FBQUF5ytUb7755pkPP/ywyk0gYGSziG9tA/0xkaAvbQPuCn89kwf60jagJxCgbQAAAAIAUPgHpPD3p78/WJbx67nOvG7duoSdO3eqH9Y9FB0dPU4bGs2eBHzyWGGxWMITEhJmLFq0aIZ2xaZNm&#x2B;ytra2NxcXF58vLywuOHz&#x2B;etXv37rz09PSmjo4OX9oGunQW&#x2B;oEeFRDMbQN6Rgh4CxeMoG0AAAACAIRY0W&#x2B;08PdnGb9A9fd7CwIML&#x2B;P30EMPTfjmN7&#x2B;5Zfbs2esiIyNHsScBxlgslsjo6OhI9W/obnWTtWvXdnzrW99qqqmpySsqKrp85cqV3P379&#x2B;e&#x2B;9dZbZeK&#x2B;VcDdZU8hQH&#x2B;MCuiv5QdF/GsbGMjlB2kbAACAAAAhVPj35zJ&#x2B;rgp&#x2B;byFAfy/j94n&#x2B;/pEjR0a88MILC7du3XrflClTVmjvaLInAQE6JpnN1oiIiIQJEyYs0bYVK1Yojz/&#x2B;uO2Xv/xluSorIyMjPS0treTll1/Obmho6JCBW34wkAGB0ZBAPNymt21goJYfdHU/AgEAAAgAMIQL/6G2jJ9J9Pf1u13GTy1E4l988cX1S5cuXZeYmJjCXgQMCFNYWFjsyJEjZ2rb3Llz73/44Yfbd&#x2B;7cWVFTU1OYnp5&#x2B;Lisrq&#x2B;Sdd97JPXbsWH33Y7rEvyUH3YUAetsG/AkAvN1HxPe2AXHx73hrGzC6/KCrcwTzCAAAQACAYVT499cyfiL6h/frKfhdzur/9a9/PWnLli1LV61atVXr72cvAgb5OGY2h8XGxk7WtilTpqzevHmz8qUvfam6sbGxoqCg4NKpU6cu/vWvf80/cODAdTdFfd/LFi/3CaW2AaPzCLgr8vsW&#x2B;Cw/CAAAAQCC4sXyAkV9YfR7ow8brsv4Oa6LiIiw/vSnP122fPnylEWLFn2KYf5AUDNFRUWN1bbExMT56t/tZ55&#x2B;&#x2B;ukam81WWVRUlJGamnrp7NmzJW&#x2B;&#x2B;&#x2B;WaJel2nDGzbgJ6WAj2fGw0JRHxfftDVfUVYfhAAAAIABPErYhfviPhQ9Lt6seZLf39/LOOnJwCwiIFl/JKSkqJ&#x2B;8IMfrLj77ru3sIwfMHQPf5GRkaO1TTV38eLFjzzxxBMt//7v/15aU1NTnJ6ennrs2LG8Dz74oCQjI8PW/Zj&#x2B;aBvoPWogEAGB&#x2B;HgfEX1tA4qO4t3f5Qdd3Z/lBwEAIABAkBf&#x2B;gezvd3U5EMv4eSv4P75uy5Ytic8995zW378pPj4&#x2B;ib0ICLETotUalZCQMFPbpk&#x2B;ffueDDz6o7Nq1q7S&#x2B;vv5abm6uNkIg88CBA8UfffSRNnKgq09xrnfJQW8rD7i6n7eAYCguP&#x2B;guMOhb4NM2AAAAAQCCtPAPuWX81ILA8sQTT0x&#x2B;/vnnd0yYMGFudHR0oo8vOgEMwUNmzzwCkyZNWn7HHXfIV77ylTpVUWVlZe7FixfT9&#x2B;7dm33y5MmavLw8u4ti3siSg0YmE9Q70aDez0VoG/D5PEogAAAgAEAoFf0igVvGz12x7y0EGPBl/MaOHRuxa9euRY&#x2B;qRo8efau2Djl7EgBt&#x2B;cFx48Zp24KUlJSHPvvZz3Y0NDQUVlRU5BYXF&#x2B;e9&#x2B;&#x2B;675y5cuHD9xIkTDeLf3AEWD4V&#x2B;f0w0KBLYtgFvIwHEQ9HvS9uAL8sPugsJCAQAAAQAGHaFvy/9/YO1jJ94KfR1L&#x2B;M3b968mP/4j/&#x2B;4Z/ny5XfFx8dP09YbZ08C4I52jEhISJihbbNnz5ZNmzYpdru9prS09GJtbW3F/v37z&#x2B;7du7coNTW1vrttwFWrgLvLekcPiAR&#x2B;VEAwtg0YGSEgQtsAAAAEABT&#x2B;ASv8A7WMn7tif8CW8dOG&#x2B;e/YsWPSP/7jP967YMGCu7R3&#x2B;IRh/gB8PARrEwvOmDFjg/bJ0qVLH925c2d7ZWVlRnl5ee7Vq1dzf/vb356/ePFiQ1VVVbu4bhXQu&#x2B;Sg3hED/REIiIGQQMT3tgF/5xHo&#x2B;1ijgQBtAwAAAgCERNHvrtgP9DJ&#x2B;fWfwD5pl/LRh/v/8z/887&#x2B;GHH74/KSlptbZuOHsSgAAfm80WiyViwoQJS7Rt8eLF8sgjj7TYbLaq/Pz8M7mqw4cP5/z&#x2B;978vamho6JD&#x2B;axvwVNT31/KDIoFpG/BnHoFAtw0QCAAACAAwpAr//urvHzLL&#x2B;E2ZMiVq165dS7Zu3frImDFjkn0MTwDAJxaLJSouLm7KwoULtU3UY5H9hz/8YXVlZWV2ZmbmpatXr5b&#x2B;9Kc/vVxUVNTS/RBX7QHuWgD0rjwgYqxtoEuMzxvQ320D4qbYD0TbgOLmvMk8AgAAAgAMucJ/WC7jt2zZsrif/OQnW&#x2B;bMmbNo3LhxC4Vh/gCCIxCI7FltQFt&#x2B;8L777lOeeeaZ6qamprIrV66czs/PL/3LX/6S9f7771fJzSsM9C7wvbUQuNqMTCZolsC0EYiPIYF4uC/LDwIAQABA4R/Awn8gl/Ez0tfvdRk/bVNfSE996qmnNixcuPDeiIiIkexFAIL9OB8dHT1W2xITExesW7dOHnvssbqWlpbrxcXF6WfOnDmflZVV8eMf/zhH/GsZcDf8v8tDEd/lZwDgrW2A5Qd1nv8JBAAABAAU/XqKe0/XB/syfu4K/k/0&#x2B;KuFvnXXrl3JO3bs2DZx4sRFVqs1mj0JwFClTU6qbdpqAykpKVs7Oztbn3/&#x2B;&#x2B;dKGhoby06dPH83Nza148803czIyMmzdD&#x2B;kyWPjraRvoPWrAW5HvTwBgdG4Bd0FB3zCgP5YfdHV/lh8EABAAYMAL/4Faxs9If7/eZfy89fW7nNRP27Rl/L773e8u27p1646YmJhEbWgtexKAUKNNLJiQkDBd26ZMmbJKrf26vvKVr5Q1NTVVZGdnXzxz5szlY8eOXXv33XcrXBT17pYc1BsC9Ndkgv0xj4BJaBsAAIAAgMI/dJbx07YVK1bE/eIXv/j03LlzV8fGxk4S&#x2B;vsBDK/zhlk79mnb&#x2B;PHjl6xdu1a&#x2B;&#x2B;tWv1jU0NFyrqKjISUtLu3To0KHcPXv2lKvaJLBtA54mEzQy0SBtAzffj7YBAAABAEW/18I/lJfxu2lkgPoiN&#x2B;L&#x2B;&#x2B;&#x2B;8f//zzz3/ulltuWRweHp7AngQATtoxccyYMdo2Lzk5&#x2B;cHt27e3NTU1lVZXVxdkZGSk7tu3L/PMmTPVp0&#x2B;fbpT&#x2B;W37Q2&#x2B;SBRgMC8fE&#x2B;IsaXH&#x2B;yvtgFflh90FxIQCAAACABCvPAPpmX8XPXyD8gyfj/5yU/WrF69&#x2B;s6JEycu1d75Yk8CAM8sFkt4fHx8krbNmDHjzgcffFCampquVVVV5ZSXlxe8//77pzIyMmoOHjxYbbfbFXHdKuDust6VB6TP/QK1usBALj&#x2B;op21A8VCoe5pHwFMooAdtAwAAAoAQLPyH3TJ&#x2B;VqvV/NnPfnai&#x2B;oJ1/j333PNY9zB/AIAf1GPpRG1LSkq6Y&#x2B;XKlZ9vb29vqqioSK&#x2B;tra04evTo6QMHDhQcOXKkpqqqql30LzmoJwRw985/f8wjIAZCAhHf2wbcjR6gbQAAQABA4T&#x2B;ghb&#x2B;v/f2DvoyfWvhbXnzxxeS77rpr2eLFi&#x2B;9jmD8A9J&#x2B;wsLDYyZMn365ukpKS8uCXvvQl5fr165kVFRW5quz33nvv0smTJ69nZmY2S/&#x2B;1DfTHRIMiA9M24M88AoFuGyAQAAAQAAzBol&#x2B;k//r7zRKky/hNmjQp6pvf/Oa8hx9&#x2B;&#x2B;P6pU6euMpvN7KsAMPCnL5M2h0D3PAKyZcuWjpaWlurS0tJLlZWVpX//&#x2B;98vfPDBB8UnT56s736M0bYBvSFAICcTHIy2AXFT7HtaTtBdaODp/iYPgYA7frUNEAgAAAEAAlP4D5dl/G76fPbs2TGvvPLK/fPnz185duzYZB8nRwQA9M95zRodHT1&#x2B;1qxZ2iarVq3q&#x2B;s53vtNUWVl5pbS0NO/y5ctZe/fuzf3LX/5S0dra2lO0e2ob0Dt3gKe5AvorEBAfQwIR78sSBsvyg36PEmAeAQAgAOAFEsv4GV7Gb/v27eNeeumlxyZNmpQcFxc3lb0IAIbE&#x2B;c4cFhYWpx67V2jb8uXL5XOf&#x2B;1xzQ0NDaVlZWebVq1ezzpw5k/erX/0qT72uQwK7/KC74CDQAYHRkECE5QcZJQAABAAU/ToL/8Faxs/du/x6AgCflvHTtl/8iyzbuGbiHTPmxK4MH3kmTsJb1FcKyeo9ItipAGAovrCwWqNHjRo1S9uSk5O3bN26te173/te9fXr1/MvX76cmpubW/7qq6&#x2B;mp6Wl2bof0mWw8O/SGQLobRvwJwDwdh&#x2B;RgW0b8DSPgKv7s/wgABAAoJ8L/2Bcxk/E2PB&#x2B;nwt&#x2B;bUuZJbH/8oysXL9M7k0cJckmuWaRhtdFaXxdvTVKJGqOWv8vEoldLxIxX93mqddHsrMBwBBkNpvDY2JiJmrblClTVmvXffGLX6yur68vunjx4vGcnJyyP/3pT1ePHDlS66ao7&#x2B;pT0OtdeWAotQ24K/yDsW3A71CAtgEAIAAYboV/MC3jZ3QWf5&#x2B;W8dM&#x2B;blkviU9slSUbVsjD8bEyTX0Gb/x8lp5XAC0izedFaTovUvM79fookYjZIpGLxeQIBOapl1MYIQAAQ1hUVNQYbRs/fvySe&#x2B;65RwsEqpqbm2vy8/MvpKenZ548ebLw7bffvjYIbQN6Wgr0fG40JBChbYBRAgAwEHXsQB9fg2VON19/bpbxMzarf0S4WB7eJBOe&#x2B;bTcsSJFPhUZIaMMP&#x2B;ldvS5bokXCZ6uvHueLKfZukYg5IpHz1a/KCAEACBUdHR22pqam8qqqqrzMzMyMI0eOXD169Gj5iRMnGnws/PW0Degp8o0EBOLjfUT0tQ0oHgp8xUMwoOgIBhQP9xcv99fzuS&#x2B;v2wgEhintV9/35XfPddrHrq4usVgsjo/O&#x2B;2nXOXc7s9nsuL7no7YXaXfRPlqtFvVY06k&#x2B;1nlbV5fy8eOde5v2ubn731O6d2T1Ou2lrslZ0yhdiuM67QG9v5Z2W6f29bq/J&#x2B;2yWfu3TIpYzFZp72j/xBienu&#x2B;ts9P5bzh&#x2B;Rum5TXE83tbcLNHRUb2&#x2B;7xvPQ9yIWKmrb5TwcKvj9huPN3Vfdn4B7TE3ng/n4zs7O9V/X/3Jur&#x2B;u9s30fHtt7e2O57f3c9zlfIIlIjxc2tranAeaXr&#x2B;T3r&#x2B;jnp9H/Z/jcs/jnT9j9&#x2B;9D&#x2B;6/7&#x2B;9K&#x2B;F&#x2B;0&#x2B;kWrR0NxsV7&#x2B;uqft7NTkOwd3fnuP70e6rPQ/t7R1i1r6/zg7HY6OiokQ9h2hL2zqeC&#x2B;3f7VBv0x5j7v55NdOmTgmq/XygMAKg/4t&#x2B;keBdxk/E&#x2B;Lv9upbx0&#x2B;73s&#x2B;/KknvXyIZpE&#x2B;X28DAZ4fMvwNw7DGgWaTnv2JTrb6p7sDZCYK5jVIApZoP6caG63ap&#x2B;B1HsuAAwRFmt1piEhIQZ2jZr1qy7HnjggY7m5uaq2tragpKSktwDBw6cPXfuXOWePXuqOjo6FHHdKtD7ssWPEKD3/cwytJYfpG0AAEAAMECF/1BZxs/Tu/7u&#x2B;vrdzuqfNEmifv4vcvfC2bJ88jhZHvhfSp9ns6tFpCVVxJYqSs3vnS0D2giB6KViilopEqNuYVPU7yyWHRoAhu752BoTEzNB2yZPnrzy9ttvf7y9vb3p&#x2B;vXrOepWcvbs2fP79u3LOXnyZE1eXp7dRTFvZMlBI5MJ6p1oUO/nYiAkEKFtgLYBACAAGDKF/2As4&#x2B;drX7/bCf16ti98SiY//oCsWjJPNiSMkOkD98vq/mjpFQjYL4i0XFBfSfynuoerhX&#x2B;Y&#x2B;u3ErBJT5BLHR2cgMIIdHQCG8Kk6LCxsxPjx4xdrm7bawOc///mOurq6gurq6tzCwsLcP/7xj2eysrLqz5w509jR0WFkpYG&#x2B;m8VDod8fEw2KBLZtwNtIAPFQ9Puy2oCeQIDVBgCAAGDIFf3uiv1gWsbPXdGvZxk/jxP6SXd//z89IbMfvU82zp4md4aHSdzg/yL7fOxqEmlJc2yOVwFWtfAPmyESvUxMsfeKRM4TCU9iUkEAGPrncevIkSNnatusWbNk06ZNSktLS/W1a9fSa2pqrv3tb3878/e///3aqVOn6mw2W5e4bhVwd1nv6AGRwI8KCMa2ASMjBERoGwCA4DlfDvdJAIfQMn6u3tn39i6/kXf9dS/jp22/&#x2B;z9yx92rZHPiaEm2mCV8yOzxfV&#x2B;yWKNFIpaKRC0QU8xa9eNt6nWTWHYQAEKMVvh1dXXZy8vL0ysrKwszMjKu/Pd///flw4cP19hstk7xvLSgtyUH9YYAg738oIjxtgHx8DgxcLuI5wkLvRX7io77&#x2B;LRf8NcR9H&#x2B;7TALIJIBMAhhAw3YEAMv4eRwFYHYVAsyeJjH/9wXZMne6LBs3WhYMzV98n4&#x2B;dzSK2IyJNR0S5/iv1J40VU0SKSPTtIlFL1Y&#x2B;rRcLGMakgAITAeV998Rc1adKkZdq2ePFi&#x2B;cxnPtNSW1ubW15enpulOnjwYNY777xzraqqql38W3LQ4mMIMJDLD4oYbxvwZx6BQLcNMI8AAPhyPhyGIwCG&#x2B;zJ&#x2B;egr&#x2B;m6777GaZ8N2n5dNJk2RpTJRMCPm/ip6XbNpPb4kTU8S87kDgNudH60T1NgIBAAi5w39XV3tzc3N5RUXF1fz8/Kvnz5/P&#x2B;/Wvf32le2JBEdftAf4uPyiiv23A13kD&#x2B;qttQET/KAE97/6z/CBc/Q4YAcAIAEYABNBwGQEQrP39g72Mn8sJ/bTr1UI/7KWvyIJPbZB7p06UFeoxMnrYnGl6LzvY2SBK80mRJnUzq0&#x2B;XZYRj2UFT9CqRqCUi2kdHIEDLAAAM&#x2B;cO/2RwWGxt7i7bNmDFjo6rz61//ekNNTU1&#x2B;dnb2&#x2B;cLCwtLXX3/90uHDh&#x2B;vk5hUGxM1lvXMH9MdkgoFqG9DbHsDygwAwBIR6ABBqy/i5m9BPb1&#x2B;/1/7&#x2B;Lesl8TP3Scp9a&#x2B;XRuBiZZB5K/f39uQdZul8zdDaINJ8SpelUdyAQLxIxS0wx60QiF3S3DNyizU/N0QUAhvopwGSyREREjJwwYYK2LdGue/TRR&#x2B;taWlrqc3NzTxYWFhYdPHjw6m9&#x2B;85tCP1cacFfod3ko4rsCFAgYDQlEWH6QtgEAQ/fcFqItAMHe3x8sy/g5rlNf3FgeuDMu8WtP3XbnbVP2PhAdIYkuxy/AtZtaBkaLREwTU/SdItG3iUQtFgmbqT6PZp4nAAhBnZ2dLXa7vba8vDwrLS3t3NWrV8teffXVLBdtA3oLfz1tA3qKfL0BgT/3EQls24A/Ewt6u5&#x2B;7gp&#x2B;2gSBHCwAtALQABFYojQAI1DB/d4W/P8v4&#x2B;dPbr2cZP0MFf&#x2B;/rXn755aWbNm1YO3PmrNXh5qp4saeLNF8QxfY3EXueSHtx9xGJQMCtm1oGrovYrovSdM75XFlHqUfHmWKKul0kdp2jfUAi5vBEAkCI0CYWjImJiZoxY8ZEdbtTW2zgq1/9aoXNZqvMyMg4nZWVVbhnz57cgwcPVtvt9r5tA&#x2B;6WHPQ1BOh9P7ME1/KDJqFtAAAGv2gOgREAwbSMn6uC31sIMNDL&#x2B;Dmue/3111dv2LBh49SpU1e7faY6KkRazoo0nxfFtk/Enq8WuCXOlxcEAsZeMvQ8Z9YEkch5YopcKhJ7p0jUMpGwSTyRABDC1MJfW2qwqrS0NOPSpUtXTpw4UfDGG28U9Vp&#x2B;sPdmZMlBI5MJ6p1o0NcAINBtA&#x2B;Lia4mw/ODweynFCABGADACgABgkAp/f5fx89bf7&#x2B;ndfZO4n8BP9zJ&#x2B;8&#x2B;bNi/nBD36wZu3atZsSExMXGlsKUf1Db9cCgZPqdrE7EMhV/5Ir1a37K/jyWxmOgUDv9zy04j9iqphi7nK2CzhaBqbwPAFACFNffLZpyw82NDSUp6amnjl8&#x2B;HD2kSNHKtPS0mzi/9wBviw/6EtAID7eR8T4hIMi/dM2oCcQ0BMKEAgQABAAEAAQAPRzAGDy4756Cv/B6O8PxDJ&#x2B;Lmf137p169hdu3ZtnTFjxm0JCQnTA/Ob7BBpLxPRZsi3nRXFflSkJV39y26kZcCXQKBH&#x2B;CR1mymmmNUi0WvVI&#x2B;ts9fMknicACPGzgfpitaS6ujq/tLQ077333juVmZlZ98EHH1S5KM71XPa1baA/VhsYqssPeirsGSVAAEAAQAAwZAOAoTYHwEAX/u7e/Tfa3x/IZfy8Fvzd11t27tw588tf/vJj48ePT9ZmMQ74rqPNdh&#x2B;vbZ9Wj2fqH1J7voj9gkjjR6K0nu0VCPT5ieF6L9O0l6pH2lL1leCH3S0D49Sj60IxRS8U0UYJRM5Qn/fpPG8AEGJng57lB6dNm3bH6tWrn2xvb2&#x2B;oqKjIqK2tLf/oo4/OHjp0qODAgQPXGxoaOsT1MoOulhzUEwL4OmLAl8/FQEgg4vtqA/7OI9D3sX0fx2oDAIbuCWcIjQDwtfjvj8LfLP739&#x2B;sNACxiYBm/hQsXjnjuuecWb9q06e6JEycuNpvNg7OMn6K&#x2B;Pmm9qm4XRZqOiNjPidKSoV5vc77UMAujA3Q9j31eMoSPFYlYKhKVIqaYDSKRc5xBzMc9GACAUNTV1dVeU1NztaqqqiA7Oztz3759mXv37i3rXm1gMNoGfA0ERAambWAw5xHQcz9GCOj/ORkBwAgARgAMwwDA5MP9vF321tvvqbiXPkW8P/39Rob7u53Vf9u2beO/&#x2B;MUv3r5&#x2B;/fpPR0dHjw268lppVY8g2SLNqSK2o&#x2B;rHD0XR5hDQJhBQCASMvQrstddZ1V&#x2B;1NqFg1AIxxdzpXGEgfLKE1gIfAAAXLxY7bTZbeVVVVU5BQUHWhQsXcv7rv/4rOz09vamjo0MR420DeloIPIUF/fG5L9eJDF7bgD/zCPgdCoRqIEAAQABAADD8AgB/in89y/npmcnfaOHva3&#x2B;/oWX8rOqR65lnnpn65JNPblq8ePGD6ueRQ6eIrRVpzROl5bhI41H1cpqIPfPG6Y9AQOfRQnqtymByLDtoilouEjlfJHaDSPhckbDJ6m2MEACAEA8EFPWFeH1NTU1ecXHxlaysrNw//elPV7S2gdbW1i7x3B7gz8oD/d024G3UgKfrxGBQ4KmY13u7t&#x2B;BgwAKBUAkFCAAIAAgAhlcAYLT41/Ouv57l/HyZxd/X5fu8LeP3if7&#x2B;uLi48B/96EdL77///s2TJ09eOmjD/AMdCLRkiNJyRkTrf2&#x2B;9rG45N5/7mENAXyDwcYei2bHsoClyhUjUIpGYVc7RAmFj1BvDeK4AIMR1dHQ0NzQ0lJaVlV3JVp04cSLnV7/6VZ6b5Qf9aSHQO5kgyw8SCBAAEAAQABAA&#x2B;FX8&#x2B;/Ouv7dZ/fUO7/elr99QwS/d7/pv3Lhx9Le//e21t9122/oxY8Ykh/Srls4akRZtVMBZUZo&#x2B;cgYCbfniOKKzwoDxQMAxqkLdjawjxRSpTSi4XiR6tXMOAet4nkwAGAa05QdbW1trtLaBzMzMi8eOHct87bXXcsvLy9u679Il/s0doHflAV8DAn9CApHAtg34Ewh4u5/eUGBYBAIEAAQABAAEAHqLfyPv&#x2B;ptd3Obt3X13hb14KfQNL&#x2B;O3c&#x2B;fOWevWrUu&#x2B;8847P6Pu0KOG56uWSueqAi1nRGk6JNKaqx6R8lhy0J9AwBKmbmPEFL1SRAsFYteJhN8qEjaB5wkAhkkgoGq4fv26NkAgPTMzs2D37t1Xjx49Wtc9j0Dvol7vfAFGQ4BgaxsI1DwCRm73dNloABByoQABAAEAAcDwCAD6o/gP9BJ&#x2B;vk7kp6u/PyIiwvriiy8mf/rTn75/2rRpK61WaxQvVXqd2zoqReznRVpSRWk84JxgsL2kVz88gYCuMKD3yxpLuLqNEoleJabIxSIxa0Qik50TDQIAhsWZwW631zY3N1fl5eWlavMIHDp0KPf9998vr6mpaZeBbRvQ01Kg53OjIYEIbQNBFQgQABAAEACEfgAwGMX/oM7g3&#x2B;s68/jx4yN&#x2B;&#x2B;ctfrl&#x2B;9evXGcePGpajPF9O5e6UehDoqnGFA80nnKgP2DPUoU63exAgBw6HATSMExoopepmzXUCbRyB6qbqXjuTJBIBhor29Xa05mqvLy8uvXL169crJkydzDxw4UHr69OnGfgwBvBX1RlciEB/vI6JvlIDeFQVoGyAAIAAgACAA8CMAcFf8e&#x2B;v3N7u47K3gN4n&#x2B;Xn6vRb6r2zdv3jz2pZde2jpjxowlI0eOnGFyHnHgaxXbXuQMARoPitKqLT2Yph4zam4cbAkEjAcC6glLW1HApM0bEHOXc6UBLRCwjOZ5AoDhclpQlK7m5uaK2traosLCwitHjx69dPbs2Yr333&#x2B;/wkDbgK9zBwRqVECwLj9o5HZPl40GAEEdChAAEAAQAATWUHt32Z/i30h/v953&#x2B;C0eAgGzh8LfsWnL&#x2B;H3rW9&#x2B;a&#x2B;eSTTz4wffr02yMiIkby0iJAu0nYVOc2YrPzgNd6Vd2yRBoPidJ6zrHigHTW3lhyUE/0NEyfyhvPS4dIe4EobQUi9f9PO/KqR5BpIpEzxaQFAlEL1G2xY14BAECInhbUiigmJmaCtk2ePHnF6tWrtQKgvra2tqCmpqbkww8/PHHp0qXyP//5z6VVVVWu2ga6ul8/&#x2B;bLkoKd3/o2OCvB31ICIf20DJi&#x2B;Fvrfb&#x2B;97H5ObreXt1o7i4j&#x2B;LDfmEaqEAAgJ/H8SAbAWAa4OLf6PB&#x2B;3RP3uQgIPr48ZcqUqG9/&#x2B;9sLHnvssccTEhKS6O8faJ0ibTki2uoCLRdEaf67iL1QPVs1EwgY1XeVgfBp6jZDTCPudk4sqLUNEAgAwPA6NShKZ01NTXZDQ0N5enr6&#x2B;f379185e/Zs9YkTJxrE/7YBd4V&#x2B;f0w0KBLYtgFfWgP6ex4BkSBvG2AEACMAGAEQWEO1v9zk5bKRSf2MvMvvdam&#x2B;vsV&#x2B;78tJSUnRP/7xj&#x2B;9Yu3bt3YmJifMZ5j9YtEJ1tsio2d0pmE2kNUek&#x2B;ZSI7bgo9jMidvXzrrYbgQBhgPu/RFPvYCXXsUKD0rjPeX34LPXskCSm2LudYUBEinrUSeR5A4BQPjWYTJbRo0fP0Tb1tc/6LVu2iM1mK6uqqsquqKgo/OCDD06fOnWqat&#x2B;&#x2B;fdUuinpvly0GQoBAjwoYqLaBXmXhJwp6T7e5e73s6v69L/vyKkcxuE&#x2B;YAhkKAAj9AMDk5QCld3Z/T0P9XRX4Phf73Zcd93/qqaemPvLII0vVwv8hbcgcu12w7V0xznertW3UM2LqalaLWG3JwfMiTR&#x2B;KYr/gXHZQIRAwFgioWrMdm9LQHQhEzBQJmyWm2DtEotUtcq76l0LnCwCEup62gWnTpsmKFSt2aJMLVlRUpJeWlmZfuXIl549//OOV1NTUhl6rDfRtFXB32VMIYJbgXX5QJDBtA30DAaOhAG0DwHB7uR5ELQDehv97GvpvpPj3ZcZ&#x2B;I5vjsZGRkZZdu3al3HfffatSUlLuZ5j/ENbVKNJyScSeKtJ0xBkIaO90K50EAkb1fmmjLXARMUfd5okpdq1I5BKRqHnq85nA8wQAw0xHR0dzQ0NDsSq9qKio&#x2B;L333ruwd&#x2B;/eyvLy8jYZ2OUHAxUQGAkJRALTNjBQyw/quV/A2gZoAaAFgBaA4RcAuFrWL5DFv9fJ&#x2B;jwU&#x2B;r0DA8f1EyZMiPjJT36yZsOGDfeNGzduvrrDhXNaDzHa5IGtl0RpPuecR6A1wzmnQM/fEisMGAhXel02W8SkBQLh80RG3KGeVRaJRKaof13xPE8AMNxOtZ2dbXa7vfratWsZxcXFuWfOnMn&#x2B;8Y9/fLm5ublDvb6niPdn7gB3IYDetgFf5w0IhtUGhvzygwQABAAEAKEfALibANBVsS&#x2B;if3K/vgW8u8t9i/5PfL5mzZoE9cS0dfr06QsTExMXmnSsd4gQqWA760Ts2mSC50Vsh9TLV0Ta850vIVhy0Hgg8PHAQqtI1CwxhaeIjNBGCCxVzzRaywAjBABguNEmFmxtba2rra3Nz8zMPF9UVFT26quvpp0&#x2B;fbrexfKDvlzuz8kEA9U2oGc0wLBaflAtDBUCAAIAAoDQCgCMvPtv9lD8u3u331WRr6vg77n8ta99bfoTTzyxMTk5&#x2B;Z7IyMhRlHrDnXpA6ajpDgROijSfEGm5qF5Xrv5ld7nem&#x2B;HhaCi9ghStZWC6mCKXi8QsFYle41hxgDkEAGB4niG05Qebm5trcnJyzhQVFRXu378/69e//nWRBK5lQG/bgJ6WAj2fGw0JRIzPIyA6wgI9gYCIsbaBAQsECAAIAAgAQi8A8Db0391EfxYdxb&#x2B;rzz9xnVroW1966aX5n//85z83duzYZKvVGsN5GG7Pd&#x2B;3X1KNnlkjjfuf8AVrrQGeV8&#x2B;UCSw4aCwOkdyAQoZ55Jospao1I1EJnIKBNMkggAADDkjaPgN1urysrK7ucm5t75dy5c3m7d&#x2B;/OS0tLs/U6gwS6bUBPka83IPDnPiKBbRvwJxDwdj&#x2B;9oUDARggQABAAEAAEXwDg67v/Rnr&#x2B;zTqKf0/XWZKTk2N&#x2B;9KMfrVu7du32ESNGTFZ3pghOtzBcxbblO&#x2B;YMUBr3i9g&#x2B;VC/nibRfd7/Hw/NLh55AwBwjEjZBTNGrRKKWiETfrp6ZZtMyAADDlFo0dLS2ttbW1dUV5uXlZaSmpl45fPhw8V//&#x2B;tdKF20DepYiNBICBGpUQLDOI2Dkdk&#x2B;XjQYAfhcu2u&#x2B;eAIAAgABg6AQARof&#x2B;e1q6z22h3/ujWuiHbd68OXHnzp1b5s6du1ndocZSniFwf&#x2B;2tavFfImI7KUrLGfXjR84VBjobbqwwIOxxusMA6fWSyxKtnt0niilmpXP&#x2B;gJhVjBAAgGF&#x2B;plCLlYbGxsbywsLCi6dPn067ePFi2Ztvvllis9k6XRTzRuYLMDKZoN6JBvV&#x2B;LkLbgD9BkUIAQABAABA8AYCeSf/0TvbnbZj/TYX/yJEjw5977rmZTz755OOTJk1are4w0Zw30f9//XbniIDmVMfoAKXlnEhrpnrEbLkRcxEI&#x2B;BYIaJ06lnEisavFFLFU/bjKsQShY&#x2B;QAAGBYUguBFm2EgLqVnlRdvny57M9//nNhdnZ2i/g/d4C7Qt9bUW80IBAf7&#x2B;Ou&#x2B;PcUCIj0T9uAL8sP6g0JDGlvb1cIAAgACAAGNwBw9&#x2B;6/2UsIoHfI/03F/6pVq&#x2B;K//OUvL9i8efMXEhIS5qrfbxinRwyeNpGWdOdSgz1zCLTmqMe/lhsnDjPPkqFQoGezRomEzRCJWSMmrWUgSmsZmKo&#x2B;n3E8TwAwjNXX1xfYbLbqK1eunDt69OhldSs/cODAdRfFOW0DngMBb7d5K&#x2B;CDZpRAa2ubQgBAABAqAYA1SI&#x2B;9JgO3e5sE0FUw8Il&#x2B;/&#x2B;eff376li1bVi5cuHBbdHR0Eqc/BIdwZz&#x2B;7tiXsUM8brSItF7oDgb&#x2B;L0praHQi03WgZYHSA5yNHz/OjtIjY0x2b45BrjRcJmyYSvUJMUcscHyVcPTGY43neAGAYiY&#x2B;Pn6ZtEydOvG3jxo3S0tJSXVdXV1BZWVl49OjRcydPnix97733ynu1DXR1v650ddlICODriIFAtg14K/L1tg2YXFxv6nObu1Cg7&#x2B;v93o/t&#x2B;zhvr3oUF/cxXGlFRITf9G&#x2B;0trUp/KVgyL4cDtIRAK6G/5vF9bv/7ob8e5rl3xEAjB07NvzZZ5&#x2B;d9sQTTzySlJT0oMViGcEugSGlq1ktYNPU7aIoTYfVj&#x2B;fVs1KeemprJxAwqu9Ll7A4EWuSSMztYopcJBK7Rr1uCiMEAGCY6&#x2B;zsbLt&#x2B;/XpWfX192cWLF89/9NFHufv37y/PzMxslsFpG/A1EBAZmLaBwZxHQM/9/C6G7Ha7wggARgD49TKUFgCvS/3pne3fVeHv&#x2B;Hj06NFPzZ49e&#x2B;Po0aPvNDkbfIAQCAQaHWGAY5SANoeAXRshUKxe3/7Jvyp4DwR6Hx6tI9RtukhM9wiBqBXqmW&#x2B;GekRhehAAGNanC1VDQ0NRTU1NQVFR0dXjx49n/vWvfy04e/ZsQ/dqA67aAzwV/npaCDyFBe4&#x2B;7/JS3IdS28CgzyNAAEAAQAAQ2ADAlwn/bnr3/&#x2B;mnn56wbdu2JevWrfuq1Wodoe4Q2tt6nfT8I4TSAHWPbnKOCmg&#x2B;rW6nRLGfVI/kFepRpuPmvyzofko/ZolRz3xzRCIXisSsE1Nkinp5tvp8EggAwHDPBFpbW&#x2B;tqamryiouLs3Jzc/PfeOONS&#x2B;fPn6&#x2B;vqqpqF8/tAf6sPNDfbQPeRg14uk4MBgWeivkhufxgS4tdIQAgACAAcF/89y1NXA3/91T89yz5d1PR72qrra39bXx8fLL6PHRqM8Fqs/13dHTYw8PD49SdrVPdYSycxxAy1WtHjUjrFVGa9ovYjjkuS0fZzZ10BAI&#x2B;BgKR6plwgZi0lQViN4hEzRcJv5VVBgAA2trzLTabrbyoqOhCaWlpyZ49e9LeeOONIjfLD/rTQqB3MsH&#x2B;mEiQ5QcNsNmaFQIAAgACgJtLkEC8&#x2B;/&#x2B;Jof&#x2B;9NmtPAJCQkJDS68nv0sIAxZkItFqt1kj1oN0eHh4epV1HuwBChtKmviKpEmk5LUpLqkjTRyLtWc4RAtIrboNvgYA5SiQyRUyR80Vi1jpHCkTMpmUAAOCYR6ClpaWqsLDwXElJSdGRI0eydu/eXdC9/GDPGcWfuQP0rjzga0DgT0ggEti2AX8CAW/30xsK&#x2B;F1QNdmaFQIAAgACgBufm3uVIyb55GR/7ob9e3r33xEA1NTUvDZy5Mj5Hn4ZXT2burN0qDtOuDYyQN2hIroDAd4vRQgFAhXOVoGW0yK2487VBjrqbgxTY4SA8UCgZzJGtfB3jA6IWOicUDBqpXMOAZOV5wkACATaWltb66urq7MKCgqy0tLScvbt21f4P//zP5Uuinq98wUYDQFCdflBI7d7umw0APA/FGiyKQQABADDOQDwtKyft3f/XRb/3QHAbzwFAK4CAZX2f9oogS51h3K8ereqOH0htAKBVpH2EpGWVFFsh9WPF0XsF9Sjt&#x2B;3mv1wCAZ3Pp9y8OJIlXiRyvpiiFovE3KmeReeq2ywCAQBwWyXXqa/swtTjZOi3VmmvMdvb2xvq6upKysrKrl64cCE9NTW1&#x2B;De/&#x2B;U1ha2urkdEBgWgb0NNS4GsAQNuAAZVV1QoBAAHAcAgA9Cz552niP3fFv/bRev369f87atSoZJ/PRd17kBYIaO0B3Zv692OmLEKIvRppV88CV0Xsl0Vp&#x2B;n8iLRkirZfUP4LmG/ehZcBYICDdL6scR6w4kcgFYopaJBKzXr0819kyIExDAmA4Us85rTnOEFprUesoVK&#x2B;6JqbOVpFZR7XFnIdf/tHZaVeLmrLq6uq8S5cuXTh//nzh&#x2B;&#x2B;&#x2B;/X5iWlmaTwVl&#x2B;0NPj3H0uPt5HxPiEgyIh3jZQ39CoEAAQAIRaAOCp/7/nskXcL/mnJwD4lT8BgIuDszYqwKT&#x2B;MWjtAtrzq4UB2g7Hq3iEWAHbpr44uyxi755UUJtHQAsIOlsIBHwNBHo2x9Es3jGRoClyiUjsOpHw2SKRc7oPXQAQ4mrfEKXoGfWVXof6ml&#x2B;5cT5R6w7TnJPq8XAFpw1F6Wpubq6oq6srysvLu3z8&#x2B;PH006dPl7/77rsVLopzPZeNtA0EalQAbQMBDgVszc0KAQABwFAKAEx9ygZX/f9&#x2B;9/33FP/aVl1d/cvRo0fP66&#x2B;ft729vVMLAlpaWtrUnbCnXcCs4eyO0AsEMkTsaaI0HlI/nlU/z78RCJhd/MXDQCAwUn3BO09M2mSCIzb2CgTIFgGE4CEwd7VI4/FPZp5a3TFig5gSdzpDAEusuAxGHfPalKvVS6FzVRbtGDoMqMVYfV1dXWFVVVXB4cOHT12&#x2B;fLniD3/4Q0lDQ0OHi2LenyUHPb3zb3RUgL&#x2B;jBkQC0zbgbyAgEoRtA9ooAQIAAoBgDwC8TQDoqe/f29B/VwHAz/szAOjLbre3W61Wi/YxNjY2Qv2j0SYUtDCXIEIyENDmDGhJF2k6KIr9nHoWKXIGAkwo6Fsg0POySuswcswhkCymSG0OgXWO9gGJmKbeGM5zBWBoH&#x2B;5sB0Xy7lHPEZ3uj4emCOcxL2yqMwSwzlGva3Oce0xtuaK0lzvmrDGNuF9k/PfV42bCsHwu1cKpvba2NrehoaHiwoULp48ePZr7v//7v9cyMzObZXDaBnwNBEQGpm3AU9Hf34GAnlDA78Kttq5eIQAgAAjmAMBb/79Fbm4DcDX5n9VFCNBzXVhVVdXLY8aMmTsYv2TtuWhpaWlXd9Iw9cDcGhsbG97e3t4VHh5OIIAQfBXSKtKa6pxM0HZElOYj6lmlxHkUFwIBvwIB7XmzjlLPxLeKRK8SU/QykSh1C5uk3hbJcwVg6GgvEaXoIZHms588Jyh9zhNdLkoz7brwBMdIKdO4Xc4lWHETtTAqrqurKy0oKLh88ODBi/v27StNTU2tt9vtihhvG9AbAgR6VEAwtg3oKfaDsm2g&#x2B;nqNQgBAABDsAYCnEQCe3v3vPQIgTLtcVVX1s8EIAFz80h1/ZzabrS0iIsLa2NjYFh8fH97R0aGonzPGF6Gns0ak5Yy6XRCl6UOR1jT1hV&#x2B;Z9nbFzX/90B8I9D6chyWq23THkoOOUQLRy9Uj3yT1eY3iuQIQvMr/RZTKf795DhnHyCdt9v929bL6savdORLKUT2oL5Es6ss60zgxRaU4R0QlbHeODIAu2jwC9fX1xaqs/8/edQBGVWXt72XSGy0QegdREKUpWOh2V9de1772Lb&#x2B;r667u2nYtW1y7q7u2tVdEsdAREEEgdEjoIY0kJCHJZHq5/zn3zSRvaibJACHeo48pefNm5s57557vu&#x2B;d8Z/369QVz5szZlZeXV1deXu5E9FKBtpQQHI72g4AqG2iV1dQcFIoAUATAkSAAIon/&#x2B;Vf8tTDAPwHR6/5NPuDfSAgcOHDgX&#x2B;2BAAg&#x2B;AbjVIJvFYnGnp6cn1tfXu7p27ZrCmgKcIaCmK2UdC7zSROKp0gkB&#x2B;3rAvAzCuZlmnQpfgAeVIdAWQoBvU3qQxxtKwfFECpLH6xkCyQNV20FlypS1H7dlWQ4UnkcxvrnJ3/tr/nPu46iVtk40N&#x2B;yliC5Db1fLHVQSMnWfxv5M&#x2B;bQ2m9vttrCwILcf3Lt37&#x2B;6PPvpow7p162rjUDbQWjHBI9l&#x2B;MNrxwhEC0Y5zKAiBWPZrM9g7UFUtFAGgCIAjSQBEWv0PRwBESv/3ZwAkVlZWPt29e/cR7XpCpN&#x2B;ITlT5Q9HJzNoBSWaz2dWpU6ckJgpYVFBNV8o6VhTo1jMErKsA&#x2B;xo68VdC2NfpPaC9ihBoMyHAltQVSKWAOX0stLRJFDyPpee4rZbSEFCmTNkRMMv3EPsuIh9fFQANta7XAf3egBI8PaJxqNtisVSWlJRsqqqqKv3222/Xf/XVV8Xbtm2zcqYqmtL7W6sdEGvngdYSBK0lCZp7Doh/2cBR0X6QCQFFACgC4HARACZE7gAQTfk/XPq/vK2srPxHeycAIhAC0llyhgCd5Ik2m82TnZ2dyBcIdx1Q05WyjmUu&#x2B;r8SsK2FsCzTdQTsqwG3OdR7KGs5IcB&#x2B;ObEHtJSRQObpQOqJQBqXDOTQ3xQhoEyZskNszj1S9E&#x2B;4dul&#x2B;nPXqU/sAPR&#x2B;H1vkqKGKy/RECZNb9&#x2B;/dvKS0t3b1t27Zdb7zxxtaNGzfWU1zqReTygGjAv6UkwJEuG4i1POAn036w8kCVUASAIgDiQQAYOwAkIFQAMBoJEKz4HwL&#x2B;&#x2B;baiouIfPXr0OOYod8TsiQVfHA6Hw5Oenm6iW29GRkYi/01TioLKOlz0wYRAMeDYAmGeD9i20f01FDQ2NO2j8mJaTwiwm03OhZZyHJB&#x2B;GpA2hrbx5DFz6U9JaqyUKVMWP8dj/hai&#x2B;Ffkv/f43A&#x2B;B/fSZ0Po9TX5ohBqio2VWdrmsZrO5dM&#x2B;ePevLyspKZs&#x2B;evfmLL76oqKmpceHwlg3EUlIQy&#x2B;OWkgRA63UEopEFsRACQDvUEaioPCAUAaAIgNYSANFKAKK1/ksMcxtQ/09bckVFxd&#x2B;OdgIg2LhcwGecluOli8DEt34xQcUHKOuQhIBzN&#x2B;DYBtEwX289yC0I3ZZASVFlbSAEegApo6Cln&#x2B;ojBCbIrAFFCChTpqzVVj8LougW8tUHdR&#x2B;dMghaz78Ana7whWnKjlbjDAGHw1HLZQOFhYW716xZs3P27Nn78vLyzIeQBIgF5MdKELRlHyC&#x2B;ZQNtIQSa2y9WUiAOZQNVQhEAigCIRAAkBN1vjgBoTvzPKPxnvO/PAOhwBECYE0rwic56AUwO0EXAv7tITU01&#x2B;dNzlCnreITADsC&#x2B;DcI8V97KLgNuqyIE2koI8Mbq24k9KVg/BlrGVICVt7lkgNsOqjoMZcqUxeKja98h8H&#x2B;z/jiNwrCc30LrdClFajlqfDqgUQzqYkKgpqZmT1FRUcGGDRt2fPzxxzu&#x2B;&#x2B;&#x2B;67g2HAeawtB2MlAeKVFdBedQRa8vdo91tKALQZRJZXcJaAIgAUARCY9q8FAX&#x2B;jDkBztf/h6v8DwD/f7t&#x2B;//6mePXsO/yk5Ybfb7dcPkOUCXD6QmpqaoEoFlHVco2DTvpW2AqDhGwgb3XcWKEIgboQA9BaDqUOhpU8F0ifQ/VGqDZcyZcrCm30TRNkD0EzpEF1vhJZxqq7mr&#x2B;wnZTabrYpi0YqioqItK1eu3Lh58&#x2B;byV199tTgCmG9Ly0FvFNDujTMhAKiygVYblw0oAkARAJEIgHBZAC0S/zMQAE/&#x2B;1AiAYGPdgOTk5IT6&#x2B;np3dnZ2kt1u96SkpCRwpoCanpR1TPDqohN/M2D5EaJhnp4h4NoNsLam6jDQdkKAxy6pJ5A2Chp3GuC&#x2B;3KnkZpMGqXFSpkwZpMqfzP09kiVE5O8dO3UyovoV8lMToOU&#x2B;pX6aI3lWuN1WikWLDx48WLyKLD8/v&#x2B;L111/fXV5e7kTbywYiAf3mQH1LCQK0cp9I4D8aIQAcmrKB1rQfjJUkaJGVlpULRQB0bAIgOOxuLv0/WgeAcOA/MQj8s6Rs4v79&#x2B;5/4qRMAwcYdBbg8oLa21pmVlZXodDplhoAiBJR1WPPW04m/QW7CspBuNwOuEnrerQiBeBACCXqXAdYO0LjDQOZU8sDkdpMHQKVeKFOm7LA6Jtd&#x2B;wLoSouZV8vWb6HGFL&#x2B;pMgTZ4nk5YKmsvgMhdX19fQlvF9u3b161evXrnokWLShYvXlwTBpyrsoHohEBzf2sOwLebLIGS0jKhCICfJgEQTfzPFAH4GwmARhJg//79f1UEQHSjC8jNGQEHDx50denSJcnlcklhQVUyoKzDmqdWthyEfTNdAPMh7Pk6IcATRoIiBNpMCEgP3lNqB2iZZ9DtWNpG0vM91TgpU6bsEPgfN4R5NrSDn0M0zNV9PLyBvpwTEhIJDPR9Fcg6W41Z&#x2B;yMD5I3Vaq3ibgPFxcXbN27cuHXBggV7v/7660oua0X0UoGWthxsbcZAPMsGmgP5LS0baKuOQKzEwWElBMr2lwtFAHRcAsCE0BaAzbX/i6j&#x2B;73&#x2B;&#x2B;rKzs8V69eg1TrjWmE1N2FuBSgYyMDBO3dunWrVsyEwJKQ0BZh0auHCxaV/kIgcUQ9o2A&#x2B;wCFBx6VIRAvQiBpCJAyAlr6KUDGaXR/KHnp3mqclClTFh8CoO4ToPBa8jfeJn/th4HshJJ7Q8s4HaLTxdCyL1Fj1o5AkbG3fLC53W5LbW1tyYEDB3bv3LmzYP78&#x2B;dsWL15cWVBQYMWRKRtoLSEAHJ6ygSOpIxDLfm0GpkXFJUIRAB2XAIgmAhgpA8C4&#x2B;p/kIwD&#x2B;qgiA1hl3FeDb&#x2B;vp6V2ZmZiITAl27dk1mkUHOGFCEgLKOaR69ZZV9NWChzbYGwrqSnq5XhEA8CAHp/TVdQDD1BGhp44CMaUDKYPLcvdTAKlOmrPVW&#x2B;QhE2aO&#x2B;aJJCyNSRBPxHQut2k046xk2nhIljmiesK4Cs85XfOgxEgH8fbnxFwK&#x2B;surq6cN&#x2B;&#x2B;fQUrV64s&#x2B;PLLLwu3bNlitlgsXoQvD4gG/GMpIYhGFkR67I0C2jta2UBbdATaTAoU7isWigA4OggA45aAltf/R0r/N5IAfgLgL4oAiBMs8njkyVRXV&#x2B;fKyMhINJvNXDKQzM&#x2B;zyKAaIWUdlhDgmlL7FqBhgd560Pa93mFAeAOlTZW1jhDgeSOJJun0MUDaOGjpkyloH6oLDarBVaZMWcx&#x2B;xQ6x/w/QvGZ9pT/95Pi2HfTUQJi/obngR9q&#x2B;pLmhHNqg2UDmOWrsDwMBEAlI2Wy26tra2sLS0tKd&#x2B;fkFOz/88IOtTAiUlJQ4EL&#x2B;ygUORFdCWrIFoz6GFREE0MH9Uth8s3FckFAFw9BIARhIgEZGFAIM7ADRqAJSVlT2mCIBDcxIT8PfyLWsIZGVlJfFt586dk7jtYGJioqLDlXXQk58zBPbpnQUaFklBQWFbTYGhuUkhX2HWthMCyf2A1LFSP0DLmEqPh5BnVxkCypQpO5x&#x2B;yU2w0AzB5K/5a/L5qwDnTnpONOWtJvaF1vcdXfxU2SEHSZGIAsNjbjPnrK83F5eWlmzdsmXr1q&#x2B;//ip/4cKFVQcOHHChbWUDrRUTPBRCgh2l/WAs&#x2B;8UDzIr2fm53JAIguAVgawiAWFoABrf/M2oAKALg8JzUgoE/dxKwWq3upKSkBJfLJVhLgP&#x2B;uOgwo69ABorMQcGyiIHEJYN9K2xrA3RDo&#x2B;ZS1nhBIMEnwr6WeDKSOpkB7itQTQGJ3xbYoU6bs0JllIcTen8nMgkaCVwvyUZwIlpwDHFNAEWk3NWaHiQRo7jnDQ&#x2B;H1el0NDeay0tKyrYQL9i1cuGDrnDlzirdv32717eNF27QDYu080FqCoC0kAXB4ywaaA/DxKBs4KgkBRQAErpGZIhABsRIAfuBvMgJ/NJUAPKoIgMNvXBbA557T6fToLTwkD8Cqnfz7CKUfoKzjRi4uwLWHAscffITANsCxQdcP8JvCrK2bpr3&#x2B;2SJJth3U0iYC6WNpmyj1BGDq7JsKlClTpiwevscOsfcsoGFZk9&#x2B;W0I&#x2B;zlLoAKSdB63wBBTfjyQcdT/4pVY3ZYQJJUTIAggkANLE3&#x2B;pNer9ftcDjqKioqtpaWlu7euHHjjjlzvtq7cOGCqjCgPla9gJaSAO2tbCBehEBL/h7tfksJgLYCXtFezu2fAgHQXBvAWFb/g9P//bdMBiTRhf1o7969hyqXemSNOwnwuWG3270s1GEyyS6DGmcKKC5AWYc2rwVwFMh&#x2B;1KLhW8C&#x2B;E3BuAjzeQElUZS2fqhu7DCRKAUEt9UQg83QKyuk2nQJyUxc1TsqUKWujr3FClN0K1LxNPjsbYMCfOgZap4tl&#x2B;j80RToeCaBk3CeafkAoERD&#x2B;GA6Hs76urraotKysIH9b/vY1a9cUvvbf/&#x2B;5zOBwtyQ6IR9lALCUFsTxuKUkAHD1lA4c6Q0AcqfP6p0oAmNB8FkCk9P&#x2B;Q&#x2B;n9FALRvQoDLAmw2m4c7CnC5QHJysmYymRQhoKyDRzYWXVBQEgJz6f4Oijy205TvUh0G4kUIJNAUkNwHWvoUIO14IMMnKmjqqsZJmTJlLTf3fsDyPZAymsD/MHQo1ta2AfBUke900Peso6&#x2B;WCjhpXso8k/znKF84ffgJgFg6AgTvH/q8LiljkAeICsiMD11ul81isVTUVNfs2bxl8/od27eXvfXWWzt27dplw5FpP9gaggCt3AeILUsg1tKAw0kIxDs7QMTzvFYEQOsIgGgdAIJFAGUWQGlp6SOKAGj/xgwrEwC1tbWu9PR0k9PpFKmpqQmcIaBGR1mHNq&#x2B;ZArCNUkwQlrkQtp0UebDIlFsRAm0lBPxhUmI6bTnQ0qdRQHsCkH4KBfHH0SyTpcZJmTJlP00H2UDzTflfCOxvATw2Xc/GzdFzCpD7ALTOv6AoetCR&#x2B;4StyAII/XtsWC4cESDoP43&#x2B;E02vEVaLZb/ZbK7Iz89fs3Xr1j2LFy8u&#x2B;vrrryvDgPpY7rekbCBeWQFHS/vBWAiBw00GiMNxTisCIHwZQKT0f2MmgFEHQBEAR6mxkGBiYmICEwJZWVmJLDCYlpZmUt0FlHV8QqCeLoA8mSUgLPPo/jYKzoppU4RAmwmBxpKBNJohekNLPwlIP12v3U0bQzNOhhonZcqUdWxz7oQo&#x2B;y3QsJDmFaceafv1VXLuhdbtZl1k9QgC/3Cr&#x2B;c3tEy0LIHQyaNIDiEYchJAAQfva7faahgZLeXn5/u0rfvghL3/btorXXnttH8Ws4coG2tJy0BsFtHvjTAgAh6dsoC2EQKzZAdH&#x2B;ftiJAEUAtI4ACF79j1b/30gGKAKgA8TtZNxiMDU11VRTU&#x2B;Ps3LlzMpcQMCHAWgJqhJR1aNTqqdVTNG1rIKwrAMsamu6rALeryXtCkQItJ1oMU7kphWaNQdA43TXjDCDtWID1BFSGgDJlyo6on7LptwlpcZhObBCVTwE1rwOuUkM3A5pIsmZC6/47Pe3/yMd8zRIA0QBVdDHA8PitiUQILhkw7uPV/&#x2B;jbMdy&#x2B;Ho/HUVdXV1hfX1&#x2B;ety7vx/Xr1u&#x2B;bN29uyZYtWyw4MmUDh0JIsDVlAy0lBKIB/niTAa0ByqK157YiAELF/7QwBID/cSJCswCaIwDkpgiADkcGyFtysLJUoLq62tm1a9ckzhBggkARAso6vLkrAMdWwLwUwrEOsKymqKNGlQzEgWtpyhBI0TUDUkdAy5yptx7kLAFFCChTpuyQAv56PfvLugqaoxjClAit0yUAdzxpizXMg6h6Gaj9siniZl/HegZdb4LW9W56PrPdxHn&#x2B;&#x2B;v9YMgFie87o6DWE0wIwag4YD9FcFkDw2zUeA3odQYOlobSqqmpXcXHxrkULF21YvWZ15dLvvqsJA&#x2B;pbU0LQmoyB9lA2ECshcLhaErYG1IvWnNuKAIgPARAsAKgIgJ8eISBP8IMHD0pCgEsGunTpkuz1emXJgBohZR2fECgBbFsBy3K6zYOgDZ5q7nMU2HBVWQsDccMUn0jTSdIxBkJglI8QyFbjpEyZsjb68EoI9t91H5IfX0v&#x2B;pjM09jedLwKyplO0m4NWs7oeOvaBvwMHniFf5m3CvkxydroCWu5fybf1a88xXqv2iy0LIJAICFc2EEYHIOSAjftGEC40vlZ4hbA7HDXV1dW7KioqCtfl5W3&#x2B;5puvd23cuLGeHjsRvVSgpS0H2yI0GK&#x2B;ygXhpC8S7K0G8iABxKM5nRQBEFwFUBICy0JidgD&#x2B;f8/4MASYEcnNzU5xOpzclJUURAso6Pmp1lgD2TRRIcrnAEgjHZgoCrT51/DCeWVnLCAG2BBrIlFFA8jBoWTP1coFUCtgTVNtBZcqUxYTMgQbyz&#x2B;ZlQM3zgKuOAPkMaNkE&#x2B;jtfHYcWpl4I2zqg9DaaB9bpvt8PBzJPJeD/hN4dpR1bS/BLy8QAhWESjJ0ACCECIugMRCMA/Ptqhv3cbreNywb2l&#x2B;/fXrSvaM87776zbtfOneb8/PxDUTYQi5jgoWw/2Nw&#x2B;QHy7FDRHEgDN6wzEjQRQBEDzBIAJzXcBUASAsuYuNOH1etm5CovF4s7IyDDV19e7/RkC3GFAtRxU1rEvAgfgLALsqynYXC6JAZkhwC0H/VGIyhCIEyEwkrbjoGWcAqTRljLQt3KnTJkyZU3AX9R/DRx8A6j/lvyIkyLXHtB6/AbIuY98clIcfFMDsP9eiNoP6O3qdT/voZu0YUDPx4Gsc9uP4Km7nLZqitZ7kL/sHh64awhflB&#x2B;FAIiUzh8Jt0UuMQglAqKB/&#x2B;DjCUQ/rhb82fk/IdxWq7WC8MvW6urq4vnz529YuHBhSUF&#x2B;foPdbhcGUB9vEqAlZQNetFw34FBpD7QkWyAWsN&#x2B;abICY9lMEgCIAlB0hQsDj8TAh4LXZbJ6UlJQEzgzo1KlTEj&#x2B;vOgwo6/gXgR1w7NAzBMyLpZaAsG&#x2B;kqdzRtCiiCIFWjq0hBEhI1DUE0k&#x2B;BlnGaniGQMlx1GVCm7KfuJiofAyqfJJ9rb/K1WRdA6/8x&#x2B;d&#x2B;UNh7cDVH9MlDzIvn4nY0Z7lpiDtDjz0DnSyhK7hPHL8O6M4ktf13DAojazwj4lwG2FYDHQtH6QGgDP9OJVIRZo2&#x2B;hGGDzJQAGyB1T&#x2B;0CEAvoYSYCwRIAI/70CygWaSgs8LpfLUlFRvrWmumbvuvXr8r/95ptdy5Ytq7ZarV7Er2zgUGYFHAkdgpa2KQRiFxRUBIAiAJQdrcZZALyRYxUOh8PLJQNMCGRkZCQyWZCQkKAIAWUdPBq1AY7tFISth2j4TopPwbFFbw3lP/sVIdB2QsCUSrH98UDqcUDGVF0/gNtsKUJAmbKfjlX9HaLkfj16DYiOs6ExOO/&#x2B;AJA8BK2q0bL&#x2B;SMd/joD1R/RybxOC7nQJtNyHyN&#x2B;Mbttnd5XQe2wEnLvo/k4C7wchnDsJ/w&#x2B;nz5wLkT4RWqeLYiMEXEUQZb8BambrY8HmoS25N7Ref5Y&#x2B;UrgroDk2QzjKgKwZQOaMqMi8LQRArPtH0wEIAuwhWgCBxEHQ5zS0EohAADTiK85q5afo1l5bW7u3fH/Zzl27dm1fuXLVrg8//KCY9bDQtrKBcCA6WtlALCUFh&#x2B;K18SALgLZ1FWgxCaAIAEUAKGuH5vF4GPcLLhng&#x2B;5pu4EwBvtVUvYCyjm6cOtpICCwG7PkU8G2li8OlOgy0eWxhyLJIBlJPgMY6ApmT6f5YCtAHtxsVbmXKlMXfROXDQPljoX7UD4VSCACnjiOfMJ3uH0MRbC&#x2B;KdHPptmdkx&#x2B;uuBOo&#x2B;gih/lIB1dRNhm3ka0PUOAuWX0kuTW&#x2B;Gv6nT/X/8FhOVHur&#x2B;K5gJbaOtZA4TTej8EdKfvqMXCGjshim&#x2B;R7W25BSsLrMLUhw7ZAHHgOTruQX2VnImBpExoOb8CevyJjp2OaG38Ah9rgchMRMZ0YUG7CCUAYtEBCO5eEHH1P9wxwugFGAkAIQwlCD7iQOjxq9Nut1eWs45AUXHBury83bO/mL1n86ZNDUEzUDzLBlpTJhAPYiFexAEQe6eBWAC&#x2B;IgAUAaCsIxiXCnAWQENDg9ufDcC3aWlpCb5zXUGhdmzFxcV49913UFVVhfHjJ&#x2B;Dkk09Gnz59mNBRgxMzK1YPOLbp2gEN8yhYK9BXf/yEAKAyBFqFBAzhEbuRhFS9w0DqyUD6WIB1BJIGKEJAmbIOdd07gJpXCKw/Qj60NjAybvS5/ufon8Rseg2FtUn9JTEgEtyErbsDyQPJL5Mv1jIg6j8k/1zo61ZCzjhtPECgX&#x2B;t2lw8st9C4k0zdLMBMm30PHdcl0/ORPlLXjrEu0zPHQuYK2rpeAa3vW/S&#x2B;qS0gGszyezSSBoI1Ej4Cyn5L73&#x2B;A3jsBQiM/KNKA/m9Cyz4nchaAMSTz4X8hoSJ9bo&#x2B;d/p4aNGFFJxKCFudDQXqYHfyAPWo3AP9nE6EaAMb9wr1/AAEQ5TWc4Op0OA5W19TsKMjPX19YWFj6v//9L3/Tpo31YYB0rC0HYyUBWqox0JrjxavjwWElARQBoAgAZUehORwOD4N&#x2B;s9nsTk5OlrMI3/KmuID2Y7t378RXX32N5557BgcOMPgfL0kAdoVDhw7B&#x2B;eefjwsvvAjdu3dXg9VS1CoJga0UBK6BsH5Pt&#x2B;v1NoQeh8oQiBchIGfELBnka&#x2B;mTKaAfLbUEZNCvCAFlyo76i13YyW&#x2B;avwUsrMOyW6bEywnKGyZyDiALw/iKRAK1yT2gZZ4HkTUDWtZ5LQPg/oNxXX71a/S5vpJgWb5XYja0/p8C3PrU/6HK74Uof1qPtgPAdjK0QYsA1jyJxyjZN0Nr&#x2B;A4iuQ&#x2B;0tAk6CWDqHAl46MQBl0FYvpef3&#x2B;suJgCUAuHMJyTQl8blbCD7Ukk0hIdF0UsBwnYDiMAQBKfuB4B/GIUNQ18ULssgIgHgIxk0GJsaikivEQ6HvcZqsVbt2bt3zZ7duwuXLFm869NPPy3jxa4wYLkt2gEtBfrxLFnwonWihvEiARQBoAgAZR16CqfrymazSSKgurralZWVZeLSAW41yCUDaoQOv23cuBGfffYpXn31VdTV1eKMM87Ab397D6ZPn8ZtITF58unYu3cv/2649NLL8OGHH6lBa6t5qnRRQQ7UuLuAdS3g3q&#x2B;vFClCID6EgJwZKfDlQDj9dCBtLJA&#x2B;US8Z0JSGgDJlR7ED1RXwHVtkPT1clfTYCthW07XdQH6Awlwn&#x2B;dOk7rQrPU7sRjE2Ad2kwb6MgCTyCafo5QJt0BMR5i&#x2B;gFV4JwcKEpiA/lH4ytG736GUJLCbIJQG7f65H2I2wiV7U43fQch9vnSig9HVm&#x2B;u5VukBt9oWB3ILx1ohp/HjDdQDe0rtkVwVNNOir/sK3&#x2B;p89EVqvfwEZk&#x2B;QT&#x2B;uq8ESBHbgMYdfU/HOJH9HaA/tcbjx3AA0TRAYh4zMbXGEmMKK8x7O92uRqsNlt1ZWVFwaZNm9dvLygoff/99/aUlZU5DjEQj5Z5EOvmbeXrmiMBgskAIHKXgXZNACQqB6tM2aEhutLT0&#x2B;X1lZubK3PKzWYzi6&#x2B;AnKc9KysrkQUG&#x2B;VaJCR46EoYFcVas&#x2B;B5ffvklPvjgffncBRdcgKuvvgbTpk2T&#x2B;9ntdqxdu5aAv5X&#x2B;7sWJJ54oCQBlcTBuc5eeo6vd82MG/xzINiyF4NpOzhBg8SgBRQi0yMH4x9cf4tTSiVwLYd1qIAR6U/A/FUg7wVcyMEiJCipTdnQ5UNkCEInToWVMD8QQnGavpemg2JRFj52&#x2B;lH4vxR/JTW6CO7vYt0lNEWimVk6mGv/fBHuMNf7WHyEargBS&#x2B;pOfH6eXMRjfhn1Rnzd0AcCYeY9qHfA3LJGkhySP7et0DQOu9886R2YUGGvp/bXujR9Mtja06SUVB/4NjeYdkeBDX/y31OOgdb8T6HIL&#x2B;UUK0byeRs4gEgYzpu0b1zKNrwmrAWDYIWDfMGUACBreyFOAL9tAC59REPzh9J9PC8GfIeUIhgMmJiVlZvOWnT1gyJChZ7EE1l13372/oaGhbPv2grxtW7ftXbBg/r7ly5fXNAPqw903RbjPW0LQrf9&#x2B;c6De&#x2B;PfgLxvtNUa1Cg2BijyRuCYjmNfCcVFRZm/RHryLygBQGQDKjhA4raurc3E2QHV1tbN79&#x2B;4pXEKQmZmpCIE4Gtf4P/LIIygqKpK&#x2B;57jjRuCBB/7EWg0E&#x2B;O1Yt24tli1bhi1btmDcuHFSB&#x2B;Ckk05Cjx49JXFQVLQP/foNoMc5OPvsczBw4CA1qPE0Vylg&#x2B;1ESAcK6RNcQ8NToAUhCDFGQsggOJigM4iCcBcMyphFmGCNX7WTbQU3pXShT1qGt9n8QhTcA3e8gsHsVtPTTWuFUvTqJUDeXjvcqhH03o4dAwtZIDhjBcdIwoNvd5G9o7uROJ8l9EX3tkWDtjkm6wKBWHwjL&#x2B;Pi9/gitxxNhYyoJZP3HsPwAreIRiLqFTSjCTX9J7gmty/VAzj3kE3tI0t&#x2B;YOdBcN4BgoB21G0AMJQDRugEEZABEyBYI/lNYfYEwxzd&#x2B;tMj7wqBHEL4Ewmq1HrDZrOXFxSXbCvLz85cuW7p32dKlByorK52IreVgLKv83hiea26fWPaPpbQBaF37wPAnU5jzWBEAigBQ9hMiA7irQH19vYtbDVZVVTk5a8But3szMzNNSkyw9UbjyhkX2L59O1auXIn8/K2oqKiUJQCJiUnIzs7GmDFjJPjft28fNm/ehPnz5yM1NRWTJ0&#x2B;R/io5OYWem4tevXph5swzMGDAAEyYMAEnnHAi1E8T118LcBYDjjzA/AMFmUwMbOb8U5qGhcoQaKsZQ5mkTjItWGoIpJ8IpE6gwLx/K2qDlSlT1q7NsRFi9wx99TwxHci&#x2B;iADwDXrKfmsUWqX6/wag5gOIhm8JVBeF&#x2B;phgYoAX100Ukpt6yUwBLf1U8jkn6r4neWhgFwJPDUR&#x2B;X3313hQ4PcgV&#x2B;15P0Z2sUNDEnZj4vscClP8RouY/9HkcTevGXHpA3x09nyA3N1THub6U/3DgPBpWC0cABKzER2kHGJYwiCTYB51nEWFAvDHTIGpZQSShQUTIHAhpOxi4T&#x2B;B3D/0ybrfbYjabS6urq/cUFhZuX7hgwRaymtWrf6xDy1P2Iz0Xy99EM897Y3jflnQUAGIvBVAEgCIAlCkL6wBkm8Ha2lrWDkjkDIFu3bql0HPetLQ0RQjEgXDhIXQ6nSzSKJ97//33cOONNyApKUmWBzzxxJPIycmRf6uoKMddd90pywjYpkyZinvuuQennHIqPvroY2RkpEk9ge7de8BisUjyIDFRVVfFhRBg/QD7FsC8BMJJQad1i48QMMwOytpGCLBxmnHyIGhcKpA6ngLzCVIYCwlpapyUKTvarfZDiOJr9IteJlOn6AQAtxrNPFOv3ec/JPbUs4Kkb&#x2B;2klxYxKcjirsKq99xzV0O49gKWHwAmAOw79RZ/iZ0hWJBUWHS/7TGHlgsEQCZNahYg9VggbQK0dM5MmkRvsxzYd2MI&#x2B;Eeni6D1f1P/XJHs4Afw7n8McBUEJo&#x2B;nj4XW8yldgJB8mvAG4jbj6n/4EoDQrO5oGQMhQn3NkAwxqfyH6yjQim4Awa8L&#x2B;RxhxAMRhQQIJRAQnDHgttlsVQcOHNhOsWzRksWL1q5atar8xx9/rHE4HKINgL85UB/rLaIQB6KNJIAiABQBoExZ68GqnxDgkgHOEDCbzZ5u3bolMyHAooJqlNpua9euwQMPPIB9&#x2B;wqRkpKKCy74GWpra2E2N2DJksWorKzENdf8ApdddpnMFpg791u88MLzWLMmD2lpKejZsydGjhyJGTNm4vLLL0fv3n1C3oOFBrdt24bCwkJZasCvod9TDX7M5qJgkwI7&#x2B;2YKPpdB2NbT/a00NVua4jNFCLTS0QSFJCwqljSYQMKpFP&#x2B;P0UUFmRBQGQLKlB2F17cDopRA9YEPArPv/bAmkVfU7eQ/O9P9fjrJmkjXv3sPPUcg3b1Xz8LyVNItHUC4fa9LhJYxk4D1yUD2xQTmDQSAYzvdXaqn8nOrWC7t8nhCs7iMpQOJuXqGgfB1GWDgn5QNrfsjQM6tkUVN7dsgql&#x2B;g7/dfCM2jzwOsuJTaH1qPe4DOV&#x2B;jkhmjCXkYwG6kWP/Ap0SxQi5oBYFxVbyEBABEqBBjufSJmAvj0EZq6AGhAc9kDYTIA/OMUlQCI9J0Mqooul6uhurp6e9WBA4UF2wu2ffD&#x2B;B5soBqtzOBzeZkC5Nw63se7bWhIgliwARQAoAkCZshYTAkwGyJKBhoYGd6dOnZKYGOjatWsyt2pJSkpSEKiVRpMPgf46bNiwDllZWXjqqaewadNGTJ06DZdeeqms/9&#x2B;4cQOefPIJbN2ajzPPnImLLroYJ544Brt27URaWjouvvjiRh9HkxwKCgqQl7cW33zzjSwx2Lt3j/y7yZSISy65BC&#x2B;88KIa&#x2B;FZfDDYK/LbTD7dZ7zLAxIB9I03TzsAZRVnrzJghkEQggGt5MyZBSztJ7zTAbQeNqbvKlClrx/6S/GLtRxBVfwes23WE7JdfC5ZK88ugJRj&#x2B;xveTc6El9oFIHQstc7Je0592PAKX64Pf16ULvzp3QXALPs7oYl/tPqCn6IdDA9L3JELrchUB/1sA7m4Szpl7bRDmz4H999E8UCZF/vTnU6F1uhTo&#x2B;Ucp9hcOdTeXyi7Xv1n50IhZ/MRHMwRACEAPt3ofow6AES6KKARAxJr&#x2B;GEmDkM8RRAAEf&#x2B;/mSIBo4yuMx6Z/3B63rfZg7fbq6qq9O3bsKFi2bGnBvLlzK7gctoUA3xMj8Pc2QwqEyxKItTQAaEMWgCIAFAGgTFlLCAG&#x2B;4fRzT1paWoLNZvMQgE3iJxMTExUh0Fr84&#x2B;VWjhaZEcAp/TfccD3mzJmDU045BbfeeivOOONMme5vtNLSEgL6RbLd4I4d27F7927Y7Q6cf/75qK09iOXLl3M3CPTt2xdvvvkWxowZ2/haJhG&#x2B;&#x2B;26pzAyYPHmy1CdQ1pIfzEpBYAFtm4D6RRAcaLq2UkjgatpHXQ1tJwQ4ZEjuQrPnKFnDq2VMoSB7pJ4xkKAIAWXK2vd1bAFk9tQGCZphW0FxRDVf1NDc5RCmAXSNN8iVfy2lJz1N17api95WNG083e/URvFQciSuInrvnbKdobCthWbbTp/BTM&#x2B;XU5SeDS2ZAH/O9TLtPzKvsA9a8Y0QliUGNGGCSOwFrec/gM5XIgBlNgtWGewnNB5LtgiU6LQScBbpIqp07EhigK0lACIeKwYxQIEoWQhRAX3gsY3dFMKVDsRCAoSSDsZMBmP2gH8ohI9k8X&#x2B;5ptdTTOukeLa0pqZmd3FR0dbNm7fsfffdt7cXFhbaYwT5nmaAf3P7NVeaEHw/blkAigBQBIAyZa0ErV7Bre&#x2B;cTqeHNpGUlKS5XC7RqVMnbjsIk8mk1kRbaawZwOA9PT0DaWk68OdV/nXr1mHevHnYsmUzVq1a6SsdsCA3Nwd//OODsiSAiYOXXnoRe/bskWKCc&#x2B;Z8jWOOOUYegzsQvPDCc/TcV7DbbfjZzy7AX//6V/Tr118NeuupMT3Q5TRU62rAupK2tfSD7WladVIZAvEhBNgSO0FLHasTAZIQGCU1BVSXAWXK2rur9Ohp&#x2B;1zew633uMZethRMbQLEh9pXcytDNnc1Re4ZFJn3QWS21g3UfgxR&#x2B;ZSeSWDcTcuCIPCf0PVmCC0xDNwSEUGW8PLqvkNqGgjOVpAEST5g2yFvtcFzgMxz9fFqhgAIqwEQhQCIBv5DCIAAMN&#x2B;cgKGhrj8EeRpLAJrEGgIIgIilES0hALSAcTdUAsBYlAARqcuCfI3X4XBUUfy1d9&#x2B;&#x2B;ws37Cgv3zvp81tal331Xg8gr&#x2B;tHAvicKKdBcRkC4DYi9U4AiABQBoEzZoTcuC2Dgb7fbPUwOmEwmmdTH7Qb1y1EhoLba119/jU8&#x2B;&#x2B;QQ1NTW46KKL4HDYsXTpMhQU5EsNgezsTJSUlPBvgOnTZ&#x2B;D5519A//79sXr1j3jppZfo9XNkp4Hzz/8ZHn74EZA/ara7ABMR9BuqLgQtMc9BnQAwL6Xgbh1gWeUjBFSHgXjE8AHhDBMCKWP09OCM0/VU4ZQh3BNMjZWyn5Tt2rULBw/WYNiw4ejcubMakLaadSXErpm6KKEpnCuieZE7DDAJmTZOCgzK1oMsOGhEXl4RAEQFH2/vORCWNbpmglc0dRBI6gFteB69X1&#x2B;dgIgA/htT8IMJgAgIPawKfwsIgOD9m572AWs/uI8iBBiRjDBkDMQiBhiJKDBmIYQKJ4qg76SFJWnCjZPb7TI3NFiKDlQd2LJ7165tmzZt3PvC88/v9oF7I&#x2B;iPdt8bhTCIhzZAuNlREQCKAFCm7PAbi6wkJCSgvr6e9QMSWUcgLS0tkTMFfKYGKU7G3QPOOGMmNm/eSmA9TXYPeP/9D1BVVY2nn/4nPvjgfaSmpuDKK6/GbbfdLgmE/Px8qUGwf/9&#x2B;5OT0QG5uLsaNG4tzzjlXtjR8&#x2B;&#x2B;3/YdasWThw4ADOO&#x2B;883Hff7yURoKw17FgFYN9EAeU6CvoW0cWxC3AVKkIgXuYPl&#x2B;QM3pmC8tEUjNOWMVWvy5XtvxQhoKxjGGeD2Ww2GePSnNrYCebNN9/Et99&#x2B;gwcffFC2jlXWVr9dCbH/10DDIj1zwItQf&#x2B;31pfBLBJEBjbORmAiQGUqTyPcMhkgkUK8lNLp7/se7dYDe1tD/hATzJmi5DwM5D/pwYyC4jQRW/fA2XDeASN0GmtMBCFg8l&#x2B;VWCT7ywhv4Go9Ff2/N1PQeIYA&#x2B;BkHCCGUAsRAA/lX9YAIg&#x2B;LEIfEHA94lEUASMjY848Hq9dqvFst/c0LBzx47ta0qKi0uee&#x2B;7ZTeXl5Q40rfobQX5bSYBwZQEtyQJQBIAiAJQpO3JmtVo9ycnJGgFKJ7ccpCDGm56enkjPJSgyoI1xituNnTt34IcfVhJgr8QVV1yJv/zlL5g9&#x2B;3Ny8h7cccdduPnmX2L9&#x2B;jw888wz2LFjB7p164bRo0ejf/9&#x2B;6No1B&#x2B;&#x2B;99zbIR&#x2B;Gyy66Ux1q&#x2B;fBnGjh2L22&#x2B;/HRdeeFFjq0JlbTRO6/RQMGnLg6ANlu/0jgPusvABprIWjq9hS6CpW8vU9QPSTgUypwApw/WSAWXKjjJj8dilS5eSj6/AcceNwsCBA6V&#x2B;i8lkagzoCwq20bYdXbp0weTJU8AkfLBxhliwpoyyiLOrriPA2QDcCcb6g64p4Con4O/VwXU4/8OWkK53G2BCII11TE4m/3MsHWc9xL7ryTfVSvE/4WHwTiC77z&#x2B;Bzjf5OqCEX6UOBLWIAuLD1&#x2B;yHPU4kIUDNB2/sW2iuWkPfuYJeY4FG8YbXsw&#x2B;aJwsivTe0zjdAmLoj7BsGfb7Y2wdGXukPVwLgR3bhCYMwdETEMoAg4iGIWBF&#x2B;dsTAJngpyHK73OVms7l0//7SFUVFxbvnz5tX8PnnsyoNBEAsJEA4zQEgekmAIgAUAaBM2VEUo5M1NDR4OBuA1Ve51SALClIwk6jEBNtuTqcDq1evRl7eOsyYMR2jRh2PTz75GNddd53ERBw8LlnyXeOKfkODGbfccjM&#x2B;//xzZGSkY/ToE/Cb3/wfhg8fjuTkZJSUFEuhwk6dsjFgwEB0795dDXLcjOZ8135Dy0EKtGwb9VZWFGA21p0qQqBthIAeFNBsnUOB&#x2B;HiKsU8AMlhd/Bi9y4BSbVTWjm3JkiX45z//Ln32a6&#x2B;9IbvHhAP23FZ28eJFGDJkGC677FLMnHkG3R&#x2B;CVat&#x2B;wLJlyyUpwK1h&#x2B;/Xrp8q6WuVPHOSbCbjbVsFLflqzrqGnyHc79wd2hTG&#x2B;xNeRUHAnk&#x2B;QeEO5qemzXwSRDO9MwaL0fgOhyg69cwBsWt8XSDaAJpMauBRCq8J8gNVX4c6LqaYiD79AcVdrY4k9WJqT00MmK7rdBJHSl/U1G9Bz6eQJKBWIjAIL3a0tLwJBSgCDBxuD9ogslikY&#x2B;gcs3AggCH9vg9rhrHHZ7RW1t7eqS4uKN27Zt2/nxJx/vK8jPtyEwMyCcVkCkWyMZEHy/xWUAigBQBIAyZe2CEKirq&#x2B;MSAVNFRYU9JycnhcUFWT9AEQLxseLiIjz77LNYuHCBFA&#x2B;88MILZSkAawdwC8GammqMHz8Bv/zlL2WK6RdfzMb69evpvlu2HWQxQt6/U6dOuOeee3DMMSOkvgBnEvhXoJTFCbE6d&#x2B;v9rc0LdIEoGwWYnuqmRQyVIdB2QkC2JSPXktBdzxBgHQHZbmy4TNtVA6ysPdnDDz8s28L27dsHt956mxR2TUgwYejQITh48CD5aSc&#x2B;&#x2B;2wWCgsLZdZWWVmZLAdgEjghQUOXLp3xm9/cgyuvvFKt/sc1dvHo5QHOAgjWeuFSL87scpXI9PhGUKmF&#x2B;iFB0ELrfA3Q629S&#x2B;V8Hln5MF7j6r0UUyUMEsK01YUYhIpMFIVkAupiqqJ8Nrep5eC1LfQKNwkcAdILW5SKgx0N6JpXXQU&#x2B;7AzMLmLg2kA8B3QBEmOXpoP1jIQBEBNJAQ1OWQKgmgIaQfIeImgExkgARMhsCSwfoVPB6Heb6unljx5x4L5ovD2iJLkA0cUBFACgCQJmyo48QILDpSk9PNx04cMCRk5OT7Ha7BZcMkKnIvA3Gq/2c6t/QYMGsWZ9JYUFOI&#x2B;W60WOPPQ533nkHVq9eJSe0G264Eb/61a9lNwGuM12zZg3OOecsWXLAq03nn38B/vKXR7FlyzaZjsoZA0p8Kt7m1ckAVoluYFHBtRRgbqGn65pKBhRFFkdCoIfUD5DiXpnTdEIgaVBgj25lyg6zcfo/d4Hh1f0NGzYgKSkRdXV1EsxzRtaxxx4rSdkTTzwRPXv2kq&#x2B;pqjqASy&#x2B;9pLHk66yzzqa/n4ARI46jfYcjKysbeXlrsWLFDxg7dgxOPfU0lRXQSheiGYGu6wDgLoaw/ABw2YB9IwS3HXSbyWezmHwGkH060PXX5GNm6PokBPwDMVKoJF4kIkAIf1vBBMi7DD&#x2B;9Ht1ned0RwX8gAZCg1/rTXCOqnqOT51V6vYeOZ4JGAF3&#x2B;PWMitB5/hcg4mf6W2JjxEHbVPCTDIDQDICwIFYHNA6Ot&#x2B;ge&#x2B;H/TvLsIAdRjLAMJ0OBDBGRDhSwGMOzWRDaEkQHB2hZcel5WU/Pvtt/8367X//rcE4UsCmusW0FxJANDCMgBFACgCQJmy9k4GsCidqK2tdXKGAN26DISASakJtt04kOSVfRb8YzFBzhZgN/i73/0OJ510kkw3XbBgAebNmytbCXKwyZoCvJrELQfvv/8PtE&#x2B;mJBNOP32y3CcpKUmmmXKAGq4OVVlrjeIE&#x2B;3YK1CiwbFiiZwjwqhOvNqkMgbZH8gbeBQk0tSd2B1KPh8Z1vBmnyPtI6u2b4pUpOzLGJCyTshaLBRkZGfK5e&#x2B;75P9kJ4OSTT0JmZhbuvvtXcr&#x2B;ion1Yu3Yt5s&#x2B;fLzvGHDxYi0GDBslygmXLlsoyr9mzZ2PcuAkh78PZYjt2bEdKSkqAsGBRURHy8vLQp09vmiNODnkdZ4sVFxfLzLJJk07pQFkH3hAHG4httDAlAPWEpesJlNv0zABTN0ksioRUBkYBQnThYZKIIARIjxMS9dd47TJzTNhoLmCNAfNyaDm3AZ2voxe4wh678TgM/AnMi7oPIfbfL8UPZUq/vnQNQZ9V6/EnIPt8CFO2D/h7m1ymCCIjGlf79bEiCByUJh&#x2B;dMDC642DA7ydARPjaB0kC6G/tjUwchPvgaGod2BwBEEw8NP1Ghr8z98LlAXTroTEcNmTQGAPw96Bl2gDRhAHD1YwIRQAoAkCZsg5n3GKQNy4Z4O4CLCrYs2fPVNYQYIJA8QFtMyYBeFVo1649KC0txrp1a7Fy5So4nU65wsSpqNxGkEsD7rjjVsyd&#x2B;61MRb3qqqsl4N&#x2B;0aRO&#x2B;//57ufrErQhfe&#x2B;01dO3aDZWVlXTbtVGxWlncoAAFfPm0bfMRAnm6qKC3oYkQUPxL20iBRlFBGszEXkDqCCDjNGhpY&#x2B;n&#x2B;OF3o6yfUZYCzfxgUMvAcMkQPaerr6yVI5E3ZkTF/C9gffliBHj1yMXPmzBB/y4B8167dssyLQf/KlSsaCeAePXpg2rRpGDVqNEaOHCn3P/fcs7F79y78/e//xC9/eWvjcRYunI93330PEyZMwJ133tUYbzPZ8Nhjj9BxV2PKlNNx2WWXYeLEU2S3gqPPPHrplbNUF/5zboewriNfYIE24FPyB9kBaedR0IhPoA5Ni/pCNAL7UGCGqNitqXbeQaD9fcC6ke6S/7dtpengQBO2JT&#x2B;lHUtzg9sRngBg6JJA54dtA1D&#x2B;V3jNX9GTTj2bgDMITF2h5dwF0flaaMnD6PVOme6vfyV6raZ3BxB&#x2B;sC9fR/uwoCFrJWgpXA0PP1kqpHiAJsdV5zx03bvGdHp5DMPYIHrtf6QxD1yVDy4BQEinhPDHDiUAmMSg6LORhNAQpC0QgTTgx0MGDRwXgQAIJgLCtRFsTRaAIgAUAaBMWQeOzcmnMBnAK8xcMsCaAZwpwKKCnCGQmpqqitPbaDabHZs3byIAX44ZM2ZKPQBe3bn88suwaNFiChyzZJA5aNBgDB48SAafTA707dtPZhDY7Q6pJ5Cfvw2nnXa6DBbHjRsnWw0ebu0Ar29VgFfNmNDgOYID5pSUZCl85F&#x2B;l4mD1qCWSOIDjYNDK2gErKWBdQY8L6ctbFCFwKAiBpH5ACk3r6ZOhpZ1IJ89YHyGQfNR9NQaF7FM5eyfS&#x2B;b9nzx4CeI/KsiCuRedr57nnnpP733jjTbI2XVn7nCs//vgjfPjhhzj77LNlO1i/Mem7YsX3Mkvgxx9XYd&#x2B;&#x2B;fRg2bCi6d8/FcccdhzPOOBNjxoyR/pPLDxYtWijbxY4aNarxGOXl5XQePEO&#x2B;/gv069cfN998My655NKjWx&#x2B;GO7Xsu5wujD2h2UHZU6H1e5Ou/4GxgSn/9SRL6b1hQVh44B9FC4AJgIqHIMqfaUpI0hIkVIWbcGPqUGgjdhKEDCYANN0/eWrgrfsYqPwHzRF7IOi30gSDc/p7pwsI/P8KIn2q70O7fKnvvn6rwqaXODi2yC4GcO2mz9BXPkZSH3quht6jMzRTqsyAQPKxhJQy6RD02mT2ES6ZeSASB/iO56a/Z&#x2B;lwiXUVElLoc1ibQHu0NoDBK/LNdAMIXPwXMREABpgfwDQ0om5vKOng358fDhk0YEIQARCOBPBGAf&#x2B;tbQ&#x2B;oCABFAChT9pMIcgQDS9q89fX17oyMjESz2ezq0aNHCpcRKEHB&#x2B;NjevYV49923sXr1GtkZ4OKLL0ZGRiaeffYZbNy4QXYhSEvLkKtKujL1BRRAjoXNZqXgskjWpJrN9fT3zkhOTsKECSfh5z//uRQVjEegy2mrLIbFK2K1tQcb0145U4HnBW6VyAQA18Xu2bNbkhfc6YBXwCoqDqB3714ycOU623HjxmPAgAFynz59&#x2B;hx9K1nCoosKNiyhbQXFjJsoSNulB1nCMOMpaxsh4A/yE5kQGAZknqYLC6ZzhkCPdk8I5OfnY9OmjbK857jjRoasHFdUVEgRUW4Reu&#x2B;992HixIl46aWX8Pnnn&#x2B;Giiy7BL35xrawp98ddnIrOWiOTJk2SKebKjryVlZXC4XAiMzMDOTnd5W&#x2B;1f3&#x2B;Z7BDDBOj1198gM7e6dcuRPpT9ntE4E2DmzBnkH3vj&#x2B;edfkL6RBQhfffUVfPbZJ&#x2B;jcuQuuvPIqOheu6xi/OafVH3yVQPZjBKhrQq/7lL7QBsyC4PKg5jIAbKvJ9&#x2B;6B1uVKA1j0RhDmQ0TsFoijEumY64GdJ&#x2B;nAVPORBZy2n9ADWh8C9l1&#x2B;0QTehe&#x2B;z8Ko/Z4ztvwde8wL9dT7xPi2hJ9Djd0C3u2Q7QkFj0EhB&#x2B;AgAzVMHUXwVhDVPEssBmQ2a/h6CIRC/r9dX&#x2B;&#x2B;8N4DII&#x2B;CfruNXUG8JE7&#x2B;mtovuD6Ctl0m5MXoyByLlHJwa0xCBwHos4YqTsAR8sNwozisjdAMIB&#x2B;sYdAsiYyCQFv2bwwAETwxAA4QgBbzNEQCRBQK8iABQBoEyZMv/87fUyISAcDoeX7xOo03gVg7UD&#x2B;O/8WI1Sm8ZX&#x2B;lneFi5ciEceeZgCyCofiDiOQP1F6NkzV3YZ&#x2B;Pvf/4Yff/xRrhyeccZZBKj1doIrV67E66&#x2B;/5mtNNYBeO0J2IvALWcUC&#x2B;Hfv3o0tWzZh48ZNEnhwZ4MhQwbJLIPBg4dIYUKuieUVKw5MeYWTNQvcbo8kIDhjgb&#x2B;L2WyWwH/79gK5GrpnT6FMdS4tLZGpsykpqfK7jR8/HjNmzEBubs&#x2B;jD61yCyv7Rto2AObvIJzbfISAYX5WNFl8CAEOJZIJJCQPlyUDcuP2g4ld0J40BO6&#x2B;&#x2B;y5JAHz55Rz2jQGxE4vPvfvuO3Sd/oBzzz2fwP5FUgyUtT8YCN5yyy2NZQBMqjHhx6UBr7zysiwd&#x2B;te/npHEGhvXoDMxd/311zdbKsBAlK9ZpVh/aK2urhbvvfeerNdnX8e/4aRJp&#x2B;L0009HeXmZdAaVlRWyhItJWy4t4OwBPk9effXfdG68K/37TTfdjMcff1wSwZGM9Qj4fGJ/m52dFVYbhv353r17sWHDelitVilMyxljR9RYeLXoRl0QL3kAXcPHUUQ/lEAsgez0SXQp50QBVZoUbBWFl0E0LCBQ/jKB8hsp&#x2B;Ej1QbZADYDoJECCD/SammrdeXU9vy8BbLPvMe2VcQpEn&#x2B;eBtBP8S9M&#x2B;wGrSgXnV8xCV/6K5YB8dxwd7BD2ffRbQ80W5gi8zyYSxzt9QHO8qgXfnFHp9OYSPVBf&#x2B;SUMSDanQev&#x2B;DfB/5BY&#x2B;VtlL6O13vbrp1ldHHyIKwltB&#x2B;xfS3OqlfI7gVLoP9rOnQMmbQZ58oxVjDZUs0VwJgBPohYDw4C0CLTAD4v26sBEDjHgIhmg2DBvY/FXoDRY/hNlomQCRxwFg7AwSDfkUAKAJAmbKfrlEA4qWgQ&#x2B;PsAAKBGoE8L2cFsHaAIgTiMr6N9aT&#x2B;FUROL&#x2B;XVwoqKMgm8Z836QtaZ6uDCLoPP&#x2B;&#x2B;77nQQOxxxzLC655GICJL&#x2B;Wx4hGPHCa6tdfz5EpqbW1dXK1ivtdn3nmmXIlMjc3N65EB4tebdmyWRIdGzdulIEzayLwaugRD1BbbR49ALOtg7CtByzfUbC7hQK8Yr0ftRIUjC8hwIAnaRC0FAIQmVN0QcHUseR4Ojeuch0Je&#x2B;ihP2PZsmUYNGgAXUeDaBsoiTK&#x2B;PrmdHGt4XH311ZJI4xTy&#x2B;&#x2B;&#x2B;/j67Z38tyHgZxvIr86aefIicnB6tXr5Y6IF9&#x2B;&#x2B;WUjGORV4qeeehKbN2/Geeedh7vuujv82ejxyNd/&#x2B;eUXMgunpuYgfv/7&#x2B;4/S&#x2B;vGjz/h34gyPN954nQB/FXr16okuXbpIwUDu8DJ27Hj6TdPlvkyWvvDC87I8jElX/u2YEB08eDAmT54is7l4Xy4ZYSDPG/tsvl21ahWdK93ofd6SWVh&#x2B;430/&#x2B;uhDSQjz&#x2B;/3617&#x2B;RAoOsHXPkXWU1XaNpMjVdD/kDgVSoQF8jEAGchRC76Xp3FukqdanDgdyHCexeQIfKMKjXo7FNXuNiuXFlXUJBAtTugxBM4lo30MPlEA1zdSiYPgai8y3QOl9M7qSnXq8vfN0ApB&#x2B;yEfB/BKh4FkIinUTfoQnIZl8Cre/L9HwX374uHwHgbVzdblpt90LUfyGzIkTNf&#x2B;ScIeS4&#x2B;MCz10VDNQno/wH5u/5NNf0&#x2B;jQB/i0LB5IBo0DMPvPXwuquhpY&#x2B;HbEUouBzJAWMJgF9IMHyLv9gIAP/j5rIsAgkAP/T3tTo0CBoGEAEGViE4G2DQwP6n&#x2B;4B/MPiPRATEUg4QjgQAwmcBKAJAEQDKlCnzG2cG8IovBT4uJgQ4iElJSUnwdReA6jAQD1LARSD/XQIOH8lAkWuEmQiwWBqwe/ceVFSUyzThSy&#x2B;9FDfeeHPU1FFePVq9&#x2B;kc899yzWLx4sWw9yADhrLPOokD18AWJTFawgNbrr/9HZjVcfvkVePzxJ47CjIAQqoPCjAN6m0EOLLmftXWtrgrtX4lRhED8CAEOiFMGyfpYLXMy3R8NpI2hiCLH19YLh/Gctsk2c/v375fAnQFez549Zbu47t17NMZTS5Ysllk7nE5utdplH3rOlnnkkUdx9dVXyvIBBne33XaHXE3&#x2B;&#x2B;uuvJKgfOXIUrr322ojvz/uWlJRi3rxvpGq2v4sI15/zfWWH2RMQKIu1e8vBgzXSty9ZskSSPFzqxVkhX301R4J&#x2B;zur6zW/&#x2B;DxdccKE8r4YMGYjs7E7YtGmzzPRikumzzz7Fyy&#x2B;/JLNH/vSnP&#x2B;G88352VP3uzYkAiuLLgdpPdLDoETpsSKb5InW81A9Bcq6u05LYi8B0Zx0oa&#x2B;RzXUW0VevEg20jAf4F5KMJHLvIJ/NxGGlkTAM6XU3bRfS4m1w11wj8N67cM4RhAqP8fojqd&#x2B;Vb&#x2B;1fsG8mGBJo/06fQRp8neQT5oRN1YtIndMjtBDUp2OfRX5GgZ/B4LauAkttpct5Mx0huwsT8/okDofV/XxdKFbYQFCr1APyCepydIP/IZQNNJe0BpfoaGjsAsD/yZyA2VwIQvI8wtgqM0g2gOZJHBOFrIRC2KwDbwAH9piByBkBLuwNEEwVUBIAiAJQpU9bSCZw7CTAhUFVV5czOzk4ioOdhYcHU1NQE3aUo5NNaY3KF60o5Q4BBxFdffYXq6mqZDsy1p7F0B&#x2B;AJnwUIv/9&#x2B;udQR2Lp1q1Sd5qBx&#x2B;PAROOmkCVJPgIHD4apB5WD1H//4myQxnn32edmHuwPBAL1tFfeGbligtxu0rdMJAS9UhkC8CAH/WDLgSh5I20hoGZP1DAEpKpjT7gbZ5XIiP79Aisbxtcgp&#x2B;ywid8IJJ&#x2B;Dcc8&#x2B;T1/q2bduk4ObkyZPp&#x2B;k6WZTcjRx6HYcOGBxyLywLOOutM2seEpUuXyfp0o9/gzCL2y6qDyNExj/rB0saN6/H557Px9NP/kHovl112uSwjKC0twx133Inp06dLgoi1Y3h/zii5&#x2B;OJLGtsaHq3fPxwBwIKC3j0zoblrCSj7lvV9EE1yq41cC6f3J9MrnHpLPa&#x2B;7Cd7pf4YwdYGWOgoi60xoWRfqPoPT6jlry6/S7weo/hVq7gpT&#x2B;QRE9avQPA1N2QUyfd&#x2B;k402Pr7&#x2B;9lgKR3A8alzmknwykHEvvdyJEEl2XTE74Rft4FZ8&#x2B;q&#x2B;CuM4VnQzj36S0F/e/vdsrPiYFfkg/jjARX0FghIkhHcNs&#x2B;RFrJFxF/h8DWg6HdAALGCKGfxb/yr0kyVoTVBRAROzQYug7Q/YED&#x2B;k0LIgBamgkQvPrvCQL&#x2B;zekAKAJAEQDKlCmL1cxms5szAsrLy&#x2B;2dO3dO4owBHyFgCuNjlLXQGhoaZC/qSGaz2fDhh&#x2B;9TkPg1Ro8eLVcDuY6fU/z9ExirTzMIWbFihazd19sNdpNp&#x2B;Sw8yPX6XKt8qMADr7YsWLBAli7w&#x2B;yxYsCguYobtlhBw7pUtsYRlCf1Aa2jbTKFIlQHEqvO6zYRAY5cBcjMpAyh6GAEtk&#x2B;LHNF/JQGL3dgl8uNznxx9XYsOGjTLNm2vH&#x2B;ZrNysqia2IAXnvtvxLgs96AsVsAi3I&#x2B;9dRTUmuAM4WmTZsuj8eEwgMPPIAJE8bjoYcelqQeixGyJgdnGnAdeke2lqzCt2fjspFVq36QvnjUqONlNgjrDdxwww3Iy8vDpEkT8fDDj2LKlKmyq4TROEuAzyk2YxvCaMZChzt2FMhzkEsMTjnlVJnNcuQIAB/ssP4gV8u99s1N/hIIEdFr7IYnf/oknQBkFX0C4VrGOPID4yXoZ/Dtb5/HK/MB/euDUtT1A9NmWUq&#x2B;&#x2B;zsC7VtpoFgQluvz7frnSWj6qP7sf/1xovQ5Imk4NBY1TRkl9QUEawWwngl/joZlECU3Q7DgLJoyNwRnMqQcD63/e7L8SQR0NAglAoLBfyQCQEQA7ZGeCyUAAtP8gzGycb/A44T/vY3jHZpUIDCgf78ZQcA/Vj2ASO0Bo3UFUASAIgCUKVMWz4m9rq7ORUFoAoFMR5cuXZK41WBGRoZJtRuMv3Eq8nXXXStrTG&#x2B;66RaZJrp16xa5GsgCg6xAzUJ8DAT8qaIcMHMd6bp1eQQ0lvoEAc1SbJBFraZPn0H3cwio94XJFN/AmtOfP/jgIymE&#x2B;PDDj/xEfiWPjxAogOAuA7bVAAeW7oNNuaUqQ6DNnEtj&#x2B;MYt1RL7Q0ujADz9NNpOouB6hFxda4/glTN8uL0cX5NMzPEKP6d833bbbXTNBgI9vq6nTZuMW275pby2ucTH6XTJ9HEGhuXl&#x2B;/Hmm29h9&#x2B;6duOKKq2Qru46mDVBfXy&#x2B;BMfs&#x2B;HisuxeB6&#x2B;o5o3KFl9uzP5bnBOi4sOMi/J2eH8O89YsSxqKmpwoMPPkhjkYQ//OEPuPbaXzR73Hnz5uG///2P1KGYOnUqfvvb38qMMD9pfGTAfyMoIZdZD8Giq9Yf9RatrCvgsUK4ywnU96cLx0rXeTeIxN7QUob72udl6e1GEwxhhlfHg5HaCAqEay/Aqfs&#x2B;cM419s79skOMYCLXmkePt0PYdxBYs&#x2B;vH1QyQSRhS3HlF3NRVr&#x2B;/nDggsiphxOl3zDqD4WsBVKAUH/UkO4EyArjcDfV&#x2B;F4DIHIy&#x2B;ByC33ImUBxKIB0PgaEam2v2mEGvUXjKxM8IfzTWherwgkWqJkAjTpC0oC4AwDAdBcBkCkzgDRSgGiiQEqAkARAMqUKYvjZC&#x2B;YECDwmVBTU&#x2B;Ps0qVLMnccYP0Afk6NUOuNV/R/9au7kJycimeeeRYTJkyQz3P5wPbt2/Hdd0sa&#x2B;1Wzn&#x2B;fVRAb3nP5//PHHB4AKTi/Oy1uLp556AkVFxRQUTperjcOGDYvrZ&#x2B;ZWWHfeeYfUMvjoo09&#x2B;uj&#x2B;eY7u&#x2B;NSykwPJHwM59qA82tRyEIgRa73SCSAFJCPSRdbsaZwZkEFhMGSLriNub8bXoz8Lh&#x2B;6w6v2rVSknS8fXNgPCtt97EjTfeJMsIWE&#x2B;DgRsbt5h7&#x2B;eWXcdJJE3H//b&#x2B;X7eY6krFfmzXrM1nSxIKpvErOK9Ysuhhp/&#x2B;XLl0stkgsvvPCo10jg78FCkgzaWYySs7k4fD/ttNNlJtd5550vs0hYA&#x2B;abb76WGWHcdnLy5KmNcf7atWtkhsmcOXPk67g06/jjR4d9P9ab4E4DPMYsNmus744HCRCpLj0AWAajMq/Xp8gfCuaboJyeCR5NdDAqCRCwb4LeEcB/HC8d210F4dqli/oxOcFEBevBCLNfC9BHQmi&#x2B;NrJCf16ip65Sz0QCfOdOveOAj0OQWQCmntBG5NODJDqOriPgzwIISwAEgX8pGxiU1h&#x2B;JEAj3OwSm9gcRCwbxvuDTQAR9nnCES9guAYad&#x2B;JkB/fqeFYEAiCUToDVtAdsVAaCKt5QpU9ZhjAUBKECTy1gZGRmJTAiwmCA/puDW1qtXrxSr1So1BLjzgBqx2IxFAW&#x2B;//TZZJ8qBoLFemIO1k046SW5snHLMQSOTAawe/eKLL/j0AIbhrLPOkcCCWwQuWrRIBpAvvvgizj77XKlszcZB53/&#x2B;8x8JPiZNOkXW7/PKU3p6y1cWrVab1C4y1i//JC3lGH3LvkCGanBQ0GddAzQs0pWrmRDw2pqIAHVltMDp&#x2B;IG//wmPLhJWW0QjPUvv720i8J9xMjRuNxhACBzZgTaW4HDgyYrzrB3A7d727NlL190IPPbY45g&#x2B;fVrjPpzC/cILzyGBvtfLL78SUDbQkew//3lViplecMEF&#x2B;L//&#x2B;z/06dM34r6cFXHvvb&#x2B;TafVXXXUVpk2bKle3mRTgMWaNFC6NYA2G7OxsCXq4DWN71k/gMgf241zywV1Vnn76X7JbgLHEg0H7&#x2B;vXrZVbYCSeciIEDh8jvVlxcJIkj7ibDLQO/&#x2B;OJLSRpoYUQ0mSDg8hQuFeP5oK6uns6pYbDbHaivr8Po0SfItrFchtCrV285H0QrUYsQF0QkFESTpHzTPo3gMwGaTOXXHwd2pxMh7xF6bB3LNyrXIxQsB&#x2B;a7e3WdgUZtV9o3MQdaYi5E&#x2B;qmE52&#x2B;F4G4Dzj3QHBshzN9B404xzu3kdtzwaj6Pwr6IGQBRQ/69Rn4PffXf7RPzI0vqDi37Yl9NgwiC9SLs&#x2B;AXl5vu0CbSA4YgE6gOOE/E3Moyzpn9/47g2Lfz7MyFCywE0Ldgxh2oP8E6avr9xoTl4AdpfgBEM3o0zpIbAnhBh&#x2B;k1CtNupS2UAqAwAZcp&#x2B;CuafmKqrq1lMMLG8vNyRk5OTzCUDFFCYlJpgZHvrrbfk6v/tt9&#x2B;Of/zj6RaNOacZf//997JN3/LlS2UKMgfH5557Du688&#x2B;5G4M81xBxAf/zxxxg&#x2B;/BjZTWDLlk30&#x2B;gOSQOB2gqefPpkCwBMwdOiwmAQFTz11kuwI8N13y3DaaaepHzLsj0TAn&#x2B;tfbZsgGr4DHOto260rXgvD7KusDWNs2Ex03ib2lp0FtMyZQOoY2o7R03fbkXFHkOTklMaVbO4qsHDhAgkKmexjci41NTUMGHbC17nlqK6VZyLk448/xNy5c6XP4uwk1kyYOHESfbckOTa9evWShOdXX30tS6FYeZ9LBFgnxev1yC4oY8ac6NM7SZa6Cgygly37jsCtGTfffAuB5&#x2B;vbZdkEl4twFwBelefPx51eRo0aTb&#x2B;vQ/7uLDDJ/j0hwUTfcQzOPvscSW48//xzsuSKSye4ywCXlkQjie644w6ZqdWlSyesWZMn39discrMAs4UY/KZW19yFwomnidOPJnGs0&#x2B;rvhNr02ygeahf3z40hwwP0Tbwz1mR6tpDgGgE3Be8Ih2Em6NmAUSqZ298rPkgjo&#x2B;oEKz1wpov9m3kv&#x2B;dLcVh4Kuh5u77S7bXr4J&#x2B;JSVMPeukAIHum3qEgaUDA59dL7MML64X9rBG/czPj5yNCjB0DgokV9h2hGQOGYwYMu4g49sHPG8e&#x2B;f98&#x2B;5yI0AyDWUgBj2n&#x2B;wDkC0loCqBEARAMqUKTuSZICEPjabt6GhwU0BjonFBXNzc1MogPXyYzVKunEgduutv5S1oW&#x2B;88SYuueTSVh&#x2B;L04y5lpZXevyptFwC8Prr/5XZArW1dfj3v/&#x2B;Niy66uPE1LDDGIJ41BNasWSNXKfm1HFRyWimnJjNZYFxN4wD8iScexzPPPI3f//4P&#x2B;NOf/twhhLsOi3kadCEqJgUaFusZAo69dLUoQuDQEAJ03iYTQEobpffpzjjVpyCe0&#x2B;4&#x2B;dvAKsN94ZZsBMKvJc2YA63uwJgiTAEwI&#x2B;F/LRB5fh9w9IG6nq8cT1&#x2B;OFI0L27i3E7t27ZKkTl0lwGQQTBCNHjpQghkkBLhFITEyQJQPspzj9ff36Db4a&#x2B;mEyi&#x2B;mMM2ZKIpNJTfZ5L730En7&#x2B;85/j3Xffb5N/8os9MgHBxMSgQYPiOgbcjvKVV16RLWK5nST73xNPHIM&#x2B;fRhIDw0gDfRyge/l&#x2B;DBZxIQBl45wGdiUKVOk32YCl88NP2E0depkbNmyhfz1v3Dzzbcegt/QijfffF0SzFu2bJYihAMHDpLlCCxmyb8fkznhzm0&#x2B;v8KPeUQMZyASwpStt4AAiASeG99V/mPSNQSEvwTAquu/eOr1FX93uV5KYMomxDNYLwlIyPT5H5f&#x2B;moBvIqJ/jiBGI1gMMFr7v8DHRuJBND4nEzN9K/TGY4cSASJQqDEMCRDpO/iP3L9vn/MNgN&#x2B;F8B0B3GhdR4DgWwTdD3sCKQJAEQDKlCk7vISA4OCFAKrXYrF4uMVgQ0ODp2vXrkm&#x2B;1ayfLHpk0M5ieqyq/7e//R233npbXI/P9caLFy&#x2B;kgDlP3ne53OjdOxdjx47HOeecI1d9jCtkrDHA5QXcH52FqjhNtEePXBlYTps2TaaiPvbYo3j11Vfx17/&#x2B;BQ888Cd1grcFqQoLobd1ervBhqUQ9jyK2ksolHEpQcF4kQHGWyYEkoZKVXGN2w2mn05B&#x2B;0ApQtbeBprjR&#x2B;4IwgTd5ZdfKTtt8Oosr9jyivHOnTslGVBdXUXXbbF8fteunbIl4U033RzW1zAQbg4Ms6/W/cYimZnAcSW3LWVisX2Rp3YCnFuxcuVKKZzKWVBsQ4cOkSUA33zzLfnWq/HnPz/U5nr3t9/&#x2B;H/m9Rwig98BFF/2cxrxGaqucffZZR4z85MyJbdu2NhK43GmCtQW4zp&#x2B;zvFgE9uSTJ&#x2B;KVV/4tSwG4POz99z&#x2B;UYxMP43Nj9uzZeO&#x2B;9d2TJGc8jvPF5xsQD33roXOqZmys/E&#x2B;vVcInB6ONPwBD6jZiwCv5d/IRAKHSKVuseHsRHOFD0Vnz&#x2B;14um/IOAd5ckbbIvkd7faUBfc2dCQDCRa2yzF7KiH11ZP/xrIpMA4UkMhNTvc3lIrLX&#x2B;Ihjw&#x2B;//RELMuAFu/vr1/5gPvriAiwNMMARBOByCaEGDMnQAUAaAIAGXKlB1B83qlnC/3y6b53iNlaFlMkEsH2Gdy14Gf0nhwcHn33XfhlFNOwaxZX7SqHj8W47TRgoICGdhv3ryFgsfNUpl89OjjKTAbi5kzz8CwYUNhMumr/Vx7W1i4VwbYXLfMq2&#x2B;cZssB7333/Z5AyRVq5T/eaNVTp5MB3D7Luh7C&#x2B;j2FSJX6apPKEIgfKdBICHDJwGApKoj0cdDSTpWreO0hQ4DB3GmnnSLT3n/9699g7Nix0jdwBs6bb74pibpu3XLkKvf55//Md33ny/25/ZzfOHOAwXBDgxnXXHNt2NICo5FfxgsvPC&#x2B;PxTXmvHp72WWXEbhr3y0IdQJktxRa5Iylk046mT7/sRH355asa9aslkCVOw/4V83DESKcqbVp00ZZpvDWW2/gq6&#x2B;&#x2B;wbnnnkt&#x2B;8L6YyqUOh/H32bZtm/xOrC3AGQL8uZOSEqWfZlLghRdeaLNmC8/RTDrwOfLll1/I88m/uh&#x2B;uLp3H1&#x2B;F0wkvgnu9z6caAAf1xzDHH4tRTT5Gfi8&#x2B;z7OysgGwTDhMEbyGYDhFBaEsIgMgAugkIa0ZAHbAyH7zKHuWYBlV9YWjHF/b7RGgHCIGAdoJRAa2hLaIfE0YSUJTHbQ7YB4ynkcQIJWKM5EG/vr1/zmFEGBKguQyAaC0BI5UBKAJAEQDKlCk72ox1AnwBjIvvUxCgcdDVuXPnJM4eSOTczw5sVVVVuPrqq/D998vx4IN/wv33/&#x2B;GwCFhxzSavIs6b961cPeJ6VA6CGTyMHz9BEgKchmoMMHfu3CEFu&#x2B;K1iqSsGaTqrpAiVLLloJVLB1ZRKFXuV71ShEA8zGu4n0BgLnkwNO47nj5Wbz0oSwYOr9Al17GvWrVagsz58&#x2B;fJ1HgG8NwNgDlT9g8c7rEyPqeJP/vsc1Lv46mnnsTmzZtx5513ydIdTinnVPh33nkbn3wySxJ8wQGxMW5kcuHll18if1CAa665WrYn5PcKl77dXo3HiscimpgdXz5cwvS3vz2Fiy&#x2B;&#x2B;BC&#x2B;&#x2B;&#x2B;FIA&#x2B;BTCi6VLl6G0tBglJaWNRMETTzwlyy&#x2B;MHR4iGZcNrF69GoMHD5IA9/ATIg5ZLsEr9aNGjZJj0pZ5hVfnOTPk2WefkSVl7HgyMzNaAlDkucZzO5c9uOl4gs7lNDq3Bg8aJMsGuOyMCQH&#x2B;vF27dpXkhZGIMWoIGIFnVB2AaF0Dwq3&#x2B;BwPkCERCMFkQDhQHv6GIkAEQ8FmC0v8jEhURygL8n0H&#x2B;lxAo1hda39/csQyA3/&#x2B;PFvi9wr2Gn/MRAO4I4L&#x2B;1WgDh0v8VAaAIAGXKlHUEo8DFy77s4MGDTs4GYFKA2wxydwF&#x2B;ngmCjvadyVfi0UcfwRtvvCZX8x5//AkKNEficGonlpWVSRKAMwS47SADCQYMt99&#x2B;Jy677PJmVw7bQAChtvagDPj0OkWVVRCREHCVSiEqYVlCaG09bXmyDrUxzFFD1&#x2B;YhDrg1pVBk0x9a&#x2B;ilA2mjZ&#x2B;xvJFNKYDm1bvoKC7VIkjok2rv9ngO/1KYxz6reQ6uk6AOO0a75m&#x2B;O9MFnAXEF4JZl0ABrWcKcAlAVdddbUsGWBgyN1DGBgy4ei3JUsWS20PXuVmXY9417ofLnvmmWfw/vvv4tprr5Oidj179pLgl7sFMABm3ZN9&#x2B;wrx5Zdz8NVXX0ol/DPPPFPW0LPgHvuge&#x2B;&#x2B;9h8Z/Fv74xz/KTgV33XWX1B1YseIHWWPfnHG3lQcffADvvPOOFOr75z//JclVfzcI/s2OJlKFxWb/&#x2B;c9/SiLJZrPKcpDgucm4ysxkAT/mWz43&#x2B;VzjsWdfn0zjwLd8bvrBMj92OZ3yPmelcYYAEwKTJk2S&#x2B;g78G&#x2B;Xk5NAclBJASAQSAi0nAEIAcLhOAiI0XT7c&#x2B;4QlFsKu6Mf&#x2B;GhGJqIiSBZCg6cBfCA2RBfwiZUY0n2UQrM8Q6Vh9&#x2B;/S62AD&#x2B;XVEIgOayALyIXgagCABFAChTpqwjms1m81DwoFHg5qCgycRCggRGTb52g&#x2B;goLQc5MOcA691330V5eZkkAG6//Q6ZyhqpP3a8jMEDtwbktlPff78Mu3btkQHbmWfOxPTpMykgGxDT6hHPeSUlxbIelwkEbjfFatC5ubkEKAbLGlAd6OspzvPmzcNrr/0He/bslroETz31d/Tp01ud9LH9ahRWldCJwxkCi&#x2B;lC2eAjBA40ZQcERwLKWkcKNBICqRTZ9IeWNhFIm6BnCaQcT89nHpKBZpDDwJWBe4s&#x2B;Ml2HnFnEPoUJBK4RZ10PBlCdO3fDN998g9dffw1Tp06Tuh9PPvmEXLH&#x2B;1a9&#x2B;JTsQREqHj&#x2B;Y/JPhoB&#x2B;Qdf2fWVJk16zOYzWYp3sffx2xuICA5WmYGMLEyY8YMGtceMo2dwf22bfmSXOFadZ5S8vLWSqX8adOmo1evnjKrYsyYsTF9BiZv7rzzNiQnp6F3717o27cvsrM7SWKAs67eeOMt&#x2B;ZmYDJg4cWJjt5b2Zuy/uS0lz0l79&#x2B;6hsctqXJXnc4yBva7v45KZKb4SPpnO73S6pSAgl2Z0pu9nabAQiO9KY1AuyQ/OKOPj8znDv5G8vEwm&#x2B;ZjPe508MNFzCTLrrG&#x2B;/vpg0cRJGjhwlf0fOTjOS0m53ECEQQQwwEiyTrw1DAAgRmT2IuB9CU/qbju17FE0IMAx6jQ7K6dgsAOonYSIRHCJ8&#x2B;n7Aa0Q01X&#x2B;DOGAz&#x2B;/bt0&#x2B;sSA/hvjgBwo3khwGg6ADF1AlAEgCIAlClTdhSbxWJxM&#x2B;ingNVBQZTM20xLS0vIyspivyOO9paDHBR9&#x2B;&#x2B;03mD9/riwL4CBo6tSpMvjklRAGA9z6qrXq3Ay8eRWMSwDy87dJoL5nzx4ZcHHAxoExlwCw8F8sQ8nZAm&#x2B;//bb8nF6vC6tW/SjrkXmljFeKGijwy8/fijvuuBO/&#x2B;93v5PTCWQYsTDVnzlfo2rWLrDG&#x2B;&#x2B;uprMHnyZHWCt8Vce&#x2B;gH3gU0LICwrCQ0tJFCq4amaEBlCMSFd2m0BALKKYOhpYwGMqfR/ZFA6ok&#x2B;QuDIGWcAvPji81IhnsESX89dunQmsF8kr/NBgwbKmv4VK1bIdG4GVSyY11IgymD2008/ofdhnYBLGzsRtB9fapckAH9nbrnIRGokv8mAlMnLxYuXyJR/7ibQs2cPTJs2A9dee20LCAg7pk&#x2B;fhry8PLz//gdSX4BXzZmAYIKXO7VwhwMuJWCNgl69ere7VoWMXV577TWpT8NCgzxmDLZ5HJlg8a/w82fnOWPs2DE0Vr3pPOhOz/WRq/U8TzHJwSQBkwYsQJuUaKKxsCOT5gV&#x2B;vqKiUmazcNtD1qfh8/ZgXS1279yN2tpq1NQclAQDH8fj0xDgeYaPP3jIYCkoOOGkCRg&#x2B;fDiGDWVB29TGOYsJCY/XEwKuw5YMhEnTDwv&#x2B;g17YLAFgJB6MuDmadkAEYb9wBIDeKjJBT/kP0xJBNEMeRC4tCOwiEHjYJi2DSB0C2Pr07nVZEPhvqRigN8xtsBaAIgAUARDvIKpIT6tMGU4j0QlqCUWZsvZp7GNZO4AJgZqaGhdnCLAf5OwALhs4yrkAuYrHQdHcud/I&#x2B;su6unq52sIBY9&#x2B;&#x2B;/WSQxSsu3P6K24WxYBcHaPx3rue1Wi1yjMrKyuUqO6sz8yqg1WqT88UQCqI45Zd7j3PKZadOnVr8Gd9660189tlnUh&#x2B;AW1lxQJKb2wM33HCjrH2dMWO6BBscQC5dulTWKS9atJg&#x2B;ezfa5yZcf/31MiDm1TBeheTPyPXLHPT5&#x2B;6Qra83F4ZTZAXDkQ5jn6&#x2B;KCjm00t1kUIRDXcfaFojK6SgFSh8qsAC1zit52kNuDJWQc1o/EQIlXbMvLKyRAP/XUU6VoZ/A&#x2B;DEY5I4eBu9H4OuQ0eW6/F670h4E1k3efffax7AzC3UsYCHYki6XOP9g4i&#x2B;rRRx/CsmXf46GH/oxrrvnFUfWdGWR/&#x2B;&#x2B;23ePXVV7B8&#x2B;TLpfxm8OxxOOV/wb3zCCaNx2mlTJIHBbf4YoHOLWZ5vmDgxmy3ky6tQWFhEIN8pyWbOAqsmMN&#x2B;VMwEsFvLvA2T7QJ6neI7o37&#x2B;fJBP69u2DrKxsWQZQUbFfkslcwsIkc0lpKdIJ4HMrRp7TeJ7gjSZ6ZNL5e8wxIyTpzN0PeD48ZsQIZGVm6j3v&#x2B;RL1ZRX4WwhGAoUCUYT1wq6cN6OIH0VoMNbXRCoF8IP/aASCCPrcYb9DOHFAhC87aMwECIXXAfv16d3rcgMB4AoC/q4g0B9MBASD/2ABQK8iABQBcIgIgGKIvdPplLNC6/NvIPsCFeQoU3aUEAJms9nFOgEU3Npzc3NTKFj1sqAgEwJH&#x2B;/fjWnlOU&#x2B;WNFa&#x2B;5BRiD&#x2B;QMHKmSwykEVj4GuXG3H8OEUBGVlyhWcAQMGymCfSQIG&#x2B;hz0x7PHN6/6s5ggK1BzLTKriHOK8W233Y7Kygo8&#x2B;eSTsoa2S5dsXH31tbjuuuvl67jVGafsJienyjmdp02v1yPbnt1yy60466yzDosoYse/OByyhzXsm30lA2vp8S6a52yhUYKy1pMBMBACsj94H2gZU4G0cUD6BCD5GD1zoB0ar4J//PHHkiQcNmwYxo4dF&#x2B;IjuKTgX/96WoI0brFnFAptDlxyH3t&#x2B;/YUXXihbGsbT/xxp4MyEy29/&#x2B;1v5nZ555lkMHjz4qJo3GfC//vobmDPni8ZUfl6l56wJFoO87rrr6HacLJvgUgbOcJg7d67MmvBrTvD&#x2B;TJzw/JOcnCQvAvbdunClST6v&#x2B;TQB/LoVTGinpqbBRI9l5kCPXIwbOwZjxk7AtKlTZRvayspyLF68GO&#x2B;//57sxsAdajIy0mSde6OGAB2TyW9&#x2B;Pyat&#x2B;PxlgUxuhcgZMEwyGEkqPaPAE5oeH0YIMNx4&#x2B;ffltH6vBNUtae/XjA5AyP4GAkLq5Gg&#x2B;UcXIbfiaExOMpisQjggQhu8YXhxQBBAlfXr3uiICARBJCDBSGUAkHQCvwdsqAkARAHE06yrA/K1&#x2B;buX&#x2B;RQU2ypQdnYGZYDHBlJSUhIqKCmdubm4yiwpyuQDrCqgROnQBJWckcEoxA4rnn39eKmpPmTIV9957L0aMGIE777wD7733nmwL9fDDD8tUWX&#x2B;v8Rkzpsn62&#x2B;zsbAoy5/vEuXTj1cmW1kQrC2NeJgS2SEIADYsg7Ovp8V5JfKsMgXiOs&#x2B;G&#x2B;qROQ7NMQyDwdSDkO/8/edcBJVV3v78723htLE6RYwI4aO9YUTdTYSywx6t9ubEk00URNjL3HHqMmGlts2BVF7IAoAtLrLrsL2/vuzP2fc&#x2B;&#x2B;UN29em2VBwHd&#x2B;DDM788p97d7zffec7yBzAp3vTaOU3EMPPaDSdDhHfdKk3VBcXBKNAGCh0v/8599YsmQpTjnlZKXYbvQ5uUoBk5IcqcRAjtOWIn3BV199hQcffACNjetw8smnqAojPPvLIGxLIAG4T&#x2B;KZaiZW99ln80pj4nKBjz/&#x2B;T5WewDP9XGqSZ&#x2B;kZQP/0p4fjtNN&#x2B;hVGjRqtokeee&#x2B;y&#x2B;mTp2qUkcYbDOAZrKIIwXCejxx94QlBrIQD5Ss8A9ESwUyMaAjySpVdBhHkx188EEqfYBT1m699Ra88sor6j4z3j&#x2B;RmW0O/eftcKQKG18XJi4m7TZJRS4wkcHHxFUyeH0mKDiawAqgm0F6PLiO1wywrQbgIgbIJQ/tqgcYNfcY&#x2B;KvzK&#x2B;BOIJi2ISJdkakSgJMugJkEiF/e4mgM6QNDqiqPNxEAXqsB9JvAvxUBYFUNwCcAfAJgsAZt6jj6FtMAvY3vBfnm2xZifX19oZaWlj4WEVy3bl1vVVVVJjkJQQKafqz5BneS68PAXWDBggXYb799VNg/Kz2/9toUtLa2EchYhf/&#x2B;91ncd989quTZDTfcoGqXs5PGy9577z0KpEycuKMSFDzuuONVHu2WMpP4/bI2PUA3Cwl&#x2B;GyYEvgR6V5D71e1HBwzaOTa88ys1F0gfA5G1A5B7IJC5rSYFROb30jyO4uFqAC&#x2B;99JKKBuAonNTUNAXyeEaYZ145ZcdcIYB1BB599BEC/ZNx8803KT0PLq3HAIwF5J577jkccsjBSkgvQihwuPxFF12ovj/rrLPVsjx7y/v5IRgD77vvvgvffTcfxxxznBJg3JjGfe2TTz6lRFi5AgyTtZHosaOP/qWK7mDxViZ1mBzgygqrV9cgJydbXaNIVFbSOMdMAIS/09EA/YoMYGKIUwr4IeH7r6SkFMefcAJuuP4GtQ6N4Xjk0Ydx1513RSsKJO7HQAgwsRDsR093j1q&#x2B;qLBQbZOFdjlVYJ&#x2B;998Hue&#x2B;yuwHwCARCe2Faz3yEZa79Leb8EMG&#x2B;YrrerBmAXAaBy/LlqgikqQABJkQ9W0QDm5Z2IgJAMWaQPxFojY6wCEwAn0KdeWAsBGjUAvJQE9AkAnwDYiNbxAeR3&#x2B;0NUXQxU3T6IGw6qMk6aWPDNN9&#x2B;&#x2B;N1&#x2B;cjB0DjhDIz89Pra&#x2B;v5wiBDK4ykJOTk7q56wdsqrZixQoVHcA5xgz2WYiQ9QNYGZpTGNi5PO200xS450gBNo4M4BBTVuzmNIMXXngBS5cupnVyVFTBY4/907buN4sdcugoz/DsvffeKhx0Q5U03KIs1KF1A7q&#x2B;oPHwC8jOD8lNq9eEAOBXGRhMQiCaMpCjUwSyd4TI3g/ImqB9he&#x2B;BENCAPEWB/ggw51n8//3vfzjnnHNUShE/R1zTncOzb7zxRgKORytC75e/PIaA40JcddXvlM7Iddf9OUEjgGeUOWx&#x2B;2LDhatb5jjvuUGVIDzroIJVewKKEW3IfvHjxIlx99dUKF&#x2B;61194477zzN8p&#x2B;ue999tlncfvttyrgz5EYfG35enM/&#x2B;49//IOuwSHquj722GO466471XKcMsZh/TxbPVB8otAZAXwF9mnsjYB&#x2B;LgHI/TfP6HPUF/f7Y8dto2brtxo5QqUBrGtsVOun073I0QlsDz74IK644jJVYcHyXhGJbeAX749JBD7ugw8&#x2B;FGf&#x2B;&#x2B;tdKO4ABvmspQAuAbkUAWAJOU5qB6/JANLIiWlXARojQ/FMckDeRAFFBQtvZfQcdBNPyiTyB/mJIZcUJBtBvJAK8RAHYgf/g5kIA&#x2B;EmLm7P1r6KBtxiy/S3yIP8AUXEtPTFpOi2AhX0C&#x2B;QPcbgPkkgOB8ishin5D28naPM5HqEuRIsj50cCP3TffNiHjagHs2JaVlWXwwDB06NBMBv9cdpDTBLjaADkkGZxGwOKC/hlbb8KFHPxlOPfcswmU16rwTp65KSsrRUFBPiZMmEBO2H7YbbfdVH3zRx99FMcff6wShWJQsPPOO2Py5AOVrsDnn3&#x2B;m9BC4YkJd3RpLjQAG/ixmxTOQy5cvxdix41S0ADt933zzNb7&#x2B;&#x2B;hulhs7OJIeH&#x2B;mb2PAmMZu&#x2B;pX4TdRLBJawh0fAh0zYbspPGgby25ZL1&#x2B;hMCAO6Hwe6R3kR10bmeql1z3KHmRTAhso4gAkROpMjCe1tvwNeQjJBnPwEbszDN/raIC3nnnbQKOnyugzsCeRdemTHldPV8M5PhZ5xKfrFGy4447qLBxBnW8HAO&#x2B;Cy44H6NGbYVrrvlTdNs848yz4l988YWqLhCvm77l2ejRW6sqARuL5ODz/tprr&#x2B;G6667D4sULFeHKYFsB4r4&#x2B;Ver1ttvuUCQpX79f//pMFQnCy7AOgI4OcAdQ5tnkSH6&#x2B;BvtB1f/qkPxSjBi5FcaPG6eAfmVllbp/mKgVIoCm5kbM/uprPPvs81ixYpkiTLiKBZcFfPnlV9V4wboELBDI4rIJY4DFadXaOD0IBUM46OBDcPppp&#x2B;OnP/2ZAs4RoUNI98fVTgTQZQA0bUvovHnDT8ZzF0upiIB7EdtTguAAExsy4TqYvlDrmKeJo1EPBsIgQVgw7uDN&#x2B;zAdQ&#x2B;x/44hgnoSGxfdbVtfuRwBshhEAoSamKIHWVyHr/gwx8r&#x2B;Q3&#x2B;0KUX0vUPp/QM0lkO1vQIx4SVcJCLVqcJxa4dUNhly0Cw3wcyFGv0vO1V6bLuBvfR3I25&#x2B;udjE5ea1aGJGPt&#x2B;h0iNJLteKxb75tmWBVsrPAZEBHR0eQNQQ6Ozv7y8vLM5gc4BQC/ywlb&#x2B;x88Uw&#x2B;g/eUlFQVmskOpnl2kB3GTz/9BJ988gkBgi/VezM5hCxiyGW9uEIAO4pXXfV7BSa4ykDEOH/16af/g9tvvx0LFsxXKtN/&#x2B;tO1OPDAg1S5qSeeeEKVuOJwVhYjY7VuFjvzLVlEUa&#x2B;j2ZgY7voKsvMj&#x2B;m4djRF9YQLBJwQGZyw2fE7NAtInEDrfBiKHxmNOHUjnKgN5m16zqf/kMH8m2z76aLoKOWeib9Wq1ark29/&#x2B;9jcceuhhimior69X9ea5zOkxxxzrX/NBtnfffUdVX5k1a5YClcYIqAjoe/zxf&#x2B;GAAyar72655RZce&#x2B;0fVX/rcbxUL&#x2B;63WflfV1BIU2BfV6spVQQsp21xxMeYMWNVWgm3Zd3atVixcgW&#x2B;/fZbzJnzrSKH586bqyIFuC9nYJ6Rkaa2x4Qx9/8XX3yJiirh8ePd99/FWb/&#x2B;tZ61t9QciI0pPPPP6Stnn30ujj/&#x2B;eBVBxuNIpP0W3noCfhdGDCylJQHgTZjPOgWACY64sn5O24vbpr1ugVVJQqtraH5&#x2B;LVMBYMz3N68nlTAjv1dVVpwEPeNvnv23iwJwEgI0RgAYqwH4KQA&#x2B;ATCI1vUp5KpzCPDfBTl3PwLA1PxgA0TeUUDljbRANwHhH9MZqCAAPxVy2aFA5yz6/DaQsUP4yWnVpzBgUwu47VnIJadAbDOHBu9N9PSEOiAXHgCUnQpRfH7M4Wt&#x2B;ArLtNTo/D1HbR/sjq28/DKxDoJ/Hj9bW1n6OCAg7DLKwsFAlrDJB4J&#x2B;lDWcctsriTxxqzCriM2Z8iaamZlU2isYYAvcHKrVnVqO&#x2B;7757MW/efOy66y646KKLccQRv8DKlcvx4osvqnDW2to6Ah4Hq7zb008/fZOqW75Zo1RFCHCEwFQaEzl14BPIvvoYgvUjBAaBmTS9pxKQy5iohASVsCBHa6QN09UHNjFjsFZbuxoLFy5Ss/wM&#x2B;Hp7exQwXLDgO7z66it4&#x2B;eXXCIQeoF2xrk56blcqwpDByI477uQ/q0naZ599Rv3h3XjzzbcUADaXe&#x2B;TzyaHwO&#x2B;20M1544UU10z9z5gwcd9yxiqQ1EqtGYMgAn68npw2wACBjD9ZsGTKkSinvc0lZFu/jF4fnc2oBp3wwuF&#x2B;yZIlK41q8eLGqFMNaE7wdbh&#x2B;Pq5HyrxoMpySAUBYCPPLII/GPfzyg2sLHePoZp6ErXNo2ob0yhPa2dqU/c&#x2B;65DPxPQGVlZbQKgBNAtNQCsAGSrqX9TKjcvDy3PcCv8D1uVynA63a9iANakQEJVRHscKw07y8&#x2B;NaCqsuLkMPi3SgMwlwK0IgGsqgBsNgSAnwKwOVrWJIiRr&#x2B;hBdNg1QMtzdJu2qNl&#x2B;Wf9ncm7eI&#x2B;BbTbfycnJyPtF/5x1OgP4AAvTrdPfQ/rZOFah&#x2B;2PqpoX0gJY1u5WZTT9USDq/fBLykQA7E2PepjR2GO7ocKDoNouA4Oj9D/XvFtx&#x2B;MhSsGiOLiYgX4OVWAB&#x2B;q1a9f2cioBkwL8d1FRUToP5Onp6b6nOojGjinnaPKLjcP&#x2B;ebbo7bffUmDi73&#x2B;/Wc0WcflAnnG69trrVEkuVue&#x2B;667bcffdd4cFB3&#x2B;klmWRK859TQriqnrXzSpigR0JdlJ9iw4Y9JBU6heXvFOsWQ1E55eQTAh0fQ10f07ftcWt4luSJkzvrMfQSee143PyLB4hvyIbImO89jGydqJrsY&#x2B;OENgEovUYzA0dOly9eKaZnyEWwItU&#x2B;&#x2B;CUoNdfn6LA4bJlS9VzzZoCLEzIGh5Tp36ocsR9czcG7/fffx8efvgRFfXEANxOXJGBd0VFeZQcWLx4iarowOkdkfB9fle3nQL6hSpii8scsogepzJMmLC9qubCqVs8q85ELEd1vPXW25g&#x2B;fRqB/zWoqVmtZu9VOgCB8lTygbOy6L4UAaQT6M/k/tgKWJuAZUtLM3baaccoMcD3CUeWxYN/Ls0XRE9XDzJoH2eddZaqPjFx4kTVj0fIBqvSfUYgHafwj7D&#x2B;n4Qj&#x2B;I97XK1m0KOh&#x2B;JFt67J&#x2B;iuxAbHZdGHGAkFbp/wnbjB29TgkIeVjH5pA8VHNIXDGWOhC3lFUaACyAjrBYB9hMaWM/AmBzFgGM3vm95LjMV2HwsuUZYO3N5P3XARkTIEY8BrloV4jyqyDX3k5/h4mDlEL6nn4fOU3n60Us2ADUXEgOEYsprYEoPBWovo/OPnV8wUZg9bn09wNq/ThjISYmvjjlQOR8v&#x2B;dj2RGQ7e9DjPlYnQPffPNNhbZzWAC4soDCNjSi5&#x2B;bmphLITAnPYvhznxuqi6bzzqHGnCZQV1eHY489Vjm711//F5UKUFtbj8mTD8Axx/wSp576K0vgr2eSPiVA8h3Gjh2LcePGR9MS&#x2B;DcuY/bXv96oalBvv/32KoT0kEMO8U&#x2B;&#x2B;Z6PHomcZvebS&#x2B;PG2rjTQM4PQR7tfcnCwLTIfpry4XIjMXWmsHh&#x2B;rMsCRe5tg&#x2B;h4/xwwa2VasWK5Kh5aXl6vnj3UHzj//Ap90czGOlnjssUfxr389riqtcF8XmU23s2CwH2PGjMOUKVMUeJ89ezZ&#x2B;8YsjlL4KA3rWbmCNFNZm4Rl9/szXhaM3WKmfCQOe2Z816yvqQz8JR3rUKuImPBaq/Hx&#x2B;xZUJjCW3Ax7QHq/HJO&#x2B;QIdWqDGFubp6KHPnxj3&#x2B;M/v6&#x2B;6JoMqlntn/c3cYcd8NtLf4vJBx4YFf&#x2B;TJoTqNrseRwCEPyRsI0wWhCzUAp2qAYgw8I/uAInbNhMMtu1NqDRgnZrgnJZgXQXA7jOi50MmtKmyopwjAKzKAFqlAJijAKxEAN2qAfgpAD4BsKEHV3JYumZB9q6CKDoBsv5qAvU30Bmjx7/qBvr7r8CQm4H2D&#x2B;j1DsTWX9KZGK7XXXUyZN1T4bNTSrd6Dw3MVRCjP1IRBXLhbrT8R4m6AG3/g1x6JETW9sCoqXT2SzbCaExtq6NjyztCzyKwJkB/DeSSg4ECakvfCmD4swYaeZUWNNwYbfPNt00ckLJ2AA/s1Ad2E5BMb29v7y8sLEzLyMjwCYGNYK2tLWr2ix3Fn/zkxzjllFMtZ8AYXHBqwZ133o6nn35GqZ5zmbNzzz1PCVPNmjWTfrsDr7/&#x2B;unJ2WYzw0ksvU0JZvq3PQ9JLY95ioOdbyLZ3gO5v6DWbxpgO&#x2B;3kg3wZwng0vDi0OZJIfMQnI3I7G9f3onTUEhn9vZQfdjEPDGUgy4IwYz0bzTDLnSjNgtRIATcYaGxsVUE42ImjTOk89eO21l/HQQw/j44&#x2B;nqzB6r8fDQxGfyylT3iCwv43Cg199NVPNkrMGAEdmMDFTX1&#x2B;HVatWUp84W1Vu4fSMtrZWjoJT14TBPe83Eh0VyWO3yyM3NEDPRBtE7syPPbeFqxIcdtiPcfPNt6G6eoi6B04&#x2B;&#x2B;SQlMFlUVKjWUgJ/1KdvNXIkLrviCuy/3wEoLS1BX39QRYdZAWUncJwAoqUJVRrAtiIALKIKrAB6QAQgUoR6T0gFiKxjAvORiAFrGQC7CgHxGFiGq43YlRuMlRZEUgQARPxvYQLgFAPwd9MBCMJZB8AnAHwCYBO0YJtW7G1&#x2B;ih7oPMjuWUDz&#x2B;3Q2BFT8Td5&#x2B;EMWn64E22ADZ/iGw9hb6nYByyfm07NsQw&#x2B;7U6r5zS4GhDwP5Rybuh7YvO96HyD2UAPgxG8VzkHW/16kAZVfrtIYMGhy&#x2B;2w6i6u/0258gxnxGV3mEXrrxAYjmfwOjPtAqxtReVN6wyToWvvm2MQkBcmL7yCkKUJ/YxYQAObbBgoKCNI4QENr8E7WRjEWfGhvXYc6cuXj00Yfx4osvKGf5kEMOVXXK9913X/rtG3I0b8Ybb0xROaeTJx&#x2B;E3/72t9hrr72UqNmMGTOVxsCECRPhX7vBeEjIH&#x2B;ydT0hmLtD2Jo2j9N49R6eg&#x2B;RUGBpcQQNhlJvChIwQmAtm7A1k704ve04dukhECTMDNnPmlml0uKirBmDFbq3Sf9dUFuOaaa/DWW2/guedewLBhwza7S8pRS7fffhueeOJxAsD9BNoLooJ50fJxLsYAm8Pj//rXv0UFUb/5Zg4uv/wyNDU1KqDf0LBWCfzxDD&#x2B;LCPL2I/vwBPRtgH80AiD8WYR/45r33QTomVyoqKzEYYcehqvpWhUVFuHDDz&#x2B;kz3/AHGojpyRwn86EwPDhw3DeeRfg0EMPVWJ/XLWA14/P5bcX7YuM15FjsSQAjBjbpRpAhFSIquszuOJzZgyvt84pcIwEsCMB4q5BrJEwN9dZTDA&#x2B;ut8rEWAuLVhRXmYkAKyiAKx0AMwEQAjWYoA&#x2B;AeATAJvAeNr6LDksb6kwfZG9N4HevxL4/Q8kawCwQjKLIPWspkGVTkn2vvTalZb9Vq/DOfUFR0GUXkFnqxpYsC1k7v4QQ&#x2B;7blBgOfbnXXErHdhuw/DgC&#x2B;//Vd0B6KUTWj4D8o1QEhFz8K4jxH0DW/QFonwVRcAQw/N&#x2B;&#x2B;0&#x2B;WbbwYLkVfChAA5T4G6urpu1hUgByyUn5&#x2B;vCAH/DA2uLVmyGFdeeaUa5jhslfP4OcS4ra0dlZUVSon8qKOOUiKCLDB48823YOrU95TIIDuSrCfAzjEbpwJccsnF&#x2B;OKLz1VeLYejHnXUkTjhhBMxapQvijp4A2uPShdA9zxFPsuuWTpioN9PGRh0QsBYGDy1hLD/1uHoACYGJtF3w&#x2B;lcf7&#x2B;EAAO84447hp6/2QTUn8cuu&#x2B;wSdehZSI6fxyVLltLfWqBu&#x2B;PARSjSQy8qxvkDEOKKAKxDw8z9//gK0tDQpUTjOf&#x2B;c0g/WNJvg&#x2B;jLVNli9fjoULFyhhxS&#x2B;//AJLly5VJRg5MiA9PU1VXInMytvhEo60YHG8u&#x2B;&#x2B;&#x2B;BwcffIg6j5wWcO&#x2B;99&#x2B;Dzzz9XqQJc4jFyjpIG/A4kgAiTOKFgEMFQCN1dXYpoGDdunCr7es455yrNgUWLFuGpp57Cw488hHYC/NwHs4ggpypwlNdxx52g&#x2B;mpuFpMaVuA5DuzKeC7CHtwmRgsY8/Wdlos8WhxlwTP&#x2B;lmDaQmzQCN6kyz4sQa6T4KAVwLeLIIiSHtaigNIqgkD6BIBPAPwQIgBCbZDLCOh2TIMY&#x2B;aISBIzdbd06tL/5P2HBwI&#x2B;1A5OSSWecfgsFGA3QQDsSYvQ7BLJvhux8D2LcAut9rb2TBmYa&#x2B;LK&#x2B;h/BTrnww5HYC/VsBba/SMT0DND/LdCYnkdE7XfL&#x2B;PjoHD0KuvhKimo5l9fkQW9NxZ&#x2B;5oOF&#x2B;tNNLQeSr8lcuIv4jOU56qtuCbb1uysYBgS0tLH1cSqK2t7amqqsrgFAKuMBAWH/RtPYxzYV966X9K8bmzs0OFE5eUlKpcfnb6eQaJbc6cOapGNs8GstjglVf&#x2B;ToW0corAVluNxIQJOyA7O4scy35ysBfjzDPPVKXN6uvXYr/99sX770/1owE2GFDt1oRA5wwaI3ks/UilpEVTBuxkpXwbOCEQoJOZUkpjPvknTAiwqGDWbvT3CDrP6Ruzf1S57U899aQK92ZjfQ6e4a2oqFDg/4EHHlBk3FVXXYGxY8fj66&#x2B;/Vs99R0e7&#x2B;p7z2CdN2l3lt9944/X4&#x2B;c9/ocAkL8NCdV7L3dmeNkPt9O/bmCxhTRTuzz75ZLo6Zlbe55l8LqnHRIAxJz&#x2B;CU1SOfFjwb&#x2B;&#x2B;998INN/xNESj8Nwsz3nXXHZg27UMVCcBEiyAwy9vibUQiATj83hx1YKwtH3nnaxp5D5fbVTPjXBqwIL8Ae&#x2B;zxIwL&#x2B;&#x2B;&#x2B;HII49SBA5HZHElg4cfflClHkRm/fkYOHLrV786DZMn6xKGasZfxofKW8&#x2B;yW&#x2B;fVm2fSzeA8AeyGN2AHzDXwty/r57SvuFQDm/x&#x2B;O3FAc5i/VTSDdFjefMiOwN8C65aXlZ6KWPi/uRKA8dVnAPxGEiAE&#x2B;3KAPgHgEwCbCglATkjXlzp3XzgwyL0r6LUAsvUlWi4FovBkuvVXk2/zjRISRMPtkHVXQGzXFR86z8JJjY8C/MoYr8oPbswBWJMP1LbVl0MMu0eJCMmmJ&#x2B;hYvoaouls7ZDxT00YO8KgXIGvOJwdtPt1FPRBZ&#x2B;wKV12nigJ2J3nmQ87aFGDcDyNwZaH8TyD1Y33J8HgNa5FA2XK8Jj&#x2B;y9IUa8qNvQ9amOnCj/Q/gW9M23LdAH12KCPXl5eamsIVBdXZ3Z3t7OhEAaOVo&#x2B;xNnAxs4yhwJzNABHDnz66acq9JXDjXnmkYEEz6499NBD6O7uxF577UPA43cqdcC3jTXmtusIu46PaPycSeMIC&#x2B;vW0asz3sPxbf0JAYRdbPYvOXUxYyRE9gE0Nu8AcOlB1jgSG06cj8H/TTfdpJTtGZAyANxnn33VLD4ry&#x2B;fl5auZfdbs4Bx2XiZCHLAoKM&#x2B;Is3gnlx/k5Xg2u6SkWOl8sGAozyIn3F5hIOtkHHI&#x2B;ZcqraG1tw&#x2B;GHH6HIiE2RAGSgvGzZcnzzzWyVvvTll1&#x2B;GIwTWqfPBIDpCCkTAKJ9znu3ff//9VcUUrp7CZfRYL&#x2B;GDD6bio4&#x2B;mKfG/VatW0HdNalt8zjg1gPPweVtGsM/nkt95P/x7Tk6uIhG4ckAxXYuddtxR9a8/&#x2B;clPFbnD/S9HNEyf/jFeeOE5RWZwpAMTsrwt3saEiRNx8UWX4IifH6Fm1iPA3wbjWwBgi1l9ztwNWYNyvrIRVX23EP0IHoso&#x2B;ztwD4lgGonK/FYpB&#x2B;Z9uhEAsWWNWxf25f7M4oAK1JrJB2N1AjmYBICVEKBPAPgEwBZs7a9DLj8KYrs2GKtIymU/IUfnA4jScyBrb4MY8y6QM9n0sHbpagLevKfwc5EEiA62Qq46BWh&#x2B;RXcM9CiKIQT0q&#x2B;7Qt09/rX4&#x2B;OVyQqx2sPIMcsy/pcV&#x2B;jd5dZTQ7DzhB5P4esu07PKAx7AnL1OfR5d6DwdMil&#x2B;0FUPwKkb61FB9fdA9n2KgSnVWT/SJEFcuFhQMVZtO8HgZbnabs02Gds6987vm2xRo6NJMerNysrK9DQ0NBbWVmZyWUImRDwz84Gxpnk1PLsF&#x2B;fZcokydp6ZIGhv7yDAv7cCEKeddrplvWzfNqIFm4CehYQWPwK6ZkB2fEJu5QqOKfY1BAabEIhLGSin8XcYRPZkrSFAY7wqOzjIVbA575&#x2B;B7Lvvvq1msTlEnevNJ2M8y1xTU6MAJAPVqqqqhGWYMJg2bRqB0Wra17u0zBBVc76oqChuuTfffAP33Xcf8vPzcOGFF2GnnXbebNIHGPSzav9XX81Sef4sdMrREA0N9SplgHFERMyPIwLS0lJV&#x2B;cVddtkNu&#x2B;66q0qt4IgKxQfRMTOwZ3KFo6GYIGClfi7vyH1iT083CgoKVfQBlwtkcE2YQEVeFRcXIT09g34vUDP6HI0xc8YMLFi4kPrZz&#x2B;h9EZpoe7wPvl7cHgb&#x2B;w0eMwHn/dz6OO&#x2B;44RVLwNiMCf1Laz4x7IQAi20hQwbdLAbAS62PgH0iJEkhOqQfOJEBY9C8KvG3abSAAbCMBEsL0ZQLBYHXcVpEAxrY6RQHYEABWIoA&#x2B;AeATAL4p4Myh9SwOaLxpF&#x2B;1D4Jccm7w96f0TiLKLdTh&#x2B;lDh4n4D0BXTGKyGGPqDL/ETRQz09Xks0Ux8x1i1ABpB/RLIN1KC7c7pW&#x2B;y84kTZDlzfYArniGGpoC1B8HkTGRFURQLY&#x2B;owUPC89QFRGU9kFYUgCSbpGyM&#x2B;jGS4dcezcw6n1g1elqNkGwkGDcCQiqiAl&#x2B;l0v2pse9BWLMXMh51UDp2XQ&#x2B;/ujfO75t&#x2B;b63Hk8kOUEhThlgvQAuOzhs2LCszs7OIGsI&#x2B;Gdpg5MxajaKZ9A45JSdV982ReamCej4lMacr2jsmQbZPYMuXiN93&#x2B;8TAoN&#x2B;rg2fmRBIHwWRTf5GTjhKIHXIBo0QGAyj/lQB4QcffBAzZnypcs5ZF4Bz6/lzRBywrq4eDzxwvyIHTj75ZJx&#x2B;&#x2B;hmbpW6A0RhUs8o/R0lw1NMXX7CGwBKVRsDpTkyC8kx2JGyfzwuH5VdXV6v0Cs7NHz9&#x2B;HNraOlQJ1UiaFBMsTLiUl5dhzZo6FWmxbNkyRcSwoj9HcjDob1jbgHo6r7VralU0RUZGmprRZxKCzy33uRyRwGr&#x2B;v/nNuQr48/VQ81DBfnsQnRDxHgPVXkgAK5AdBdDG5QyoO4VAfyAlxZY4sIs6sNMfiCtB6FAm0EwEJG7fDtRL1zbAQuzP&#x2B;nzHf/YJAJ8A8AmAwbCuL4CmZwhQ/4euTJ4WQ8r/KYHv7TWIX/VrGnS3o&#x2B;9nQhSdQ6D4kti6DddB1t8AMfx1IG&#x2B;y5v5Wn0uP3FKIkW8MXhuZFGimNvbMhai&#x2B;D3LZ4eR8LYDI&#x2B;zGw1RR6dMn56llC3/HszLsQoXbI5tdjd2faKKaTabkeiFHvhWcRyNb8ASiifiRjnP678R7Ixschtv5CiyZyVEH1PxNTLzo/p/19TevtqIUXffNtCyUEOD2ACQB20jo6OoLl5eUZrCtAjlqqn5Pum2/kN/Y10HgwW0XSoetrSI4UCLb7EQKD3ikZXG4WPGNx4/StIbiUsNIQ2JnG&#x2B;apNjhDgWetly5bQexcB2GwV3l9bW6NC33mmmmfG33//fTz00INKmO7aa68lELz5k39W2gUcacGl/WbP/kpFPnFZQSZC&#x2B;KWrAITC6QJQn5kYUNxPaorSWeGoCD5fGRnpBNw5AiBfCfVxGVYWGuSKK0wC8DaMVQTSw&#x2B;H9UpXJ06kDfF04OoDTEE466SQVfcDG&#x2B;0nUqw/zUaGQYSZbJIBksyq/JQFgSJCXRtW8MJjWREJsBRHQ4f4Bqzx/F/0BS7LCQzlCo&#x2B;CeFcFhBPZ24f0J5IaVFgLrlFmWF3SOACgrLfEJAJ8A8AmAQbO&#x2B;VSrUX64&#x2B;C2idpot6poTLDVb&#x2B;nsD2T4D6G4GRL4UvRwhyXiE9NvT8BfsIKN8KlF4MrL0NsuE6iG1aBr&#x2B;NoU66e7LVjL&#x2B;suYj2eReQc6BFB9hNo&#x2B;6HSj&#x2B;AowDQ/E/6Kix&#x2B;mEptztkDyD0MWHUJMOxOiOILYqt&#x2B;mwuxHTlvq89WMztiq/c1MRI3ii0DFu8O2V8PMWqqVjX2zbct2Li6AL83NTX19fT0KK&#x2B;MNQMiqQIZGRm&#x2B;cIZvvrEf2btSiwq2vaM1djo/VYK&#x2B;SpQX8CVmBpsQUGhF6BKDTO5ztaOMcJWBtKpN&#x2B;oSzH8&#x2B;6Aaw3wCHww4YNT1iGNUEWLVqsZtE5tP6yy65QIoXJGofnM4BlkGwG5kawbhTuM362AvVOf5vXtTImBDiEn4UV586dq84F5&#x2B;eTf6&#x2B;APK/Luf2cKhAIpERz/s3CfwrYm75PwDBhIcGO9nZFEBx&#x2B;&#x2B;OE4&#x2B;eRTlb6KjkIIKe0AnbseSth&#x2B;ItgTicePWPi6sFneiJwigD8kQ7FzHpLR9qalpiScT9twfIeIgGRIgGj1AnirRJCwPQ9VDmwBs0kbIHYuRdy59QkAnwDwCYANNap2z9eRAS1vEbjdhsD29eTh52kAnsniPLtqxn3l6RDDn4Zccbxi48XI/9Ej1kR/HwFsNQ0ia9eB7d/TdEkInms1capCx4fkjM2D5Fmazo&#x2B;pW&#x2B;gK34ml5DDsA&#x2B;QfCpH7E8glB0IMuVVFFchlp0Fst4KOzaJ&#x2B;b&#x2B;9CvV3OD837mX/b&#x2B;PaDsv7&#x2B;/hA7U5wmQI6X4L&#x2B;50kBeXl4aO2LktPmF1HzzTZLP2b&#x2B;cxtM5QPtUGlu/0fo1/S2xoe4HHCFgBDNeAorslot&#x2B;H4rlUCOTwHTqaBrf9yVfZGfyWSZCpgwlYJWaRPsGrsBvBtJmEG38jmfAFy9eiMmTD4rbRl3dGpx44olKBLCtrVWlCH344XQMGzY0bjme/X7llZex/fYTomVFI9tes2YNHn30UdTXr1Gl7Pbcc0/1Pc&#x2B;cc/57Sjis3AzkzW23Avd265mxg9Xx24wraGhowMKFCzFz5gwlLMhaAvX1der4&#x2B;cpGhAXdhBTN4L&#x2B;zo0MRALvuupvSVuHyrJwKEGKxuVAoXnQuCu&#x2B;k5f0QeTeL&#x2B;hkhrzAsr5ezB&#x2B;3SUDOQw/E54oEJDyPOtDq3rkKEhiAGN3FAh1UTKgSY0x3iIgFs6h8aoX1k4j&#x2B;uLYbOQNqcc58A8AkAnwDY2NbK6vsXK3Cveqfejhj2LvypLkNY8EuAw&#x2B;eHP6kJgYo/Q5T93rCRYFiJP995Xzy73vZqglbBoBkLAHK1hK7PtVPGeZwd08ISrHx3ZkIMfUjNIsivhkFs&#x2B;yGQvY81qdDyb6DodFpnPcL12EEUqf495ttmbd3d3ZwmIGpra7uzs7NTOG2A0wRyc3NT2cEkp80nBHzbxMHoRii3Jnv1GMdEQPv7WruGU9f622LAQ8T852RA8IYG6YOx/8HYltU6cURC5BxKHcgYXTZ9CL04MmAniJx9ITPGQqSN0BpANveC1Wy4Hbi1A/lWINm8fHNzMw4//CfYeeddsfvuu6OyskrNjDNAfeyxx7B27TqceurJBF4nKaC/xx574MADD1LrM2i&#x2B;8srLVcnQ66//C4YPHxHd7meffYrrrrtWieb9/e9/V2J5L730Ip555hlV4u7YY49TJIAIl5KzapsXcGNFDNidI7vzafXsMWBnAmP5iuX44vPPMXfut6r0IOsKsHI/kwD84hQAO0IgkufP4oInnXQKTjnlZBQWFqlta9AfP&#x2B;sswv9LxSbZg2ZLUG0zC2&#x2B;ZC2&#x2B;ItY/McgdSuOxhKoQ1xkyuEoFpASsCwLZMoGHXyegCWN4D0gj/7VMCLNtsQ6qVlhT7BIBPAPgEwEaz3uVA&#x2B;xQg/1hdmq&#x2B;TnJf2j5UqMmRfeBCljmvk85BLjwYKD4Oo/hddzTDg5zz9mguBof/UgLd3KV3FCvpsUrjuWwG5aBcapA&#x2B;GGHKTnn3nKgT9a&#x2B;jzVoN/XMFm8smWAB3v0LF8BfR8Q/t9QOUTym&#x2B;zIIY/R8d8dOJ6a66CXEPtKzkZYtgTA3euas6l00HHVfhzck7G&#x2B;feZb1uEkcPVz5EBNTU1ihDgygJMCHD5Qf4&#x2B;NTXVz4rehICt3TKDAYoHE1gPdFt2wCaZbTuBOad9xeULi3jnSYZ6IfoW0RA3V49Bnd/Q2Eiv/rZE78oO8ArvBIHxN6fZdCMBYbUvt31E1nf6bAZEVvvw5pvat9vstEqjqGB6OQKZu0Fmbg&#x2B;Ry4TA&#x2B;HDZwdR4F1/AcjZ4oEDYDhwz0H333XdU&#x2B;DuDcg7VLy4uxpgx4&#x2B;g1hv7OxJw53&#x2B;KWW25SOgKsgD9y5AhVKo9FBl988SW1PBvnt9966y3q&#x2B;7PPPheHHXYYamvX4O6771RCfMccewxOPeVU2k9WUsD9e8Qc0XYy&#x2B;GeRP66a8vEn0/Hd/Pnq3LHYYmpqGgFoFYGmluW0Bz4nRx31S1x44QWortaRE5xKIK0E6MwBqKY89AQF/yTC8M3PklELgNscUOr&#x2B;wubelwl9kGcywKkNbiSAeRNWUQPSWrwvro0OWgLWpIGzOKBPAPgEgE8AfO/GAkirgbY3ITs/o0dxPsSojyDnFOpaylnb0WsHGlx/DGSMhlxxnJoxF&#x2B;V/hFy8JwTP8heeROu/DOQeSndKhn6QVp0BND0HMfZjLUbY8R6w6hxgzCy6e3I28CGtpXbkqEoDWH0mAfxLAHIQYr830h1Kg&#x2B;ySvSHzfgLRMZ2O4RR6HR87Jy0vajHFsivdHdPmp4Cay&#x2B;lTC8S45TolwTfftjAA2t7ezoQAl9zqycnJSWFNASYE8vPzU8OzT2IgoHR9wO2GALlegKbdfr3kzDo5o3Yzjk77c8rfdZu1tAMzbsdgFz7sdrxWwMSq3VYg3QrQWM1Iegl5tjpWp/BoO6dd/Q1T5exQD2TvQoiumTSm0vjX8TmNsYsh&#x2B;1qV7p00eF1mUO0VNNsBb6vPbtu0Cmv27lMOfN3B6ZiMJz6FcH&#x2B;JTm/MmKDTAjO3DRMCKY7gZEMCXutnPqRKha5YsQLz589TVUO4fChHDJSWlmGHHXbEp59OV&#x2B;/HH38iysrK8Pbbb&#x2B;OGG2/ANuPG47o//xnl5eWuoMXped5UCAEG8iwqyIr/s2bNUhECXGmBv&#x2B;MZfiY&#x2B;LrnkMlVJgC0y62/Vh0pH5GvdH9nO7Ftsw/oZEwr8R9Iw7MkFa1HCuLQFQ9h&#x2B;AgFg8bBFvjanMTiSAFalCSP7dCo/aBlBEN6CdLivbDQBfALAJwB8AmBTMxXiT&#x2B;C5413ItXfoCIG&#x2B;Rv1bGl02UUCP4FqIUW9A9nwLrHuCQD6B&#x2B;u92gKy4AKLwTHW7yObHCHz/ngDxbFX6RzY9Ciw7k5Z9x1r0b4M5CJ1hUsLgAHRMpTbsD6w4HrLtVYj0bSH7V0Ns/Wk4WoH6m9UXQzY&#x2B;AOTtDlF5t1Yntj9p9K8VsuV/Wmgxtdy/j3zb0gkB2dbW1s9RAGvWrOkpKipK4/KDHB2QnZ2dGhF0cgLoTiDS7Tcv360PePYC5r2CVjtH3C0H1wnsOjn7yQBerz6Dm8CYG6h2BNA27fDSxmRnNjf8TKhI1ALgagJ9y2jc&#x2B;QhgUqDjE/13f/smoh8g4GVmPHE5u/WEybf2uv1BaH/E3WdjnYDUIojM3Wj83l6P&#x2B;RwhkG4iBKQlFlhvX9vtWTUbh7lzGbyvZ39FzQugsqJK5fovWPAd7r33HixatAh/&#x2B;cv12HnnXRKeyVBYnNLY5/J3PHtuFAxk5X4G1iNHjlSpBPJ7ZW/sSU7WTVixcgVSRCq2n7C9SqOIC/V3UJePXkkJS5znFAWQjCI/N51L&#x2B;qUagL/brL4VCeCkC5BQmtBmWXM5P6vjiJQKlBYNsxP5ix2XNXlgXDdCXoRcCIDI0ZcUF/kEgE8A&#x2B;ATAJm0ctt&#x2B;7DLL1BaDzC6B7Dl3dPHJklgKZlfRo1tGTfDYELSe7F0OMmanD73jG4&#x2B;utIcaHAX/3l5DzJkGMftY6HD/yADbeC1F83oY9ptbn9DGkVOlIBU6BUKNnNh3TNhDcXi6f2D0bsvZyuvnpdh32CJBL3wcK7bfLaQiR8oTRUbiZuqWOcB&#x2B;Uqvs6zln0zbctzJqbm3vJ2UxdsWJFZ2VlZQaXHCwuLk5n7YDI2ON11tULaLYDmU7g2c7hHKhj76a67TZbvTHG&#x2B;&#x2B;/byf9hmxUh0ETjI6fjTYdsf4vGme/UeAmuWR5ZNuAFpAvYzSpa/y5MIMQrSLcD/l62Dw8kgbBpk9OycD8eaSAFZJgQSCkAsneHYCHk3L11GWDWFbDEit&#x2B;rfx41zpdn&#x2B;ZVx47ZR4nlGsMlie6&#x2B;/PkWVHNxnn31UqDyL7b311puYNetrHHXUkdh7773R1NSMq6/&#x2B;vVLnP//8CzF58mTk5ORsMk&#x2B;JsW&#x2B;2IndtZ/ydwukTMLc9CWCe/TcL5JkXYqKFr0WkaoErIWF7K0nP67ilBJg3KyHtj8eFCLBK43GOBDBqIVich4SoA58A8AkAnwDYzIzu174auvrpAAFj2fUNfbUW6OTv&#x2B;vUihcfSwLofRNbukEv2hSi9Eqj4Iz2C6yC/pYG2&#x2B;DSI6gesN8/llr7bDmJiEO7VAbjDCQ5MfK97DuTivSC2baD105Uuglx6EjkGI7W4U0&#x2B;zXi5zGMdz0vKr1e5E9lgljIiCY5FQP5ZFD1eeDDHqA11lIWK1F0A2/TuWuJiSBzF&#x2B;hX8r&#x2B;bZFG6cHcLlBrirAGgJMCHR1dYVKSkrSWWjQDlAnA759823zJwTofu5v1kK2nbMgOz/UOjY8zob6TBECdqDdDbzDAbA7AXk4AHIvlX6kC3kAj&#x2B;sn8z0ctm1APTwcp3CEQJUmBJgIyP0RkDFGVUOyFGz4vu4Yh6giFg78&#x2B;99vwS233IIjj/wFSkpKVTUBFg7kRQ88cDKmTZuG&#x2B;&#x2B;&#x2B;/H/vvf4ASz4vk0NtpBqwPQbq&#x2B;JIBXosCOEEjA&#x2B;8Ka0ImA9hhJasCoFir5MhxhERbDdT1PTscibdpjFZUghDk6IaKMaULoFjn8VgSwEajDCNSjyv0u&#x2B;gFwLxeY0G4b4qDYJwB8AsAnADZzC9YBHTMhm/9Jn9cBbeTABOl5TSVgHaAuNI1A9Zg5CqjLRTTIyhKIrd&#x2B;gv9MsUEMb5PzRECP&#x2B;454mEGqBXPVriIo/aY2BZAebBTup/kLkHQjZtxKofx5iu4/prhypKiJI1gVgoUR2zLImAenkFLROgSg5D6i43nD8jZC1l9A5&#x2B;Iy6qUUQlbcBpRca9jOOtrOA2nkZ9TTdEOnbq4gJ/SP1ew03aUIhwxcP9G3LNS4x2NjY2JeVlZXChMDw4cOzuMpAUVFRuhC&#x2B;lqBvPiEQ9Uf71pJLTGNm23RdbpA1BFjXxkgIaIcu2VEPGy/XQDoD8aTasaHaLWPpAryLlAzyWyqB7F0UISBz96HxelRYQwCDTgisj5hlxJ9ftWoVpk6dSoD/EyxbtgI5OdkYPXq0KiM4atRovPjiC1i6dAnOOONMHHTQwY5RVfx3MBjCX/5yHfXXfarcYG5uLkaMGJGQzrU&#x2B;x&#x2B;YF2HshCKwivqQBGMdFX1ncSU5CgDHArZcLqDz/lGief7IkhvW&#x2B;rNMBkhIHNP1oPeluEwlgmrFPJiXAjiHwVCEg/KNPAPgEgE8AbGnWNVPlOsr21wn4zqZHco0u2VP9JGTTQ0DLGxBjyaEJ5MbW4dB5FuxLrYJcvIcSGxRDn3IZMfog11yhHCMxdAAK/ixwuHgSZOc8/XcKdY3jlunBPrqPLqBnmQb/XPqwv0aLC6bESgbK1ueBJb8Eys6l7&#x2B;kYOj&#x2B;H2OqdqBgi1t4KueoyoPIKiMqbTMfQA7n0p0D3pxAj3gCydgFanwEKT/PvI9&#x2B;2aOOSg6whkJaWJpqbm/s5MiAYDMr8/Pw0nxDwzScEDNa7UpW9Rdv7kExIc8oakwQyHHUX8dCQDODauGUIN/S&#x2B;B2Wb4drlIkIKMCGQEiYEsnbQGgKKEBgad6qjZQthPSvtlPZkBfzc0pbswuW5DOGSJUvxzTdfYc6cOcjOzsbEiTvg6KN/qV2eUChOM4CXWbu2QZUiNM6If/jhB7SNbzBjxgx0dXXilltuQ2dnh0o32H77CSgoKIgDS3alE73ooZjPidU23UA2HwsTFBEdBMvnyBB6LgzrmMP3lX5V&#x2B;ILKkFQl/VINwN&#x2B;NoDCTKvaEACwwqIDXlADrsH6P4BuGmXonosIgDmhLkiRUCEg8Lru2FBcV/qAJAL9wuG9bnrFYHr0Ez4L3N5Kn/wXkosPIeXkVIv9wyI73YQ7vl63/hWifCoxkEDwRaJkWfs5THQkA9DcAGWPJIZpF6&#x2B;2UXDuZgBg1DYKFDIOdNKgPiQf/qj/OUpoAsSd2SKK7llIIyakB6&#x2B;4nZ6GIupomgMUDuW9joqD0Eoic/SCXHACZWgFRclFMgIhJgoIjleAigvWQ9X9UBIrwCQDftnDLzMxM4RcPuIWFhemtra19PT09QXIyg11dXcGysrJMJgRYVNA/W76tP0AcvCoSg1kSEVaueci4fXpPH6ZfuQfyrJEu59s7V2sIMBnApDtH37E6ugKu2q2NB2DeALJ5OXP5QKvfY0DOeh3zdq1KCFrt065tVttPto3WwCr8Y0p4G0zQ9y2HaF4O2fxCmBCoUhMayNoNInsSdWTbaZFjoVkYtQWpYVPcrLTRZ3CogGEHHo0EgvUMsepHsfPOO6kX//rIww&#x2B;raICoy2OYxV&#x2B;1aiWOO&#x2B;5YHHzwwYoAiGy3qalJhbgffPAhOOecc1UpQhYRfOWVl/Gvfz2uBAhXrV6Fiy&#x2B;6GNttt30UdEdEXwdSEcVuZt8tKsDu/MhIKLu0SI4J3xx21yYMjenaC3UeUlNTPD/rxuXc9W34O25HIHK76JRWi/vEfO8DsNYogN19bt8GMwyOuydN&#x2B;3CsKBJunJWKR2LFEj&#x2B;VT50HPwLAjwD4QVj3TM2cc0/HIoI5e8aTALIXcsF2EFu9oRT65cpzIMaSY5M5MbbImqvU7DryaLAq/a1KIZBrbweaHqM7aSuI4U9rwcKGW4DiM3QpoI0V7thfD7S8QE7CixAhAvLtX1HbS7TAUP4hEPlH6eNafhbEyH/pkoMRC3VAziug799T4lCy9iKIMfN0RIRvvv3AjLUD2KlsaWnp47QBJgHoXZaWlmZw5QGuMOAD2e8XqLpVT/CyfoKz6RGcJ7tvt3KTTjOWXsGM02yn3XF6mTW1BqoiWkpQ5zkHFSEgWD&#x2B;n7QPI7m8gur6EZPI9AoJSwsurfTgDfDvQbAe&#x2B;zS6s3W9m8GBXPjDZsoJe2uJlWat14pYLTygzOaM7Kj6v6ZCpwyGyxkNm7weRPVH5LCKlBDKQFo&#x2B;EpHniEbZgbzD8fH699dZbeOKJx1FRUYmszCwE6V7JzspWoD0vPw81q2uxdm290g0YNWoUJk3aA//4x32YO3cuHnroYQL420W3ydEFDIj5fc6cb7DTTrvQdsvjqg/U1tZi/vz5GDN2LIZWV9tWJkiGDPDalxj/jj5Pceg2Eb3a5dsHAiIq8OfUp3htq7U2AJcQCCjhbNn5Cd1D22t/MRLV43JObFMCbMoE2s3Cx6UDhJsVLUUoJaz2Ypvjb9EGY1yAuQ0/9AgAnwDwCYAfursfIwLW/hWyZwlE4YmQ300moM8qvQfQ&#x2B;4&#x2B;B7rlA3eU0uFIH2TWfAPJn1Fluq9cLssp&#x2B;gyIBECKnZ&#x2B;VvIDvepu0cC1Q/jLjyfxvDOj8jR&#x2B;xFoI3Vnb/Rys5sWWOom1uqHgMx5isduRBhZpcdBuT8CKLsj5Bf0&#x2B;A9do6eWRiwh079peymU5vn32K&#x2B;bdbG4J8dMS41yGGY3d3dIRYR5LKD/ABlZ2d7fsDXBxDbATY3IOsELO1q1XsFuF7CZL1sy2mmyur4nEKbvaznBIzNbXebPU2WXLA7Prtr4eA/eQ5rTsaxtCsRab1&#x2B;eCbT2CzWCeC0tZ65utxt92wlKij7m2LLBKxcQG/gO1mAvjmbe/FCs4YAubjp5M6mj1bpAiJzgo5oTC2lc55mIAMivs&#x2B;GIf&#x2B;Ms/GtrS2oqVlDwL0JQfJFcnJyFSGQnZONgvx8VRKQAf/8&#x2B;fOwfPlyvPPOOxg1ejT2329/VYJw2LBhuOuuO/H000/jySefwi677GIJ5nl/hx56CN56622cf8H5uPuuu&#x2B;PaW1OzWs12V1RUuPaT0kKt3wsAT4gcMKPgyG822&#x2B;G39PS0KIGSLPmQzHIcMSJ58qrmIshgG0SgGhgzje6V4fHQ2aYvdKwQYLUA4gF73HGbqgPEoWILkT97IiJuJwnrGIm1UMgnAHwCwCcAfGt8ADKlhAD&#x2B;1QT2D4aoul2Fy6uwxt5Oll2luy&#x2B;oxHl0hMA7epDN&#x2B;3lsG8YUAAa/ndOB9reBiuvwvWXaBFt1reeuzyE7P6V2T9d/B7t1m3J21erDeT/VzV57K8TINyDn0OAz4hU6vp/Fb6/jA016pJa5DzhcWqrmt7o8Y9GvfCLAty3Genp6QjyO1dXVddO76OvrC5HzGSgtLU1nJzQjIyMlGTDtFRC6lS50Art2pQPt1rdrj1dQbOdX2BEPboDeS/lCr&#x2B;Udnb5zA/921ycZ/8fL9Xbb/0B8ro3j64XdN6NQYIh8656lQPcsHUHX8YnSE9ARAjFCQM&#x2B;RblraG4Ml/edUoNBquYEtYyo5qMoOpkCQryIzxkLk7AuZOUFrCaSWmAgBQ8i6sAf&#x2B;XiNFzPefHekXIQqMRv0qpk&#x2B;fjnnz5mLBwoVICbDQYA2OOOJw/OY3Z0dz4c3t4O1MmTIFDz38IBrqG/DRR9PV9/UN9Yo8uPeeu/H73/8Bp5xyqiO5YQfq7Z5Hq98tt2V8Dg3rREiMtLS0hBQGr4SMF12AuGV55r&#x2B;e/Nw1V6v0U8mXgP4TQ&#x2B;4Fin9jiU9j6xu/s7o/TQDcWHpPOhMTVmUChQUZYEcCJJyPcBmGmJZAPIFRVFjgEwA&#x2B;AeATAD9oa3kCcumpevAbT85J1h76meyrg&#x2B;x4S6vrpxYQoCcATEBaFJ2idQSy94LgCIFMAv7Lfw5sPZOWq4h4PToyIKU4ubZwbeYUAtiB7A1ACDRC9nwL0bcSsvVloO1NXf6Ju4C0bD1jMOI1YNFOmuAY/mxs3c6P6BwdQceXDTHyHSBjvGEGwSJMLdSt9QQaH1XpFopQ8M23Lcx4/GTdAHbi6uvre8iB4zFVkpMaqKioSOfvybELuClfewXUduHbyQD4gY7bbjPCgwFYvW5jffblBdhv7HvIS1i/2/eDuW&#x2B;voMPTuiIQ7&#x2B;31d9A4t1oL9XK5QSame1kHpye2jAdCwAyqjY5kMvr/ToX73IoIOgF7q/Y5FTm0OhbAvogiXD/HUgWi&#x2B;&#x2B;dcDI4O4Oi/nP1U9SKRsxNhvzIFCo0NIGhqS9RZ&#x2B;PKW/VIyxJ0RyEesu7sb7e3tyM3NQ2ZmhgLLZi0CczumvD4FF15wAZ5//nksXrwEc&#x2B;d&#x2B;i9y8PEw&#x2B;4AClR5CZmeXpOffSj1pFCliWA7S6jobjYPDvNR3Ja1ttl&#x2B;PnkdN1vmXtiEyg4HDyB9k/64EsPBViyEMmn066ECTmY7VX6E8E7PF3fJywoLHioAUBEFciMYkSgT4B4BMAPgHgm&#x2B;GJC1IH&#x2B;BwBYwLfpVc4AOh1kCt&#x2B;CbRMpTuHOs7&#x2B;bv3opnI8EX3IOwSi9GwaYCdSd7EQcuUZEONXxQT32Hq&#x2B;03V&#x2B;YZ3bheW/oMG4BGLYw/qWb3tdpyAMutFAypUPeubRPt7WpQY5BaDib8CqkyHXPQVRfDJ9txeQuQOB/5/QQHEEnYMOGj/oMRr2NJ2H/xDIv4Ha&#x2B;oQmQaysfw0k7UPkHODfZ779IAgBFhAMpwx0s8ggpxDwO1cX4NkrsQmXGNiw4nKbRrsGa1vrC56twE8y&#x2B;3PTFrAC6&#x2B;ujK&#x2B;BGArgJrullA9p1D3t5UrnIzRBd82icmAO0v6vHyJ5vaVjuiwmpGwgBaQHC4QGgWwFxp8&#x2B;uvqxDG6zAu9W6XvY/kDbZUx&#x2B;6wkBsGeqPMkeRT7KTSncUmdtCZkygr/NV9EB0NRnBMOtPFHrHClD3i1Esz7yttrZWfPrZZ1i0cCGKiooU0Gd9gJdeegnXXPNHVFVWYdttt0F2dk70HvSiAaBn5qWrMGRCmbvo8yATQ9MNKyh1/0BiWb&#x2B;B9k325zjxDpS8/eWnko9HflvllRCVf0Fo4SR65mZDZk1CYKv3aOkMO3xquT9rPQDD3ehW7tAKqFvJJpiS/&#x2B;1K/sVtNyEVIHZ&#x2B;Cwvy/SoAvvn2gzYC6KLgOPflUgiYjySw3PwIgfxxNEAWQ7a9BHTOpO5hPgHid&#x2B;lv&#x2B;j01X6v5d60BGu8n4PxLWreU9kOPW9O/6WlvpU73dl0GkEG4QWgQacMIgN&#x2B;jVX5Lzodc8zsIzqMsv0ZzWgzYucrBeltAhQbqVIbDddoCt0f1iqdQ27&#x2B;BbCaQv/ZJVZ6QCQ7R9TVQdRPkqjMguARiC/2eOgqy5jyoqACrqAWRpmcdfPPth9CVkHMS0QQYOXKk8jrb29u51GBgxYoVnVxRgDUECgoK0ng5JgrCUQPrpRDvlsM&#x2B;mKDeKeLAS8qCU9uTLVXmdn6c2jqQdAHjsm77cxLcczp2K/Bkt4xbqTM7x9IpzNluHavZT7dya4k1xkMmZ52QfaCQwOee&#x2B;lV8JgHUVsiubyG6CZCwcC2NRaJvqYoQkCJcHk0IG2hiSnN3WcbcSukA0mHjtTu569LD99Jl&#x2B;WTggHSlB6DDvaMWhOxeCPCr5b/0Wzr5BOMhMreBzNlHawhkbEc&#x2B;QKEmBKIHHfIIDOV69DP6frETjWRb19ikUgZmz56N776bjx133Imru&#x2B;Bfjz&#x2B;B8ePHR9sQDIZM96F71Qe3v41YNPI5FiIvLKFwhMRKTQ3ElfVb3/7ZkmiJql72a98z8ozzV&#x2B;0vK3dSFJ2kSaCUKmrbbAgWsZbBaNCObl8ihZZI9BjOiQFgS4sFrCt12ESURfenN8bPvR3JZRbYjGkdGvatJt5k0s/VFuuv&#x2B;BEAfgSAb4NgoQ4CzV9rUNzJdZI/1R0PhzWmlxGg30PN5HMJJbmSAPPWU5Tiqlz5S4it3tOaAb00CBccB7n6/4DWl2mZT&#x2B;jzxUDze7TMo1qptW8VIYvXsMGrC4So3d1fkgP2MR3LFxC5&#x2B;0KuvZu&#x2B;W0677qH2vA5Z91eIimu0dkDVHXQ84&#x2B;K3wYMJHQsLEort/e7WN994vOVyg2lpaWLVqlXdhYWFaawpUFxcnM5RAlagzwpsec2hHwgZ4Fb/29XxhHtag5Pf4TX33y2UP&#x2B;KCWiu9i/VOlRhs1fTYcRrTZ933oQ91SylrlRKvH8DjZf9aiN4FAI1FsvMLGo&#x2B;&#x2B;pLGlhr7viQEVAW81Bgf63EaAU7S0oRnoMiEkbf&#x2B;2&#x2B;84ID&#x2B;1/N64rHGiKyH1gBEP2&#x2B;4vfgYiFBsSQKn2dBZExWqcK5O4DZG5LnydCphTSuQ/EJnhDIdPxWwNmK6BmVwHC6nuzRXLmebm&#x2B;vl6OukJpaSmTsOjvDyaCU2FfktGqZKQGktK2gkRse9JiHaPInb5vUsKz/nbP/6BFJqGfQP50yHU3E6hvB4bcSj7orrohXC1q1fGQqVsjsPU0FXEql3KVqP/RdyUQYxbTic1JuG6mJ8FyXLASBkwoF&#x2B;gUPZCE4J/xC0dhQIcKAQV&#x2B;BIBvvvm23sYdJue6q/KC3J0soq6gjTrge1StZLQS4F/3CmR6un7Ia66AKP8DLbcMaLiJnsQqyBXnQEw8EWLYvwn0/xPyu4m0XVp&#x2B;yKUAVxTgaIKeGm/t6f6OuqmlKnyft5388WRojQN6RXnrghMgV58HcNRD7mH0/h7kooN1zWJxWVyev&#x2B;S21t1A&#x2B;y7UXSKLEDIJErG1d9B6RbSd/YC0kYZ2z6T/6Jgzt/fvKd&#x2B;2OGMHj2f/&#x2B;fPYsWNzucRgc3NzH78vWLCgbciQIZnt7e1BLjnIlQbYwfUyq2YnXmVX29sun9ep/reds&#x2B;n1e6ttu63rZdY6mXYNpN3JbyN5LGqnru2lPeY8Wm/7cwZYXo8h2WO1AlnxFjS5xwGliSOzy2hs3UvzAr2rVeScaJ8KyalrHIGnCIHe2JQRdPi4e/a&#x2B;NUjX74bzqgBy/DqJgF2Yrp25woGMfhdZL7afRJIgvi3SQGjFt9G8n8hysTrv8fuNlnIUse2Fv9Hh6ZFTRZhFoEuXTe6aoyMCA5lAxtZKDFjm7q&#x2B;iA1T5OI6GDDdDnyaNeaRDOriFWLvj8lamNQE0EZCWlo7hw4er7yLg3277CbPENr&#x2B;7tcEI9hPC/g1/BIQu65cYVSBcU2eSH2MIa665gnysu&#x2B;i5COnrueZKiK3e0he2e4aKChApldSwgnCaTUpUQT&#x2B;&#x2B;fKEVeeREGJv6FquJKhPrEt8fmMalSNQKLMhRGCN0EpdDHGFnuCZCuN9YPxDzCQDffNsQlq6DSsTQR6ij6dWEAAPmzvd1Kb7&#x2B;RsilJ6jwelnzJ6DyXM0Rctm&#x2B;7B/F1hc59NutepuFJ2lQ7cXRYkJzxTEqMkGM/gLI2mV9hhT9xikQw5/Was78bcU1NIBkQXa8C7Dqf2xYBpreA/pqIEp/DdlXD9n6AkSEAAg1Q666TFdWSCsByn9Py12q283pDjU0WI2bFz0Hvvm2pRqD/JKSEsUK5ufn5/X394e4qkB3d3d/bW1tT2VlZUZnZ2eIKwzwsm6A2itIdlou3kdKBhB7B4NOy3oBpQMB2QM1p9xfawfc2zbNy3uZFTU6wV7PhXnmU4cqO4dBW23buL7ddt2&#x2B;s/K9rY47DsxEaoKHwqA&#x2B;rVq/eEaaU9P6VtEQuwiiY5qKDpAcgResJYzTHytKEEkbMIBmI3g2guR40CwSxkG72X5rIG4G9xHQKBJ&#x2B;c/pst7w9MBW2RET8/SQS2hcPTo0VHaQu7cuEQCe9mv9L32dCZo6mtx20eHL2rpA8bqeV0dIphth3Y61C92fCKz6LLOOW1x&#x2B;/byPItE9LioDHRHJVxoX5RzQArKJ4&#x2B;J1n/M2VDozgf9A1V9o/gFxzh77vU1Kphf1a44mvGxM3XTP0ueAqEEpjgR&#x2B;LSGWFFAtiwup6CAPRJDz1fW6RAGYy2jj&#x2B;GNcVcWqKIl5Q0bSPH1LJUJ8A8M23TdFEui6fRy&#x2B;B86lH6tKzGM1PkbPyoX4Ma&#x2B;/XM&#x2B;XcAYfaIZcfSw7Oj/Ts/RomCK6FKDgGsu4GiP46VZKQQTfXVhaFBPRNooIqd2&#x2B;rtyFZ6Z/rMK8XAWCyiOBfzwI1gy84j7DrC&#x2B;jIKN2liIK9aMyfC1lznU7GaXlBl0nM3lvpHIihN9EgdZkSVkTDgwCXCmSCoeRSfWyhVv&#x2B;&#x2B;8e2HNyCnpnI5QaXAxJECLCjIKQJNTU2969Y19lVXD8nk78rKyjLcnGIvANEKnNmtl&#x2B;xssR1gdQOqVqDXzrn0OpPtJfzX7nsrJ9IMcp0AvHnbdr/btc8OGDnNbJo/W23DLqzZ7fo67dcuD9f4biQgzOfAboY29h4yTeoHIFk3h19ckYd&#x2B;5yo36FkIdHyoqwx0fg4ZbKCxJhQOa9f4RRqS4Z0AufVxC0eA7hXkegW6g0dmCc/tS1zW8HCmGAmBb8mP&#x2B;ZZ&#x2B;&#x2B;7eaEED6cEUGiKwdw5MZI6ljK4&#x2B;fsk3QEHAruOilDoPVcnD4G0iMBIltU5M80kMIPP8dSjiOlJSAZbi/EdwOOvjvXQa59CBd1WnI7Rr0N9wNEWzRk0tcvYmfD/MxRAiaQFHUl7TWRDHfJ84pKTGwbogyQXim3tTh2PU/zqleCJeuFLEIBqeoAeO2Nl0tXp8A8M23LZcQyNJhdBV/CndVPGP&#x2B;H8h2FhCs1j1afxu9voTMpL8bX4XIP0SD&#x2B;PQhQNfnQM7BkKtO08ulj6KBdrfE/ahBeI8NdxzpIyAXTCBnaw1Q&#x2B;FNDd0IDSOnFEByx0PIcZN9iiOZXIJecSMddQOuNVRUFuG2SUwOyhsXlnKHgRHhRHLa2EGwrLPjm22ZmWVlZKfxip6W8vDyjvb29j8sM1tfXd7e2tvZXV1dnsqhgYWFRuhVATQY0OwFSL2DZbbbFCfw45em6ASUr8OgFWDkB9GRAm9VnM&#x2B;C1C3t2207yAC/58&#x2B;Vln17Opf2240GalOa/7bbnBgoNwMUAMpA2Qo1NyD1I1wzgiDsmqzs&#x2B;ILw6U2v09DeEQwpgmOH2x40kHRkTIcDWpas4dH8H2fg4fZ9L12Ko9kVY7FhNaoyka1Suy9FFCYGgC9CPYw8swLiVNJyEfdqH1fZsjpFTIYQxvSN&#x2B;PSaljLP5YWFX5zNnqGwwqAKtdX/Q7Sq9BKLoN5Ad70Cse5Bu9R4t8Me/BdvCbpohwkWEdD&#x2B;VMUILBppBdlzqi1U/mRg94jktybCxxPFIxM3ux66AjOsapPddGK6lHxrgEwC&#x2B;&#x2B;fa9Gw0WRSeFFVnDndTQB4HW/0J2kcOSkqk7ZUHvmfsBrIjct4L6L&#x2B;rUh9wKWftbiFFTESfdGnaOZOO91OHResVnDX6zU0ohxn4NrL0FKLnUoncpo&#x2B;/P1f103hHkeH2oyxpyOFrNF7FcQxY2bH6SnIRJOve/ZyFk0&#x2B;MQlTcgabHDYDNkDQ1&#x2B;pefp7fnm25bgaoc9o7y8vDR&#x2B;MQlQVVWVuXbt2p7e3l65atXKTo4U0NEDgtMJ0oxOq5dZ5GSArdv3zuAxXKV8PcGvG8C1b2MMWFov61Td3VPLXAGu/bbtZja9ru9lWaf1ktm/17bY7VdaAD27bSexPVY9N85eM0GeQa/8wyAYaPYsCee1fw7ZTuNmz3w1bkQJgYBhXPYteV8mLnOiXZ/f7vn6OVAVkqrVhIXI2EGVHlbiwalFJmwdtADodiDfCcxJl3dvy3vVFEkG/K&#x2B;XiGjXLPINPyOXL5vu6yNpx3lAqE2TL4EUiHClKJFSDhnIJHzfA/Q36&#x2B;MR4XMrw2Ibqgl96rNgTYdAukUlDzMhYATVIu76WAvAmoB9JFTfqtRCQsSBhditMdRfGDJUDNtwjgQANriQtk8A&#x2B;OabbwOyohPUS3CIHSsfZ2hRPJE5XEcJ8Ix5Xx9k8z9pjJ0Jue42Ar2XxTrZ7tkQjfcAjU9AZu0OsSEIAEUCEMivuMl9uZx9IeiFkt/SQLSaBrAZkJ3TIfpqIVv&#x2B;B7mM2pdCA2fWRD07wMdccIz&#x2B;m6cXeHkWfuLv2PrrIFtfoY48nc7TqYb25NL5mEq/vQox6l1af8ewH0Kfc/agE5jj31u&#x2B;bQmEgPJeIukCLCLIzlFDQ0NPX1&#x2B;fbGlp7u3t7ZMVFRWZ7ALl5eWnegNuTgDQCcCtD1C0A3/SBfAlC4TlALdld47MQEKsx7FID4DcKwgWDscqHQA4PABwYbM9t79hsQ070OU2Oytd/jZ9pwgBQ5syxgCZ9Co8krBQB4HTBQSc5gAd02jc/FqFtOuSuCEDDyB8wJDMUx7FdiZCgFP7eujVPU&#x2B;DMR6vmQAgwCpYpT57T00QpBSbboNgnBq/tzbIQcmzNwN2MxiNAH6ncH&#x2B;rdkW2HTX2izhVUnaST3MObbDAYuVeVXUJddfqz3yLlnwAMfRhOrddOrIFYZ0MtYNIQTTWZezQKaZIRdwEOGtUyTa9HqdvQER1DYzttQP2iRyGiNOQsSoZGEcCmBkCi21bXb8ETQEzqDdGFhjKMvoagD4B4Jtvm4mnT/57zj6xvwuOVbnyYOa36iqg/gb63EPvdxIaiBEAqPsDZPsMiGGPQq46jwbdeTTQbvP9H4/KEdxavUTBcfoQO6fTmPeZKjeI9vd1hACzuYt2VsQBzxKInqVA21QF6GXz8xCt/yPU0wTZs4wct3cgWCiRIw64gkD5hQCLDCpNAg6UIOdu9ZkQQ/4B5B0W3x5Ouwg26lkipZPgz/r4tvlZRCCQowKUL9nfHwoGg1i3bh0TAaGWlpZeJgYqK6symSnIzs5K9QbA3QCf8LCctAF9XogAgeSro9v9JhyAuNs&#x2B;pAOgd5pdFB7Bq9N2vLZNOKznBTQbq5W77Vd6PK5krlsyy9gvaw/4ZCIhIGgczd6Jxhh6FZ0MweV8u&#x2B;frWev2d2nsoHGTSQECV7q8GmJFqT2MFcnqbySzjJsQZLIl9qxSgMzbs/vei76HXjcQvdXUerI9PBkwA2h8SFcNSt1KVVQCpwxk09jPaY&#x2B;KEBDRyygR1PDPcK2tqpq4AXE7kG9FHETAv&#x2B;kek4FAQAxKGH/DbeSjjQZ664C1NwEVN5oa3A&#x2B;5/BdA6&#x2B;uxbovxPJdqZh8m1Env9eH7OiMG8aLnPFX9JpGmT2WQlueZfyYcgnWKHBAZOzueQ6tz7a2/tlvaFNZvQQIk3kOJaQFxAoEyLPhp2gcvERDCcj8&#x2B;AbCZEYz&#x2B;pfPtB2ksdqSeABoAC08B6CVrzwaaDSJ8sk&#x2B;HgwXXQK79h2Z3udRg9T80ocCrNz8GkX8M9Yi5HgYmAtel/6e1CzaERcsNhlTlAPR&#x2B;p3I2eYYfnTS4tX&#x2B;ISNqoXEzL9TQAlZdDlF&#x2B;tBYgW700/0Eg47DHd4Rf&#x2B;CpIH08ix9a&#x2B;lba6g1/LEfRPwlwuO0mFzI14gx2Oyf4/5tvkP7KmpAS47xWUF&#x2B;W&#x2B;uLMBOU11dXQ//3dTU2MekQX5&#x2B;fmpaWlogLS094AwcvQI&#x2B;u5ntZAD2QMB9ssAyWXA8UFfESfU8ZHCypQcAuz5t8RJi7x1MO82u2pU1cwJWdsua1zMDNvN&#x2B;rEpdmkFL7O9wmW5pVLzPVkr2ImdXoOhEHSHQMxey&#x2B;xsIGocUGdC7kLBYJ&#x2B;GqWISAVtB3U&#x2B;a3nn10qvTghVSwE1B0AvduqTtOVRui2zM/RS4aHJbCmCJg4AgJmnEqRv8sXWlIpQwUQqaNousxSZU0lqxpxJoCPAkiRJhI4AWD4Q2H4aDpnjGWqHMiA&#x2B;zezZ8jof7Sq/qjBYCOu29Xn66Fm9veB8ouhqz7cyJ12PBn8vNeh0gvgeR7s&#x2B;1NyN4FtNFenTLB0aJBeqWkx5/0yH4CRWEeoCBc2f47FUmpNAF6l9CjkEb3/s6W/YDz82elCyDi7gU34kCaSVMBy5soLnJC8tMbSiw1GMfzxm5GqwoBPgGw&#x2B;ZtXz8E337YcEykEkJ8nT/6fOqeRw&#x2B;Yjj7NIgxj6BGTTQ/T7s/T1UMh1j2tgnUVgO4cA8&#x2B;qzaEDlQXW72DZ5Vr2Ztpl3IFB4QoxF7pkPufxoDZCZQGh9joDygXrQTSkdxIPi0LWh&#x2B;kXbF8Xn0r4J4LOic&#x2B;dHNFjV0r5fVqy3XHs70PIMRO5hQAEB&#x2B;PY3Y5vhNmVPiqreipz9yXGgga2/yYIAGA1s/QFEPzPnff595duWyRsSyOf3YcOGKRavp6cnyGkDy5cv78rJyUnt7OwMsrZAYWFhKhMDTCAMHHQOHBQn/haCU6muRHBqJTg38BrbbmDcDbwmsy23drg74sIW&#x2B;NoBD6c2OpWQtCzVZZPT7LRPq3KUkXBjtzbY/W1uh1XItfVsb7j0G9ev5/KCDE6ZRM7eXb1E8RmEs1oglKDgZ7qeOlcY6F1Gt2l3TJgsGoosHAG7EyngRX/D7Tu3EGfLjHrpfZ8Szu21e7Ttj1PEgz9W4Q81A10zEaKX&#x2B;pojBNJGQ2TvBsmlB7NNhECkz1Cz9SHbc&#x2B;WFLIlfNnaPG&#x2B;9Pr8&#x2B;VHRGgrHuWTm3kVMieuQTQKwjkj4xfoZd8oHX30/GT/zX0UYj8I8i3eQCoOVeH9asD6TcA37AvqIiBYDhaIFsTLpwCw2KYwbVA7RXat&#x2B;rrBqr/qlMybEC38/Ekgn8vy8fSAWLrSSHdb9QwaSAQqy4QB&#x2B;7D/0kZv8OEtAGfANgibH2mBXzzbfPkAEouVuquPEMvqv5s8viHQ5T/BSi5hIDvSsiay6mjn04A&#x2B;lPIwK06TGrNhUDuj2kw3VuHntVcQr&#x2B;lK0E&#x2B;kVIE5P9cb6v6HpVXr8oZ8kPV8Tmw&#x2B;hxaj0D2iCnhJ43AcyvPoO9PvUrF4B0ki9LQC/m/CA&#x2B;WMyE7Z5FT8LFKF5CNj9F436c1nxbtqNWG8w6ByNyF2vOi1hFgy/8ZrTeNfIrLElVuM3fW7Rep1t0HR1MokZ0OTYAIP3PKt83bMjIyVGLoNttsk8cpAe3t7UF29FasWNHJ5Qe5sgDrBuTl5aaFc1uFV6DrDr6NInzOs8Fm59vNMY05lYl5q16AsBUAHmiY8UCAr9s&#x2B;rQCxMTfZaT9Ws5pm4sANYBvBTzKg3EvbnEC/k1ia3X7djj02KyxNoDem7h6JENB3IRMChZBhQkAlYPfXQzABwFFqPbOBji/pu&#x2B;UErno0gDWVHBysMoCuVRnCUMd6nVg&#x2B;tCPCcvdAYFcCLga1Yu0IRZewaJvFdzpcPUCYVUZbLFjkt3&#x2B;GShtAlBAYSb5IJGVgD10BgvPnRVo4o0VfR7OGgDkiwKoMabR14fveTeDPM&#x2B;g3Gkc95v0UctVZGsxzOH92fNlmyVGYvQTYy84hX&#x2B;aI8AbDbeGZfRXtWGex8X59/IGILkAKRO5kyObn6Lsg0PSM3lTFxUD5Va63gRXh6EwGxN8X5siB2PLCnimIXgPrez/&#x2B;TpNxHIRlCVdT2oBPAGweAF&#x2B;sJ8Bfnzg/33wbnNu4h2elJw4eCcB5/yVnUmduMxPPuXP0Elu9SWPBGjVzITvfBzrJWWn/Amh8DzI9VefAB2shhvxbMe5ovD9GAIgMGkuH0Bjao3L4RdUNtE4lbW&#x2B;dYZxZAbnseIjxc2IEQAttK30MgfLdBu8UElhXgB10zMEWxZijcyq1&#x2B;Sug7T36/AANlg9oQUEOD2NHreQiiKLTIXmwY3GnlELTRoOQa&#x2B;&#x2B;ksTcbKP6/2NddX0LW0N8cBsrljUK0vaLTgIrr/FvZty2HSCTLy8tLNRICXGKQowCWLVvWXlhYmM4RAiUlJelkKRwhYATXTqDaKvw6AurtgL&#x2B;TQrZb3q4XMO8GKr0CUDtA7fRbMiDZi0K41317AdBe2izXUznLyznbqCOyqVyj8btEvBbSYCrazIAe61IrlcCs4BVVCttSyI5pOoy9YyatsgKiX5PUapsiUmpADgB8C8Na0sYp9jYTHQPd9lsUFoA&#x2B;8r00AHoD5rLYf6IOSDxBkNimyPcirk0iTKrEgJ4INUPS2M&#x2B;vCCEg0kYrPR/Bor8ZEyBZZFDNfqdGiR2tHxCyvM7xGgla0C7AKYJiMO43C1KQQ/f53io8mfwlAunNj5KPcUv8Mo0PqEVE8fmx7zitkc9D2shweqZJ&#x2B;FLdsj36syjUFZbYCn8FrLuT7s25LB5Df58IVP5lQLAovu&#x2B;10xWxJxGs73B3XYDItYkjAaxm&#x2B;I18gAjfzRZlBX0CYItAV7bfe60B4ptvG9LVJqB5D40m6RCVt0Tz8ddvkxz&#x2B;Vepp30itAgp&#x2B;AUEvjgpAqF/PXPBMOQ&#x2B;g6eMhlxwNUXIsffcmUPc7nZeWtTvkwh10CoCaiU&#x2B;jZS6NDTKKaBgSxtJtsQePwyRXXQBRdT0B63MH/3SmFGjmn19sfSt1vqYSEpxNxzQbcuXlEMyQ8yDHIf59q&#x2B;MJgM6PIOtuVBEFMthL4&#x2B;SpUe0A2f4GnZ8vIXL3hEwdC5V7wKKEXoxJlH7N7Pvq0b5tboQARwHw5/HjxzMhABYRpK/lkiVL2srLKzLb29v6y8rKMtPS0gSLYJlBnN1srtOsbDIzxk7rDyZg3WScG5uccS/rJYTbiuTW9bpdu/YNtA1OYnXm/dgJ2Nnty62EpJd2KgBpCDPnlAGZWk0AlF65e9NPBDR5DOAUPY4&#x2B;41nrzlk0bBJwCwX1PhTKDcQBaWfoHw/zzcDcuGw8WI8H1jI6CypM0Ct&#x2B;WfPvTmSDNC0jDeJrsNhf/O&#x2B;JxyIt9pm4TIpBizGkUgYknWfROQOhxgdpyM7XaYDpBH7z9icfh8bxzG0huYpSOEJARogdyATwr7s2YXsfJJvSY7k86x6wxgSnY/Lsf&#x2B;6P47WZgg0q2xIlP4&#x2B;lbMpuyHV3KJdGDLnZ9vqoEssstJi2TUwEmid0hr8CcAopf5f3M1fi1dx2Ow0OM0hPvHesdTssNS1g0alYVBNwJBCEjJMTGGisi08AbJ6A3209/17wbeM615U3QdZeomavkZoaewS5kw8URMPsN6yF1WQ5l27I3RDFv9KDUKgdsuFGyPr7tbps7d90B5tZqLvjhr9CMInALDWD6tqLgeqH9CY5MqBgsq6vzGF4fKwV19EgdZcekDfGyWWBRHqJ3EP1o01gXzZcr9vEThYL3JhK66hQOK4iUHYp5JrbgXW3AWV/1D/ywJjxEJ2Dboih/9LOhFejgVyuuYL2&#x2B;SMdheGbb5svIQCOAuDP2223XRoLCrL/19vb27906dJurjzQ0dERrKyszCQQJMxOnVcA6AbW3ECg1Tac/rYCe06/eweGic7w&#x2B;hyrnQ/sJB5nB86dwLXdNpycbStywo0McCIQrMKy7c6XlTCd077srqnV&#x2B;l7z6BMIARVqHvnGoGmTu6/2NvuWQ/Qu1Sl13V8AXd/qFL1QyABkA5Y3gBV4Nn4WJjCdCLSFq9NrTQxYOc4bZkT3sl37ZQLRt0icAZcdlJ2f0xj/uZpZl5zKxyA6Y1tdmjhzG0UQIJCvc&#x2B;XD1y8G/mECqsmlQZnBsqVROyT5UiK1nHwnuk/yfm7aQCrE2E&#x2B;VOGV0v8uPBnraIaouJRdyuAlkh7Q/x8bHzrelsZIUG0d8ll5uCfBdZ&#x2B;htiIBEYsDu2YyH4U5lAhOIAIt&#x2B;xUjYOJEY0WdehEkwvw4gRy1t3JNgeljM9KLxFbB4Twm/Bwx/m1&#x2B;phhf/nWb4O83wNzs0aatXr75uyJAhW/tunm8bDm/XavDYszgcMlihwwRXngQx&#x2B;iN9Ky89ABj6mA7n2hjW8gyBc84ra4UYN9tQNoas7o9ajKb4HMg2ngV/T6cP9DboWf&#x2B;sahpECeS3T1EEgppd5xC0pochm56EGDU1OhDJBdspIkCVL3Syxn8qZl6J9w2qR8Flbjh1IUef/4xRMUeBh5Y1vwca/qZ/5zq66RPomkyha2SIaFh6iFLbFdus9h610c8VGO6AKDpTi&#x2B;745tsWal1dXcG2trZ&#x2B;9iXq6&#x2B;t7hg4dmsWaAuXlFRlCaOkAr6rnTjWakwXudkDPrQ60G3h2IwXcALEXUJ3gJNkdh0wEdAPZh9P52hwtMbg8EcyaC1duiP3Gth8O3ScwJyM6d3yie5dBds&#x2B;GaP&#x2B;A3r&#x2B;i17dKnI3TCdTygeh/nkmkgS5nt06y0SduJQvdiCi7vsHuGXYqcRj/u1Qz/br8YDj6giddCAyLrN2BopPIDZikwv0dMIsbprElAOKWk71aW4jFC5Wf0ayvc8DDJEPvIsi55FOkZUGMr41NanDlpAXj9HYqrldlluXiPamDriff5WPy2/b0cO3sq3q4ree0fGJ/mpj&#x2B;YtbiiKtaYc7xl9KR/IvbnrWCoPo2Nyf7VGj1597we7/Fe&#x2B;RzMPzqN3w2vkKGd&#x2B;NLGt6NLytubaMSE5sbARAwEQF2BEAE&#x2B;KcYgL/5Xb1qamquq6qq8j103zac1THApNsuc6yeDWbRveA6yG/KqQfaQTPSTc9BjPmEPu9o6Am6w&#x2B;C1wPvAvfoMiPJr6M7eytsKHR&#x2B;oMnxxwnZKTTYMmvXoRN3fGp0T3/ykKr2HznmxNMZsenxyDtF/ND4IsV1vzDtdfgJh8EUQW39p74b1r4actxNQcjjEkEc27rVhTYCW5yFbntYhgW2v0HsZXZedIHIOpeM6QKVsyFWn0M/bA8Me0cu5oqIZah301UIMfRTIP9J/Dnz7QVhbW1sfEwC9vX2ytbWlr6ysLKO/vx8lpaXpKYEUkQzoHExAurmHfxrBqhvA3XhA2g7wet9WNJ87ieMxAwLzZ/P&#x2B;EtspHZezW97qGNzWlwmSeAZagMfdSLpMqBuiZyENvd8BTAj0zIbomkPfN2n4EIjXEHBLw/BColmBaa/PohNRliwpt77klFMbLH9XcgJBLZIvUhAov1wGyi4UAVVNyR3cew39t9RH6foUsuYiiOKzgaIzkn8ma68C1t0E5B0NMfzpmO/Wt0qlaiLUGE4h4LLKneR7HAix1TvJ78clJcAJtEoPAN0K/8YTCfbPvtPG&#x2B;c8EUVULXQC2HJ8A&#x2B;F4JACMJYEUAIAzizQSAHfi3igIwvuJm//lzTU3Nn30CwLcNakEewFsIbH9E3cwCoDys2N/8BOSyU2N3fNn5EFV3xR4JzmNfczUw8hXdMXAoPZMFtrPQNKAt/hHQsxRixPOJYV&#x2B;DBpp7dPhifz3k2vvDtZEbYqrHWdvp8HkunaSU&#x2B;u&#x2B;B2L4v/GiGrf01yDV/AgpPgig5E3LuBFp&#x2B;Kxqopn5PF0l7WLLhL0DLC/o69Xbq48mm4&#x2B;HwvNb3IUrPBKof1qs00CBcdqXFCNWp60n3zqdtvQLZu0RHSsSRLN06B6/gJP/58G2LtIhv0dTU1Nve3t7f19&#x2B;PttbWvurqoVm9vb2ypLQkPSAM&#x2B;gEOYC5ZYLq&#x2B;wNZpeTcwaNduN1DpBXTareN0PGaH2QksD6RN5n04gW67fVqdM2vgDNvP7gSQsL3PrJY1H1Psb2HQ0RdxpMzAqakIKk2Nat1J2aVmdaEIARpHeZzllAH2JaTBQ7aJEPDNabgP6muWO1mmVP0VgbxJAlz6MZoCsP7g33J5Tg1ctAdd04UQQ8l3Kj4nuXaTLyEXcUnjTogx05Q&#x2B;U&#x2B;yY2sj/21/rD0VcmuKjaT&#x2B;PGyZzBt6PJ7usFQmQSAhZRwLwOQuFpGN/bEUA2BFSdkTAD50A2JQ1AAYrSsvqRLvpBPjm2&#x2B;AZl9TjV1Y3ZN0NEAR6wXVec38CkU8dePkfgdrf0W/3QLZ/Sr3SJIjcg1U4vOxZBMGz0nmHAyuOBkouA0rPV6JCyNo1rP4a3RF19k9AzhunS9bFDRxL6WkvUmWM1tsCGTqKgR/M/KN0KBvXku1eANlG4LmTHJW6m3SYVWqa7o1Z8yCSC8/M&#x2B;&#x2B;qLdGpEE4Hp0kuAtBL6e60OjUtGB0Ep3A5GN6a9KVF2DZ3ji3WYXednul5u27tAx1TdY3RMj63S9CQdWi9E&#x2B;e9iXWl/PcCVA4Y/p0QVUVSgdRMSuJpWyBq6ju0fQ1T&#x2B;Wa/HOhDZ&#x2B;/rPi29bhEUc3&#x2B;Li4nR&#x2B;SW1ZTU1NfWTBmtU1XcFgvywsKkrnRIHcvLzUgAO4NAM4O4BmB2TtwKBVrqkdODTv2w5c2&#x2B;3PvI5MKIcm40Ch3X6s22JV4E24EhtubfH6vdV5c2q32/7t9uW2jifQ4LKu87IeW&#x2B;A59t7glvL4F03roLGTa91n7aDK2QomBLrn6VfHh5DdM&#x2B;jz4hghEJ028wkBB&#x2B;RP4yydrKyxSKm6Afh/9r4DMI7iev&#x2B;bK7rTqfdiFfduugkYF7CxwcZ0CC0JEEogJEBIaAkkECD0FOBPjemQH6GX0Hvvvdm4qbjKsqxersz/zeydtLe3u7cnybaM58H6tszOzq52Z9735r3vkf4ieUvC4T4bDIsHYqwf9P9WmUkQ6dAWF3QWnBTUnZqDgO5msOpbNfAv3pfOD7T3RIQPFP8JWH&#x2B;5dh&#x2B;CC6nkLwMmm7ZLz5nac7Aj8EtMFWhFDMii/yWQBBrOsQLUveeqT&#x2B;RHkQXAyqJixv4PZQBQstVEsNGKfK/fjddmlQVwJnDIAnsDw24H2/APAp1vAA0fg6&#x2B;/mQBkngTDvO5EsKqHNDdyCZh/Q&#x2B;Dxd2Dl/&#x2B;wF4tLwKCy/ngq6TqlGiNc76HQS4D6Vrr0/nfv7wb8vQawjmGtpYYVnRdMNvgl0fAre8pgk4okjwhOstMGV2j37d9Y65Zz54Gv/n4x/FGmV&#x2B;Oo/gKVPJAB9sv3HT8&#x2B;MCcOGdKVzYVCiOiVR0M69bZPAPFgLtDwTn9JQWPCXzgBvfYHufW&#x2B;wDPpbpO8CLsB882N0T4fRgH0gkLE/gfzLNUZeYdwQ3gS0sOyDtb9z4a/BV1CZzH2VAUDJj9kgIAkBRDpBsUQiEU4L6uvrO0VqwbVr1nT6/H53TnaO1&#x2B;P1sIyMDE8yYGYH3vTAOFUwmAy4OgWOiW1yeh5P&#x2B;RrmtTi8Dx1Y7fdMNo8aPpwGgA&#x2B;qFshhyTrptLxZW50yVloxRpq1xzEpRXQysXd3mkxvJ3PE5x0DJtLT9vwgQ/PkWNvxDm3XSeMy9PhSeQhozzFCb6c7n7sqLoM79zAGkco4EmEa&#x2B;Z8V8aY14V3/OkFX/7&#x2B;FjneBtm9IzxgBiPABEZK55hz5DrDRn0oDgNA5kDVXg3au9MHuv5MaAsxCHuxJ&#x2B;Zija/U&#x2B;Mm7SR1lkIej79HTEhL2MHGwAHjvKADCUwL/VttEAYOZ&#x2B;EVFqmZItKmWXgQlmWjGrH9kE5B6ljdRixn7YrWDCNVxYdEXKoNZXwUVqu0gH&#x2B;FICh/5KcDHAN1yhkfA1PdBnABAzyiuo8w/Xa29191JdypgOrU6WuXkMAAm9SqlG&#x2B;kcLK71CMh/HA&#x2B;wcAr8L5eDFhTdEz3QauA4H1vwNCDVongBNdxO4b5KWbRYD3WIWXli5CWT3jaeZ4CtPAev8gp7tNeAN14EVnjMgl7cEcRdpi3/X6LNu1oh3hBeHGGmEl0D7O1omIX&#x2B;J1sZa&#x2B;ruOel2GOGD9VUDJRfJ&#x2B;WdZ8Ut5O1OrJoL9p2uO0jKJnUK&#x2B;FHShRsp2ISB9IC4YPHx4Q2yUlJRHhIlBfX98ljkmDgM/vzs3LTXPTdnog4E4dFENL8WUDCPulCNqBRluAGUnOdtYfAG0HTOyAbp&#x2B;/c/L7dIYSnOXvS4WB0UnguvEaZjT&#x2B;&#x2B;klIZvLckqVNMIINrksyHjvPLhWB3f1aPZe49ke08LteIJmuGQTEkidSDjZqY60wBHR&#x2B;ScP&#x2B;ezSWrqTxqrMvZIABP24PAaZ7JaKqvsiwIJ5X0dnck/9LxjImS2NALAzADoCafxLckVcAG2SjF9/w/zTEFpgJXnss6YdPaH/btEpDx5q1eZ9wPwwh/fEiMOMg0GcISPDeskg7wFjsveCDY8RRBoAtAuyZCbC3mrlPNttv9aveBCVbeHyiQbviNrDgnzX7k3APF6Ryq8&#x2B;QYJ8NW6QZBUQqmKKLwMJraFAnQNxMYL/lRXD/SKD&#x2B;Ii3VjdsjjQMsaz8CnjuAVd0D3vgPYNMzNFhcTXh/lpbzXoQfCMtwd91WuF&#x2B;3lnLGKKVXA8ITQs6Ab9KMBRmjtdkLkTs5azoth9Lxy4Dqp7RzRFq/db8HG/dJXz15NBDW/lpeh7c8C6z7C9V19OZl3u/6DLzpLo37AD6wES/KDAOCzRltL2neAu508B/oHjJ20rgSGq7V0v1segis1wAwk85rkaSKrOh32rlKlGynkpaWJucsR40alSGUtJ6ennDMQ8Dn87nXrVsXFh4CIpxAQNY0n89lCt7MwGMywG33awbUkuXFs2NBc5JPz&#x2B;xaVjPFydpjVbdZTj4rw0E8xkquOdkBcSftTFa&#x2B;Pzn7EoJBHdahjzGOmLgZc5g/EO5gHzcnJ0v&#x2B;N4zOXcUMAoK/xp0P5inS0sXxMJgwpgdrwNvf0yYUxBJcToe6&#x2B;&#x2B;wA0lfcZbiMyHvPe9f7Xgdu&#x2B;QLoz&#x2B;nbjkKz6DFjGX3Z&#x2B;M&#x2B;RW54fa4dZu&#x2B;Jnk6kMAXxGNxnJnMfTSs9jPHO2lpIkHB4wAN7i0v0N6QfPadlAmh8inaJL&#x2B;zO4/dqMfwpE0YNlBLAD9FYp&#x2B;axm9rXN&#x2B;L&#x2B;f0YPAtC6ezBwUbwRI5VxlABjawi269WQz/7ElEn0R1GugZEujYi03sF6qHgTr&#x2B;EC68THpFYCou3i1tggrf3ETmIj5IhDJOwUJ30ag5WEC/SJHvZsA/xxpCICPBnwx6C&#x2B;fDRT8Csg&#x2B;mMDmXBo4Tk&#x2B;0&#x2B;wv3t&#x2B;5v6bwpW/gZCIv8KQSGT9UMFIIgUBDiCYOF8CCoJRDftbSPX0CEBuQcBdZwPfjaC8BKrtCMC2Lgy5wkB3UW2BNcsN8KbgE7A4A4LtL7&#x2B;cb2r&#x2B;mBn8gUiNj4uXTfl7F4genasw2L8IalmgLSeINkc5bhD2sv07ocFz3vVafR32Q&#x2B;/U32I9RDXXDbK0D&#x2B;6VT&#x2B;X5L8ScWmKdnue0hS0AToF&#x2B;tjxowRlNbo6OgIeTwe1/LlyzsCgYBHpB/MysryZGZmesR&#x2B;EUaQMrB0qsz3F8DzfnoXWAJEh0BzIG1PWtbhtQZL0eOpOyjYOSEkiw5wUs9g3EuCjYo7j0tOtG9FoinuQlp7aXxlwmtNjKU0Pklyu&#x2B;A6aQCQPDadn2khgyIUL9ITTVEoPKxdCW0wAu6&#x2B;Z8IMx5jpc0p0aGEGg4L&#x2B;xWK9x&#x2B;OfFUs432pbo/YnwOgbAVfxRdxdcCKDi9oajkQNJ/osDM7&#x2B;tlt75pg33qiRSYt2Rgj8C&#x2B;5UwRVVco02kTBE&#x2B;/CBPTtzS2OfF0D80Ti3/lghFxTQt3vCQzQLQMw&#x2B;mSwNoFlKQA/iMwHYpgJcs2bNFaWlpWPVq6Bk25JoXiCRbq7lCQLxXwKtb2tGgZhlWLziPa1gwy4Biv8C/nUAbOzX8TPyvAt85XyNi6DywS3bfukOq7NBipR8whtCGD5owOONi0hBWQxWeDb4htsJsI&#x2B;i&#x2B;6Jjze&#x2B;CjXpKkijKmf8N14NtvA8Y&#x2B;zn40j3BCk7tc7M3k9VnA10fAyPfHtgttL2ohWC4AtZlwutI8VqrpVtse1VL0dP2lvbn8&#x2B;bJdIss/ySg9Drw74eBjVvmLBewEiXbubS2toaEPlFTU9OZk5Pj7ejoCAvvgPT0dDeJa3PP1G2J0HYYsSFL4do2xsRkwDZZfnarfamCdStniVTKJXPasItCsPAaTgCvyVLa2YX4m5U1u55dpEMyI4LxGmYqNnPRWMndUeTEJScNC9ZK3iHe9p5mFKDxivEQeidkaXw2GgD6r/snqcfGs8RxCk9qe4QFuKfkAuYuPl/TF3ikz2PCwCtu9c4a&#x2B;45U&#x2B;hLbsqHVpKP8hH7p2ZffBuSf6uz7/4r1fdO&#x2B;aulByUSmpcEMdexXv8Qdg3xjhgDju2p&#x2B;Ok9aVx9pZmJmEbsMAaKOQCBdZQEYIpLK3JdTl38zT4CIYV2Jkm1Qom576buCCe8AmfO1Buj&#x2B;Xsb/QRDKifz1m57QPACEeMs1LgC9AYD5wSrukrPqsl8Ld9Cgmb1l2m9wPdRy10Y/18BuGilezRGS6ZYV/EqzgofatfCH2mPo3neSs/7wjdP4FIRkLSBk8Ky9ASC0Frz5Hc2bIlnGAcHYKzwkRJy&#x2B;9FTQSea85LfpLgGjRbL0FpwhuzguvAJE/J6I1ez4lP4uI7V2&#x2B;HfXeAD8u6nXW4mSJCJm/8XvpEmTsgShoDAIiO2VK1e25eXl&#x2B;drbO0LFxUV&#x2B;r9frcrncKdsDkoFsp2H5ljO&#x2B;cAb4jAqSnRNDHDiM/mMX1s6SGBSSgV79MbuoCbtrmgFnO2Br5WiRSuSG46gBh5EITupLViYlJ4yU9kdd5CNRPMOj4693GLggC87Yi8bXbi10TWS/aXtd0yG6v9IAa5hL7jUWNQj0V5mPcPucFHYOENyizt59wmgRps2iX8FVcA7cmWO1cI1IKM4IElvXvwf6997MzdwpIIsrK2brWx6X6f6QTXpCYJ/&#x2B;d3QinXAX/WbkAEXngeX&#x2B;PJ7keStKfwwj8RwKPIkBK76cKf&#x2B;CzjrEwCw7MGPdWyWUY4jJUAsBsP3GAcdUuWaWFm5hCFCi5MdhEPCO0BbByB/r5Er6XPtZBgFLT4nhS&#x2B;mRvASs8v/kDACvPw5szJfxXYMAwL6JA2te1&#x2B;faoOUucFZ&#x2B;02ME&#x2B;G&#x2B;j9pHS4p9Kg94xYEW/p3q&#x2B;BhftaXleAn3eGk3L58mN2jMmgjfdARbeGJ95QBuVIR2CRFqlyEPixiCZle1EGAsEk3&#x2B;kDWzkuwMMldA4zFgmKQNiEa58XZ9pZILSmDOZ7qNKvcpKlKTa&#x2B;7lcTHgBiHXxGwqFIi0tLUykG6ytrW0vLCz0tbe3h4uLS/wej0eQDzIz0J04S5Q8vN4Iiu1Ar1OQaAa07cCvHQh0yjGXrB4nQNa&#x2B;vlgcr3NQ7OSZOQXjA5lYc0r8Zn6/yc/Vl0mWfi7&#x2B;OXJTEGp&#x2B;rh6A6WbFYwaBtNEydI4J/YF3k2qwgobIJUDHm1q4QOe3dMo6qTlr4QLi1xNvnII5eZeTfcwCBHAzI1jvjrAk9Itk7cfdBI5dOXszJkmVw&#x2B;aEm0jtu7YE/7xVkDBJ7784lnlRaetT4Osu1tIhi90bbwYb/gIQ2KOfutN3BPwXaOmCY0TE26gY3/P4dWujoxlotyIItErtmqyfVgaAbeg9gnVqP25jCEjwAiBFQL0GSrYPKTyfBngDgI10Aj3LNMOASBvTvZwGrEVamhnxgQRJCVi&#x2B;L9iE1QO7tgDrG&#x2B;8EG/1R4ky6maJScqnmiRBaD5Z9SBQ/FwIZIt3e3tS&#x2B;06jdNdI4wTf9h7B9u1bGN1zLeiByJsf1DiFg9alA&#x2B;c1Ux56aFtH1NYHuPWV6HR5aQ9c5FAm5edNGSFc9LkIGRLq/weRKcPlJKdiz765JgXFsIFGiRIm1YuPxuEQ4gOz2CgvTurq6wm63G21tbT1r167pon3&#x2B;7u6eSFFRkZ/E5QRA2wFCPejsUzD1Cm5/lOXBBa5O7sOuLVY5to2g0wr4Gq9j5j5sVibV43b7kl07GRC3IjQzI0XT122ZizwJ2LRysTZNqwab65n9jeLaENZ4AiIxiE1L2jiZuhjZB4FFusCCy7QZ7bbXaTz8TAJTLrh5orHWWtiAx5Kcy2qfmWGAJ1H&#x2B;Y3H&#x2B;8E3kobwzeVrJCaTK&#x2B;7RxXhxjTPd3Y7aGOzNgafXO9p605iKg4EzNM1BvnGh7AXzlYRrRYCwwWWRoWv1rsP6GHAqdR&#x2B;om277YkQdaAXozc1EiQWD8d5AA/g2eAEqGvgGAWxgJzfbbMfxbpQBUWQCUbF8Sy2sf95WJXMKLCYhOk4M9G/Uq&#x2B;PIZBHafA8sSOeynS1d9vulesNxfmJwfjLoFJulVhWu&#x2B;yELA22gjL3lbXRlgxX&#x2B;2KyDBuQToWQdAm90XPdowsMLfyl&#x2B;jesTb3gZbfzkhgrMJ&#x2B;BcC7W9JAwDveJ8G9HOBMZ9qrvpGY4RQgGjZ7KLAvxIlm6fr8/vdYhHr5eVl/ra2tlBzc3Nw06amrpaW1nBxcbGvu7s7Qr9&#x2B;K9CU0C/YgjSWABytZ76YPRgXRgXGo&#x2B;78zBbcGX&#x2B;tQLcZsLXO192ndtmVi4FKO1Csr9PMYGBZr8VxK2BsB6adnGsG&#x2B;o3n63OLO7le/J80ueqZDPCnUqf&#x2B;HhLipBOuEVWNeTf6yABciKRNBPNN0kIKI91gQm/oXkzjKo2jXR/R&#x2B;gppsO/9PFx6Ci97g1LcrCyzMTwJP3/x9/EO4z2BwyOByktdXm&#x2B;uS/MECGp/tyQIz9wTxqGHh3hnCMyj8T6wgnO07di5bS8S&#x2B;D9Y403I/ym4t4jK3UrbPRq/giA07g/Drztvm&#x2B;hjU031Z2Z8cwYL7erRvTdWhgBDWWUAGNrA3&#x2B;k5VoDfbJ&#x2B;emEGJku1YaOxcfw0N7OMJDO9ByzThow40Pwne9KTkEZBEOj3L408LN9B5BKa7vqWvqIXK0SCVuTeB799rRH5G6fiABsinwOtXSs4ByU48uOg52qNRvYUXmYw2brCyK8GXHwFWQu0WGRO61mqH8n6uKbfL54ONp/tx5Sae3/6alj0g59i&#x2B;fZEm8DXn0UDipzGlA0y4BIqUjDmHq9dKiZIhLCJzgFhi2xs2bOiORDxYtaq&#x2B;XWQXEB4CoVCYFxQU&#x2B;JKB7QQl1CEgNAOWlmm1dIAtAbxx89lmp6RcyconKxfXfjgDrXogmkpbUwHZdmW4njlMty/WngiPwCxiXV8m4X4Nx/qn/PKEHOdOjhmvb&#x2B;sGravD7H6YaRQul4TBwu&#x2B;fR/UG&#x2B;HYA9&#x2B;8IlnNE1JPwB407oPNj8PY3tbS9oQ3a6S7dOMyYpSu2NZGkltaPswzuyp7NeMkNPJAx3C29FsLBKL&#x2B;D03AL58A0UY/5hED9PYA3R9OLhEeEt0pCKb7&#x2B;as0wUnIhUPK3aOaF1UDLI9ELd2hpoH/k4sQQYOXKn2iUtOcEcNQew/sOlnodygCwdQ0CxhAhJ2n&#x2B;9GDfBXMCQK7SACrZrkXEyaeNBF9CwD9jFy22zV0IVv0YDXYfywGP93wO&#x2B;CfHn9d4E7D2hmiODa0ONFwpZ8vj&#x2B;QKiMwn5J9MH7Kf6CEi3UN35v44eD9L2k0D6VBpIqwdpBHLrLRVaiIMwUEQaNS5X0SZxPyJOsGcF&#x2B;Io5dO8/ocF8LdD8KJB3Ut/pIdq36V4a3EX83UxSdo7u02YEq/&#x2B;6f5MSRHWzAA32DWD5P3fWRqEYeAqTkxAqUaJks4vgCNArrWvWrBFoh69Ysbw1FIrw/II8n9vlFjwDaS6XyxYURxBJCgStQKnVebHyRmDax3a9ORQvbgkY7YCjUyA80PqsQK7Z87EC7cb2mIF6J38nJ4DdyoBjvH&#x2B;z8lbGILO2JyufMPNvsm12jfiyYiY&#x2B;HGVgZ5oXoG8HGiN3ovHzOBo3WyQpMRPedV1faQaBnnp6gZu1d9kVq8&#x2B;NGCmfFUjngsiPtPVQYHrEW3op8&#x2B;TNFjtdjAd7jQZ9gJGZgMVEA0OqYLRPnWigAyHN4FF7PHioDmy04Eyi7qL1Ve2&#x2B;iv8SLUwbGbNIp3gkagQJ6LIR/LjF6cy&#x2B;3fM2c&#x2B;9PFhKgNxzozzHvj5QLwFA3AJgBf2YC/pMZD/TljKkZlCjZfoUAKKu4mwbva8GbbpM5gZF7GBCYSYPXHK2IAMECrOo/rNanwYpPkWntePOztH4eAeilMrVQnAGAwD1vuBps1HsE&#x2B;o&#x2B;nRcygu&#x2B;MANl91Olj184NnAIgTUta7PtVi9rprgfR0TeEQMXWCU0BY5YOtwMaHqS1CMYnvEvl6Gsyb7gUr/xf4mvM1o0hg96jxJFv2RoJ4UKYUFO6PnmJnHVvLQ6QcUbsq71PvoBIlQ6U7jGqO5eXlMhRAZBegBatXr&#x2B;7q6unhG5s2dodDYZSWlvjokCAcTJN9gI0yaTczazejawXGrYCaHVC3AthWQFT/ayxr6UKe5BpW62b1WoFxY3y4FfBOBpitwD2L/md231bnGu/DrJwTAG5VxrieEAMrdyRvT4LbvY3qHImBKKtAXKOaLRuhCxkQYDd9B5mpR/ILhJqAnpXgnR/SuPc5jcnvUvF6GR8vWyKjBWLhAjFET&#x2B;p5OALuG8E95ZcwZB4Jb1o6i834mzH4W8OHeCOA9Tk2&#x2B;5nu7QtvojH8ZbD04WDCS3LNH7RD2SI1sc5pKDYZ4RZekcLY37ld9aNODAFm/BT9Id101C6L71kZALYh45JDsG/mCWDmDaBEyXbeCxQBZdeAFZwGOUUuXNr0bvxtz4H3rAErOrd3PwvMprHsa6DqLhrcO8BX/pSA8VSgcRGQsStY5gKZohDeEjqfQHPby1pqwrpTgaKzAf8OWnob71iqcgQpA9/R&#x2B;ZuD4VaA/aOltsBXnw9W8kdtt4hljJWYWEvX/wLY9Bq1Ye/407u&#x2B;osG&#x2B;G3zTMxpr/4br6J7/qx3LmAM25kXwuhNIATgHrPQq563KPoqUoU9lzmWnqZWUKFGyZUVkCxAz/lVVVdJ3NxQKcSHCICAMAxs3NvYIHCI4BIRymZGZ4bEDcSwJ8LJz3TaDbXZA1OrXKRBNcOd3AB7153KDupZsZt1JW5M/ETPMys21RRNgGzHOHlr9rcyo7AdLwY09amY1osW32RHu5YbzAOt8W3pgzRyUN7kB&#x2B;R5HuvtOdGWTPrALLbsB&#x2B;TTmhTaCibDCzg/B297ROASC66IEvlEjhCuHo&#x2B;xinlZwhIv5qsVY6RKcQ0a2eHPAbk8l6DzmnPX9CNLDVedomZPErqzdwQrP0dq69kaZ1ZgV/in&#x2B;9M5vtHMzDqRnkEW6RKdu6jG8XRkCkhkB9OWM6/HGBKuwAPMeQm/IsuQGUAaAbc4IkCzGnxnAvstgCBDrYRUCoERJVIQbv5kI9/w1c4Hs&#x2B;X1EgnkngbfMI&#x2B;xaBlQ/Cqw6A2gSsf0FQPN/wRv/q31xGTPonDLw9ZeBiTQ47gB4/UlgI18BX3kQ2OhPqcw0UgKeAMv7mQF8fwJ4Rw4OCU7OMTRgL6Q2ZZpo&#x2B;elR/oPEND2s7Cag8TZq3zPSW4I3PUy/hwO&#x2B;XTTOg8y5YMMfB1/yE62dxRc7a0/HGxo78Kpf0jX&#x2B;rnkjKFGiZGgrTB6PnKKsrq4OiO1gMBgRRoKVtbUd1N25GhrWd3nT0lzCM0CUjREPWqmndrO/ZrHQEWMIq0MA2luXVb41J3WlWJ45qacfx8wAsv5ZMTMwDQf3bUdRz3TFuYGRWgeQ9c&#x2B;ZIx6oGsv2Rm&#x2B;w&#x2B;Dr1bbB8HMziHvW3xE3wvgn1PtfnUdffG0&#x2B;E0cxwvYT3iifWLedceZjqDvfV4s6l8XZ3mRqP5Z8KHmoE6/4evP0dmXKwxzUs4i85gbHAbi55fqQnWiVzQN5mNauPBDBpCUbNLiJIg1u/h4hkZCJ0svI/ms7U&#x2B;ZGm6whUEUvpKz/WNs2wwV1guYdqhn6ZoYAKF/5KI0beTsQufZ&#x2B;VYcbMA0Bv/LH6E5plAjF7JZgKAdhmsgCYZQBIxvIPJPcAcCmVRomSJOKbDDbmC83lvXff6D7GfALQrPJOAtn7aS7wLIMA8ysagBcMwcI1vqcO/Nt8LQ1hK4H&#x2B;Tf8njQe8/XUqPhNYe278NUNrwFccKmPzZYiCK2Pg9yEs8NrI7PzTF7MWFbeBhdcRaP8UfN2fgabHCLw/JtCAcE8EE54NdO987SVggelA5j5aFyO8GtLGms/w5xwVJUak57PpHqDg9&#x2B;o9U6JkGxOv1ys7klEjRsgOSqQbFEpnXV1dJx1zr&#x2B;noCGVmZnozaCFhIj2hVGxToTo2m5nVA0qbhOoxcGk8ZgSNRtAbd54FNtfr1nFg1&#x2B;LeTMndYqAe8dfTg3xumL1mZvXqAbOuDQlKIzcBw0ZQzk0UTsO99gIQi1x3CaCboXdaihueNePmaaxsXoM&#x2B;oG4J/mMBE4nNM9Zh4JOMe87c6v1A/N9E//fjsesLsj/etx1nuZLGgBiHAH1C7mJEAmUIevYKpxVxV7rHzwgnMybi/w1gLc7Yw&#x2B;ysRdbvnzm41KPLLqDledJP3pKhiazwTC2sIYv0ntAKujcvXFH3ft75ucT08pI9NOZ7y7V6Ot6m8f1DLTVxbnRygwld6S7Sa2Zvl/2lU7d&#x2B;q2wneuONOTeA/XX0WQKUbNseAMwB6DfzFIjoF&#x2B;UBoESJk57CENtOAyDLPy1&#x2B;X/ZPe1UMlh6Nkw/WaEy5wTrwJgK63V8RqM4GrztNowLomkeD6hF0fA0NmO/LGQEpzQSwQw0Ejh&#x2B;hsfgbsFHvarMGA&#x2B;04Ot4D23Q/UPg7AuejnZ/oLqF2ztfAvpipEDP4rTTAd7wEvv6WPsV61Zlg477S8hHXHgMIMkVdrmCE1oHXnww2/Gmwsn9GYyDD6v1SouRHILEZ/7Fjx2YKRbWzs1PEDLDa2tqOjIwMb3t7eygnNy&#x2B;NynnSvF4COS6WAHSZibLDzYGs3gigB8J6UG0G4szALWA&#x2B;e8zsrAAmmpnpTLdB8Y67H54I1OLuDRYe&#x2B;9wCf/P4mWqmt4boNEfjzLbxnrkZ8I6tR3T1MHuHc6OhhlnYDcxy4/UCIeaAVJKx&#x2B;PeD6eowKWtplYmCdzN6fq53yTZ57lYhAQmvoO4anMa/7q72sMfjQbrf52Iu4WUTAovEyveFxdjN/CZ7SfXg3yodpixE&#x2B;gZfezHQ8nh0rsBHOssEGv/3B/MUgtccEvVqiJpYXFEiX7fgDLoUbMQcLZxh9W/k&#x2B;axEFxYguJQ8s1VHOQAjQWL6zoQSvW&#x2B;l81APZQDYFoC&#x2B;1VhgBP4RXV8dW8zCAiLhcLhHvQZKlPRDhEt9QsdrEEHsFyX3Y3nHE3heIlAw0HQPePMTpDHvQl&#x2B;kn77IdBpYF4Ll/hwITKPB92Ug90DNZb/5cfC6XxBofgIDdtoRMYeherDgqtQMADrDB/xTwGhB/m&#x2B;03L5d30pSRLR9ABQc11eu4DfgtYfSczoYTLAB&#x2B;yZoyoQwHrQ8A2TT81t9GlB8iRY&#x2B;EGmm4znqvVKi5EeiyAYCAaljTZgwIUsoom1tbSHSOXh9fX2b8Axoa2sPF5eU&#x2B;IUngfAO0MwBhtlOE3CbACJ5PEjtBdG9INICqHJz723AcnLb0jPAjKVZgnQeBXA6MGpVtxGUmrYplnkhloLRBNT21qnzv2c6N4E4gGtMWxYDzHHpDc329z3xGBjkcW7HfeCdG9oMK1BvcF3mfX/IuPrMnkcCcNfXYbxf3TNKeTrU8NziKfvRZ3DgPPHvbPg7iRCaSCTM/QT83R4P08BfJE6fSMhqwBKNH0lBo8sd9TowB5JyXRhQWp6lMfsoAvBtmqohzXndQE8NkDk3jgiw95oi80E4iqZa3wJfPkMSHkqSw5y9gLyTVWeYBMT3t4zBPmVh&#x2B;HHCI7Cd/h22tHXE5EM1y9vh0m0zHXA3/potbt2i3/YYjoltz/Tp0/MXLFgwYv78&#x2B;TOKioqGl5SUTKCB2KdeDSVKUpTwhtRi2SObNNd&#x2B;SdD3Oxo8CUR31/XlDXYHwLIO0vLtBqnutBFA&#x2B;U0Dtyoumw6WOQcouXSwH0B81xWqA188kZSBNq23Ea6BWQfQvZByIMiMqp8BX7EvmMiaULEIqKFjVU8Z0hgqUaLkxyihUCjS2toaEsSCdXV1XYVFRb6W5pZweXl5uuAPcLvdLJYijZuBLz14SQbUEn1kTYGziUad&#x2B;j4zcGiV&#x2B;N3inLiZbzvAGdMpe70gePK2OUMSKZ5vTzq37YmzGBUnKRpNz6L/RbiMz&#x2B;dzedO8jOlyAdplxjDO4idN&#x2B;ydSdoqahDehSG/MuGmMuYg3AG8B/3Y0jc9UNv9IIH1nYP1Vcj8rv4X2nQbW/gIigrvIkws28oPemH&#x2B;&#x2B;hM7rWtY31SiWvP3AKh&#x2B;i6yqjvrUtiTsC&#x2B;mblrM5J3M0twX9aWtovoCWH7on&#x2B;hkx&#x2B;Y&#x2B;vRuBW5HTZZIrpf/WJMQW9lA7W9r&#x2B;3BAGAE/czGCBBbd&#x2B;v2uW1&#x2B;PUbwb1j30IDrOeSQQ8pmzpw5Yt99992zsLCwUhgFmOwdlChRYilNt4E3Pw427Lb&#x2B;p/MLiTCAj8A73wPreJc0hMXULa/TukdvtswzzEa/pespe8AbrwcrvDC16/R8D153CljFzRongbiACFXwDh&#x2B;cZyFi/0TYQ88P4GuvJKD/X/DWJ4D2L2j/t33TdQGRJmkyPbsHwcavAK//lUybxEqvVu&#x2B;TEiXbmXR3d4eFQaCzszOyfn1DT3Fxka&#x2B;9vT0ybFhFelRvYpYznSmA1V6ouo1OgzlJmzjQOvoHbFMD1MnSQyZrm10ayf6knrRLGRkD5lbt0QP3vvfMvC4RFuP1pjGP28Ukh4ZVvHbM&#x2B;GWw/5jjCLM6qGoB6hv/BSZ0ieoHaDuigUnpEQDEvA0YYTpeezQgvBJLLwIr/rMMQeRL95CGfFZ&#x2B;s8ySxFtfAGoPkuGImgGgWrt21zfA8ungkQ5p6GdZBwNlfxPpklTH5tAQ0J&#x2B;yZudZGQDMjAnKADC0DQDQAX07LwCmA/t2ngBmXgBmBgH5m52dnXb00UcPnzVr1uipU6fuVFJSUkX78gFFH6lkOxAxIy9I8DzDkpddcxZ4x6dgw27oyxQwoBEhKAdeyQsgjALtb4Ll/RwoODveALBsH7CcBUDRhdHPnPrf9TTw5p9M7S6L72N7SAnwChKfWvAlNLB7h4GN&#x2B;QC8&#x2B;T9Aw/Vgo97TPBJC9XRuRf/bHm4mxYHAfVstUHwsWOUDve0V4QIiDEFwIfCNtL&#x2B;nSWu2x0/tEe31go1drN49JUq29&#x2B;5XMwaE29rawo2NjcHi4hJfd1d3pKSsJN3tcscZAxIBXSosg8kBcCrA1wlATVZnf65nvHd7YBxfxg6A221b3asRCJs9m2Sg2aouu2sONM&#x2B;5k/Otyjg5t621rSczM9PjEehfz7ZvGhLB4HJsAEiEEsztBl9/FXjdhXBl7Qk27l0tjYaoNNSqheOJ&#x2B;H3ax3q&#x2B;Bv9GGOQLwSY2SAZ/vnx/0j3e0cgkxcRG3ql9HgDuLNp3B3jrc2Cl12kEyT1LCSbWS9JkGeuvZNCNAck8AaydjBIDnZQBYNswAMSAPpBaGIBx3Qr4m3kHmBkL3BMmTMieN29exfz58yePHTt2dHl5ebXP50tXn6ySH6WsvxR8w01ydto0fZ5eIgTGa2nAzD4SLP/0wW9LpF37jF2Gz00A6e9p4A5MAcs6kAbwSeArTwErpjaUXddXrvNj8GUz6fhEAvofA&#x2B;0v0QC/AKzgFPCcI4BlcwD/eDr2pmZUqLpvYIaMUCOw8VYg/1fWyoDweOj8AlyETgijRRcpEHkHglU&#x2B;qt49JUqUxMnGjRt7Ojo7wy3NzeHW1rZQUVGxLxwOQXAIuN0uZgfYkoHzRFCLXoBsBfCSAdlYXcn22QFcvYI42JrqQMGy8QnzhJlGgKVgg0m1/OauZ7CuLTgvaImkiVl/mQUjARRYvq/6IvYs/iY8AWKWf/W54A3XgQleobHvgIU7JVEfWl8BEwaAkr&#x2B;Q3jAXaHla8hKh8Gwa9yeD1xwKbHodzOuhv2oIropF4LkngrW/SMcO0kh&#x2B;JeFBOdiEr&#x2B;lauaqDGgTgnywcQF8m9ZCARCOA1&#x2B;tVBoBtwABg9ABwYgTQg36jAcDMGGDnIWDKK7D//vuXTJ06tWz&#x2B;/Pk7DR8&#x2B;vLK4uLjcTaI&#x2B;ZSU/jh65iwbB/2gpbMIb6Y0v0FLaiXg6QYxjnCUXM&#x2B;srCFSX/BXIPkzrMwUZTtqYwW9bjG8g3Aj&#x2B;tWDWpcE82N1nJnQXgRWdCWRMB/fQ4FxznObNIDwJCn9PA/2ZMk0hX3WG1jd3fK6VFzmJF&#x2B;9O9xyN39tiEpEhA4jQ&#x2B;OGfqN49JUqU2CrCDQ0N3R0dHWFaJJdAaVlZejAY5CXFJX4xy8m2mXux5MOzBbLGrAjGtGC256ZY3uyaVvWZph20mMlOBCnOwbsV9YLZvRnrtaN&#x2B;MGu32X675yhJJ3lExrp1d3eFszKzPGZt029YeYuYPQ8rA0DcbpcbfM35wLprwDKngY15B7zuZKBxUd9Z6TtrYYWCtFd4A3QvAV86S3rxseH3ga&#x2B;&#x2B;kPSKH8Aq/g2WdxLpD6&#x2B;QjnMA3Ui3Bumy9wUb8SKUU/DWMwQkA8923gDKALBtGQDMvAHcsA8HSGYASAb4LQ0A&#x2B;m2fz&#x2B;c58sgjK3fZZZey2bNnT6mqqqrIycnJc5GoT1rJNiOhtRobfdo4oPMjAs1TNXe4b7O0VHzpewItj9JA&#x2B;nMaIJ8jgD1LB8oJjC/eQxoI2Lj3pUs7X7ITWPn1mkEgtE4bod3FA29n1xfgay&#x2B;I8gasoEH8KS3VYOcX1I4mCfTRToBafH5uGtxD1L8XnQpWcDp4DbV99BuSeZ83XAusOg/IOZju52HJ6s9/2IXuvwps5JvqfVCiRMmQV5iFrF23rqu7qyvS3tER7urs5CWlpf5wOIy8vLw0Lal6/0G5HthZgVmzMnYg24xP0AyQOgGdZnVYgVezuq3OTwZ6k13HLJsebIwDVoDers32&#x2B;ra9oWDw9Pq&#x2B;&#x2B;iKRCCfQH3HRO5eRkeGO6fwJf0sH4N/4zBLJ/6zKM23sX3M&#x2B;uDAAZC8AAjvRWP83wOcHi3RprP8ivfHI98B8I6jhTRppb6gFrPpBIHMf0gVIfwmtAMpvBRPefN2LwZftqRFVlvwRKDhHkfZu5n4tFWNB4rb9u&#x2B;71epQBYAgaAABzHgD9ejIuAGYA6cmMAZ4UQL&#x2B;RZNC47qKOL&#x2B;2kk04aueOOO5bNmjVrx6KiosJsEvVZKxnSQsAaTXdoqelantBS2IhY&#x2B;&#x2B;VzwLwlQNUj1JW1APUnacQ3Y7&#x2B;NP7/1UfDVF9MgOwys4l5g8U50&#x2B;nqw8R/TQEz7sw8cvBCBdX&#x2B;iOv8GVnwWUHKtZsUX/a/wXBCJmlv/B972CrXzc7DADAL7t1OPn6F1LjIun8rUHgPkn0infAtW9bDkAOAr95XGAzZpBeLSDoqUfxvvoqpbwYrEwD&#x2B;0o3&#x2B;6u7vlYOL3&#x2B;9V7rUTJdiICgLlcLlZfX9/Z09PDBY9AMBgE6SA&#x2B;5nKzjIxMr8sVD8rsyO&#x2B;ttlMBl1YgPBVg6RS0Okk4sDlA8OYAQIyxIdMGu/aIY2Lp7uoKcx6J&#x2B;Hx&#x2B;N407LjMQb4XujUYAMyOS&#x2B;cy/NqPbd8ilxfmL7dXng6&#x2B;/Bsw/QpsoKDpRevmh8V/gmx4i7J4JNuoDSdzHl8&#x2B;SOg0b/a428dFOvytmae7&#x2B;JZeTnvEnTWcQvESufMA/Dmrmf/O/e04xqp03gFV/sL0bADxD4e9s&#x2B;IrMvKwSE6/G79enoI0lEXXr1mE4ZpZhIGy4nn5xG45FdPXHDAJcbwAQ7L033HDD97T&#x2B;Ay1vVVZWBk466aQxkydPLttjjz0mlZSUFHs8Hq/6zJUMKfHvCJReJcEtb34KTBgAWBrYcAL2P0zRPsB1fwEy99Xc6UVoAPODrz0XrOyfQNbhNIDuA157qIylB9qA8gs1kpy2r2RqPwyWAaDkCrDsg6nNO0TBv/giO8GXzgYCk2iwPw8s52gNuLuyqOwh1PY/aqkGfeM0A0E3tb&#x2B;rhrp/AvtNi4CCM7XBv&#x2B;0j6VEQl9Gg5Qnw1WdRr5kLND8PjH7BmuVXeBKQosBE7mDT4x1RPoPNp0C8/PLLuPPORdhll11wwQUXQkUnKVHy4xdXFN1XVFRIC6VIMyiMAmvXru0KdnVhw4aGLo/b48rNy0ujPsGVnp7u1vdDRv1Tc&#x2B;fWA0F7MG&#x2B;2PxWd1uxayeroU/Cj5H66X2O&#x2B;d2N9ZsDWuM8KCMflkefmOer7jnPT9HVW9RnLGu8hWX1m5c0xOLNsp9k9GOsUSzAYjPR0d4fS0tJcGRlZ3vgUe8nBv94IYDT6mKf8S4QD8vmLWX9OOsfGB8FF1qDYe91F43vu/mDDbtVc/cPraDx/DDwSFlSDNN6/TvrAF2C5e2vjP6n2IlyARUKyXlfPkj7jguATULLZpc9zxJkRwP472TaMfltaPNtou/UGAZhYVWIg3aVbNxoCmE3dbpN9euDv0pXTX8vofeCKHaurq2u95JJLPqf1Lwn4vzR37tySo446avzYsWPLpkyZMpYG4YDiD1AyNHpejfCPdX5NwJ5AdN4J9AZnS6Avc9g3P0cD6j&#x2B;1ssLd3lsKbPiPJMth5bdJ13pkEPBtvpgA9XFgxX8VIzOQtZPGvjuYkr67QfvNlGl8QO1G7WHAiDeplyvSjmXMBBv5Fg30z0uLP9L3AMvZG7z9KaCnh45/p9139tHgjf&#x2B;P2ro&#x2B;3gDQs5JuIwMQpIht7wCdn5AyMMO8ExEkQozKZuyj8SYYuhO&#x2B;8SYw8exKrtxsf8ZZs2YJxQyLFt2Bb775BjvssIN6t5Uo2d6UPI9HTnJUVVVJa2VPT09EKMWrVq3qdLncrvq6umB2drY3ixaRlk2mZgNMAagZkLUDiE4AthnI5TqEbnctO8Dam//bxshgdB2Oa4MpsIYpmO7NKcCtjRrGtpjVb7YOQ71cZ2lIvOdkdVm3za4&#x2B;q3IC&#x2B;Iv0laI1ubm5AvizpF4LDrwa4kMlePK0f8wtVQwEmwi4/5TG51eB4U/2lRSPbPhz4Ey6PYO78qSKLtMBijG9/QVNYw&#x2B;3gQfXgYlJjuBamaqX&#x2B;SYC&#x2B;aepjmQIGAOcvMtODAbKEBB9DkMgBMDka07gAIj9ugzrZgSBRiJAuxSBZmEBZjH&#x2B;VuVM3f&#x2B;TLHFtFVJQUJB20EEHDdtvv/3GTJgwoXL06NHVfr9fZRdQsnVl0wPgK39GIFgYBDppQAyD7Ui/3d8QiH6BgPNrNKi&#x2B;pJVtexm8/jSwMR9qsfg/7AZk7y9HXibi5DJnUxk6p/50sHE/bIG4ubAWzuCbRNfy2YwYXRr5XseHWtnAHtruxVWkMT8GpO/WVza4QiM5zP0FUHAK1ZulpRIyq3ZxNR0r0NwJmYkLfmgVPYtT6fn9b7M&#x2B;BREGUFdXB&#x2B;pT1PusRImSBBFEgqLLWrZsWUcgI8Pb3NwSzMvL8wUC6W6vN80dNSAMiu7HLQLxU3H13dIafJzhASlkI7AiQ0hW3rjeX7EiZUjGumjHVhgbXUMh3t7eHgoGg&#x2B;HCwsI0we5vZjQyz9ZnH/vvzPVfDxVIl4hsAGu8WU4AROp/D&#x2B;bxkK4SlCEAECEAaeXAxFUS/Gsv/Tuk28yj03PARBjjqpPAmx&#x2B;PVhkAC3UAY14m1WEU6T/DVScxRCQZwLcjB0zMGqBCAIayB4BVKIBZVhi9L5B&#x2B;th7om4VP5br69RjAt5vxt/IAYMmMAJFIxNXQ0BBatGjRMlqWC4PApEmTshYuXFgxZ86ccSNHjiyvrq6upN3KO0DJlhXhPj8qF2i4gbq8FdoMvgCz/l3lwor&#x2B;KIn/ZHaAwE800h3BD8Cpr4xQH9n5ufwMeO1BYBPbtNlwAr7o&#x2B;jTqZrc5hT4X/y4OtDu6H98UbdGLSAfkGxu/zzuCnskh4KvpvjdcTfe8Jz2TA8DyT&#x2B;kzMvTUSgJBGWe44SbtWZgZAARJoZeeW8PV2rXsjBT9kM7OTjnrf9ddd6KpaSMefPD/1PusRImSBAkEAlK3mDJlSjYpn7ytrc0rUretWLGiPTsnJ62luSVYXFKSLty7aXH3Ny6d62MHDKQAKSu9TsqnAryNaNVklr13PZWUBb37RRxF9DdZGgArFGzVVrP9xjgNJ2kRkt1TtEx7RwcB/55IRiDDlV&#x2B;Q7&#x2B;&#x2B;L2WcJYN2U9d&#x2B;wkxkY/O2bajZX2A2&#x2B;lPSPruWkV4ynobQALPfIPmON&#x2B;Mc7Mv7McIvGE&#x2B;TJkCGOImuQhG5Sm&#x2B;8AK/8zkDlHdQ5D1AhgZ6xTsu0bAKyyrRhBOkOi6z&#x2B;Q6P5vjP/nJkYBbvJrBv5dhv3MxBBgXGew8QIwGgS&#x2B;&#x2B;uqrjbRsuvLKK7/JyMjw7rXXXvnz5s2rnjFjxtgRI0aUFxUVFatXV8lmF&#x2B;FWRwAXWfNlbD1cJvHunZ8R0L0BXMyih9q1wTSNgHLhKRpZTtdXWsydGGwFl4B3PBBcFW8ACNaTVvEGAfadtNh8ZtYthXSfT2yXiON7UgPbg33rwmvBKN3fA013AxmTtTCJ1ldoXzMgQiQEgI80gy/bCWzEmzJsgq&#x2B;9SFM0XFmJdWWLPMMPgbdcBya4AAT3wAAHxY6ODsG6jNbWVvzhD&#x2B;dIRaq7uwvvvfdev&#x2B;p8//33MXLkSBQXq&#x2B;5GiZLtossnycrKkh3wzjvvnCMMAW1tbZ7Ozs5IfV1tR1Z2dhpth8rKygIet4cJDgERd83MQGl/AL0V7b8eQOpRohNqf2N5K0bChG2dOmiXvsCsvGm9PLnxwo5AwVEbHNbt6Pz4Z9nV1RUOhcMRr8fNsrML0iRPgY2anvCn0Adi276DdqCOaeGEUqOPQGS34D11pIcQ&#x2B;PeKnUGwsd9ohMWWfySXxu/De6ieEk2vyT9JkgWLyQwmUgRbcfco2dr9U6&#x2B;&#x2B;Y&#x2B;cJYDxmZhhQtoJtgwNAP7Ov6wUSjjEd6AbiZ&#x2B;r1v06uBySSAHIDiNfP&#x2B;uvXk8362xkBjOEMrL29Pfziiy&#x2B;uoYXQDj4UTL6CP2DhwoXjJk2aVDF69OgRARL1KivZfOLS4uTMRJABilj45mcICB9AX0ChBvSH3a6513d9BS6AM4t&#x2B;lunjE&#x2B;sKtYA33kG/q2ngLgP8UzTruyDb8UQH8tbnwNdfBTb8GY1jQHyQm&#x2B;4Ga7htsxgATEV4O7SvBdv5O7qHXFIilgE9q/sMI64cUkKGAQ1/Bypu12b&#x2B;wxu0fTER5IDrLgEru17LOiA8JsLNA25aQ0MD5szZB2&#x2B;88RZef/11PPbY47jyyitRVVWFV199FV9&#x2B;&#x2B;WUvB8C6detw3XXX4NJLL0cgkC5igkU&#x2B;3LhB8oUXnsfHH3&#x2B;MTZt2w/77768&#x2B;ASVKtkMhgM9ycnK8tKC0tNTX3d0d6ezsdLe0tPTUrlvfnZ&#x2B;f76P1UHl5ecDj9TK3DGp0JdPinQHQZGyCtsejLPBm5bmeM9qJKgiH4QaD57rb6xZvc79WafN6&#x2B;QhiM&#x2B;sJqrS&#x2B;pfF18ITymmzYsKE7MzPDLcJChCeIVq89cWIcyLLwaIjdQzIwJtvlIrgS6dLGXKFyC488puknUr2IUF25JwJpJXIdTGuhdLwQIXeyGS7J6s8bb6Rxl8rnH6G1KbA72Ig3qCoPbXrUh78tAMOkcf7OuEu2c81&#x2B;yIN/u2NG0j/9OcbYC30MhjFOI5xkCdkswSTrQZP1Hotfq3NC0TIhUvQ7HnzwwZpjjz32pR133PHuadOm/f2MM864jZT8d5cuXbo8RKK6BiVbVAr/ADb6FQK1N2seAL09sF/O9LPcn/ftK/59Iotu&#x2B;kSwkc/TAEwgP/dY6pg7wddcQIP0DX1lhLs9AjJ2r7d632SZu3cwFS9b8Y6iJhQAmx7p286YEdeNsuEvaIYBoURkHwisOhNoflTzcpBGBAL7jf/U7kNkLmi8iU6Phgjw7n43LS8vD6effoYE8lOmTMHJJ5&#x2B;Miy76E&#x2B;07TQL8Rx55GGvXrtFsNpmZuP/&#x2B;&#x2B;7F69Sp88cXn2HnnHXDrrbfG1RcM9uD777&#x2B;XmQPUQKlEiRIhPp/PlZubm1ZVVZU&#x2B;depuuaWlJd6yslJvW1tr1/fffdu8bt3ajmXLlrUJYjiReUCyxNuBeBNFjydRBLlNf891KqHZtRPZonmCMhm/n5u6hsKknr66zc81C/413o9uzlJXo74OHldv4j3wXlivPyPxHnnc&#x2B;Tyu1dq/oXCIt7a1hTo6O4NZ2dnuzKwsjwD/2rw/SwBaLFmIgdE4EJvvorGSi7HQ5Y1m8&#x2B;mrT6uTaeC//SOg/ufS3Z&#x2B;v2Aes4714hjChyQcmm3ti9KwAb3tT4ydaNhNo&#x2B;4bG531Id/ld9MHQP26/1haHAFPJ1pPYu9H3jtiXjeelUFP/vc9miJIA6veZ/epJAl0m65Yu9kgkB4ztM2PwN1vXl7ciHbS6BkNyDwD9PqRSRsTnzZkzp2i33XYrPvDAA3ccNmxYUSlJcpO8EiVDTARDvrB7uaMM/iECr54yCZJ563OkJ5QTAK8EXzwObOSr8WR9m9MiuekuoPaXQOmfwArP73PvF4SD7lxwUkrYuksBQSy06T7w2hOlq6JMHZg&#x2B;GiyHzu14RZv5qHqU2j&#x2B;C9h1H9V0OrPoVMOy2QWtrbW0tlixZgssv/ysWL16CnJwsjB8/EUce&#x2B;VM8&#x2B;OADuO2223HuuX8A9Rm4/fbb8OGHH/V2patXr8a3336L8vIyTJgwUQ2aSpQoSSotLS3B5paWUEd7e2T9&#x2B;obu0rLS9K6uzkhZ2bB0QRTXFyrAdSAwERCzhHnoePon1guQkQAqrQ0ELA4a922bnROdPTbs18omAsy&#x2B;/VYmDMCcvqqvHfGOrsZ9VvSDyY7HGz&#x2B;c9OLCatPZ2Rlua20LFhUX&#x2B;Twer8vFWNzJxrj/eB3fVPFPOFfTXAnwhzZoY3qoAcj4CVg0s09v3cKYvvZi8KabAZG2V7L106nlf6Rx8wpwEfv//SgwEWU44XMtlbGwBgi1d/X54IIEULx54lruHKqjQY7HbPwP9Ftomm1CybYnTrCssYzb7d6uSQCHigHAiRHAygDAbBYnRoBkjP1OgL7LQd3M4a8T0G8aLmCsJycnJ23&#x2B;/Pmle&#x2B;2117DZs2dPLi0tLcwnweZMPq5Eyebo3DfeApZ/uqaS1R4JJtwAR78LvmQHMMHIX/DbLdeWmsOBDY8BWWPoI6O2CHLDcCspGn8BOr8CE1wGYz/TYgzbXqJ9H5GC8ywpHt/R0tYXUJR7GJhvNNVFis0kUoJWHgCWtQAoPGdQ29vU1ITvvvsOL730Ij799BNJDlhYWIj33/8Qw4dXYdGiO/HCCy/IWP8//OHc3vOWLl0Kv98v8okn1BkKBUGKoeU1hQHh2Wf/h9122w2TJ08RqcjUS6xEyXYmmzZt6mlpaQmLUMbGxo3BkpISv3BSLCouJmDpdvXpg4kAlutguJwR16XhM1fu&#x2B;xPXmwi6e&#x2B;kCYM9CbQ2wE9tqpDiwoiMw23aaTCApcVZycn90EfDfuHFjd15evjczK8vLmA6us0QAb5bKMQHzmxkJRB1iVr/lBfB154N1fBnVXH1wVd4Fnn0UbYY10L7xdvC6X2tqbXo1QbUaGm&#x2B;DcBUeD155N1jXcvDFoyQsc01eAqSNSTQA&#x2B;MtpHF5H1whrhviSayShr0NsomQbAP9O3PqVAWDbNwCkYgQYiEeA3b5UZvfdmxH0uyzu1fTYsGHD0g899NCK3XffvWLGjBmTy8rKin0&#x2B;n191H0qGfAdfdxxY5QPaRriBBvzJYOO&#x2B;BhdpfkK1kOn0okz6vGcpsP4K6UXAso8G8o4e3MZE2kkpWQTe&#x2B;HdSKmq0Dqj4bCBzFrXn12BFFwMFpxtuoIPauR7oeJeWT2SYAG/&#x2B;n5YtQXTBgXHUU2RIjgA2Zslme45C&#x2B;SalXPIATJo0CRdffBFuvfUWZGVlE9j34eCDD8GcOfti2rRpdHwCzjnn9/jtb8&#x2B;MG5zuvfce3HPP3fjzn/&#x2B;Cvffex1yR7OrEr351qjQiXH7537DPPvuol1iJku1cRCy5MAgIQrmmpk3hopIivwsuVlBY4Ot193aAup1ksjMDzUbvcCMdgRUAtzpuVo9VmWT1G9tt10a78&#x2B;31b/MyXd3dkU0bG7sFj0NZaZlfxs8b2iO8AMx4ByyBvwno59KRgNRRN4H/xkXAqjO00Df5p3dJsmDm34HG9i&#x2B;0v1PXZ&#x2B;BLdgG8&#x2B;WBltxJoPxh8KR3vWExjLI3r1f8B69QMAIyGUjZlJbi3mqrrMwBg3TVgeT8FCs&#x2B;QPEPI3A/w5MU9CDX7/&#x2B;MyBjgVl8ulDABD2AAAE6BvZwRwmaw7NQL0B8Bb1dNf0O8E0A9KuIBY9t133&#x2B;J58&#x2B;ZV7bHHHiMIDIzOzs7O8thN6ylRsrVkxb4E5H8J5B6rba/&#x2B;HZBWST0n9dv1F5JisDeQfRBYYCb4&#x2B;kuB1le1Qb6nB2zS132hBJE28PoTZH/OKu43Z&#x2B;h3bAhoAto/kAYJ4Qmgkf41RkkKk0TdiPSAXZ9o2Q/C7eBNtwDdG&#x2B;j&#x2B;DgCrfmazPcZPPvkEX375heQF&#x2B;PnPf4H09HSsXbsWl156CT766EM5&#x2B;IjQgZKSEqxfvx677rorrrjiSlRUDKN9pXjttddwyy03g/oN3H333XjxxRcRCJgTREYiEaxatQppaWmyPiVKlCiJKbnC1byhoaG7ra0t0ti4sYe5mCs/v8BHSjkTPAOwIYfrBac67dkJAN7a9&#x2B;wUYG5OMGqse93atV2hcChcVVkVcLndzPhMjSA&#x2B;mU5vRfzX&#x2B;y9zg2&#x2B;4Flh7gXTbh6&#x2B;CrhcGC66NEvkdDDbiCTmE8i&#x2B;KaahuABv3DpA1DWij8XYFjfWhLrAi0gcqFskMAL0eADvUg3uG9RkAVp0LNN8FVnoNkP/LeEuRof3KAPDj6FecEv2JY8oDYNswAFj9Gve5LAwCRkAMB0aAVNz2U/1NFaxv9jJZWVnegw46qHz27NnVpPSPGjlyZGVmZmYWUz2ikqEgm&#x2B;4GX34iWMkp4L4xQNNDYJkzpOs/X7YHdc8bqYulvtfjpi6Y&#x2B;tr0caREvAReexhY2b&#x2B;iJILUua75LZ37H8BbKtMOssr7h8b9idSIXZ9qMYqBmZvtMsI1X8T/f/311zjnnHPw7rvvgJRtXHfddXjooYeQn18ojQSfffYpOjs78PDDD6OxsRHl5eXYffef4PHHH8OZZ56FCy64EMcf/wuUlpbgmmuuM72WIBi84447cO2110lDgxIlSpSYiUg3KFSNZcuWdbg9HrahYUNQcBrlFxSkiVSDgUDAE9MfjUCN62K4zbbNgIEdKLDTU82u5fQ6Vtc2O8eol5vVZXweZufY6fctzc096xvWd1dUVPizs7K9CddJAv7NgH&#x2B;cx4WJC4asI7gSfCmB&#x2B;chGuPJPAArPo3Evm4D9Qhr7JhJYv5a2Cfj3/AC&#x2B;ZEdSTvcGG/4o0PEdjfVUhq2TMIsVnwxWcUefAYAgmmvHei3rjvAkcLnARape/3gwuU/lj98eDQJ2ojwAhr4BwAr067ft&#x2B;AGMXgGpzKoPZBY/WZ12wBxbAPTbhguMHTs2Y8GCBRX77LPPyIkTJw6vqqqqSBNTeUqUbJWevBtYfxX42ku1FD/iJa36B1BwtuaS3/0N0E6DfeeXcrafNz8C&#x2B;MZqfXWkA0j/CVjeMeANpFx4ysEE2V7nx7ReRApD9faocEuG/&#x2B;uuuxaXX34ZfvOb39LvFQmDpzAYfPLJx3jnnXekseCwww7HjTfeiMrKSowZM0byCtTU1MWd9/TTT&#x2B;P555/Dd999K5cPPvhYpiNUokSJEicSDAZFCgEsX768w&#x2B;32uDY2bQxmZmZ6MzKyPH6/z&#x2B;3z&#x2B;dxxINMC8NrlDbcEyNE6zYwMSZTbaOZBblmfFoKQus6tPzfVFGbG8qFQKLJmzZpOkdYvPz8/zevxuuJn6c21crPYf&#x2B;Ntmm/0kTMyVxp4/YlA491ggR2AUR/QPr92nfaPwDKmRp8P4ajQWs1lX5D6Nd0JvuYcMP9UOrwerH2xNACg4g6wrhWIfD8SjCAa25HGIm&#x2B;FNADI68b4rx2mjFOyfRkBlAFg6BgA7IwAVl4ATo0AbKgBbDjzTnBSPpXr9YtHQGQRmDZtWv7&#x2B;&#x2B;&#x2B;9fOX369FHjxo2rLiIhAKGYvZRsWRHp80QcvbcSyDyAwL6FC3/XV&#x2B;Ar9gO6SYnwuATi1ZQSQSokXuvcn4EVkAKRNk6y98ePGMFoOqLtY3BcuXIFKioqZQpBO&#x2B;ns7JQz&#x2B;cIgIEIG3n77bdx662346U&#x2B;PiitXUVGOs846G0cc8VOMHDmCyn&#x2B;KXXbZufe4MAqIfMzjx49X77MSJUqSiuAMEGkFV6xY0ZGW5vM0bdoYzMsr8FF/JFLTuT0ez9B2VrRj8HPCCmhWRyp10m9PT0&#x2B;kqamph/r8SGlZqV8A/z6m/eRx/HbM/04MAHLsbXsJfOk8GpNpz7g6OVvPxHgrNVs6zkM65V5wBdDS9DD4yp8B/iq4xn6FyPI9wdo&#x2B;Bys&#x2B;hQab26UHgMgCICAc22U1nVNGl&#x2B;cpufQrA8D2aQhQBoBtwwAw2EYAZgN6nQBqOwMAkBo5Hwawz6lBYrB4BORCA67noIMOKp07d&#x2B;7wXXfddcTYsWNHZpCodINKhpQEV4E3XAWWNU/rf1v/By5m/Tu/oS68R1MuvIVgI94EfOP6OmDBIdD5JVj2AiB9qnYsSjCoRBNBJvjyyy9h7tx50pMgJqtXr8IhhxyCNWtWS&#x2B;K/Z555Bv/857/wi18cL48LXoA77rgdV111JY444kjpdeDz9e/ZirHrq6&#x2B;&#x2B;wg477KD&#x2B;IEqUbEeKvDAIiKW&#x2B;vr7LS/pIa2trKD8v35ceCLiFQUAgW&#x2B;ZEHelf6oDU6rNi9rM7z4rlzwLcm5aNrovwCpHWb8OGDV1l5WX&#x2B;rMwsjxVy1ycVtAoBMAtxcDz7v3gMQa2lYGXXgxWdQwNC0BoXiCwBzY&#x2B;C1xwNZO8L17D7wGm8xreZNLa3g&#x2B;UfAVb9MI3pPwDLp2lZgkr/GvWSSA2TqPh/ZQBQBoBt1wCQqhEAFsDfCmynajAYKLgfqIFii/EICCkoKPAefPDBFQcccMC4MWPGlI8bN26UIhNUMkS6/fjuQqTm6/oGXBDwidR8rc&#x2B;DjXpX8gH0ntHxFikeTwIdguBPzCgMo&#x2B;NjwQr/APjUrHUyERkGXn/9NTzwwAMyXeAPPyzBvHn7S0LBmTNnYdSoUTJ04MILz8eOO&#x2B;6Mv/3tSpSWlqZ8HVJoMWPGdDz55JMYO3Yc7rxzEU444URpnFDRSkqUbB8iPANEmkGx1NfXd2ZkZHpbWlpCJaWl6b60NGEQcMmpbv1sd6p6rx39vxXIHwLS3NwcJAmHI2EuskBpaf0MbP66VH9xCRdM0v6ZAWY78B9nAAitAf9BjLOdcI18K27M7cMFrmg2AJEdJwz&#x2B;TTrtygYbvwzMW0Cd/q3g9adHi&#x2B;WDTWkEummM5q1U3zgN/A8OFlGyHRgBlAFgaBkABtsIYAf8AevMAU6AeapGg8E&#x2B;3h9vg82edpCAv2uHHXbImTt3bvkBBxwwsbKysmT48OHVSf6uSpRsHeNAeIOWCYCZZMMUxoLweqDlOfDOt8ByaKzI3Fc71rOMziHlxFuuZRZY83uw/JM1j4HkKisNIasAT&#x2B;WPXTFHfX0dbr31Vrz22quoq6sD9Q&#x2B;orq7GwoUHYvHi73Hfffdh4sSJOPHEX&#x2B;L4409ATk6OzD5QXFws6yDlFU888TiOPPKnCfWLdIYHHXSgTDkoshK8&#x2B;uqrOPvs32PPPfeQHAVDRZ566knk5eVjxowZ6pNTomQzi3B1b2trCwmDQE1NTVdOTm6a2C4vLw8I7gCv19vrrMg3o2KSrG6z49xGCY6VN/6aSVt7e2jdunVdGYGAq6KyIt0YHxEH6nXx/zJNn6Fis9h/JwaAhIwBHR&#x2B;A1yyg8TYNLul1NybeoOCKepKFNtHYmA&#x2B;0vkjl9wPSJsI1&#x2B;n26KI2zi3en87tkil/4p9L&#x2B;t&#x2B;k5uOhcJgaclEC9MgBsvwaA2DunDADblgFgsIwAVkB&#x2B;IAYCp8YCO2DfXyPBYBkG&#x2B;gX67cqQQp&#x2B;222675S5cuHDEXnvtNaaqqqq8pKSkSBkElGzTA8m688E6vgVGPA1svBW87nQwPyk045YYUHAb0PkRkL4TfRl52r7gGvDVp4BVPaIZHgTBoZjxcGX8aJ8XKeOoqVmJ9957Dx9//BE&#x2B;&#x2B;OADVFVVY8GCBViyZAleeOF5vPHGm8jPL8D06dPw9tvvyvO6u7tx9NE/xbhx43DVVdck1HvCCcfjueeeRWFhIUjJJ&#x2B;BfhccffwJFRUVD5t4fffQR2ab7779ffThKlGxhEe7vzc3NIepLpEGgsLDILw0Cw4YF/D6fm0n/gHgSPJ5EATUD4amcY1RmzY7BYp/dNbp7eiK1NSvbRChESUmpPz093Z00lZ/RAGBVzkSHN1Xne&#x2B;szHGx9Brz&#x2B;WDB3AdjI1yX5bh8HgYcGiVeB9ddrs/mj3wTfcBuw&#x2B;nSNjyfnOBpv3wLSqoDiS8GCtbTvUDrfH/eElAFAiRMjgDIAbLsGgFSMAEBqaQOZg2NOFitQ3x8jwWCHJwwI0GOAIQUE/n1z5swpPuaYY6aQUl9VUVFRnq5yhCnZ1iTSCf7DZLBRb0tjAODTshGkjaeX/M99nXnNgUDLM6TDjAWqbgcCs2j42AD&#x2B;TRHYpPVaFoLOD0gxOhms&#x2B;jE6f8x28fjE7H1WVlYvf0CMYFDIqaeejOnTZ4L6CDFAY&#x2B;PGRowZMwqPPPIY9t13blw9l1/&#x2B;V9xzzz14//0P8fXXX8nsBrNnz9l6r0UkglWrVmHYsGHSeNHe3gYCHAgGe2j/atTV1WLGDC3N4zvvvI3JkycjJye334qMuJ6eg0GJEiXJDQLU/wQ7OjrCq1av6SnIz0vrCQZRVlaeHiUTNCUUTAWMm3&#x2B;wybXb/sSiR3V4vmzZ0rZIOMIrKyvTc3JzvEZaASvgn2CkYH1l9aEC/WH&#x2B;1x/iTfcSoD&#x2B;VxrxhYCPfkGz9vR4FLg9Y/W/B198ElrsfMOp58IabgTVnaPWEqGWeArBx79NQOzqabUFcI9KvGH4F/pVE34Pt2gAwFEnbeApluMU5Zg/a&#x2B;EeA4Q/ETf5gZn/MiO5YOMmLYLaEdL/G9WRL7CUM2hw3e3GNv8Z1s&#x2B;3Yvp4UyvQkK7Nu3br2Bx98sObAAw/839ixY2&#x2B;dN2/evy666KJ7Xn311ffWkASFpqxEyVCVXsbidC2tYOONYL4dgQ3/Brq/AtZfS4D/v5KAULr5izzEBb8CL/wdKUAPaB4B7kytDuHGKCT9J1o8ZMsz281jDAQC&#x2B;N3vzkZLS4v2CHQ2wP33n4/a2ho5sz9t2p6444474Peni3jWhHrGj58gf/1&#x2B;H2bN2nurgn8hImThtNN&#x2B;hZdeeglLlizGsmXL5X6vNw2fffYpjj32GNxzz90ivZm8/9bWtn5dp6urC1de&#x2B;Tf5q0SJEuciZsXLysr8o0aNypg5Y3peUVGRpyA/37V6VX3r1199tWnNmtUdNTU17YJbQCjjMYWc65Vz3qesy308UYGPHes7n8cfh6EOg3Zr3B&#x2B;7jr5&#x2B;IatXr&#x2B;74&#x2B;uuvmwsKCtPGjR&#x2B;flZ2jgX/AnpIgbqYoutJLaRBthGQMiEuH2Afok8X&#x2B;x9&#x2B;zyMzXZVCN40/nHS9oiCRzpizmCuwuwxHkudl7gFU/CJZG4F&#x2B;k&#x2B;KNFgP&#x2B;EZ&#x2B;cQ&#x2B;PMhxtWgRMnWkG05jZtZSFSsX7MyJDCDQcDogeVk245k0GVxjBvKRXTHI0gtFCG2Pwx7TwCr405CCLYYj8Dbb7&#x2B;9npaGK6644iuR0mfvvfcuPPDAA0futttuND6PqswlUdkFlAwZEe6IwuXfUw40PQjkHEkA/wyg42Og/SUq0Aa&#x2B;8ijAV61lDxBvbnc9WOn1tH6KJDaS4qsiFPcp/Y7Vqq28L9oVbB8iSPomTBgvZ/6zs7PxzTff0D6vnNH&#x2B;5z//idtvv4OOdWDcuLF47LHHZEy/MAwYJTc3D93dXfD5EjkcvvvuOzz55OO44II/btH7uvHGG6V3w9NPP40RI0b2HhMGCmGoOOecsyE4UgV4z8vrm/0X99vc3GJJiChIDvfYYw9MnDhJ8iQ8&#x2B;OCDOO&#x2B;889Q3qUTJAKS4uFimIamqqkoXwFDEzlO/FKlZubKlo6M9UlhU5A&#x2B;HIhCkgi4XizMCxGafJdA1MQIYQX2CkcB0n3VdeiNCS0tLkNrYnpmd7Zk8eXK24DbQx&#x2B;WbYdw48j9TBZn1XsMMOCcAf71lwIIAsDdhQezqsZC3mGLM3DSWPgb01Ep&#x2B;AGTur42Tgd1kiB0Ld4JlLwTc6YT7wxY8BGpGX4mSH4sBwCk3ixn4N56bSliVGfAHnGcYMCvPTAwAVmEDzMYwEHFoPHBiBBgIV8Bg8QgkGBGEa95zzz23mpa1tP3e6NGjM2bOnFk8b9680TvttNMIAgHlgUAgQ322SraqRFqAZaeTQuIFyz2Strs0t//w6eDLZmmz&#x2B;bwBaH1ZEhMh&#x2B;D/wpbQv8BOwzH2ADEFsNJwQ3&#x2B;dAztHRnqYL2HA9UPSn7eYxnn76Gb3rYiZ//vz98M47b&#x2B;Hggw&#x2B;hbS3bwr333i9n/hsaGpCRkfjpt7Q0E7DeR5ILGuWDD97H1VdfjQULFm6xVIFCER05cpRcX7NmjUxTKNIhChFGgR122BGHHno4MjMzCLyfK2fxDznkUIwePQZvvPE6LrzwAnz77fe99X3xxRf4/vtvcdRRx8htQZp42WWXy9AIUvgdK77C0OL3&#x2B;5WirERJku&#x2B;3tLRUWhNHjBgh99XV1XWKzCIrli/bFAwFWUFBgc/FXCwvPz/NKlzADHibGgZMDABGgGsE7SKtX21NTTtJaNz48ZnUL3rM7yUeiOt/49IIssR2Go0ERhf7OLxvsDaYGRhkWQHuxTExfgbXgqWP167duQS8/hd0Y900/v0aSN9FMwCIsTNroXZuhOqPhBP&#x2B;VjEDjGNgYXjGSpTYYMEff383BDkAjGA91XLM5nwzPgCr/Vb7rI73Z9tpqkLA2sNgsLMTDJZhYFDTDgovgKlTp&#x2B;btvffepaRQj544ceKIkpKS4jSV70vJFh8agsCm/yOFpREoPJu228FrDiFF5iugex3YyEe1bAE9PwBtr4N3vEu/b5DS0ygDYdh4Ot72GrgIDxh2C5iPAKMrB3zJeLDhTwH&#x2B;XbfLx7pixQo888zTOO644yQZoBN59913JKjOzMw0PS7qO&#x2B;CAAy3zQr/yyiuSY8Asy8BA5ZNPPsacObNx8cV/xvTpM2RIwGWX/RVPPvk0JkyYgFtuuUUaANraWjFsWDktFXjxxZfw0UcfSdLDzMwsat/L&#x2B;Mtf/hxHiujz&#x2B;VBfX48DD1yIjz/&#x2B;GG63vR3/yy&#x2B;/lM/h/PMvUHwBSpT0t9vXODe4MAgEQyG&#x2B;sbExSB2LKzcnJ83jTXPn5OR49XqukXHcTBfWE5JZ6cr6Y8uXL2/r7OwMVVdXB/Lz89Os9GpT4j896I/&#x2B;MoOWbA7eWYLNwO5iiWkDoystT4DX/QxyEMzYG6zoPG12bO3vgfbvwPzDgAn1ApTQdSKmfXbifTqDCArwK7F4L8w4AGKhzGbh14oEcAsaAFIxAsAG1GMAhgCnhoGBGgOstl39MA70J52hU2LBLRkuYFvPwoULS/fYY4&#x2B;SOXPmTBgzZky1CBdwKw1XydaQcBN4/UlgBOQx7EZ6Ow2ANLiWhpVvwDc9DFZ6JdD6LHjt8dqshr9EKkToXkbrY8AqHlTPcwuJyEpwyikn4YMPPjL1MBiovP32m/jlL38pZ&#x2B;CDwRCmT98LN9xwEz7//HPsueeeSEvzSSOGIAQUIQvLly9DTU0tysvLsd9&#x2B;87DXXjNw443/wnPPvYCGhvW46qqrcPnlV0ivCKcGgPvvv08aOhYtuhMqmkqJkkHq8sNhLpaVNTWdpLWzpqamHvqevdnZ2V5hEAgE0t2IusAPVBoaGrrr6&#x2B;s6qquq06WHAmOmOrURpDPEexBoTP8GiM6swb9Z/baWBl09CfaGrk&#x2B;AFfvSeocE&#x2B;XB5ZSy/HAOFN93wZ4GsfeV2nPeCBcmfWSiAMgAo2YIGgBDiSS2UAWAzWeLYAMo6NQTAAegfiDFgoAYBp8esDAUD8RrY2uECycrItp100knDSamu3H333UeNGTNmhI&#x2B;E3jel8SrZQsI1hYY5sEGJGMiWR2l5GrzrI&#x2B;kGKYeO0jPAym5Sj3ILSIytv7W1VeQOx0svvYijjz4mrowA7q&#x2B;99qp0B54wYWK/rrN69WqZAjEjI1PO/IvrCfAuCAMfeOBBUF8Vd70nnniCgP2HePPNN2WKxJNOOgV///vfpadCRcUwPPnkk5gyZUcsWDAfn376WcL1Hn30UXz22We46KKLpNv/f/7zoDQACF4FJwYAkU5RkDIqW6oSJc4lFApFqB&#x2B;JiFSDkUiEtbS2heg7kgYBX1qaO83nc1mBWjNPALG&#x2B;qWlTz8qale1FRUVpFcOG&#x2B;X1&#x2B;v9tOnzadNbdJ&#x2B;webFIGpsv6b16Ef87qAZbsDXd9rWlsMFvnHgVX&#x2B;GwhMk5YCJzP/TvFEfzIEKFEGAJiTrpsZAIzAXxkANpMljg2wfH8NAf0xBjg1FKRSJtVwgf6mGEzFCMDsADm2Ao8AouECguX3mGOOqZ41a9ZIUrqrq6qqKr1er6cf75ESJZvZbkCKUdfnQPvbQMYsIH2qeiZbQC6//DICyRfL9bfeehNz587GunWNyMnJ6S1z9tln4bHHHpXEfHfc8W/suONOg3JtwV0gvABEqINIBSjGYZEdYM2atbjwwgtjgALLli2TJInUn8l9ImSguLgIBx10MKZPny45AQR/gigj5IorLsPLL7&#x2B;MxsaN0mjx5JNPpWQAEPW99toruO22OyTHgBIlSvon3d3dYZFqsKamptPlcrtbWluC2dm5/szMDI8A8h6Px&#x2B;Wy0IfbWluDdXV1HcIZfvy48Vkic0EvotZN8evd882AeBx/gH4m30ITTnTft3H/j6vPCqDr173gHR8BDZdoY507ByxrLlD8V8A3TLhUWN9LEi&#x2B;AzYQ5lPz4DQA/R2LWsqCNAcD4u00bALalLABOiQGNDzVZVgD9MWNmAei2uQlAN7uOFSEgsPm8AwBrQkAz44DTcIFkJIKphgukahjoV0hBJBJxrVq1Knjdddd9S8t3NNC6p06dmrtw4cLqadOmjRo7dmwlKfQlpAyrKS4lQ2AU8hPo30NblGwR2bhxoyD36t2eMWMmLbNw883/D8cff4JgBpcz9V9//TU&#x2B;&#x2B;eRTyc7/5JNPYNy48XJWfaCSnZ2DmTNnxSmpu&#x2B;02FZdccon0AhAz8HfddReo65L7hQGgvb1Nuvwfe&#x2B;yxEFyoIkxg//33Q2VlFbV9uuRBuOmmm3DvvfdhwYIF2HXXnbFy5QrzwdFiVuy//31IegCYkSo6rUOJEiUQXB1useTl5aWJUAFBchw1CLSJyQjqX0L5BYXpWVlZXn90Zj8YDIZXrlzZ0bxpU8&#x2B;YsWMySoqL/dxqBp8ZifosYv9NlF6eoHxGPRH04QIm3gUWZP9Jswto7QuCZUylce4RoGelVpF/vNaYcDiOS1BGCLjiPSJS7WvMPCpUf6VEie4b2YY8AMyA&#x2B;0DOYw7qdOIZYGYUsAP&#x2B;cAj&#x2B;ga0XLgA4Cx1IJVzADrQnMwwMKo9ARkaGd7/99is55phjJo4aNaps/Pjxo9P1iciVKFHyoxbhlj937hx88813vfsWLVqEc845CwUFhZJYcNq0aTJ&#x2B;/uGHH5PpCO1EzNZ/&#x2B;OGH8pyBSkxRff755/Hoo49IcsTRo0dJb4BVq1bjpZdelqELggdAhCeITAHPPvsMenqCyM3NRV1dvTQCiBSI06fPlCSDIpzg5ptv6R1/r7/&#x2B;Wuy6627Ye&#x2B;994q59&#x2B;OGHor29A88993xvWZGa8eKLLxJpx6QHgQiXCATSce6551umLFSiRIltf8EFi79IN7hiZU1nRkbAs3HjxmBbW3uYQL9v7Nixmejl6GMJ4N&#x2B;oS9vG/kcPahkFdIqnWZYA0xR7poq8ibLsIByBRdWwWGQmj02MxpfXGwCsYv1V3L&#x2B;SQcCjeg8Aveu//je2WHkA6Gf9VQjAFvwo2SCdxxzUmYoxwKpOp&#x2B;SCycD/QAwARqC/OcIFnHoJbMlwAct6pkyZkj137twyWsaNHz&#x2B;&#x2B;kpTrcq/Xq7ILKFHyI5ZddtkJ8&#x2B;cvkO70Ytb7gQfux6hRI5GXl48XXnhext8LL4BwOIzZs/eR6QQnTZqEnXbaOaEuAbL32OMnuOqqa7Bw4ULT6wkG/46ODqo/r3ef4AFI5mq/YUMD7rnnHpkR4KqrrpbGCaOIekTdoq6///163HjjjXSdXDz99DN4//33cd111xHovx477rgjioqK8ac//ZHKd&#x2B;If//iHvD8B7MXYfPjhh4GASZwB4M47/43zzjtPZkqIRLSywkgiyAiVKFEycBGeAc0tLSG/35/mEsjXCKpNpt/NDAAuXdpA7TcabG90/09iAEgG5I3u/0YPACs1P75&#x2B;ew&#x2B;DZPH7KgOAkq1kADDLAqAMAFvxY2SDeG4qngEDMQjY7U9132CSC/Y3XMDKCDCkwwWMZdLS0ty77rpr7lFHHTV6l112qR4/fvzwAhIVLqBEyY9LVqxYLsn4Nm3aJMG5ALcrV9YhKytLguINGzbIFHpvv/2WTM0n0vrNnDkTDz/8qF5xlwprenqAwPmVuPXWW7F8&#x2B;Yq4WHsRbpCfn4/a2hrst99&#x2B;ElwPHz5cHjvuuGMxcuQonHHGGQmz6Y2NGyTQjolokxNiPjGmP/TQ/0nPgQsv/KP0EDj44AOlkUNcY/LkKVRvATIzM3D11ddKjoDCwiLMnTvX1AAgvBDOOutM3H33vdh3333Vi6NEyWYQ4WnTRt9eb/pAB67/Vm75prH8Zr7/sJ/9TwD0SVL&#x2B;mZ1jXW&#x2B;qBgPnGMKYhlGJEov35Gewjv8PmSxhGwOA/pcrA8DWscaxQT6/P94BVvWkQjK4pcIFzEB/KiECdsB/MMIFBgToB1qmsrIysPPOOwuDwPhJkyZVjxgxojI7xrilRImSbVoEyP/hhx/kDLoA5VVVVablhIv/4sXfy5R748eP793/2Wef4rzzzpUp/ebN2x&#x2B;//e0ZuP76f2D27Nm9ZY499hiccMKJEmD/73/PyBn82HVefPF56Zo/adJkXHFF34z6qlX1OOKIw/HAA//ByJEj5b76&#x2B;nppSAgEAinfZ1NTE5YuXYrnn38W77//gVz/97//LbkPXnjhOZle8LXX3qBrHiY9A5599rm48wW3wO9&#x2B;dxZqa&#x2B;t7CQmVKFGyeQwA2qy6frbeeuY/URll/5&#x2B;964Br6v6&#x2B;98UtAuIAAQHZS0QRHKg4QNy4q6ittXVrrbZq1b&#x2B;z7p/aOuto1bqqtrXuvffeA/feWxBxQf7vfiHh5eXNkCDI97T5QJKXl5dI8r7n3HvOFfTk60UAEBcLuFV3wZF/AmqDXOu/8ZpffHvd7k1t&#x2B;6eEn8ICAsAHEK7&#x2B;C40BpAJAFvtwZnZ3AED2sgtICQAAxpX/jFzMaRewFOmXtAuUK1fOtnz58kUbN27sz8LVxcXFOS8O86agoMhxePnyBfTt24&#x2B;M7cNKP1bpkdw3bdoMqlevTsg&#x2B;CgRWVlakfR&#x2B;r8FjF50aOJCVh635eg&#x2B;C9N28SwcHBniXbTnD&#x2B;/Hlyf4cO7UlnwZQp00jgX0bw4sVzsLa2Ic&#x2B;JXQzh4ZVg69bt0K1bVzhz5jTMnj0HPD299EIFkhMMKDxx4jisW7ee/sNTUFhAAMD8DYM1uUwFXKjyL5b8r7sq3LIvRrjFmT1/P2qq&#x2B;PzqP19XoG3/FJkoACgdASjWBZBCBYCsKwCYSwyQEwAYBY&#x2B;xhF1ASghQQv4zGi6oMfF3DWS8U0DJfRbLEcBxg&#x2B;wiv1hISEixZs2alWEXyyUcHR1L5MIyIQUFRY4Bkn8c64ddAlhhP3LkEGnht7cvwRLtQqQDoEuXrjBx4gR48OABTJr0C3kcCga9evUkYXzosecCuwOwhb9x4yYwdOhQqFmzOuzbt5&#x2B;9fQv7e3qHAYby5c2rPLIEwwP/979xLNnvQar5W7ZshilTJsOmTVtg7tw/SF7AkyePiWhRrVo1KFcuBKKjoyEoqAw0atSA/BwzZqzZ3jvsrkDyo&#x2B;Y1UFB8jgLA68Q36VH4KgQAQeKfxqq5o6642/P3KUv&#x2B;ueMHQTgrgO/hF18Op/Y36DbhV/5N5Q9yuQEUFLy/l7ZgPgsAPwdASwWArCUAGLzJTMYORmk2AMiQfTFBwBJ2AXMIAuayC5hLBFAqDFgyR0B/vXXr1iVDQkIc2AVzoKurq1NhFuyfmYZ&#x2B;1VJQ5AygneDZs2dw8OABYi84e/YsIdUODiXI7fXr14UhQ4aBj48PuXz3XU/YsGE9XLtmPLIPswnq1o2G6tVrwMqVK0nbPhJw3ShCPI/Nnj2biA1oTcDOA27&#x2B;gBgGDRpIttuzZzdcv34dFixYCJGRqf5&#x2B;7FI4ffoUCQ/cvHkzXLp0CZKSEsHJyZkIBigUnDp1EoKDy5rl/cL3Z/LkX8lro1&#x2B;VFFQA0BqyaR2Rl/H&#x2B;86cFGFLt9FWXWAeAaOu/gBAhJgDIr/mNBQYl1X9TRgBSUKgQALiVf6n2fyHyTwWA7CgACBzb52QXkBILMmIXELMESN1nbruA2hDBT5IjYGdnl6dNmzZulSpVcqlYsaIPThfAcYMMPTtRUHz2SEpKgjt37oC7u7tB0n90dBScOHESbG2tITQ0DD5&#x2B;TIZ79&#x2B;6whPuo4H66desCs2bNgb1790LVqlWN7r98&#x2B;RL8&#x2B;&#x2B;8KuHv3NkyYMIlU7vnANv&#x2B;3b9&#x2B;SDAEdcMJB374/QkBAAHTv3kN0GgF2Axw&#x2B;fAQOHNgP&#x2B;/fvhxcvnsGmTdvAyUk6CwDDFe/fvwdPnz5jj6kgFCpkTd4LfqUfOwBWrVpFMg/4pz&#x2B;0P&#x2B;BoQxx7SEHxuQsAiSQDwJjlC4XyCQoAYqmAINEtADK5AiKt/2TxQ57P8GMrHcAnMbpQpHqvpu2fVv8pVPLRNmBc/X8Phu3/cuRfyAZABYDsJgCYUQwwVRDIqXYBU0YMmtIVIGcFUEL6TR47GBISUrh27dpOkZGR3jhdwMHBwT4v7XuloPgscevWbRKqh1X&#x2B;WrUioVq1qrBkyRJS8Z4wYQJLojfDrl07YffuXSzBnw3NmjU3eDzaCSZNmgj58xcgWQNt2rSFunXrGT0PEui7d&#x2B;9AqVLuoseCKf74VTNhwsQMvSa0LDx58sRoYgEf9&#x2B;/fh5YtW8CDB/fB3t6eHCNaD0qXLg0rV67miAtPSDdBiRIO4OXlY5CNgEGITZs2gZkzZ0P58uXpHxRFDhAAOBkAIkSYkQny05NhMKz88wk8A8qEBe6TygX&#x2B;Sa/x5bsGhMi/GlJPyT&#x2B;FSj4aC&#x2B;Lt/0qr/0JdADrCn6z7eFMBIBsJAGYWBCxtF&#x2B;ATeqWCwOdqF1DbFWCRjAC5bWJiYko0adLEOzAwsGRAQICXlZVVIdodQEHx&#x2B;eD8&#x2B;XNklGBcXBwh//fv34V16zbo2&#x2B;2RUGOXALbW58tnmCU6YMBPMG3aVFiwYBGEhYWxJP47WLVqjdFzbNy4ETp16ghdu3aBgQP/T3BUYHBwEJlUgJ0EmXFu/f33OfDixUvIkycX&#x2B;3rXkUkHz5&#x2B;/gCZNYtj34hIZQ4iYMOF/MGzYUNJN4OnpTbIOqlRJ7XK4eDGO3b4xLF/&#x2B;t9nsBhQU2UIAUEH&#x2B;DYi5nqgLrxgFJwNIEXqhTgIZIi/u/U9vFVBiF1A7yo8unShMFADei5B/seq/UACgkACQIkL8s4wAQMPKlC9qtBkQBLQi34ZygoGW95M/yZXhbSNE9rUiYoJWQkAwl10gBZTZBVI49yn5XYjoJ4Nyu4BS8m8u0i/YXbBmzZq77OU&#x2B;/l6qVKmC9erVc6xduzYKAm6urq4l8&#x2B;uMvhQUFNkSON4PLwgM1LO2toaKFSvp70eyjuMHheDr6wuhoaHw4499SGU8X778xFbArZJjZX379q0wceIk&#x2B;O&#x2B;/f2H37t0GIwh1wBZ6Hx/fTHvdt2/fhh49ehB7w9KlS6FZs6awc&#x2B;cuMsIQMwcKFbIir6d161hYsOBPIgjExV2AGTNmQuXK4SSfAE&#x2B;xqZMR6MKeIqcSFMPlnFDbv5azlGQEFoP8bRmJz5OIe0AR8Zcm/2l7YAwzDqUeq4b8U1CYSu04P4UIuiRZl&#x2B;FxWR5UADCDIGBC1VbtH42QIMAIkHgp0i/2GEbgdnPaBbQS9wuRer44oCYzQE4EAMhcu4DibW7evBk/c&#x2B;bM1&#x2B;zlKt4XHBxs26pVK49y5cq5sBcfdoFchF0M56GfPAqK7InataNVbd&#x2B;hwzfQqlVrOHfuHAkURDLMJf8IFASOHTsG48dPgDJlgqBFixaEaDs4OMCLFy/Azs6ObIdjBB8&#x2B;fJRJpIUhRB/Jv4uLC8knGD16NERFRZLjbd68Cbi6loLIyEiIjq4DU6ZMhS5dOpPHoGVCSYihEvz993Jit0ARBa0T/A4LCoqsv84UJ&#x2B;RCxFy3yGMYERVAhqwb3SRxAPKrXuE6l5rVMq38U2SCAKAV4FdSZF8r8ThtdhIGqABgZjEgEwQBRuAxWjDuDpATBITuE9pHZtkF&#x2B;KRfTBzQiDxGd7ucCCB2vxILQablCJw&#x2B;ffo5e3nB/n7C1tY2L&#x2B;YHfPXVV/6&#x2B;vr5OaBdgb7OlnzwKis8bSIorVKhALkLIlQsr5bmgatVwkjXw5k0imTSAxL9z544wbNhwKF06iIgHGDCWWcAgwvj4ePK7m1spmDZtOvTu3Yu9LQGaNGlCwgT/&#x2B;edv&#x2B;O2330j7P2YB4KQDT08vElaIzU958&#x2B;ZLGw1mvP9Hjx7C9es3iK1BCPjcM2fOgHv37sOSJYvZ7aqAvX1x&#x2B;gdFkbXBK5HLtuiLPI7wdjmxQG7sn25HZn5p5k78p6AwgwAgdREi/VLcTeltVACggoCsIJDV7QJS5B5UCgBSHQFiVoAUML9dAEwg/&#x2B;bKETASEV69epW8c&#x2B;fOt&#x2B;zlMd7m4eFRMCQkxK5NmzZBnp6eJdiFvye1C1BQ5ESBwApmzPgN5syZBUePHoHGjRuTVH8EttIfPnyYCAAFCxZgSXVqBRy9xtiiL2Y9UILk5I9w7tx5CAwMTGvTN4SbmysUL55OuLH6PmXKNJJ5gF0MLVt&#x2B;QSYTnD59GrZt2wpPnz4hIwdxQoKbmxuUKxfCvg5/8jWInQRcHDt2FH766Sd48OAB9O79PXTu3FVQOHFwcIRu3XpApUqVoUgRO/rHQpF9RAAFNxu15KeN/tNyybbAtpKVf/5sPrJPns1AJPhP2LtsaF/g7lpIhBC7Tfytosn/FGYTAADEq/liVoEsTfBlPz80BDCzv9uz7XQBKeIPGST/XMKrZHuxLgBzjhgUEgHMIQyY1VLALr417CLcplq1avZNmzYt7erq6sAu7F2pXYCCImfhzZsk&#x2B;PDhPeiag7CqjsGDvXv3Ji32aEFAi8Djx09IG/7evfv1j8UgwkGDBoKvrw&#x2B;7/Q9QqFAhmed6A1FRtaBYseIkeLBy5UoG979&#x2B;/ZoQfaFAQrHzMU4OOHv2DGzbto2IGTg1AIUKf39/CAurAPXq1SfH17ZtW&#x2B;jYsSP7uz/UqBFBqvxcsUGHMWNGQ2Liaxg9eiz946DI8iAhgOxnWCvQASCa/M&#x2B;t4HNXXAK9oIw&#x2B;gE98FJ/Yk5me/s8YPI&#x2B;gkCEqeChr/6cCAEUG&#x2B;BiO3tGF/nGD/9RMAOAG/iVD&#x2B;tg/bgBgiozg8Em4KRUAPv0foCUFgc91uoAY6ZcTB9SMGJSyBpirK0AJ6Ve9n&#x2B;jo6OLh4eEl6tevX8bZ2bm4o6NjCfbPTAMUFBSfNTBgD5EnT27iu0efPVbbly79Cxo1itETexyvFxISAs2aNQN3dw/Sco&#x2B;ku0OHDuDs7AR//DGPVOKlcPnyJbhy5QrcunULunfvYdbX8eHDB0hISIC9e/fAmjWr4fjx43D37l3InTsXCQ/EY8eOgo4dv4VvvvkWWrdubbSPhQsXwIoVK&#x2B;Cff/4hdgIKiuwiAMi1/huk/nO3FxAABEcEch5jRP6FphAAo5L8C3cZmNsCQAUACjMIAO/BfOP/5ASAFJDpHKACQA4SAMwsCJhr3KC5ugMALGcXEBspqKQDQAnxV5oRAPDp7AJy26AXOG/9&#x2B;vUdq1ev7hoeHu7r4uLiaG1tbUPHDVJQZH2gV37lyv&#x2B;gatWq0LBhI8F2ey4eP35MxgVu27YdihcvBrt37yXVcWy951bjx48fDz//PAxsbGzB3d0dIiKqk9GE&#x2B;fPnhS&#x2B;//JKsS7B9vlev742CB7nYt28fOTZL4927d3D69Ck4f/48BAQEssf1HSQmJpCvuiFDhpKwRD42bNgAv/wygX3/1oK1dXpHA2YMXLt2jdgXKCiymgAgRfyNCD1HANCCfIK/bPCfRPVfRBuQSf4X3rXuMcY5BJT8U2Qq32oKxtV/ofF/H0WIv9gIQK3ATyoAUAEg08QAKSKvVjCwpF0AFJJ9MEEA4JJzpeKAGMlXYw0QI/igktCbLUdAt42fn5919erV7Zs0aRIYFBTkUaxYsaL5sKRGQUGR5fD&#x2B;/Xv46af&#x2B;ZArAokVLwNvbW/YxWCmfP38&#x2B;qfKj/193vjt06CAh89hqP2rUKJg4cSJLqs/AmTOn4fDhQ/Dw4UNiH8CvgyJFisCdO7ehbNlysGDBQuKp1wHFhAMHDsCuXTtg6tSpcO/eA8ibN2&#x2B;mn7/79v2RfU0HYNOmrWS8Ih/r16&#x2B;HtWtXw6xZcwxuP3hwP9Sv3wCmTZsG7dp9Sf/IKLKMAPAm6S3PAiBB/nXradxew5hE/KXa/8XGBUoLAIbRU9zn4D6XEHk3ZblLyT9FBjlWEzCs/AtZAKQEgBQVAoCi7AAqAFAB4FMIAoyCxygRBLKiXUCuCwBAnV1AjPArmSZgDmHALDkC7KI9d2RkZLHo6Gi3sLAwj4CAAPfCLKhdgIIiaxEDDLwrWrQocLM&#x2B;b968wZLfzVCjRnXw8/OX3U9CQjxUqRJOwvsmTZoEffr8oL8PRwbi/uLiLkLFihWgZEkXkiFw7949MoFAd&#x2B;r5&#x2B;PEDDBo0CK5evUJI9F9/LYFu3boTmwH/mM01zk8MKERg1oDYQJQdO7YTwQPDELnAbIH&#x2B;/fvCV1&#x2B;1Z9&#x2B;Pqpz3JwFGjBgGXbt2Ay8vb/qHR/FJBQAj0iwT&#x2B;iclAAitveUq/8aPV7KWZ2TFAiHir7tNaUWfVv8pzMSpYsC4/Z9L&#x2B;sUEgBQREUDLEwKACgBUAMiKgoCl7AJypF/upxz5BzMKAGrtAlLE39QQQSnSrorQQwZzBJydnQtERkY61K5d271cuXKebm5uJQvJpYFRUFBY7ByFY/0w5R&#x2B;r9IsWLTY4f7569ZIl4fUgT548MHPmbBKWx8WRI0egdOnSBtX7uLgLcO3adahbt66snUAI2F1QoUIoGTnYp8&#x2B;PpMKOkwimTp2m3wY9&#x2B;7/9NoPkAsTENP5k7x&#x2B;OArSxsREhW8mg0RgGFF69epV0WHz3XU&#x2B;D12MKMBtBSbcGBQVfAEgVzxhp8s8RAIRWYbrkfpLhL0i6pck/I9PCL7yWF55ELZcZIGYHyOocguKzEAAaiZD/DyBe&#x2B;Rfz/4t1AGipAEAFgKwsBggR&#x2B;exoF8iIAMAn&#x2B;kwGL0qtAZ/aLiC6n4CAAOtGjRqVDA8PL1W&#x2B;fHm/okWL2uXPn78APW1QUFgeAwYMgBs3rpHqPFbijxw5BlZWVkbnsXv37oK1tY1RJXzs2LHg4uIM7dp9ZbZjQi8&#x2B;tv8vXrwIVq9eRQg2XoYOHQahoWHs87nAs2fPyH0//zwCmjZtSlL4&#x2B;cedVYHiReHChUkmgqlYtmwpbN26FebOnUf/iClUCwBCFgBhQs7oGYSBvx7kg/XMV/0XmjStLjOAjvyj&#x2B;IS8qQEYt//zg/&#x2B;k/P9iAYBUAKACwGcrCJjLLgAKiL9Soi9H/tVep3YB3rFXrly5SKtWrbwCAwOdQkNDA7A7gI4bpKAwD86ePQvDhg2Gv/76G86dOwN169Zhr49gyWhVqFq1Gnv/OShVqpTBY/7552/Yu3cvjBw5ykgA&#x2B;PjxIzx//gzs7R0kSYeprfpoGbh06RL07v09aZ&#x2B;3s7MDFxdXqF&#x2B;/Pmm73759GxktWK1aNejbtx/7euoJjgXESj2eroR8/NkNuK4YMmQw3LhxHZYsWUr/qClMFgDkqv9i3F2VAMBj6dzOAZDQCMTb/w0FADkSb0q7PxUBKMzIk&#x2B;qDeu&#x2B;/lP9fzQhAKgBQASBbCALmsguICQKMivsyyy4gRPrVWASkiL857AIZJfQZ2oZdrOepWbNm8ZYtW/r6&#x2B;Pg4ly5d2hu7AzSWNv5SUHymQLKOwXy9e/eBx4&#x2B;fwI8/9iGj9pycnOHYsaOwdOlyMrZPh6VLl8LUqVNIUGC1ahEwefJk/X04DWD06FEQElIe2rdvL/qcOB7wzp07hKCb&#x2B;tHF58JRgBs3rieCAFoPkpKSoFixYlCgQEHSbv/06VPo378/dOnSjYgWaFto0qQpeTz68e/ffwCLFy8x&#x2B;b3DAMMiRew&#x2B;&#x2B;bg/XFeMHPkz&#x2B;&#x2B;92OUOvhyJnCwBc8m9AyDmEnRFZeUkJAMZd&#x2B;8bj/vgCgDLybywA8B9r6sg/nQAgJAZQUJiC169fPzp58uSWiIiIxaAu&#x2B;V/p6L9sIQDkpn8KOQNazl&#x2B;VCWKAVuSbXk4w0PJ&#x2B;8s8QDO8DISQEaEUIvVbgujntAiCwT/62uhVzCuc&#x2B;sd/lRIBkMI9dwFKk3&#x2B;D5ExISktesWXOXvdxH0u/g4JC3SZMmJaOjo719fX1dPD093fLS4dsUFIpRpEhRGDNmLPnd3t4e1q1bD6dPn4bly5dBwYIFoGfPHsRbHxISAjVq1CREE/MB0C88a9ZMDpFIhu&#x2B;&#x2B;6wHv3r0nXvQSJRygTp26gs&#x2B;JxB1D/YKCykC9evXIbejzx0q9o6OjouPGY8VLWFgYWbzcvn2LCAEoKFSoUJG9LYV9nttQqJCVXjAYOPAniI9PJNcxKwAD&#x2B;Y4fPw7ly5dX/b7FxcVBx47fwrJly0gHgqWA4wOxq4LGolBk7uItfdVBFjoSyzdu6j&#x2B;XNBuuBcVDA0FaH1BAvBnR1n&#x2B;1QX9ihIiSfwpTwX5/J7Hni71du3ZddODAgWdg3LIv1bbPJ&#x2B;5aAY4jx52yFGgHAMXnaheQEgKUkP&#x2B;MhgtqTPxdyi4AGSD/pgQDmpQjgIJAaGho4ejo6JJRUVE&#x2B;bm5uTq6uriVpdwAFhWl4&#x2B;fIFrFu3jiTb4&#x2B;i&#x2B;e/fuwOvXiSzhLUn8/5jCj&#x2B;n12Eb/4cN74sf39PQAX18f2LVrNxw8eEhwvygwNG0aAxs2bAY/Pz9SSa9Xrw6MH/8/iI6uk6FjRgtAeHgVksTPR0CAH2zcuAmOHDkK3t5esGfPHrh9&#x2B;zZMnDhJ9fNg3kC7du3g4sWL4Oxc0mL/Biim5M6dC9zdPeDUqVMwe/YsIpp4e/uQUESdvWHs2NFw/vwFgw6ADx8&#x2B;wJgxoyExMRH69esPxYsXp3/UFAbADoCkt6khgAZLMi05qRJWTQi0jpgb5&#x2B;0ZCQBi4//EGD6jMsBPaNkmNvKP/1ilYgCt&#x2B;lOYA7du3Trz888/L5g3b941SA/6k2v91/1MkfipBWH/P3CuA9AOAIqsCC3vLy6DHQKMwB&#x2B;4ENkX2kYrIhhoBYi80PMq6QQQIvPmEAT4dgGhTgD&#x2B;dkK/J8uIAMkCJDwZzNsVkKEcAXYBozly5MhT9vJs1KhRZ3R2gaioKNfw8HAfd3f3kkVw0DgFBYUiFC5sR2bW4wXb63EqwIUL58lIv61bN8PUqZNh4cKFULFiRahcuTJ8800HWL9&#x2B;PWzevAXevk2Cd&#x2B;/eQr58&#x2B;cnYPG4F28qqIHh4eEKJEiX0t506dQZsbQsbPD9Wv0&#x2B;ePAmhoaGkfV8Jpk2bBmvXroXJk6cQUoMkOF&#x2B;&#x2B;fKQ9HgUNjA/58895cPz4CXJ8S5cuM&#x2B;m9wePJm9fyUSSXL18ER0dncHcHuHbtKhw&#x2B;fAhWrvyPZC9gNkPZsuWgdu3aZMwgf8LCwoUL2H&#x2B;PdeDmVgo6d&#x2B;7Evu4FouMLKXL0Wky/suGm&#x2B;EPa7fqFkoIqvpDvX7/SE2n9l4Mc&#x2B;RcTDsSC/5QsNSn5p8gI4uPjH/36669/jBkz5sz79&#x2B;8/grx3PwXEK/4pSki8CMfJclVnKgBQSAoCn6FdAEB9VoASASAFDCv6GbELSFkHNApEgqxsFzji6OiYr1atWvYtWrQozaIUe71EAaEyIQUFhRHwo1KxYiVyQWAA3759&#x2B;0gL/Z49u2HLls2EaGNbPvvRIsn9SP6fPMHW&#x2B;4Ewa9ZsPUHF7gEk0B8/fiDX0Wrg4&#x2B;NlFNaXmPiahNthQn5sbCw0b95C9jj/&#x2B;edfQvYRycnJ7PPOgkePHsCKFSsgOroujh2FefP&#x2B;hKNHj8LZs6chKqq20T4uXrwEfn6&#x2B;WeJ9f//&#x2B;A&#x2B;zYsYNYMPD146VJkxgSwlijRg3YvHkTS&#x2B;znk/cT/41mzJgOZcqUIdufOHEC1q5dDw4ODnDz5k24ceMGlC1blv4xU4gsooxH&#x2B;DEMY7SiEvbsM0bt9gwjTMx1&#x2B;&#x2B;D&#x2B;FCLx3Cq&#x2B;8XKPMRYYJEi8miUlJf4UpoI97yWy55p/RowYcYA9D8WDstF9Wpn7uGRezAagVcGPPimoBYBC7b9fdh03mB3tAkIWAEvYBeSsAKpJPyjsLmCJiCYsLMwuJiamVHh4uIePj48bS1yKa/hDuikoKGSBVXb02O/fvxeOHTsOmzZtgm&#x2B;&#x2B;&#x2B;YYECyKqV68GHTp8A/XrNyBt6Ph13qJFM5g&#x2B;fQaUKOEIb968YYl4LRgzZhwhtVxgkN&#x2B;xY8fg4cMH8PXXHVQf2&#x2B;nTp2Do0CHs89rD1KnToGDBgpLbY5v9rVs3oXHjJuR8jR0OSKCRUKO4ocPGjRugXbu2cObMWQMLwPHjx0gXBE4lQEuEmrWB0GkOcwyiomqS5w8ICCBBjRs3boTvv&#x2B;/NXr6HpKQ3pPUfRQ&#x2B;s9u/atZNkBjg5OZI8BldXVxg7djwEBwcDdUNR8JEaAphkUP3XL1TSLACpv6d1AOD9IpMCJMf&#x2B;CdwgHBwot3Y3xS4AqtL8qQBAoRbJyckfDx06tGvYsGEbt2/f/gjSW/n5AX8fRO5TGvwn1v6vBWUBgIKCAJ0CQAWAnCIIWHq6AJ/QKxUEMtsuYOp0AbUigNquAHNlBCi2HbCkJF/lypWLNmzY0LN8&#x2B;fIeLFwKFy5sK/G3QEFBIQIk9Hnz5tVX/MeMGQUjRowA9nNFiGy9eg1g0aKFMG/efFKRx1b8hg0bwIABAyEyMspgX1evXiGWgyZNmqg&#x2B;127YsJ4EEeJxoEihxEbQr19fKFeuHLRp05aQo9DQ8nDxYhz4&#x2B;vqyZNoNIiIioGbNWqQdv3v3buyxXSACAWLXrl1kuoCNTWGwtbUh3QcoPCgBTlyYOXMWTJ8&#x2B;3SC/AF/HqlWriPcfOxnwqwuPrWfPnoI5B48ePYZLly7AmjXrIC7uAtkv5jP4&#x2B;wdAhQoV4KefBhDRhbNwJcKA7pSKeQFWVlb0jzgHCwBG/nd99L9WT9xTLQLpZ0hJ8q&#x2B;7QhQETdqetJzsAM7dPA&#x2B;/4X7F7QVyyf9q&#x2B;QAVASiU4vLly2d/&#x2B;&#x2B;23Dex39yX2&#x2B;1TI1/9BQhAQS/7nkn4u2Rfy/avx/39yAYBaACgyKqRkJD/A0nYBAOFMAP5jhfadE&#x2B;0CSsm/6kq/UmHgyZMnaBdIQrsAe32fj4&#x2B;PVeXKlYs3bNjQhyUDniVKlHCwoqtiCgpFwCo7huPZ2dlBQkI8CQRcs2YtaUlHu0C/fj&#x2B;SMYI4cnDy5Kmksl6woJXROD3MHejTpzcRAM6dOwuDBw9RfAx4SsDRf0jOsRKvNEOgSJFiMGXKZIiNbUuI8d69&#x2B;2Hu3DkwcuRIsi&#x2B;ciDB27Bjy2vA1/PXXEuLBL106iH2&#x2B;f6BKlarw66&#x2B;TSbgghhsqFQDw8VZWBeD&#x2B;/fvg6elJHrt8&#x2B;VL4/vs&#x2B;0LRpUyKAoM8fhRWpLgYHB3tyiYioQRZ1169fJ0LA2rVr4MKFOPY9fWuw6Dtz5hT4&#x2B;PgR0o&#x2B;WjCZNGpMwRhRqEC9fvoTz51Pf/8qVw4m9QA2wGwH/HTEokiILr6l41X&#x2B;pZZM2VS3Qk3T8nBiS9dTlj1FmACdFkE/&#x2B;&#x2B;b8Lk3/huCYh24CY/58Sfwpz4fHjx3f/&#x2B;&#x2B;&#x2B;/bd26ddsvQ&#x2B;iF/P/c60Lt/Sk8Mp8C4m3/SmwAWQa0A4DCkv/W2dUuABKkXqk4kBl2AaUjBgGyll3A5G0qVqxYpFatWk4REREe7MLY19bW1iYfGpwpKCgEcfXqNWjTphVcuXIVOnfuTEil7hx4/fo1uHv3Hnt7RyhZ0oX49rt16wrjxo0Hd0y7S8P&#x2B;/fuhXbs2hITXr18Xhg4dBi1atFT0/JjSjxkFrVvHqhrzh90L4eEVSco&#x2B;VvoxiHDbtm1kXOL8&#x2B;fPh3r17hDTfvXufTBzAkEIkzqVKuZMMAyTpq1evAScnJ6NMAx2EquwYUIjBhFWrViVZCuzCEhYsmM/ua63Z1x&#x2B;6UyQKGMOHDyfdGTqBpEqVyuwxVCNdBnv37iGhg7ly5YbXrxOIvQPtB9hNoBTPnz&#x2B;DatUiICamEfz880jFQgxF5oDbASC4ZhZJ/E91AjBG26eSb&#x2B;7jBQi7gjZ&#x2B;43U7Y7A9t/KvExrEln5KK/40&#x2B;I9CCdjvzaQtW7bsbNy48Vr28yNUzecKAB8lbuNeTxERDJRU/6Xa/4WEAWoBoAIAFQTMIAh8rnYBJaSfS5ZBhESrFQGUdgl8shwBzAmoU6dO8bp165YKCwtz9/f39yhUqJB1bn4ENwVFDseKFf&#x2B;SQL0&#x2B;ffoIVq0xmO78&#x2B;XMQEVGdeNcbNmxkcK5esOBP0up&#x2B;5MgxiI9/AT/&#x2B;&#x2B;CNL6g&#x2B;QAEIcJYhkWVyAwBb97uw5NwUWLlwEjo6Oio8bq&#x2B;Zdu3YmI/gYRkP89HPm/EE8&#x2B;LyFINy&#x2B;fYc99h1w9uxZliwfJqGHWPVGywB2A7DfE/rgRARW&#x2B;PF1h4eHcwSB1zB48GDy&#x2B;GrVqhEhBNv&#x2B;ly79C/7&#x2B;&#x2B;x&#x2B;L/ftgdb9Vq5bELoCiA&#x2B;LAgf3w1VdfYoo1BAWVhhEjRhJLhJVVIXI82Enw11/qJicsX76MWBHQ&#x2B;lGrVi36wchiAgB2hXDXpkZLJo7nX8vwcgKAG7KnJWRcozEu6xsE8kmM8BNerjES6ztxAk&#x2B;D/yjMzN&#x2B;0R44cOdytW7dVJ0&#x2B;efMkj8GIdAB8lbhdq&#x2B;xfz/vO7AlIESL9J7f&#x2B;ZzU3pQpkiUz&#x2B;0GRQEpMYNip2pPpVdQIrcg0oBIAXEOwLErAApYH67AJhA/i2WI8AumJI3btx4n708ZK8fLlq0aN6GDRs6RUZGurMLZfdSpUq5FOLOPKOgyKGQS&#x2B;3HMXZ4QTRqFGN0PybxOzs7Qs2aEcQmUK5calv63bt3oWHDenD69Fky4o67iMHAPyTTXl5esGXLFkLmsV1fCVBYuHTpIrEMrFu3AZ4/f06q&#x2B;Ojn59sTENiO7&#x2B;XlSS4I3P7u3Tuwc&#x2B;dOEib4&#x2B;&#x2B;9/QLFixQwEAMwO2L//ABmbqDsVnT17jhDvFSv&#x2B;Y8n/ODI2MTP4SP78&#x2B;SAuLo7YMmrXjia34ShGHM&#x2B;I2Qw3btyEDh2&#x2B;JkGCtWpFElHjzp078PTpE0Icf/31V2LLkHNHhYVVACcnZyJuUGQ1GCbt60k0I7EaEggBTK/8p5EJjrGf2x2gYTRptgGG5/k3JCLpyzR58i9E4pVW9LmTBmgHAIUYrly5con9bl73559/3uBU/eXIv1hFX2wqQDIITwYAELcKZKv2f/KZox0AFFniD5HaBYSucwmvku3FugCyol3AXOGBotsEBgbaNGzY0Jld7HoEBASUKlmypHMe2vdKQWESsDX&#x2B;4MGDsHnzZoiJiSFEFFGzZg1CUtu1a8cScG/im8evcz8/HzIycNiwEWQywY0b1wkBR3KPXQi6tnwk2dOnT4P&#x2B;/X/Sp&#x2B;PfunULGjVqAPXq1YcRI34mVfGbN2&#x2B;Au7uHCed6FCpug51dEeDqgY8ePYLy5XGkX3My8aBMmWAS5tehw1cQH59A7AHbt&#x2B;9kX/MBWLx4sUU7AHA9smTJEva9GsqS9DDInTsXEQO6desBAwcOIuIAHseePXvgyBHsbngClSpVInkOT58&#x2B;g5CQsjB//gKIiooSfQ7seKhZszrJeJgz53fyPFLA9&#x2B;DXXydCp05diI2CwrIgFoA3ScakGER89CICgBAh55b2udV/fl6AtF9f2PsvNy2Aev4pzAH2HPJwxYoVu3r27HlQoN1fSVVf7jFCooCQQCDW&#x2B;s9t&#x2B;U/hiQFZsgOACgAUOVEQyGl2ATlxIKMjBjMaImguu4DkfiIjI4tFR0e7VqlSxdPb29utGAsNncdFQZEhDBjQH5YtWwZv374DK6uChEhXrVoF7t27T9L49&#x2B;zZC69evYTBg/&#x2B;PkNTRo0cRP//IkaPI47FN/3//G88Szc5kNGEq&#x2B;XwFdevWIaRoz5590LfvD2Bv76AqfFDJGmDBggXsMf0Bly5dYYlxAQgMLA0lS5Yk0xDu3LlLLAs4ThDJ&#x2B;dKlyyz&#x2B;XqJVY/HiRWRSQkhIeejYsSOZeMAFCiYXLlyAAgXyQ1BQahAgigPNmjUlQkbduvWgbNmy4Ofnr7cTIDA0cfHihTB79h/QtGljuHz5quQ4wq1bt5IRkcePnyRdHBSZIwBwK&#x2B;FCAoAu7E9IAOC28AssqgzFA4M1Oef5BMMEjcm/srwAKgBQZAzs913C/v37j3Xu3Hnz7du3E0VIvRTxV7KtmO8/RYEAACDcFQCg0v&#x2B;f2dyUWgAosiQsbBfQipD8z9kuIGYREPtdyi6gJCMAIHPsAoq32b59&#x2B;0P28pj9/ZiVlVWeRo0aOcbExPiEhIR4uri4OBXE0hgFBYUsMHTv/fsPEBd3niWVS2DDho0sqU8i/nsc&#x2B;YdjBTGsDlvzO3X6llgGsKKNYYLYit&#x2B;1aze9AICRHYMG/R8hQDogccWv/C&#x2B;&#x2B;aE32cezYMVkbg1rg/r/&#x2B;&#x2B;mto2bIFIdSYZYCv6/jx42RiAmaLYscAvs779&#x2B;/qF2eWJCr4GvEi9Tx4TDhGEEUCRHJyChw6dBCCg8sR6wMKLShg&#x2B;Pr6kSo/tv3XqFETAgMD4dWreOjRozt5LP574O1iyJVLQzoiuMeB/0anT5&#x2B;CBw8ekNyFlJTU01pQUBB4e3vTD4YZ/iYFCQB/zJ82nfhrpTqOuSl9krQjfZlh3LJvvMyRIv&#x2B;0fZ/CTIJYypkzZ8727t17ze7du5/wSLoU0VdC/qUIPr&#x2B;qL9biL1XdB1D4qfuUoAIARbYTBDIoBggJAsJnQmOyrxUg/GLkXuwxjMDtjIigoKT6LyYQqLULqL3IdQ1IZQpIWQgyJUcgMTExedmyZbfYy23kM35&#x2B;ftatW7d2r1ixYim0Czg7OzvmwshtCgoKI2BFuH79eoRwTp/&#x2B;m34kXYUKFeHbbzuS9vEjRw4RwojV/d9/n8OSzo8suW1KAgNxzB6O10MxAAWAmTN/gy5duqQvTHLnIR74hw/vk&#x2B;vYGWBjo2x8HXYUYOZAREQEKIkAwVA9JMl46dixEzx79gxOnjwBL168IAS4SBE7uHbtOpQvX469hEJ4eBWSG4CZB&#x2B;jdlwJOMpAaFShFBOWAVow1a1YTKwOS&#x2B;bi4y1CihAPJWkARY/fuXbBjx05YtGgReR34b4RdBZijgOIMdmxIAb/&#x2B;DELkWKBI8vXX7cn&#x2B;UERAoQa3&#x2B;&#x2B;WXyfRDYZ51jgGBTvXwG48G5JJ&#x2B;0ZGBEu0AhvsTqmlwxa7027Wck6jY3yz3J//1UFAowb179&#x2B;4MHTp05Z9//nmT5/PPKOlX6/nXyggCQtX&#x2B;bJMFQBe4FNlaDDCTIAAqxABTBQGh&#x2B;4RMdYyESGBOu0AKqJ8oIEf85UIE1doF1AoDJlsKLl68&#x2B;GL48OGvcI1rZ2eXF/MDYmNjfYKDg918fX3RLlAUAOgqhoKCBZLfbdt2kBA6XRs6F0jWo6Jqk98jI6MImUZiumnTBjLKD&#x2B;fYo28dH1uvXj1Yteo/KFu2HCHWqeQzF0u8i5AsgFQBwJ5Ur5UA0/&#x2B;xdb1z5y4wefIU1a&#x2B;taNGi&#x2B;mNHYG7B7NlzyChDJNWbN28iXwWYe4BiBuYIhIdXJdYB7qkIW/V79eoJ7969g8GDh4K/v7/qY0EBZd&#x2B;&#x2B;vSQMkS8kNGzYkGQDnD17hkxGQPKP8PDwIJeWLVuSKv3ly5fJcR85cgROnDgBb94kgJWVNVSvHmGwP8xmsLa2NiCAfGAw4&#x2B;XLV2DlylXs46tDUlISGSdIs1bNLwTwAwCNkvXT/tPdnvrvxaTzfVEvgKFlQOh5U/cHnH2m/dRJD1pGcTimmuUZFQtyNt68efN6ypQpKydMmHCWPWe8A&#x2B;EWfVMvKSL7ERIDhEb6CZF&#x2B;OT6RpUUAmgFA8dkhg/kBSsMCxbZhZPYjFyYo9lOO/EMGBAGl90kJBRowLWRQyW1qhQGz5gi4ubkVDAgIsGnfvn2Qn5&#x2B;fM7u4drPmrpQpKCgUAwkxEttFixaSyjX611PbyQEiIqpCjRqRhFxOmPA/EvyHQXw//NCHdAFgIJ4S&#x2B;Pv7EUK8c&#x2B;duOHfuHEnNN0f&#x2B;Z1LSG7h16zY5Zhynt3fvPrh37y4RKzw9vdjjrgHly5eH4OBgcHBwwEoWfPllW9JVgJMIsENCDbDKj9MU1q1br89H4APfO7RJKAF2bFy8eJGECDZu3Njgvr1790C1aumiAIoGsbGt4cCBQ/oJEcnJyTBr1kzS1bFx40YICChN/6DNBF0GgH5tyhi31BsE&#x2B;HGq&#x2B;FwfPwn6S5/lZ0D4&#x2B;Z0EOhFAuHU/bZ9plgPDMX&#x2B;G4oFY6r8aQk&#x2B;Jf84F&#x2B;x32fu3atbuGDBmyLy4uLkEhmVe7jdh1tYF/UlMA&#x2B;MKAlD2AZgBQUFhA3MmKdgGG92WQ2XYBMFEA4BN9JTkCcnYBJdaAT20X0F&#x2B;/detWAnt5nTZukGEX97ZhYWFFmzVrFujn5&#x2B;fq6OhYIj8L&#x2B;smjoJCHLpgOK/R4efbsKTx69BD&#x2B;/XcFCdwbPXokjBw5gnQXjBkznmxra2sLaj5i7EeSiAiIlStXsEQ10CwZAgUKFAT2M08uHTp8Q4j9pUuXiBiA4wMxwG/cuLHg5ORI2u3xGLA9/ocfekPt2lGkKj9o0GBSoecv&#x2B;v799x/y3sTEpBNzfF/Qi482CTEoJf8IFCrCw8MF7zt58pSBAIBdGCkpyeTfRycA4G09evQkVoBWrVrB/v0HwcbGhv5RWxDpFXmtfoWhxYq8Qe8gh/zjNc5jdEGCxvs1jAcQJOx61m&#x2B;4yBHrHOCPDlQy&#x2B;o8iZ&#x2B;PGjRvXe/bs&#x2B;e&#x2B;mTZse4mhnCYKvtAsgRcXvQhYAoZZ/sSwAKXKf5TsDaAcARU47mX7K6QIApo8b/NTTBcxtFwDIpnYB/rFHREQUi4qKcq5Ro4a3r69vKXaRXSQ3mpgpKChUAaugOK7u/PlzsGrVahgzZjQZ3/fddz1YYtyUkGg&#x2B;Jk2aCD/&#x2B;2NfgtubNm4GLiytMnjyZtKmjX51PVHENcPFiHKncI4lGsr127VqSA2AqHj9&#x2B;BAcPHiJt&#x2B;bt27YSbN2&#x2B;S53d1dSUXtEFgLsDGjZvJdS6QVM&#x2B;ZMwtmzJipv&#x2B;2vv5aQ9P61a9ez74OdRd97zGdYsWKl/vrRo0cgIqIalChRgnQuhIaGQp06dchUgsKFC8O3334LwcFloFev7&#x2B;kfrpn&#x2B;9hMTk1K5gZE5kOFwcT655pB2ru8ff2pSbQLcEkOqoCCzPjdQBxjd/7LrebFOAEr&#x2B;Kfh4wmLevHmbx48fr2v3T4GMVfLFHpcC0iP&#x2B;kjkkPxlMq/qLVf/FyL42K3BTKgBQUEHAfGKAWkFAbtwgo&#x2B;K&#x2B;rGYXECP7UsTfHHaBjBL6DG2D0wWioqLsGzZs6FG&#x2B;fHkPd3d3F1sWDF3tUFCYjAUL/oTY2DaC1e6QkHIwdeo04sfXoVev70g1HacNHD58iL0cJin4GFCIVWzdGqB37&#x2B;/J6L/OnTvD4MGDSEs/TjRgP8cZPmYUHVDMQAtCpUqViADx6tUruHPnNpQrV87ga/rhwwcs0XYkLfY4gQCnHmAOgVIBAKv0//d//0deE&#x2B;4DySR2TYwePUZxCGGtWjVIDkPPnt&#x2B;R68uXL4Pt27dD3bp1yfQGTP&#x2B;Pj48n1oaaNWuSzINx48aRfIRWrVrLrrfu378HOGjF0kJGdhYA3iSmWgC0OsKd1tpvRLSBMRQAdAxdhHTz2/754Y6Crf8cC4BQWJGcAMC9ToUACh1es9i1a9eR3r1777x27dprEcKulNyLPU6qyi83AcDUUX9qpgNkCQGAWgAocjSygF2Af8blXlcaJsgl4hm1CygRBDQyYoGG84Wp1i7AFwHMZRewFOk3eH6cLrB69eo77OUee30fThdgF8v2kZGRXsHBwR44XaAARmhTUFAoRvv2X4veN3jwYKhfvy40adKMJbG1SIt7njy5iZ3gf/8bB46OTmBvXxxmzZpFSLGOrOLX/bBhwwkpR7x9&#x2B;x58fHzMQv4RmDng5uZGFnQYxIcBhzj1AC98HDt2nIT6oTjx&#x2B;PFj6Nv3Rzh16kwqdWMYSZKEUw&#x2B;GDx8GO3fuhHr16gOGZn/8mEJsBmomEAwdOhx69OgKf/&#x2B;9nBzz27dvYevWbcTK0LdvP5IbcOLEcRJKiNMF1qxZw753CaTLgQ8UIfCYybx6Fv36/UiCA62tC5HuB0dHR8FjePr0KREIdCJNjluP8IL7BYlzmjrAJQqMJu1EL0AejD3/DBnfqPP&#x2B;Cy9r0gQFLWO0eFFK2vmWAKMQQ0r8cxTY76kPly5dutKtW7dVe/fufSpD3pWS/GQRcq/U4y/n99fyyD/IkH9Zgp&#x2B;VQAUACgoBMcBMggAoEAP4goA5xg1aerqAVuZ&#x2B;IYLPFwfU/C43XQAyQP5NCQZUnCOA0wXYy6uZM2deZRfDGpYEFKlZs6ZTjRo1vMqUKeONdoFcOXW1S0FhIjDMDokifkWfPXsW2M8Te9tTGDLk/wghxgR&#x2B;d3cP6N69JxEEnJycoFmzFtCgQX1S5cZQQLIAyp2b&#x2B;Pjd3d1JhT4&#x2B;/qXZjxVD&#x2B;iZPngSVK/8reP/&#x2B;/fvI8erg4&#x2B;MLJUu6wJkzp4iI8P79Bz2RFlzEsa8Bt09O/ggdOnwNwcFlTTpOfA/37t0Pu3fvYc&#x2B;FyaTVH8m/DhhCWKdOXXIZORKInQG7G3DcIh9xcRfI47Fjo1&#x2B;/vnDr1k1YvXo1HDhwgNyG3RFdu3aGqKhoiI2N1T8O8x/QMoEjGbFbI&#x2B;euRQxJcto0QMFUf4YrBuDfCScrIFUv4Af/aY0fB7xqvUaY&#x2B;Ksh7vxKJl8EoIn/OWdd/fTp0yf9&#x2B;vVbtmDBgpsgnMafkgGiL1ft1wqQf26rfwpnG27FX6raL0b&#x2B;lUwHyDLiABUAKCgyRxBgQHiUIP88KzZukJHYPyMiKIgJAkrtAkoFATXdAkKdAPzthH6XEwGSBUh4Mpi3KyBDOQIpKSma/fv3P2YvT0aNGnUG7QItW7YsWbFiRSd2ER3g7OxcAu0C9JNHQSGNly9fkKo3pqbv27eH&#x2B;O4LF7aDa9euw6VLcbBly2YyIu/773sCxnGULh1EPOxILleuXAkDBgwg&#x2B;7l79y5LNL&#x2B;B06fPEMtAfPwrIiBwQ/eQzGIlHUcfKgVWwHW6HnYVzJr1uyjhSU5Oge3bt0Hr1ult9AEBAXDjxi1CljG1f9CggcQSEBYWRqrnfEHgp58GkE4GJPE3btwkHn1TUKRIUWjatKmibXXjBoVw/PhxcHJyJu8j2iCwS&#x2B;DRo8ckXwGP/ZdfJsHDh49g2rTJBgJAx46d2X&#x2B;TO8SykWMJIiO&#x2B;mNDoTuQMf8ofVuy1BkGBBqsORkg0ECD&#x2B;3PBAkQPhB/1xyb2UGCBE/KkI8HkjISEhfs6cOevZ79vj7Peq2Eg&#x2B;tWRfSVu/2HWtQvLPDwIEkA8A1GY1gi/7VUMzACgoTPo7tmSYoMQyQHbcoFyYoBjxB1CfFaBUENCovM&#x2B;UixC5NzVEMFPsAvzfnZ2d87dv396zbNmyTuxC349d6DuwpCSvxN8CBUWOxahRo2Du3D9YEjkNGjZsZHQ/EvkzZ07D&#x2B;fPnYePGDYRI48g&#x2B;dOBUrBgOoaEhLGGuBd9915NUpmfMmEHa6JctW26QNYDj7jCUENvgdcAKNvqoc&#x2B;XKbbSuQL/8tWvXgP0sK34t5coFkxGCtWtHk44BDAMcM2YsCTL86af&#x2B;7Os4A7dv3wRra1sICgqCChUqQJUqVcHdvRTZBoHjFTt37sQeex74/fe5n/TfpmfPHjB48BASIIgYPnwojB8/Hvr3HwAjRoyAqlXDYfHiv2DVqpWkw6F///4Gj8fXopsWkVNAQgDTxgAaEPu0nwyPwKfbBDhjAI3GBGqAW/HXZwNqNMJZAWRiAOcZ03aL&#x2B;9LIBP4pXf&#x2B;LPS8VBD4fsN&#x2B;P79evX79n4MCBe9nv3XgQD&#x2B;RTSvalwvz4twlV/MXa/fnX5ci/XPVfiQigzSrclAoAFBTZVxCw9HQBpeKAJaYLSNkCpEYMyokAoIL8y1kBTCX9ss&#x2B;VO3duja&#x2B;vr3WHDh18S5cu7RQSEuJrZ2dXmE4XoKBIP4djor5Szz52C5w8eRxOnToF69athatXr8LLl6/A29uLzLqfMWM6HDp0EBYtWmIkJHz48BEKFMgPiYmJ5PnQJ4/BhG3atIMvvviCtOrrSFzr1l&#x2B;Ah4cnjBs3XvFr2bt3D3Tt2oU9npdEXECSv337Tv39eDv67y9cuECmC1y4EMfe9pw9lkJkdB&#x2B;26mP&#x2B;AXYOVK5ckWQmYACiwMKcvHbsiPD29rbYv02XLp3hwYMHMH/&#x2B;AiJIYKdFo0b1iX0Apxx0796dBByWKuVGBI&#x2B;5c&#x2B;cTmwZmJuBjW7RoQcQQHTCM8MiRw/D11x1E8wM&#x2B;FwFAOFrIUAJgjPvyOevr9Oo9t0uA6w4QJe&#x2B;MYeu/UZuiSB6FGgFAShiQEgkossXfcMqhQ4eOz5gxY99ff/11B&#x2B;Tb9dXep6TqrwV1FX9zkX&#x2B;gAgAVACgosvp0AT6hVyoIZLZdwNTpAmpFALVdAebKCFBsO7C1tc0bEhJS&#x2B;KuvvvJnF&#x2B;6OLEHwsbGxsQbaHUBBYdL5//nzZ6TiX6iQNUm6nzp1Knh6ekCDBg0FH4Pk/8SJEyzhrkY8&#x2B;xMnTiD76N27DyH8OhLXrl0b8PLyhp9/HqnqmDB079KlS4QQIzmXauNHco0hh7t37yZdDleuXCEihYtLSdK9sGfPXhIsWK5ciEGgHIoM2J7/9OkTWLVqDZQta1peAB4jZgBgloLQqQ47Fjp1&#x2B;pa8T2ifePjwIRQtWhRWrlxN8hbwvVyzZjVs27YVNm3apLdMoECA4wcxzBDfv/z585P9HTt2lN1fZ/a15SadA5YULz6tAPDGOCyPd4plhOfxGZBnDflpLBQYcn1GVAAwsBuAsGggVcnPyPqfZgVkT7DfQVdY0n9g1KhRZz&#x2B;iaipP3k319ZvS5i8V9CeU7v9JyD8VAKgAQEEFATlBgNoFMtcuoJT8m4v0y27j5uZWoHLlysVatWoV6OXl5cRe3PPrVssUFBSqgYF2pUuXNrodLQQYzYFunF9//ZW05nNJG7ZT37t3D/77bwV8910vaNOmtUkCgKlAMo4VdqyQHz16lHQ5vH6dCI8ePQJPT0&#x2B;oWLEiS6gbsIR7FclK2Lp1OwwY0A&#x2B;ePXsOCxcuMilx/9atW9CjRzeYM&#x2B;cPUrkXAlouFi1aSN4fFAqio6PB3t6B5DdcvHiJWBcw9M/Pzw/Cw6uQMMT169dBnjx54cCBfWTMYOXKVaB69QioUKESeZ4ffugDa9euhb59&#x2B;7K//yi6rsuOhFFIAEhv5Zdpt2e4XQJavVDAFwH4AoC&#x2B;8s4TA/SBRdxj0YkLEoGUUu97Rir7VADIunjx4sWzlStX7u3evfuBd&#x2B;/efQDTKvlqWv1NJf1ChD8zyT8VAKgAQEHFgGxrFwAJUq9UHMgMu4C5RACAzLULKNlG8LnKlStnyy6wnSMjI73ZBXWpEiVKOOTR9SVTUFCYDEyvxxn22H6O3nUkol9&#x2B;&#x2B;RUEBpYGb28f0uKOFWpMrsdReX36fE8mEPAFACTEBQsWIMRXySkAi2hY2ff391d1vFhdx1b/v//&#x2B;G/bu3U0sDzhaEP34KAqgSNGr1/cQFVULdu/eC6bqhleuXCYjFgsVKiR4P3YIdO/eFWxsbGHhwoXs86RPPx0/fhyMGzcWSpUqBSdPntbfjp0AuDbbtGkjHD58BPbt201sD5i1gLYI7G7Yv/8AvH2bBOx3HXTr1p10C&#x2B;jeT&#x2B;zKQOtAcHBwthYAQH8y0AgG&#x2B;Olv1PN9Y5uAMOk3nCygs/mDUDdA2nEg4cdjE&#x2B;wYADASCOREAFM4g9BEAYpPC/az&#x2B;nHPnj2Hv/zyyw337t17A6ZX&#x2B;dWO71PT6q&#x2B;k6s9v/zeV/MsRfEWkMzO5KZ0CQEGR&#x2B;eKTJacLiBF/U6cL8IUANeMG1dxmynUu6RcbPagReYyp0wWUdglkao7AyZMnn7OXF&#x2B;PHjz9foECB3GFhYXatW7f2Llu2rJuPj08pOxYaqdINBQWFIBo1akRC6TA8cOjQYaQLoHfv78l9SM5xrGBoKKbz25ORgvh1zp0igNi6dQt07NiRBNtNmTKFkFY5YKp/x47fQOvWsdCpUycDAi0FXSZC586dyeXp06dw6tRJ8PPzhf/&#x2B;WwVTp04m1XYc68c/9eg6GuTAftfAP//8DX36/CAqABQrVozYGNCGgMeAowp16NOnD1hb20D16tUNHqPrRsBQR7ygkIF2h3379hKrQKFCVrB&#x2B;/QYyVaBt2zbENoGTC7BbAC8omuzZsztbCgBCpNd4hB8Yn8YZw9M7ad8XsQCkZwDwlghpG&#x2B;s7KEQIiZj/nxxr2nZiXn5TSbsQIeJ3elCbQObi4sWLl9q1a7ec/R54xX5nJIP5qvxq/P1KQv2kWv25hN/S5D9rfs/QDgAKiix38v&#x2B;c7QJS5B7AfB0B5rqY2imQUWHAbJaCUqVKFQwLCyvSvHlzv9KlS7uxcC6ExmcKCgqT1g7Xrl0lJBjHDWIuALbgIxG&#x2B;evU6xMa2IuR26tTpxDaApBS99y1atCQkdfHihdC3b3&#x2B;wt7eXfB58HI4ovH79Gixf/o9Bqz2OOPTy8gJTmnywMt&#x2B;p0zfQrt1X0KHDN/rbExISyMg&#x2B;bNeXwvPnzyEioioZq4gJ/n/9tVRwO2z1x4DF&#x2B;vXrw4IFi8z&#x2B;74AiDL7/2NWAQkOVKlXAwaEEeV&#x2B;6dOma7f6uhDoAuOQfp05wQ/yExAHG4BSYbgUwvC2t/R&#x2B;vMYanct1VRoDgpx6DRvF6nnsf3zpgTsIuth8qCpgfDx8&#x2B;fDB27NjVc&#x2B;fOvZ6YmPgBTK/yS6X4i1X&#x2B;lST6K6n2axVcwMzkXzHhpBYAKgBQUJhDDDBVEMjqdgEu4VWyvVgXQFa0C1g8R4BduNuhINCoUaOAMmXKeJUoUcI&#x2B;F3&#x2B;eGQUFhSKgBx9zAt68SSRe9iFDBsMff/wOdnZFIDAwAKKj68CKFStg8uTJ4O8foH8Md9SgFMmNiWlMEv51mDfvD/jll9Qqvq1tYZOOGTsakJBxBYSzZ8/CnTt3CGFHDBgwgHQJVKpUibTf29jYkNsvX77Ckv9yMGXKVPj110kwbNgIaN68heDzVK5cCWJjY&#x2B;Gbb76F77/vxW47HFxdXc323qNogd0NBw8egB07dsDt27fJGMcyZbKvBSAlRav3/msYrpefQ9Q16dX11NA/DdleJwIIrxp4lXiO358z8c&#x2B;wsYArLTA8&#x2B;4EI0WdkxgVaiphz903Jv3kRHx//avny5TtGjx59/NatW4mQsWA/tR5/rcDvUmn&#x2B;atL9pfz&#x2B;AOar/GdJAYAu&#x2B;igosjDMbBdQKhZkB7uAVoUAkALCdgE5cYD/u6l2AXN1BSgh/bL7OXbs2BP28mzmzJlXra2t87Dkwr5atWpOUVFRpZ2cnOyL46qfgoJCEZDIlytXTn998OAhxDawYcN60h3w888jICkpCSpUCGPJcBuoU6cOIageHh4kM2D06FEskZ6stw1gWzuG59nZ2bH3P2YX368Mng8nF7x7lwQZ0ezQisAHhiAmJb3RH8Pdu7dh2rQphPhjt0JAQGmIioqE4OByJFQQpybgGMUDBw6KCgDYaFS1alVin8DXizkI5hQA2O8vMgaxatVq0L//API&#x2B;Y9dF9j3fc6r0kF7xBzBs6RcjCYxMg1/66iH99Kkj/QYnZ5GzvTZtYz7plyLkckTHXISdFvXMj3fv3r09evTo6V69em1GiyGY1tqf0WA/c3v85Vr8tTJE32LkP7NBBQAKipwrCKjND9BKEHCtwNKBUSAUCN1uCbuAWEYA//YUmd9TQHnXQFazCxhtk5CQkLx69eo77OUee/2og4ND/ubNm7uEhIQ4RkZGlinKgl1kFwI6bpCCQhEwVK9ixUrkgl/Xt2/fgsuXL8PGjRvICL61a1dDsWL2sHXrVkhOToH58&#x2B;fBF198QYgs&#x2B;XLQaCAh4TV069aVvV8LzZo1N9i/p6cXHDlyhIQPmhNFixaBjh37Ee89Ev758xdAlSpVYdSokWQ0IgYdDhs2lGyL0xLQZ3/xYhxL8guK7tPGxoqICejt/7//G0wsBlL43//Gk33Xr99A1bGjDQDDF/E9b9GihUHeQDY7wxuN/Uttn&#x2B;edXDlnWQZ0Sf48pm5Qedfq90VuZsS0fN2pXKMn1YZkP9WKILpgEBAG&#x2B;CP9&#x2B;GTd3MRdaN&#x2B;0G0AdklncvXv3Tu/evVesWrXqngyxN7XlX027v1IBQE2yv9KW/8&#x2B;S/FMBgILiMxIELNwdICYIMAIkXor0iz2GEbidEREUlGQDiAkEau0CpmYGSBH&#x2B;ZFBmFwC1hB4yaClgF9KJv/3222X29yvsZa&#x2B;Pj0&#x2B;h2NhY97Jly5asXLlygI2NjW0BLOdRUFDIf2GyX8lubqXIBdPp0dd/6dJFlgg/IBYBrMTPnj0b2rdvT8b1VatWjQgBPXv2BPbzBoMGDYA5c&#x2B;aQtPyQkPJkf9ig8&#x2B;LFK3ZfyZDXjMVuJM&#x2B;hoeUhPLwyORbsSNi9eyfUqFGDjD7E6vq1a9dI/sDOnTvgzJnTZLpAo0ZNDAgXhvbhxAEUMlxd3eD69Rtw9OgR0g1x7dp1CAgIYIn&#x2B;BOLb58Pb2xsOHDigWgDA54uMjCLjCY8ePZaNBQAQaOXnVP&#x2B;1qb59hnMm1hpU5FNPlynsRWN0KuUQYb1gwB37Z1gPECL/asi30HQAqUq/uck6X1jgH4Px66O2AQS2&#x2B;48ePfrfiRMnxnEC/kxp&#x2B;Vea5m&#x2B;udn&#x2B;lPn8A9S3/YiJAtiX/5LNGMwAoKD7bxacl8wMYBY9Rkh8gdJ9YrkBmTRcQEwvU2AX42yu1Biip/JtDGDApR4AlA0VjYmLcg4ODXcqWLetrY2NjzRIFOm6QgkIFUAhAgozVcfTGf/jwniX1L&#x2B;HChfO4ACdt8nXq1CMj8DZuXEdCBdu1&#x2B;5KM8MPRfj/80JcluzehQIGCsHTpUiIKREdHm7wWwuNAXQ9JPlbhjx8/Bu/evQcfHx/o1asXGXcoQBRIRd/T09MgSwDHJs6d&#x2B;zvUqFGT/X0NGX2IVfmIiAjyNdKsWROoW7cuTJgwSfBYMJ/A1NGE&#x2B;Hh8b7PjBFTMAHid&#x2B;AZStClk/J82rRuAS&#x2B;4JcQVOnZ6EAaZdx&#x2B;o8A8APANSJB4KJ&#x2B;QxXADCMA&#x2B;T7/Y1T/UFw0oDQWp9vB&#x2B;AvTaSmBWQGMae5AcT2k8R&#x2B;l2z97rvv9icmJr4H&#x2B;Sq/0pZ/sdvEEv3Vhvup8fdLVf2VEH6Lk38aAkgFAAqKrCYIKA0LBAmyL7UfuTBBsZ9y5B/MKAAo6QBQSvxNDRGUIu2qCT2YmCOAO7Gzs8sbFRXlEBMT4&#x2B;3v7&#x2B;/s5&#x2B;fnVZAFQ8soFBSSwLC9KVMmE0/84cOH2J&#x2B;XoWjRonDv3l1iEzh06CBs2bIF/Pz8oWXLL&#x2B;Dq1Suwdu0amDTpF1JF79mzB&#x2B;kiwMp69&#x2B;7dSNX98OGj4ObmJra4J8GDuiA/LubPn0tIc6dOXcj1Ll06EZtB8&#x2B;bNyU9T0Lx5M9IhgKMMixQpQmwFODUALzjOMDo6Ci5cuGjwmDdv3pCpB5cvX4J//10B7u4eOepvgggArxNTiThh1&#x2B;nVfT1B5wb3cQi8wcmOYfTigRFRF9iX0EmZ0Y8RVB7gZygICAcRCuUCyE0SEBIOzE3Wc3InALb77969&#x2B;9CYMWP2bN&#x2B;&#x2B;/YkCYq&#x2B;k5V&#x2B;u&#x2B;i9W&#x2B;VcjAKhN9Vfr9RcTASxG/qkAQAUACoqsLgYIrhlMFAwsOV1ACfkHEwUAPtG3hF1AaZeAKV0B5soR0P/u5eVVqH79&#x2B;pgd4BUYGFiqZMmSzvmE0sYoKCjg119/gdWrV8GoUWNIUB4fSMoRunBAHTGZNWsWS5D/hi1bthLC3LBhDEuq85GpAGPGjDPYx/Pnz4jVAIWGkSNHgJVVIRg4cCB4eHjqt4mJaUQCCgcPTvX3L1myBHbt2smS9RDo0qU7SxCwWyGXqrXbx48f4MGDh6TtH0UKPDbMQcDX4uvrB5cuxcGUKdOJ3x/H9j18&#x2B;BA6depIwhFPnz5FhILhw0fkqL&#x2B;HZJwCwBEA&#x2B;NX2tDvSOvcNSX4a5dbzj3SiDPr8AH7JntFd5yF1XJ&#x2B;h887wn14qEzi920CqO8BUXsAVBCwhAPCDCbMabzE3Hj169HDUqFGrpk&#x2B;ffgVMq/JnpOVfivArqfab2u4vdhvAJ6r6UwGACgAUFJ&#x2B;rIGAuuwAoIP5CRF3pbdQuYCa7ALuI1JQtW9a2TZs23sHBwc7sxbtIkSJFc2EaGAUFBQG2u4tpZHfv3oXJk3&#x2B;B8eMnAPdjs3HjJsibNzfxvPfp05t0BmBYH7a9//77H/o1Frbzz5z5G3Tv3oO01GNHwd69eyAsLIyMFtShRYtmhHAPGDDIYH304cMHUsHHUX98YUEt8FiuX78OJ0&#x2B;eJPkBN25cJ1kCBQpYQXBwEAlDRNFh7dp1JOAQ35Nevb7XP/6///6D5cuXQt&#x2B;&#x2B;/cnxf47gdgBw18vG5DuNgjNpAYAGJx5GLwDolrjpAYK64YLp&#x2B;9RrAjwBQCc&#x2B;CFf9xQQA3XNnXAAQq8J/CmL&#x2B;OZL/169fJyxZsmTr&#x2B;PHjT964ceM1KKvyS6X5J4N6n78aAUCI8PPT/QGkR/sBZNGqPxUAqABAQfG5CALmsguICQKMivuyml1AjOxLEX9z2AUy7P/PyDZFixbNxy7c7dq2bRvg4&#x2B;Pj5Ofn52Ej1I9MQUFBgC37c&#x2B;bMgvbtvyYZAGICwvjxYwlpLlzYDubNm0/GEiKePn0KNWpEwLZtO0hIHheJiYmwYMEC6N69u6AAoAOOHMSMgjNnzpr1tSUkJMDp06fhxInjsHv3LjKCUGdTwGPD6n&#x2B;dOnVJ&#x2B;KGVlRWxQIwc&#x2B;TMJCJw4cRIJCcyOPn&#x2B;lAoCuys8n7EYkXG8J4P3kFPcZ/ZmH284vfILVkX/uWl1aBEi/LmYR4B&#x2B;LnDAg1I4vJwhY2sP/uWQEfPjw4f2&#x2B;ffuODRw4cPvhw4efg/oqv6mkP6Nj/dSk&#x2B;4tdB8iiVX8qAFABgILicxQDxIi6nGAAIJ8fkJl2ASWCgEZGLNDIiANqrQPmsAtYivRL2gX8/PysQ0JCCrdq1ap0UFCQh4uLS8ncul5nCgoKWbx8&#x2B;RJu3rwJZcuWhUWLFsKxY8dgypSp&#x2B;vux6t64cSN48uQptGzZkiX5YcB&#x2B;5kjWAAoHmPZ/8OAhaNs2VlQA2LNnD/z4Yx84evS45LEcPHiQrIUrVw43aS2GgYaXL18hRH/79m3EOoDHHxgYCEFBZcgEBQwRHDduLEyaNAHY7w2YMOEXMq6QC3wMdkvkNed4hEwVAN6Q91FPNrk836hszwAYDQ0ETlAgd1Ygv/1f997rggO5RJfbxi8ezscXA1K354sV0lYBJV0Caqr&#x2B;lrIIiIkA2WXMIKb5X79&#x2B;/eaQIUPWLFu27A5kPNhPiOTLtfirGevHFwEAzJvun1HibxHyTwUAKgBQUORkQYDaBeTtAnIigDm6AkwJBjQpR8Da2jq3v7&#x2B;/TfPmzd2rVavmU6pUKSdHFvSTRkEhTRh/&#x2B;WUSzJ37B0njx0o/vz3&#x2B;/v17MHz4MFLJx6o7BvIFBASyhLo27N27F/74Yy60bdsGqlQJJ5MFEOjf79evL/TvP4CM/evT53tJAQCPo0ePHrBx43oS3odCQ0aA1oPLly/C&#x2B;fMXYNOmjXDmzBl48OA&#x2B;FCxYCAoXtiVhgfhasIEIbQKdOnXWryt/&#x2B;OEHiImJIaMLs6sAkEoywYCoG7Bm3nUDCQCJOye8Lz0nAG/UGDxUwwvtA5AK&#x2B;GNkiXj6dePuAOn1BK9bQSGHUFORt9RkAUuFEpoTL168eDZp0qTVY8eOvSAw1s/Uln&#x2B;p27QgXPmXCvqT8vmLtfungDKfvxjJz1LE/1NwU1pxoaCgUPsFpc2gIMBfHfC/iIXIvtA2YuUFrQDpF3pe/j6U2gXMIQhwSX8K7/4UUG4XSJYRAZIFSHgymLcrIEM5AuxiPvnIkSNP2csz9vpxtAvUrFmzeGRkpBu7kA90cHAoZodJZhQUFOkETqOB3r37QGLiayhbtpygN97JyRnmzPkD4uNfkRC&#x2B;jRs3EB/&#x2B;qFE/g5tbKX2lfOfOXRAb2waKFSvOfr&#x2B;nkKwALy9vqFSpkqLjiIysCb//PgeePXue4deFrf2BgUHk8sUXrYgl4Pz582T8YaFC1tCsWXMyRaFq1XCYMWM6e/7RgL&#x2B;/P4SHh4Ovry&#x2B;xQ2RHAUCbRth1pF2&#x2B;Op42KYBJI/na9Lq//lTH6K6nEXzOT/1ZHKv27LexNu2sI9YBIBaQJ3l8BhyMEVlPGAoBcqsJfj6BEMGXepylyFpW6wZ4z2Lx4sUb&#x2B;vfvf/jZs2dvZYi9WGu/UtKvpvIv5PcHyNhYP4Asnu6fFUE7ACgoKMz5&#x2B;f7c7AIA6rMClAoCGpX3mdsuoDZE8JPYBTw8PArWq1fPqXr16u4syfEtVqxY0UIs6KeNgsI0YMAgEmskzIMGDSTk3dramnjuo6Jqk8q/j48Pab3v3r0LHDp0VP9YrFRrNIbVZBQMMJTwxYvnZNJAZgBtDytWrIBTp05BUlIiuLt7AjYO4fjCdu2&#x2B;zHb/JhiE&#x2B;Jr9N&#x2B;HSDIOuf12tnzFcS6cSWw2HPWvTE/55/04MR29n&#x2B;KdIxjBDgJv&#x2B;L0XMxTsBhMQAvp4v3x0gxyf4GQDSowqFK/bmIO/8YxC6PZO4jXbr1q37fvnllwObN29&#x2B;KEPsM9Lyn1k&#x2B;/0/d7p&#x2B;pZJFaAKgAQEFBBQHTBQFL2wWUigOWsAtI2QJMGTFoil1AzgpgKulX9FyhoaF29evXd6latap7UFCQZxEWefPmpeMGKShMAOYB3Lt3D7Zt2wqHDx9iyf4huHz5Ehw4cJiE8rVr1wZWr14Lrq6uULhwYdi1axfx6nfs2Em/j7Nnz0BERFWIi7tsFDhoSeCoRDx2HDV49OhROHfuLEybNt1gzGF2AdcCICQAgFGyPofCpxF&#x2B;fTs/I9AcxzCckxSnI4DDybmna4aXF5C&#x2B;duaFCKZV44WItbpTu7AAoHs&#x2B;KZuAUFeCVIdAZoUHigkAFupG0F64cOHi9OnTd86aNesqqA/2M5X0K/X5y/0EyFpj/TKd/FMBgAoAFBRUEFC&#x2B;YjDndAE&#x2B;oVcqCGSmXSAj0wXUigBquwLMlRGg2HZgZWWVJzIysnjt2rXdQkNDPfz8/NxtWTCf6&#x2B;BmCgoLAzsDcGQfttVfv34NvviiJekYQDsBBvFhyN6OHdth//6DoBvk8fDhQzJxYPXqNeT3rVu3wu3bt2Do0OHg5eWl3zeKB0jSa9WKhICAALMdMwoVb98mAeqAOEIwO378SQfA60QD7qEP9OO9Ho1E4r4YS9Z1BWgZXnBgWo4AWg80jEZR4B5fABAj4kL2AfHTs1aRKADiL1HwmJSSbUsGCGb02OTw5MmTx3/&#x2B;&#x2B;ee2YcOGnUxKSvqogNirafmXIvx8z79WhQDAJ/yWGOuXbYg/FQCoAEBBQQUB0wUBahfIXLuAUvJvLtIvu42bm1uByMjIElFRUZ4hISE4XcCpYMGCVvSTRkGhDDie79Spk/Dll1&#x2B;RVn&#x2B;WXMDx48fg4MEDsH37dnj8&#x2B;DF722Pw9PQibf/h4VWgaNEi0KdPbwgMLA22trZ68QAJ/7p1G8HevjjZN3r5e/bsAZhFtnv3XrMdMx5TbGwr8Pb2IaGA5cuXz5YCAIovKSncEMA0om/Qys8IK&#x2B;EMTwBIMYr4Fz8h6sIEeYk8wqP3wLgTQaJLQKo1XvqULi0IqB0vyBck1IgCmSUIqMWbN29e79ix4/A333yzjf2cvlVA7JW2/IvdpgXpyr/Sdn&#x2B;xSr&#x2B;asX5Kff5qCP0nJ4ZUAKACAAUFFQMyRxAwh10AQPm4wU9pF5Aj/lnVLqBkG8HnCg4Oto2JiXGtUKGCS1hYmL8dC2oXoKAQx9WrV&#x2B;Hrr7&#x2B;C//5bZTRmD9dNSLZPnz4FK1euJKLAo0ePSHI/tuOjaIAe/IoVK0GBAgWIKHDp0kXYsGGTwT4wxK948eJkGzV4/vw5YPyH0Ji/ffv2wd27d8ikg&#x2B;joOtlSAHj9&#x2B;rUU005vywexyn/al7/QYwUewLUQpHYb6AICU3MFUvUAffqAwe9SAoEUWRcm11owzOUFkM75FRcF&#x2B;CKEmDAgFHLIiHVOcO43tyAg1Hkg9xzJLM6fP3&#x2B;hbdu2K86dOxevgNiLVfmTFZB&#x2B;JdV&#x2B;pQJAVh3rl2UIIRUAqABAQUEFAWoXMPW6HOnnEmox4q9WBFDaJfBJcwRq1KhRtGXLlt4BAQFOISEh/tYsGIY3H4uCIoeD5Rek&#x2B;i/0FYxVfPT5Fy1alFSsr127Cvv3H4Bjx44SLz52B9jbO4Cfnz/JDViwYD5cuXKddAYg4uLi4M6d2yaR9JEjR5Dnnzt3nj5sEL3/QhMQsqUAQEIAtQLsmbN2Jhb/tJZ9jcC0AELm2Xu1HJLPCJyodPYC7tpcjgzLkH8uCZcb7Sfcci9H&#x2B;JWNFFRyDGrIPP9YLSkGyAkAt1gMHDhw5dKlS&#x2B;&#x2B;A8ip/Rki/klR/NWP9UkTIvtKxfmb1&#x2B;WN2QlayDFEBgAoAFBQUlhUEsppdQIrcA5ivI8BcF1M7BTIqDJjNUuDg4JCvdevWbhUrVnQJDQ31RrtA/vz5C9BPGgWFONDfv3TpEvjjj3lG0wCwQh8XdwF27NhBAgWR7ONtaAkoUyYYatWqRSYMYHL/8uV/GzwWq9&#x2B;bNm2EFi1a6kUIzBvgYuzY0TBo0GAYOfJnGDx4CDx8&#x2B;AAqVAiDoUOHwrffdoKEhASyttOJDdlKAEhJ7QDQchhseg2cEan6c1L/DcQCgZm3Ii35euLPtRoIlM0Z7k7TDkzXNcAXB4QEASlizT&#x2B;1ixNgfocAKBIh5I5D6FiUdAQIcRpLiQIvX758MX369HW//PLL&#x2B;RcvXryDjAX7qSH9YtV&#x2B;OQFAiPBbwucvJgLIEv&#x2B;sxkupAEAFAAoKCsuKAaYKAp&#x2B;TXYBLjgFMyxLITLuARXME8ubNm8ve3j5/9&#x2B;7dfcqWLetSpkwZT0cWGj7DoaDI4cC0&#x2B;sePH0Hx4vZGBJ0PbMk/e/YcbN&#x2B;OEwYOw82bN4logKF9vXv3AT8/P6hUqTI4ODiQ7evVqwsrV64iloLu3bvC/PkLIXfuXBAfH08CB589ewYLFiyAOXNmwYkTJ8n&#x2B;qlSpTEYA/vvvChg4cAD06dOH7DN7CwAccs9&#x2B;RXFb77nt&#x2B;BoO8ee3/uN&#x2B;sEOAT4nwNswZ0GgYYfLLj97XTwPAbVKINYBLcnUBgowJ1Xm5yrx0pV1otKC0bUDpqkHp8kKpaJARvGOxatWqHaNHjz587ty5V5CxYL9kFaRfLtU/M3z&#x2B;AGau&#x2B;msFyB8VAKgAQEFBQQUBKbIPMmRfThDILnYBOXEgo5kBGQ0RNFtGgNh&#x2B;MCogMDDQJjY21genC7i7uzsXR9MyBQWFaQQ3OZmMD8TqP4YMYobAixcviGcfMwMqVaoE8&#x2B;bNhWHDRkDdunWhdu0o6N69O&#x2B;kIaNCgHhlFmDt3brKvRYsWwqpVK6FQISvIkycf/PDDjxiIBs2bN4F///0PwsIqZF8BIEXL7cvnfNnzBACGJfESo/70nQOM&#x2B;Bqc2xUgSmAFhQB5i4D8OVs5uZZP5xci/sJCgJrRgmpIvbktAey&#x2B;Uk6cOHFm5MiRW9esWfMA1FX5hQi9ktuUXMQEAHON9bOUz1&#x2B;Q/FMBgAoAFBQUVBBQIgaoEQSoXUB5RgDAp7MLyG0DLi4uBWvUqFE8Ojras3z58l7Ozs4lbHQz0CgoKFQD2/UxIHD79m2wbds2Ej6InQEYJvjNN98SQo&#x2B;Cwfr1G6Fq1XAyUpD9/JHHYuu/v78fmUSwa9duEgx4//4DaNasMcyePQeCg8tmu/cjJTkF4tM6ABjGmJUa&#x2B;u91/JZjAdAKPUZHTKVH93GJsSQ5TwsLlD55csbcmdAZIEaslfMHZTYBsecXe6/UkntTswKQpD548OD&#x2B;uHHj1k6fPv0KqKvyJ0sQfLnqv1bgd6mgP7lqv1C7v1KfvxjJNyvxpwIAFQAoKCioGGBuQSCr2gXABAGAS85NFQfkugaUBgsqqfibg/SLPhfaAry8vKxiYmJK1qhRwzMwMNDd0dHRIV&#x2B;&#x2B;fPnpp42CQj2wOwCzAi5fvgQ7duyEdevWkOkCKAaULh3EEv6HsGDBQpbYB8OqVavgr7&#x2B;WkBGER44cgpkzZ5OpAG/fvoUGDerC6NHjSDdB9hYAuLH&#x2B;2tTQP16Qn&#x2B;FZTScEaDhf8MYt8sLEnxHZpwShBcMJAvInUHGbgE7M0CoUBNSRa2WTBPhTCpSIEfz3Tuo4lE4SeM1i/vz5G/r373/s3bt3H8C0YD&#x2B;l1X&#x2B;1FX&#x2B;&#x2B;KAAgnfIv1u4vV&#x2B;23iM&#x2B;fCgBUAKACAAUFFQQ&#x2B;pV1AqSCQFe0CaicKyBF/McKvZJqApYQB1TkCLPnIXaVKlSL16tVzCw8P9/Tx8XEtVqxYcSYrrSooKLIRWPIDDx48gIsX4wjZf/UqHlavXkPyB2xtrQnBnz79N9i5cwdYW9tA27ZtyePq1KkDw4YNA/ZzmK0FgPRvbQ2hzqkEmtOyb3C2EP6a0YDGmGiLrMeFqtyGRJyR7AqQbx2QFwLABAFA7NiNBQD&#x2B;78KnarnnVtKpINshISJe/Pvvv1uGDh26/&#x2B;LFi/GgvspvCulXWvmXq/jLtflnCZ8/FQCoAEAFAAoKCnMKAuYaNyi2H7nuALGfcuQfzCgAKOkAUEr8TQ0RlCLtqgg9ZDBHwNnZuUDFihWLNmrUCO0Cnq6urs622TGWnIIiiwA7AdD/jx75Tp06wrlzZ0mHQJ48uaFJk2YwY8ZvZLsGDerD0KHDgP38ZV8BICUFk/rSUvZTx/npwv5w1arL7kvvCDCe8WdgFwCdO4DbF4ABghpB0ipEYhmGkyogd7YUYdE68s89PiUWASFdQahNX8nrEBcElE8UUJpdoJDvaO/cuXN7&#x2B;PDha//888/roL7Kn2wi6Zeq9ieDsnC/jPj8xW7LEPE3hfxTAYAKABQUFBQ5xS6ghPyDiQIAn&#x2B;hbwi6gtEvAlK4Ac&#x2B;UI6H8PCAiwDg8PL96gQQPfsmXLetrb2xcvyIJ&#x2B;2igoTAPaBY4dO0rGDWJIYGhoKLkdpwigGODh4ZH9BACW&#x2B;MfHJ/DGADIGwX7cjnb9dd7MP/E2dBAYJciIklfddSFCq6RKL7cRtxtAqRAgJghkjGcwPI7JiAoAQi9JapqBlBgRHx//asKECSvmzp175dGjR29BXZVfruVfiuzLVfuTVRB&#x2B;S4z1yzTiTwUAKgBQUFBQfApBwFx2AVBA/IWIutLbqF3AfGMHmYiIiGK1atVyDg8Pdy9fvrx/4cKFbTUaTS76aaOgMB04UWD9&#x2B;vXQqlUryJMnT7YVAFIERv4ZEV9&#x2B;2r/BSD5jgprWUJD25cQYcF4p3zq/VV1KXDBcX0sHCQqf8rRGAoGcriCX4q8&#x2B;lV9&#x2B;jKAQdVDyFLrj&#x2B;PDhw/vly5dv&#x2B;fXXX0&#x2B;cOnXqBZhe5Vdb/Veb6m&#x2B;JsX5Kff6Kyb/WDGSOCgBUAKCgoKCwpCBgLruAmCDAqLgvq9kFxMi&#x2B;FPE3h10go4Q&#x2B;Q9tYW1vniY2NdS1fvrxj9erVA0uUKGFva2trAwA0P4CCQiWB1mg02fb4k4kAEK8f38cnwgwvAZARYKDpbfZMOlFO&#x2B;9bljvzjE2Nxsi3cMSAdeCdB/JUk7SkQAaR2KVSp53cxKG/RNw5SFMsOkBNA2L/P5GPHjp0aN27czjVr1twH06r8prT8awV&#x2B;VyMAfBY&#x2B;fyoAUAGACgAUFBRZQQwQI&#x2B;qmCAaf0i6gRBDQyIgFGhlxQK11wBx2AUuRfkm7gIODQ/6OHTviZAHHqlWrBhYvXrxYfhb000ZB8XkDJyFwQwC55FcjRph1QgA3mV9X1eeSYC3JE9RfZ3i5AYLt&#x2B;AwIdggI2QSMPfnGRNxgG0aA5ol0BqQnB4CqkYJKRwuqEwLETsuSQoj27t1796ZPn7Zp4sSJcWBasF8yiLf3m&#x2B;LzVzvWL9v7/KkAQAUAKgBQUFBkR0GA2gXk7QJyIoA5ugJMCQY0KUcgd&#x2B;7cmsDAQJv27dv7BAUFOZcpU8a7WLFiRaldgILi8xYADDoAGC5xT6PBOgLLMJyRf6Bn&#x2B;&#x2B;lEPu0&#x2B;Jm3tzWkJYAQ4rcFNZN9p&#x2B;9EygmcgJac8fqu&#x2B;lpthoJBBC8kCSp9TZleCwoD06&#x2B;J2BfB/GiIpKenNn3/O39CrV6&#x2B;DIFy1z0jLv6mVfzkBAMDyPn8xESBTiT8VAKgAQEFBQZHVBIHsaBcwhyCgJECQv51a60Bm2QXMlSNALra2tnlr1apVvG7duu6hoaGeHh4eLpgfANQuQEGR/QWAlGSIj09k16Yp&#x2B;o80wxiTV271ngFGgJSmp/YbVt3TuwVA5&#x2B;3nnwR4z4WTArjJ/fywPiYtgJDcLpvAr2pioKLEPaHJAnK7kusM4PID8VO4WEdA&#x2B;r/B6tWrt/Xr13f3jRs3XkPGgv2SVZB&#x2B;uVT/T&#x2B;XzB8gi7f5UAKACABUAKCgososYIEbU5QQDAPlxg6baBaTEgozYBcQsAVL3mdsuoDZE8JPYBRwdHfPFxsaWqlSpkmu5cuW8SpYs6Zg/f/4C9NNGQZEdBQDMAHgNKdoUQd8/189uIAYInQIYkVR9TnYAwxktyJUPGI24R567TzHirdRjr0gAMFy0Sz6QL1BopU6KJnQEiL8mw06A48dPnBw1auS2devWPQB1VX450i&#x2B;X7m8Onz&#x2B;Aae3&#x2B;Wd7nTwUAKgBQAYCCgiKnCgKWtgsoFQcsYReQsgWYMmLQlK4AOSuAqaRfsV2gZcuW7hUrVizl7&#x2B;9fytHRsQS1C1BQZBMBAC0ACYlGa1O&#x2B;CGB46uBV/nVUmMHqP2MkGhhY73lBglq&#x2B;uCBc2BYk3krW/HKt9YpHCsrOH1RzbGbjMNpbt27fWrJk8Z5hw4adBvMF&#x2B;8lV/7UgPdbPFJ8/SPyeLcb6UQGACgBUAKCgoMgJgoCl7QJ8Qq9UEPhc7QJquwLMlRGg2C5QvHjxfKVLl7aNjY31DQ4OdvX29nazYwHULkBBkWUFgFfxrw0qzal8N504MwyH5gv07TMGegCTRvhTq&#x2B;KC/naOCKAVWZ9z92kU9ifTgm8Y4ac8M0DRRgqEAEbF153SUX78aQLPnz9/unPnrmOdO3famZCQ8B5Mq/Kb0vKvJOiPLwqIBftxW/yF2v3lqv1Z3udPBQAqAFABgIKCIqcJAtQukLl2AaXk31ykX3YbDw&#x2B;PgkFBQYW//PLLIF9f35Lu7u4uVizoJ42CIqsIACnwCscAatPJpUbD8AQAkaR8Rp7Q6rIDxKwB5Ik1GiQFejGApydI99WrIN1qTm&#x2B;yuQEKxABGpe6pRF94x&#x2B;LEiROnv/3223VXr15NAPVVfiGCr9TnL1f5l6v4f9Zj/agAQAUAKgBQUFDkdDHAVEEgs8cNfkq7gBzxz6p2ASXbCD5XaGioXVRUlFPjxo2DSpYsWcLJyclRk52HqFNQfA4CwKv4NLak1RN7ocp96u8ikwIMyGvaVAC9BYDvkzcO9TMYkWeQNyBxthAh3Pz9i3EC&#x2B;eR9cWEDDMQJrlWAMJz020F43KHYMXJ3mc4bUq/HxcVdHDJkyPo1a9bcA/VV/mQTSb9UtT9ZgOwLEf4s5/P/1OSfCgBUAKCgoKDICYJATrULKCH9XEItRvzVigBKuwQ&#x2B;WY6AtbV1njp16jhUqlTJif0Z5ODgUAzBZKVVEQVFDhEAuOn9BkF9jPFXL9&#x2B;zb/g4rb6bgEucjdryOfsyEhpwWwYM/PeMcWuBwhOPPOlWwxFUhQhmsENA994&#x2B;ffr0ybhx41bOmDH9ckpKSjKYHuynpPovVfnXKhAA1Iz1&#x2B;&#x2B;x9/lQAoAIAFQAoKCioICBP4tUKApayC0iRewDzdQSY62Jqp0BGhQGzWQqKFy&#x2B;et1mzZi6VK1cuGREREViUhQ0L&#x2B;kmjoLC8AEBIuMaQbKe34TNGAoCOtIvbABhJ0mxw&#x2B;tDKrNGNpgIA7/jE&#x2B;bbSkX3c15VOvo1fH9caYA5BQGrCQVJS0pvff/997ezZs89fvXolAUyv8qut/st5/D/VWD8lv2d54k8FACoAUFD8P3t3H2R3Xd8L/HuSEAghxCTkeZNNQhKBCAETHhzyZAiJEGCc0hmmytXO1PrH9WI7o3bwXqftvTPaVnsV7gVtfWhpp1ZasQOtFxCtqKBQbLUW1ELV0nvlMQkJj&#x2B;Zhd8/ds9ndnD37e/j&#x2B;fuec3bO7r9dMyO7Zs2cfsmf5fd7f7&#x2B;fzBWFA&#x2B;UBgMrUL1BfHIZSbJTCW7QJtnyMweLrAqk2bNnVt3rz57Pnz58&#x2B;bOXPmyZ5t0MoAoHdgBkBff2k2bXAH&#x2B;7RaITzql2mlcdpf4hGBjdfcWX3tie&#x2B;XtlLfMJG/Uvc5NgYB8f/TqaSGALGnCOR9jUmfe15qUO2r9t731fseuOkTNz10//1f3xfKrfKX2fJfDa051k&#x2B;fvwBAACAAAAQCLQ0Eplq7QF440OzMgGaHCLZsRkDa48yYMWP6zp07z3jLW97Sfckll6xdv379wOkC5gdAswFAXzj00ouDy9p1vfvV&#x2B;p7/ut78Eb3tI38DNhbPqdP9R9w/JRxI3bo/&#x2B;PnULcU37lgYFV5U4kKAvNkBMXMDov/Pl3DHWqH6xBNPPP6Jj3/ia7fd9qc/C9mr&#x2B;THT/NvV5x9zrF&#x2B;Rwj/ttqYK/04u/gUAAgAAgUD5MKBIIKBdIH5GQAjj1y6Qd58wd&#x2B;7cmW9729tWbtq0admWLVvOXrZs2ZI5/TzToGgA0Dt4CkB1xK&#x2B;z47sAhgri5JX/&#x2B;leGV&#x2B;RTKvq0XQKRi&#x2B;K5PfwjdgbUzeMLSaFAC08UiN0hMCqVaPjCD&#x2B;zfv&#x2B;/P/vzPv/ZfP/jBfyxQ2Mdu&#x2B;S&#x2B;78l8N6cf8xfb5Z239D2ESHesnABAACAAA2hMGlA0EOrVdIJQIAOqL87LhQN6ugbK3lW0XaKqlYNWqVbPf&#x2B;c53rjn//POXb9q06fVLlixZdNJJJ830bIO4AKCvr5qwpb&#x2B;SWBaP7otPmxkw8j7JpwqMfsyYXQHJv&#x2B;Kzzu1reFMLjhaMPUkg68393/&#x2B;eL37xi/e9613vur&#x2B;nXyg/2C&#x2B;t6O9NKfTzVvvHq88/hEm43V8AIAAQAACMXSBQiXifmECgE9sFip4okFf4hxDfGhCz8p8XDLTlPrNnzz5p/fr1s3/1V3/1rA0bNizfuHHjunnz5r1u&#x2B;vTpMzzbYHQAcOjFkTsAho8BHP7FUH&#x2B;c3dCsgBOF&#x2B;HBhfiJBiLoWj/nVn3aX3FX6oZ0J/V9XtWG1fWhFPm92QKXAUIGsHQGVhiGFQ9/qBx741nduvPHGr33ve987FFHYx2z5z7otacJ/M33&#x2B;ITjWTwAgABAAAHRAINCq4wbTHidvd0Da33nFf2hhABCzAyC28C87RDCraG9V0R81R2DBggUnb9q06XXXX3/9OevWrVu6YcOGddoFIDkAqJ/sf6JmrtSVxINlc6U6XCIP/LeS0ENfyT9yr7FwHr1LoP76OXnK/4lKMbuHv/bO9bvxR/ydODwgPRho5kjBQ4cOHvjwhz/ypVtu&#x2B;d&#x2B;Ph2K9/FmD/dKK/saj/JJe7gtxq/6Nff4hlDvWb0oX/gIAAQAA7QsDkgr5TmwXiCn&#x2B;Q8kAoLHQb0e7QOwugTLtAq2aIzD88tq1a0&#x2B;75pprll999dUbVqxYsXjNmjWrK510JQbjEAD09fWFkTM1Rxbhw8V3JaExoDJYFKdth69LFCq1j9FQydcX/tWGwX6Jn0NGUd4YCiR&#x2B;LvW7AcLo&#x2B;QCxMwmGQoekMKLx66r5xS9&#x2B;8ertt99&#x2B;34c&#x2B;9N8eeeGFFw6H5gf75RX9RY72Sxr4lzTYr36Lf9J2/7zV/inV5y8AEAAIAAA6OxBoVbtAiCj8kwr12NumYrtAW44dnD179oyLLrpo/u7du1fs3LnzrJUrVy5Z3K//x8zpAkyZAOBgbQfAYABQHTwN4MTKf3VUGFB/TZ38G3l0CT5qdT&#x2B;yTWDoujnmWMHCgUDjgxQ8XjB3MOGgvr7envvv/8ZDH/3oHzzQb1&#x2B;IW&#x2B;VvtujPWvmP7fN3rJ8AQAAgAACYVIFAq9oF0gKBSoG3dVq7QFqxn1X4t6JdoO0zArLuM2/evJl79uxZsmvXrlWXXHLJ&#x2B;mXLli3qv22&#x2B;ZxqTOQA4dOjF0Ddi9T69T78yaod/JWNgX90vmkrOqnzGtXtMe8Bg/R51DF9iwV6XLAzPDWj8blSyBxQer2BHHl346KOPPvaZz3z6m5/97Gd/Goqv8mdt&#x2B;W/lsX5JBb8&#x2B;fwGAAEAAADCpw4C0Qj0vMAihfccNlmkXiAkEpuWEBdNywoGirQOtaBdo14yAzPucddZZc/bs2bN069atqzdv3rx&#x2B;0aJFC2f182xjsgUA1RGVbfKxf8dr5EpDCDDyKL/UArly4tdMJa34jggD4v5fEBcApK3eD7ciNIYfMf/XGPT8888/98UvfvEbv/WBDzwSmlvlTyry847yy1rtTwoA0lb6k471i&#x2B;3zTyvyp3zhLwAQAAAwMQMB7QL57QJ5IUArdgW0qujPbTuYOXPm9NowwSuvvHLltm3b1q5fv757Yb/p/TzbmBQBwHAxXv8bqDJi2//I7fjZx&#x2B;3V19CjdhJETdtL3XufPXMg7V0ThvxlbuOvDyYGX687bDAhyAjh6JGjR&#x2B;&#x2B;9956v//q7333/Ky&#x2B;/fDTEr/KXKfrL9PnHbvsPoTXH&#x2B;k3pPn8BgABAAAAwcQOBidgu0IpAIGaAYOP9irYOjFW7QKvmCAz8qbUL7Nq1a/GWLVuW79y58w3Lli1bOH/&#x2B;/AWeaUzoAKB&#x2B;9b8&#x2B;AKi7qRrCqBAgrRifNq1SN1egMqL2G2oTCFl99JFN/1lBwPDuhMRfxpURg/waw4kR4UDOjoCHH374kRtuuOHuH/3ohy/lFPZpW/vLbPmvhtYc66fPXwAgABAAAAgECgQC490ukBUWNNMukNYSkPW2VrcLFB0i2K4ZAZm7C5YvX37Kdddd133&#x2B;&#x2B;ecv3bZt27lnnHHGgtmzZ58aQnDCAB2rpy4AaOx6HyqaKw0VdaVS/Pi7xqGBI2v6Su4vztw&#x2B;g8roCCEplCjyWz93eODg5/HEE48/fvPNN3/1z2677Wc5hX3ZLf&#x2B;t6PNP&#x2B;zuEcn3&#x2B;abc1VfhPleJfACAAAGBihwFlA4F2twvEhgPtaBfIagsoc8RgmV0Bea0AZYv&#x2B;qI&#x2B;1YcOG06&#x2B;77rrVF1xwQddFF1109tx&#x2B;J5988imebXSSgVMABgKA5F9Qw7Xu4HV0pbH4zggDhgrw1CJ8MF1ICgPqpxBU04KBiF0BWccKjg4iRgcAWVP&#x2B;9&#x2B;3f/9xdd9754Pvf/76Henp6ekOxwX5pf8dO&#x2B;E9b&#x2B;c8LABoL/qQ&#x2B;/6yt/yHY7i8AEAAIAAAEAqWK/ZBT7OcFArGtBGM1P2C82gWK7gpo1YyAQm0Hu3btWvjWt751zbnnnrvivPPOW3f66afPnTby4HUYc7UdAAcPHqqbwTf6eL9KzPV0w8r8yGn9I/v101bmG4OAzH77pHfOCQXy5gXETvh/9dVXXnnggQe/&#x2B;9733vC1p59&#x2B;&#x2B;rWQv8ofu&#x2B;U/7bZqSF75L3qsX9pKf7N9/iHY7i8AEAAIAAAEArlFfNFAQLtAuXaB2OK/VUV/7n0WLFgw8/rrr1&#x2B;1Y8eONeecc0736tWru2f0q3TSFSFTKgColWrV&#x2B;uvlWjE8LfkaOmabfiWlqi42yf/EVoGhfQEJkwriK/mGj38iiBj5SBljB/oe/ZdHH3vf&#x2B;9/3dw995zsHIgr7mC3/eav/aSv/Zfr8Q&#x2B;igY/2qU7wgEgAIAACYGmFA2UCgFe0CIcQfNzie7QJ5hX&#x2B;ntguUuk9tF8D5558/95prrunevn37mWvXrl25dOnSxdOnT5/h2cZYBQBDg/qOP8EqJ35SG6b&#x2B;V0Py9qP6ArxSX0XXF&#x2B;aZRXjiQyX8iqsOf47VyDAiry7I&#x2B;hyGHuKZZ5556nd&#x2B;&#x2B;7fv&#x2B;MIXvvB/Q7Fe/ma2/Get/MdO&#x2B;c8a9FcfCCQV/mm3NVX4K/4FAAIAAKZyIDBV2wViiv76Yjmt8C8aAsTuEhi3OQKzZs2acfnlly/as2fPqgsvvPDMNWvWdC1YsGB&#x2B;MEyQNujt6Q0vHDwY&#x2B;qqN2/ZPFNwjAoCGYnnUNv3Bqnn4vkNdLpGr8pn1/KgnwVCbQDX/WMGE3QH1MwLSPpdXX331lc98&#x2B;tN/&#x2B;9GP/sEPXnnllaMhbpU/a5p/byje518kAEgq&#x2B;Ptyiv281X59/gIAAYAAAIAxCgQ6rV0gq7gPoXU7Alr1p&#x2B;xOgWaDgZa1FKxYsWLWnj17lu7cuXPNBRdcsKarq2vpaf0802hdAHAo9A0U7aOL/vrr56QAYNR19lALQGQRnvS4WR&#x2B;j/mEao4BqzHGCKQ/QGAb09PQcue8r9z7woQ996Fs//elPXw5xvfyxW/6LrPwX7fNPW&#x2B;0v0uffGABkFfy2&#x2B;wsABAACAABaFAaUDQQmU7tAfXEcQrlZAmPZLtDWOQIzZ86cvm7dutPe&#x2B;ta3rti6deuZZ5999qrly5cvm97Ps42yAcCBgweHWwAa6&#x2B;TanMqkSfoDhXZlZLE&#x2B;XITXtwJk/4LM3RmQOcU//XiA4yFG1meQ8rH7P17fP/7jd7936y23fOuuu&#x2B;56qq&#x2B;vrzc0N9gvqcjPO8qvyKC/Vh3r15bCX/EvABAACAAABALtCwSmWrtAXjjQ7MyAZocItqpdIPVx5s6dO/Pcc889vXa6wLZt29avXLlyyeLFi5d4phGrZzAAOHEOYGVUPV5oB0DKNXfucX71xXhCYZ72sYcfNzVLaAwD0icH/Ozf//0nf/VXtz/4&#x2B;7/3e4&#x2B;GYqv8ZYr&#x2B;xqP80or9In3&#x2B;adv9Y/v804p8hb8AQAAgAACgAwIB7QKtbReImREQwvi1C&#x2B;TdJyxduvSUnTt3Lt6&#x2B;fXv3jh07NixcuHDB6/p5phEfACSttsf17iftEIgOAdKCgYLX9EnHCQ591LSxgS&#x2B;//PKLd99997fe/e5f/2ZEYZ839C&#x2B;v6C&#x2B;y8p/U7x9C9pT/tO3&#x2B;ab39sX3&#x2B;0cW/wl8AIAAQAADQ/jCgbCDQqe0CoUQAUF&#x2B;clw0H8nYNxA4WjFnxb0XRn/mx1q9ff9qVV165fNu2bas3b968fkG/U/t5tjFkZAtAfoE/agjg4JF/fX19A&#x2B;0CaY&#x2B;ROmm/iRAgJghIDgUGq&#x2B;jevp4HHvjWw&#x2B;95z3vu/fnPf/5qiJvmX2b1f6z6/B3rJwAQAAgAABAIZBb7zQYCndguUPREgbzCP63gjzlNoF3BQKk5Alu2bJm/e/furr17927s7u5eNm/evNf1F23mB0xh9TsA0lbnk1oAqg3HA&#x2B;ZdZw&#x2B;/T8LOgOhQoMDRfnl5wo9&#x2B;&#x2B;MPHbrzxxi8/&#x2B;OCD&#x2B;wb7/Fu95b/Iyn9jAJD3dwjl&#x2B;vzTbmuq8Ff8CwAEAAIAADovEGjVcYNpj5O3OyDt77ziP7QwAIjZARBb&#x2B;JcdIphVtBcu6EMTcwTmzJlz0q/8yq&#x2B;sfNOb3tR18cUXv37lypXLa7sDKp10VcqYBAADxwD29Q33yVemVXIn8SddVyfNAEjaMZA22C8qBKgPAuor&#x2B;pTPrfHjv/TSSy/&#x2B;5ef/4t4PfvCDj0QW9kW2/GcV/I09/9UCAUBjwZ92rF9fROGfVuQr/AUAAgABAACTNAxIur7uxHaBmOI/lAwAGgv9drQLxO4SKLMroFVzBIZfPuecc&#x2B;bs3bu3a8eOHWv7X161bNmyxTNnzjzZs22SBwC9PeHACwdDtW&#x2B;wKK9boT9&#x2B;rF96NV5kOGB6C8DxkwMaP3b9L4eouQEpuwOGPvaxY8eO3nvvvfd/4uP/8x/&#x2B;&#x2B;Z//&#x2B;WBEYR&#x2B;75T/ttmrIXvmP3e6fttJf5Fg/ff4CAAGAAAAAgUB0ANCqdoEQUfgnFeqxt2kXaF27QGXv3r1Ltm3btuzSSy9dt379&#x2B;pW1&#x2B;QHaBaZAANA4yC9kBwCJk/kzVv&#x2B;Tbi96rZ56kkBKofrII//w3T&#x2B;77baHbr/99v8I5Vf5eyOK/pjV/tgAoCOP9VP4CwAEAAIAACZfINCqdoG0QKBS4G2d1i6QVuxnFf6taBdouv8/NNEuMHv27JOuvfba2jDBlZs3bz5z9erVK04//fQ5ocBAdzo0AOgZDAASevtPHKE3&#x2B;HL9zoC&#x2B;up&#x2B;ynGvvIiFB4nV7whaASkPlWmkMA/of98knn/zp5z//&#x2B;W/efPNNP&#x2B;qpfaHNbfmPKfpjpvoXOdavL6XYjz3WT5&#x2B;/AEAAIAAAQBjQdCAwEdsFYgKBaTlhwbSccKBo60Ar2gXaVfRn3mf58uWz3va2t6268MILV2zevHlt/&#x2B;vLtAtM1ACgNxw48ELoq/blD/MbLKynVaYd321fMABIDhlGhwTVoY8RqlHX8I1vqfX5f/nLX/7mb/7mbzwwWPjHrPIX2fIfs/JfJABIKvjb0eefFgIo/AUAAgABAAACgVKBgHaB/HaBvBCgFbsCWlX057YdzJo1a/qKFStO/bVf&#x2B;7XXv/GNb1xxzjnnrF7WzzNt4gQA&#x2B;w&#x2B;80H9t2jfwz1qpjLxmzirWm/lVUmZeQNr7V8Px0wV6e3t7Hn744e&#x2B;&#x2B;4z9df9ehQ4eOhOYG&#x2B;/UWKPrzpvqPV59/CLb7CwAEAAIAAGhhIDAR2wVaEQjEDBBsvF/R1oGxahdo1RyBgT/z5s2buWnTpnnXXnvt2osuumht7bjB2vwAz7TODgAGTgEY3gGQff086vX6p1al1O&#x2B;gpq/bf/qTn/zre3/jvV/67iOPvDB4rF/sKn/sUL&#x2B;8Lf5FBv216li/tvT5K/4FAAIAAQAAwoCygUBMu0AI&#x2B;ccNlm0XyAoLmmkXSGsJyHpbq9sFig4RHJc5AqtWrTr1sssuW3z55Zef&#x2B;cY3vvHMpUuXLj7ttNPmeLZ1UgBwIPTX/2HatJC6TX/oOnpge/60aSPfPjiqv7Fnf2hlPmqKf8PHyGoRqPfsM88&#x2B;9clP3Xr3n3zuc08cPny4J8Sv8qdt&#x2B;Y9Z/a8mvJw16C9vtT9pu39sn39akV&#x2B;q8O/r66s6CVQAIAAQAAAgEBjLQKDd7QKx4UA72gWy2gLKHDFYZldA7tC/kkV/7sfqLxynbdiwYc5VV1218pprrjm3q6trUa1doHa7Z9v4BQD79h&#x2B;oK7Cro5469W0B9YV4dl9&#x2B;wwkCkSlA0jyApDDg5ZdePnjPPXc/&#x2B;JGPfPgfnnrqqVdDuVX&#x2B;pAK/6HC/tIK/N6W4T&#x2B;rzT9vun7fa3/I&#x2B;/5j2CwQAAgABAAACgTJhQFqxH3KK/bxAILaVYKzmB4xXu0DRXQGtmhEQ3S5QO13g6quvXnrppZcu37Fjx9nLly9fOm/evNcFpwuMYQDQMzgDoDpYo1ca6sbjrx9f9T9eUx4vwpODgcSdA0MnCFSL/csmhQBHjx45/NhjP3zsvTf8ly8//vjjL4biq/xliv7Ylf&#x2B;8Ff&#x2B;8bf7jcqxfVuCCAEAAIAAAgHYFAtoFxrZdILb4b1XRn3uf7u7uWXv27Fn6lre8Zf255567qna6wKx&#x2B;nmntDAAGWwAark1H1uuD6/mV&#x2B;luTWgRCdIWfdcRfklpf/7PPPvvUB2&#x2B;88a/vuefup0PxVf7ekkV/1mp/b4gb7tdMn3/abU0V/jW9vb3VxnYOAYAAQAAgAACAsQgDygYCY33c4Hi2C&#x2B;QV/p3aLhBzn8SPtWPHjjMuvvjiRXv37t2wZs2a5Yv7zejn2dbqAKA2BLC3voqveyIMrt7X7Q8IdbsEMtsABncEjL7fiQChOhgAjAgcGkKBgwcPHvjkJ2&#x2B;989ZbbvlxT&#x2B;0TLj/YL2b1P2vlv1ogAGgs&#x2B;NtxrF/pAX&#x2B;1oY8DT0wBgABAACAAAIAOCASmartATNFfX1CnFf5FQ4DYXQLjNkegv&#x2B;6ffu211y678MILl775zW8&#x2B;a/Xq1V1z5859nfkBzQYAPYNDAOt6/yvVwSK8Ujfcr1r3&#x2B;sgQoLGgz3rmJ/1aSCo&#x2B;a49T2&#x2B;5/55133ve7v/PbDx04cOBwKL/KX3T1v&#x2B;hU/7E61i/m5VS1Ff/a93j69OlBACAAEAAIAABgIgUCndYukFXch9C6HQGt&#x2B;lN2p0CzwUDLWgrmzJkz4x3veMeqCy64YOn27ds3LF68eGH/bXOC&#x2B;QGFA4ChIYD1xfzxl45P8B/IBHIH/lVHvBY78C&#x2B;p6Ozt6&#x2B;v51je/8e0/&#x2B;dyfPHLffV95JpRb5S&#x2B;z5b&#x2B;a8HKRAKAj&#x2B;/xrhf/QbgwBgABAACAAAICJFgaUDQQmU7tAfXEcQrlZAmPZLtD2OQJdXV2nvutd71r7hje8Yekll1xy9sJ&#x2B;M/t5tsUFALWCMP8IvqG9&#x2B;id2A9Q/E0YO/K8M7wSIKSqH3v6v//rjH37&#x2B;Lz7/4Kc//cdPhHKD/XpD&#x2B;lF&#x2B;7ezzjw0Akgr/tNuaKvwH/30Hin8BgABAACAAAICpEghMtXaBvHCg2ZkBzQ4RbNmMgLTHmTVr1ozzzjtv7tvf/vZ1GzduXHH22WefecYZZ8zv/zHTLtDgWK0FYP&#x2B;B0Nvbl3rc34lr6OQTApL2/CfNCqgONvw33r0WFuzbv&#x2B;&#x2B;5O&#x2B;644&#x2B;u//3sf&#x2B;d7hw4d7QnOr/EWK/qyV/2pIP&#x2B;ZvrPr800KAiMK/VtwfD3YEAAIAAYAAAAAmayCgXaA97QJZMwJCGL92gbz7hLlz58684oorluzatWv1RRdddGZ3d/fy008/fa5n2sgA4Phzb/R1c/rTsW50X8POgKENAifuNdRQcOJ9avc5cuTo4dp2//e85z9/9aWXXjoSmhvs11ug6M9b7R&#x2B;vPv8Qmlj1P3asVvgP/fsJAAQAAgABAABMrTCgbCDQqe0CoUQAUF&#x2B;clw0H8nYNlL2tbLtA6ZaC2tDArq6uWW9/&#x2B;9tXXXbZZa9fvXr10u7u7pXTa1XRFFRrAXh&#x2B;31ALwPEa/kQQkLBanz3hb2TVn/GkqtWijz32L//yzne846&#x2B;feeaZX4Riq/x5RX9vyN/i32yffwjltvu3pc9/sL6o1g5JEAAIAAQAAgAAEAjEBQCViPeJCQQ6sV2g6IkCeYV/CPGtATEr/60IBgrPEai1C2zdunXBrl27Vu7YseP13d3dSxctWrR4ygQAx3rC8/v3150CEBq2/idfTw8ViokFY32SMPSjUrdZ4OUXX3rhj//4j/72pps&#x2B;8Vjf8fMHWzHYL2/1v5rxcl&#x2B;IW/Vv7PMPGS&#x2B;P2bF&#x2B;tVX/2t8zZkwPAgABgABAAAAAAoH4MKBoIFDJeZy83QFpf&#x2B;cV/6GFAUDMDoDYwr/sEMGsor1QQR&#x2B;anCOwcOHCk3fv3r3kqquuqg0UXLVmzZqVp/YLk/R0gdoOgOee3z9cEKZt&#x2B;x&#x2B;q6Yse8Vdf/ff29vXcfvsX/u7mm276p5///P&#x2B;9Gsqt8pfZ8h9ztF/SwL&#x2B;kwX71W/yTtvvnrfa3rM&#x2B;/VvjXF&#x2B;wCAAGAAEAAAADCgOYCgU5sF4gp/kPJAKCx0G9Hu0DsLoEyuwJaNUdg&#x2B;OWNGzfOvfTSSxf&#x2B;0i/90rmrVq1aUmsXmNFvsgUAvX29g5P7Bzv2U&#x2B;Yljm4TyL/erq3yP/TQQw/feustD37j/vufDcVX&#x2B;ZMK/Ng&#x2B;/6SV/9g&#x2B;/4481q9W9R89emxU8S4AEAAIAAQAACAQaF8g0Kp2gRBR&#x2B;CcV6rG3aRdoUbtAf90/7fLLL1&#x2B;0efPmRVdfffV5XV1di2tqcwUm6nPk2EAAsO/4DICQtvpfv&#x2B;W/cVDg0LXtyNsHr3WrTz755L996lOf/MoX/vIvn6zb7p&#x2B;3mh&#x2B;z5b&#x2B;Vx/olFfwd2ed/9OjR6kknnRQEAAIAAYAAAABobyDQqnaBtECgUuBtndYukFbsZxX&#x2B;rWgXaKqgb/Y&#x2B;tdMF9u7du&#x2B;Tiiy9edvnll5&#x2B;7aNGiM&#x2B;b3q0ygCqo&#x2B;ADj&#x2B;D1zJvF6uDE38T3x&#x2B;nXj5pZdefO5Ld3zpGx/5yIf/6bXXXjsasgf2xW75T7sta&#x2B;W/GhEAFDnWb1z6/I8cOVqdNu14ES8AEAAIAAQAAMDYhgFphXpeYBBC&#x2B;44bLNMuEBMITMsJC6blhANFWwda0S7QrqI/s11g6dKlp1x33XXdmzZtWrZ169Y3LFiwYN5pp502p9MDgGefe36gIEzayHD88L7q8O6AoUL/RBvAyB/fV1999eXvPvLIP91ww3vuOXjw4NGQv5pf9Paiff5ljvXL6/PPej2ryC9c/B8&#x2B;fLg6ffqMwX8fAYAAQAAgAAAAJkIgoF0gv10gLwRoxa6AMoMBS88RuOCCC&#x2B;b&#x2B;8i//8ppNmzatOP/889cvWLBg/owZM07qrADgWHj&#x2B;&#x2B;f2hp7f3xADAoSo/9Ye2knRt2/fjH//40d/6wPvu/MEPfnAoZK/ct6ror1/Nb/ZYv47q8z985Eh1IHzpL&#x2B;AFAAIAAYAAAADo7EBgIrYLtCIQiBkg2Hi/oq0DY9Uu0Ko5AgN/ascN1uYHXHbZZSu3b99&#x2B;du10gdNOO212JW3a3hgGAM89tz/09ReKA8XfQAvA8Il9Q0&#x2B;GUbsA6oOAp59&#x2B;&#x2B;smPffT377zjjjv&#x2B;I6doL9L/3&#x2B;o&#x2B;/9ht/7GFf9ptTRX&#x2B;A8X/4SPV450WAgABgABAAAAATLQwIK1QzwsMQmhfu0BWWDDR2wWKDhEcl3aBtWvXzr7qqqu6tm/fvmbDhg3dK1eu7Dq539gHAD3hucEWgDDY31&#x2B;pFYp1P/JpOwJefvnlg3/6uc/dddttf/rj/fv3Hw75q/dZR/j1Fij6s1b&#x2B;qyH9mL/YPv&#x2B;srf8htOlYv9qq//B7CAAEAAIAAQAAMKUDgXa3C8SGA&#x2B;1oF8hqCyhzxGCZXQF5rQBli/7cj1U7RWDLli0Ldu/e3bV169a169atWzlWpwscO1YbAlgXAAx9d6sjf0rqdwP0HDt2&#x2B;O///mvf&#x2B;MOPfezbjz/&#x2B;&#x2B;Ith9HF7zRb9vSmFft5qf5E&#x2B;/2pI7vkv0&#x2B;cfQjPb/Q8frg4U6PXvJQAQAAgABAAAwKQMBNrdLtBY0McGApO1XaDoroBWzQgo1C5QO11g9&#x2B;7dqzdt2rRq3bp1q2vDBNtxusCJAKA6uupv&#x2B;Cnq7e3teeLxx3/4iY9//J6vfOXep0P&#x2B;JP7eyNvS3p70uM30&#x2B;YfQQcf69fT0VPv/DNcoAgABgABAAAAACAQma7tA2kp/1tvGol0gtvhvVdGfdZ&#x2B;B3QGLFy8&#x2B;&#x2B;corr1x29dVXv37t2rXL169ff&#x2B;ZJtSqwRQHAs8MtAPXXy9X6f&#x2B;7qvn37nv6jT33ybz772c/8W0jfgh9zZF&#x2B;RLf/VjJf7Qtyqf&#x2B;OgvxDKHevX0j7/1147XJ05c0YQAAgABAACAABAGNBsINCKdoEQ4o8bHM92gbzCv1PbBfLu0/j6wP1PPvnk6eedd96cnTt3Lr/qqqs2dHV1LV61alV3RjCUGwA889xzodqXfG169OiR126//fYv/Y///ruP9BerMcfuFQ0Cih7r11jg9&#x2B;YU/Fl9/mmr/yG0qc//F784PDBeoVZ/CwAEAAIAAQAAIBAoEgakFe4hp9jPCwQ6rV0gpugPIf3owVa2CxTZFdBsMFDJ&#x2B;HwHvp45c&#x2B;bMeNOb3jT/iiuuWFU7XWD58uVLFy5cuCj252wgAHj2ueGCsP7d7r//6//nf91807e///3vH8woupNW6IsM84td&#x2B;Y/t8&#x2B;/IY/1qhf9QcS0AQAAgAAAABAKtCAQ6rV0gq7gPoXU7Alr1p&#x2B;xOgWaDgSKzCTK/D0uWLJl5xRVXLN21a9fqCy&#x2B;88OxF/ebOnTsvKwB4&#x2B;tlnBwrC4wVnte&#x2B;Jf3vi&#x2B;5&#x2B;69dZ77rrrzp&#x2B;H7BX3IjsA8gr9osf6JRX8HdfnP1T81xfXAgAEAAIAAADtAq15PW0XQLtDgHYEA4WK/6R/l40bN87Zu3fvyi1btqzpf/msM844Y/HMmTNPOREAHAtPH98BUN2/b/&#x2B;Tf/M3d9z7hx/72PdrA&#x2B;pC8ip7UnEeU8znHeWXtdqfFACkrfQnbfeP7fNPK/JLFf6vvvZatVZoz&#x2B;gv4AUACAAEAH7qAYDxDASmWrtAXjjQ7MyAZocI5r0t70/ICGIGnHrqqbXjBufv3bt31Zvf/OaN3d3dq0455ZQzfvKzn&#x2B;3/zoPf/uYHPvD&#x2B;rx46dOhYSnHdmxMG5BX&#x2B;Mav9sVP9s6b8t&#x2B;JYv5iXUx07dqx65OjRgbpDAIAAQAAAANCqgr5VYUCRQEC7QPyMgFCw&#x2B;A&#x2B;hyRaAgj8nWQPx8grvtHkAWacD5PX2Fz3Wr6P6/AvcDzqKAAAAYHKHAWUDgU5tFwglAoD6wrpsOJC3a6DVtxVuAYgsVqsFQ4C8loC8QCC2zz/t7xDK9fmn3dZs4a/4RwAQaYZvNwBAuWu2JgOBIld8lZTiaNSB8QmPnxQEVBsK12oYn3aBvlD8RIG8wr83xLcGFLkttvjPa&#x2B;HI6n1vRwgQ8/a8AKCx4E871q8vovDPKvKrJZ4bCn8o8j8TOwAAANpz2dPi9y0zPyDtcfJ2B6T9nVf8hyYCgTLtAo1BQUzhXma1Py18qER8n2KK1/riOGl4XpEQIKvwb7bPP2nYX9k&#x2B;/xBs94fjP8xaAAAAhAEZ79&#x2B;J7QIxxX8oGQA0FvrtaBfICgmyPn7S6zH/5lnb4rNW3qs5BXxv5Nti&#x2B;/xD6LBj/RT/CAAEAAAAAoHsx25FIDDepwu0ul0gKwRoxfb/SoHiP4TibQBlQoEiq/19KcV&#x2B;7LF&#x2B;Cn8QAAgAAABaGAi0ql0gLRCoFHhbp7ULpBX77Sj880KVrEI2dgdA2TCgTMHfl1Ps56326/MHAYAAAACgjWFATAE61scNlmkXiAkE8rbkT8sJB5ot/GO&#x2B;5rwAIK2ArkYU/0WDgKSi3rF&#x2B;MMUCAKcAAAB02LVgk4FAmdMFGgu1oqcLJL1P3ukC1SaK/8bHTnp7XyjeLtDstv9KgX&#x2B;7tFXxmGGAeUV83gq/Pn&#x2B;YouwAAACYYNdvLX7fTm8XiA0Emh0gWOR&#x2B;MX3/Mf9OaVvnYwcChpwAIGvXQDVkb/eP7fPPCjMU/hDzQ28HAAAAEQVSs7sDKjkFVyWlqEtaga&#x2B;G5N0BIeF964voakYg0Kp2gbzdAtPqit6YVoKssCI2BEgrlIsOBYzp388r/NOO9csKKLKKfH3&#x2B;0KEEAAAAkyMMaEUgkCcpEGh1u0C1QBAQU/wXaRcIYfQugL7I8CHt&#x2B;1&#x2B;J/L7nbbdPawnIm9ofu8Vfnz8IAAAAmKKBQNHdAY2BQFbhW8l4jJj5AUVuK/p6X8H7h1Bu&#x2B;3/IKayrJf70FQgLYgv/tNuaLfwV/yAAAACgQwKBdrcLhITbY4OCdrYLlB36FzMnIe37m3caQFbBXqTAz9pVoM8fBAAAAEzSQGCitgvUF9&#x2B;tbhcoe5&#x2B;sECDt&#x2B;5FXTMe2A2T17xfZ3h/T599s8a/wBwEAAADjHAY0GwiMZbtACMWOGyxyW9H3CyF9xb9S8HtYJACIXckvU/g3BgAKfxAAAAAgEMh8305uF0gr/kNo/ri/IiFA1ip7Xh9&#x2B;K1b49fmDAAAAACZ9u0A1FGsbCBn3KVP8ZxXVscfvtbLwj/18FP4gAAAAYIqEAe0OBMazXSBm10DS7WWK/7IhQAjF&#x2B;/eLFP4h2O4PAgAAAGhDINDJ7QJp948d/lcp8H1oph2g6G0h2O4PAgAAAGgyEJhM7QL1t8UW/pUmv4d5x&#x2B;7lreJn3VfhDwIAAABoSxjQ7kAgr10gNhCICQtCRrFfKfm5Fg0C0or&#x2B;vNvzCv&#x2B;sj6fwh0mkUq2O7fO2Uqn4rgMATOHrzxa/b8zqe94W/sa3xfT3V0p&#x2B;jiGjsG9VGBDztryXFf4wRsayJhcAAAAwEcOAEPJ77mMDg7xAoEz4EPu1xRbnsYFAzNvLFv6Kf5jgAYAWAAAAxu26t8lAoF3tApWQPHQw6bEqJT6Xol9b1vb8aoH7KPxhihMAAAAwGQOBSkqxXyYQyPs4zXzOMYV6mWBA4Q8IAAAAmJCBQLO7A4oeN9gYGlQjP49qm77&#x2B;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" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>